WO1992009690A2 - Enrichment method for variant proteins with altered binding properties - Google Patents

Enrichment method for variant proteins with altered binding properties Download PDF

Info

Publication number
WO1992009690A2
WO1992009690A2 PCT/US1991/009133 US9109133W WO9209690A2 WO 1992009690 A2 WO1992009690 A2 WO 1992009690A2 US 9109133 W US9109133 W US 9109133W WO 9209690 A2 WO9209690 A2 WO 9209690A2
Authority
WO
WIPO (PCT)
Prior art keywords
phagemid
hgh
protein
gene
phage
Prior art date
Application number
PCT/US1991/009133
Other languages
French (fr)
Other versions
WO1992009690A3 (en
Inventor
Lisa J. Garrard
Dennis J. Henner
Steven Bass
Roland Greene
Henry B. Lowman
James A. Wells
David J. Matthews
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27505166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1992009690(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP92902109A priority Critical patent/EP0564531B1/en
Priority to JP50271092A priority patent/JP3267293B2/en
Priority to CA002095633A priority patent/CA2095633C/en
Priority to ES92902109T priority patent/ES2113940T3/en
Priority to DK92902109T priority patent/DK0564531T3/en
Priority to US08/050,058 priority patent/US5750373A/en
Priority to DE69129154T priority patent/DE69129154T2/en
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of WO1992009690A2 publication Critical patent/WO1992009690A2/en
Publication of WO1992009690A3 publication Critical patent/WO1992009690A3/en
Priority to US08/463,667 priority patent/US5834598A/en
Priority to US08/463,587 priority patent/US5821047A/en
Priority to GR980400652T priority patent/GR3026468T3/en
Priority to US11/199,062 priority patent/US20060115874A1/en
Priority to US11/761,180 priority patent/US20080038717A1/en
Priority to US12/508,859 priority patent/US20100035236A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/02Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormones [GH] (Somatotropin)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1037Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845Methods of identifying protein-protein interactions in protein mixtures
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/14011Details ssDNA Bacteriophages
    • C12N2795/14022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/14011Details ssDNA Bacteriophages
    • C12N2795/14111Inoviridae
    • C12N2795/14122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/61Growth hormones [GH] (Somatotropin)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/802Protein-bacteriophage conjugates
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/12Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Definitions

  • This invention relates to the preparation and systematic selection of novel binding proteins having altered binding properties for a target molecule. Specifically, this invention relates to methods for producing foreign poiypeptides mimicking the binding activity of naturally occurring binding partners, in preferred embodiments, the invention is directed to the preparation of therapeutic or diagnostic compounds that mimic proteins or nonpeptidyl molecules such a hormones, drugs and other small molecules, particularly biologically active molecules such as growth hormone.
  • Binding partners are substances that specifically bind to one another, usually through noncovalent interactions. Examples of binding partners include iigand-receptor, antibody-antigen, drug-target, and enzyme- substrate interactions. Binding partners are extremely useful in both therapeutic and diagnostic fields. Binding partners have been produced in the past by a variety of methods including; harvesting them from nature (e.g., antibody-antigen, and Iigand-receptor pairings) and by adventitious identification (e.g. traditional drug development employing random screening of candidate molecules). In some instances these two approaches have been combined. For example, variants of proteins or poiypeptides, such as polypeptide fragments, have been made that contain key functional residues that participate in binding. These polypeptide fragments, in turn, have been derivatized by methods akin to traditional drug development. An example of such derivitization would include strategies such as cyclization to conformationally constrain a polypeptide fragment to produce a novel candidate binding partner.
  • Geysen In an attempt to overcome these problems, Geysen (Geysen, Immun. Today.6:364-369 [1985]); and (Geysen et al., ol. Immun..23:709-715 [1986]) has proposed the use of polypeptide synthesis to provide a framework for systematic iterative binding partner identification and preparation. According to Geysen et al., Ibid, short poiypeptides, such as dipeptides, are first screened for the ability to bind to a target molecule.
  • the most active dipeptides are then selected for an additional round of testing comprising linking, to the starting dipeptide, an additional residue (or by internally modifying the components of the original starting dipeptide) and then screening this set of candidates for the desired activity. This process is reiterated until the binding partner having the desired properties is identified.
  • the Geysen etal. method suffers from the disadvantage that the chemistry upon which it is based, peptide synthesis, produces molecules with ill-defined or variable secondary and tertiary structure.
  • random interactions accelerate among the various substituent groups of the polypeptide so that a true random population of interactive molecules having reproducible higher order structure becomes less and less attainable.
  • interactions between side chains of amino acids, which are sequentially widely separated but which are spatially neighbors freely occur.
  • sequences that do not facilitate conformationally stable secondary structures provide complex peptide-sidechain interactions which may prevent sidechain interactions of a given amino acid with the target molecule. Such complex interactions are facilitated by the flexibility of the polyamide backbone of the polypeptide candidates.
  • candidates may exist in numerous conformations making it difficult to identify the conformer that interacts or binds to the target with greatest affinity or specificity complicating rational drug design.
  • a final problem with the iterative polypeptide method of Geysen is that, at present, there are no practical methods with which a great diversity of different peptides can be produced, screened and analyzed.
  • the total number of all combinations of hexapeptides that must be synthesized is 64,000,000.
  • Even having prepared such a diversity of peptides there are no methods available with which mixtures of such a diversity of peptides can be rapidly screened to select those peptides having a high affinity for the target molecule.
  • each 'adherent * peptide must be recovered in amounts large enough to carry out protein sequencing.
  • biological selection and screening was chosen as an alternative.
  • fusion phage * there are, however, several important limitations in using such "fusion phage * to identify altered peptides or proteins with new or enhanced binding properties.
  • prior art methods have been unable to select peptides from a library having the highest binding affinity for a target molecule.
  • Ladner WO 9002802 discloses a method for selecting novel binding proteins displayed on the outer surface of cells and viral particles where it is contemplated that the heterologous proteins may have up to 164 amino acid residues .
  • the method contemplates isolating and amplifying the displayed proteins to engineer a new family of binding proteins having desired affinity for a target molecule. More specifically, Ladner discloses a 'fusion phage * displaying proteins having 'initial protein binding domains' ranging from 46 residues (crambin) to 164 residues (T4 lysozyme) fused to the M13 gene III coat protein. Ladner teaches the use of proteins "no larger than necessary" because it is easier to arrange restriction sites in smaller amino acid sequences and prefers the 58 amino acid residue bovine pancreatic trypsin inhibitor (BPTI).
  • BPTI pancreatic trypsin inhibitor
  • BPTI small fusion proteins
  • T4 lysozyme small target molecules
  • small target molecules such as steroids
  • the preferred protein, BPTI is proposed to be fused to gene III at the site disclosed by Smith et al. or de la Cruz et al., J. Biol. Chem..263: 43184322 [1988], or to one of the terminii, along with a second synthetic copy of gene III so that "some" unaltered gene III protein will be present. Ladner does not address the problem of successfully panning high affinity peptides from the random peptide library which plagues the biological selection and screening methods of the prior ait
  • hGH Human growth hormone
  • hGH is a member of a family of homologous hormones that include placental Iactogens, prolactins, and other genetic and species variants or growth hormone (Nicoll, C. S., etal., (I986) Endocrine Reviews 7. 169). hGH is unusual among these in that it exhibits broad species specificity and binds to either the cloned somatogenic (Leung, D. W., etal., [I987] Nature 330. 537) or prolactin receptor (Boutin, J. M.,ef a/., [I988] Q ⁇ ⁇ 1 69).
  • the cloned gene for hGH has been expressed in a secreted form in Escherichia &U (Chang, C. N., et al., ⁇ Qs ⁇ s.55, 189) and its DNA and amino acid sequence has been reported (Goeddel, ef al., [I979] iE£ 2S1 544; Gray, et al., [I985] Gene 3J 247).
  • the three-dimensional structure of hGH is not available. However, the three-dimensional folding pattern for porcine growth hormone (pGH) has been reported at moderate resolution and refinement (Abdel-Meguid, S. S., etal., [1987] Proc. Natl. Acad. Sci. USA 84.
  • hGH Human growth hormone
  • It is another object of this invention to prepare candidate binding substances comprising fusion proteins of a phage coat protein and a heterologous polypeptide where the polypeptide is greater than 100 amino acids in length and may be more than one subunit and is displayed on a phagemid particle where the polypeptide is encoded by the phagemid genome.
  • Still another object of the invention is the production of growth hormone variants that exhibit stronger affinity for growth hormone receptor and binding protein.
  • a method for selecting novel binding poiypeptides comprising: (a) constructing a replicable expression vector comprising a first gene encoding a polypeptide, a second gene encoding at least a portion of a natural or wild-type phage coat protein wherein the first and second genes are heterologous, and a transcription regulatory element operabfy linked to the first and second genes, thereby forming a gene fusion encoding a fusion protein; (b) mutating the vector at one or more selected positions within the first gene thereby forming a family of related plasmids; (c) transforming suitable host cells with the plasmids; (d) infecting the transformed host cells with a helper phage having a gene encoding the phage coat protein; (e) culturing the transformed infected host cells under conditions suitable for forming recombinant phagemid particles containing at least a portion of the plasmid
  • the method for selecting novel binding proteins where the proteins are composed of more than one subunit is achieved by selecting novel binding peptides comprising constructing a replicable expression vector comprising a transcription regulatory element operabfy linked to DNA encoding a protein of interest containing one or more subunits, wherein the DNA encoding at least one of the subunits is fused to the DNA encoding at least a portion of a phage coat protein;mutating the DNA encoding the protein of interest at one or more selected positions thereby forming a family of related vectors; transforming suitable host cells with the vectors; infecting the transformed host cells with a helper phage having a gene encoding the phage coat protein; culturing the transformed infected host cells under conditions suitable for forming recombinant phagemid particles containing at least a portion of the plasmid and capable of transforming the host, the conditions adjusted so that no more than a minor amount of phagemid particles display more than one copy of the fusion protein on the
  • the plasmid is under tight control of the transcription regulatory element, and the culturing conditions are adjusted so that the amount or number of phagemid particles displaying more than one copy of the fusion protein on the surface of the particle is less than about 1 %. Also preferably, amount of phagemid particles displaying more than one copy of the fusion protein is less than 10% the amount of phagemid particles displaying a single copy of the fusion protein. Most preferably the amount is less than 20%.
  • the expression vector will further contain a secretory signal sequences fused to the DNA encoding each subunit of the polypeptide, and the transcription regulatory element will be a promoter system.
  • Preferred promoter systems are selected from; Lac Z, ⁇ p
  • the first gene will encode a mammalian protein, preferably the protein will be selected from; human growth hormone(hGH), N-methionyl human growth hormone, bovine growth hormone, parathyroid hormone, thyroxine, insulin A-chain, insulin B-chain, proinsulin, relaxin A-chain, relaxin B-chain, proretaxin, glycoprotein hormones such as follicle stimulating hormone(FSH), thyroid stimulating hormone(TSH), and leutinizing hormone(LH), glycoprotein hormone receptors, calcitonin, glucagon, factor VIII, an antibody, lung surfactant, urokinase, streptokinase, human tissue-type plasminogen activator (t-PA), bo besin, factor IX, thro bin, hemopoiet ' ic growth factor, tumor necrosis factor-alpha and -beta, enkephalinase, human serum albumin, mullerian-inhibiting substance, mouse gonadotropin-associated
  • the first gene will encode a polypeptide of one or more subunits containing more than about 100 amino acid residues and will be folded to form a plurality of rigid secondary structures displaying a plurality of amino acids capable of interacting with the target.
  • the first gene will be mutated at codons corresponding to only the amino acids capable of interacting with the target so that the integrity of the rigid secondary structures will be preserved.
  • helper phage selected from; 13K07, M13R408, M13-VCS, and Phi X 174.
  • the preferred helper phage is M13K07
  • the preferred coat protein is the M13 Phage gene III coat protein.
  • the preferred host is £ coli, and protease deficient strains of £ coli. Novel hGH variants selected by the method of the present invention have been detected.
  • Phagemid expression vectors were constructed that contain a suppressible termination codon functionally located between the nucleic acids encoding the polypeptide and the phage coat protein.
  • FIGURE 1 Strategy for displaying large proteins on the surface of filamentous phage and enriching for altered receptor binding properties.
  • a plasmid, phGH-M13glll was constructed that fuses the entire coding sequence of hGH to the carboxyl terminal domain of M13 gene III. Transcription of the fusion protein is under control of the lac promoter/operator sequence, and secretion is directed by the stll signal sequence.
  • Phagemid particles are produced by infection with the "helper * phage, M13K07, and particles displaying hGH can be enriched by binding to an affinity matrix containing the hGH receptor.
  • the wild-type gene III (derived from the M13K07 phage) is diagramed by 4-5 copies of the multiple arrows on the tip of the phage, and the fusion protein (derived from the phagemid, phGH-M13glll) is indicated schematically by the folding diagram of hGH replacing the arrowhead.
  • FIGURE 2 Immunoblot of whole phage particles shows that hGH comigrates with phage.
  • Phagemid particles purified in a cesium chloride gradient were loaded into duplicate wells and electrophoresed through a 1 % agarose gel in 375 M Tris, 40 mM glycine pH 9.6 buffer. The gel was soaked in transfer buffer (25 mM Tris, pH 8.3, 200 mM glycine, 20% methanol) containing 2% SDS and 2% ⁇ -mercaptoethanol for 2 hours, then rinsed in transfer buffer for 6 hours. The proteins in the gel were then electrobfotted onto immobilon membranes (Millipore).
  • the membrane containing one set of samples was stained with Coomassie blue to show the position of the phage proteins (A).
  • the duplicate membrane was immuno-stained for hGH by reacting the membrane with polyclonal rabbit anti-hGH antibodies followed by reaction with horseradish peroxidase conjugated goat anti- rabbit IgG antibodies (B).
  • Lane 1 contains the M13K07 parent phage and is visible only in the Coomassie blue stained membrane, since it lacks hGH.
  • Lanes 2 and 3 contain separate preparations of the hormone phagemid particles which is visible both by Coomassie and hGH immuno-staining.
  • the difference in migration distance between the parent M13K07 phage and hormone phagemid particles reflects the different size genomes that are packaged within (8.7 kb vs.5.1 kb, respectively).
  • FIGURE 3 Summary diagram of steps in the selection process for an hGH-phage library randomized at codons 172, 174, 176, and 178.
  • the template molecules, pH0415, containing a unique Kpnl restriction site and the hGH(R178G,H79T) gene was mutagenized as described in the text and electrofransformed into £ coli strain WJM101 to obtain the initial phagemid library, Library 1.
  • An aliquot (approximately 2%) from Library 1 was used directly in an initial selection round as described in the text to yield Library 1G.
  • dsDNA double-stranded DNA
  • Library I double-stranded DNA
  • Kpnl restriction enzyme
  • phagemid propagation were carried out as indicated by the arrows, according to the procedure described in the text.
  • Four independent clones from Library 4G 4 and four independent clones from Library 5G 6 were sequenced by dideoxy sequencing. All of these clones had the identical DNA sequence, corresponding to the hGH mutant (Glu 174 Ser, Phe 176 Tyr).
  • FIGURE 4 Structural model of hGH derived from a 2.8 A folding diagram of porcine growth hormone determined crystallographically. Location of residues in hGH that strongly modulate its binding to the hGH- binding protein are within the shaded circle. Alanine substitutions that cause a greater than tenfold reduction ⁇ ), a four- to tenfold reduction (•), or increase (O), or a two- to fourfold reduction (•), in binding affinity are indicated.
  • Helical wheel projections in the regions of ⁇ -helix reveal their amphipathic quality. Blackened, shaded, or nonshaded residues are charged, polar, or nonpolar, respectively. In helix-4 the most important residues for mutation are on the hydrophilic face.
  • FIGURE 5 Amino acid substitutions at positions 172, 174, 176 and 178 of hGH (The notation, e.g. KSYR, denotes hGH mutant 172K 174S/176Y/178R.) found after sequencing a number of clones from rounds 1 and 3 of the selection process for the pathways indicated (hGH elution; Glycine elution; or Glycine elution after pre-adsorption).
  • Non-functional sequences i.e. vector background, or other prematurely terminated and/or frame-shifted mutants
  • Functional sequences which contained a non-silent, spurious mutation i.e. outside the set of target residues
  • Protein sequences which appeared more than once among all the sequenced clones, but with different DNA sequences, are marked with a "#". Protein sequences which appeared more than once among the sequenced clones and with the same DNA sequence are marked with a "”. Note that after three rounds of selection, 2 different contaminating sequences were found; these clones did not correspond to cassette mutants, but to previously constructed hormone phage. The pS0643 contaminant corresponds to wild-type hGH-phage (hGH "KEFR").
  • the pH0457 contaminant which dominates the third- round glycine-selected pool of phage, corresponds to a previously identified mutant of hGH, "KSYR.”
  • K a previously identified mutant of hGH
  • the amplification of these contaminants emphasizes the ability of the hormone-phage selection process to select for rarely occurring mutants.
  • the convergence of sequences is also striking in all three pathways: R or K occurs most often at positions 172 and 178; Y or F occurs most often at position 176; and S, T, A, and other residues occur at position 174.
  • FIGURE 6 Sequences from phage selected on hPRLbp-beads in the presence of zinc. The notation is as described in Figure.5. Here, the convergence of sequences is not predictable, but there appears to be a bias towards hydrophobic sequences under the most stringent (Glycine) selection conditions; L ,W and P residues are frequently found in this pool.
  • FIGURE 7 Sequences from phage selected on hPRLbp-beads in the absence of zinc. The notation is as described in Figure 5. In contrast to the sequences of Figure.6, these sequences appear more hydrophilic. After 4 rounds of selection using hGH elution, two clones (ANHQ, and TLDT/171 V) dominate the pool.
  • FIGURE 8 Sequences from phage selected on blank beads. The notation is as described in Fig.5. After three rounds of selection with glycine elution, no siblings were observed and a background level of non-functional sequences remained.
  • FIGURE 9 Construction of phagemid fl ori from pH0415.
  • This vector for cassette mutagenesis and expression of the hGH-gene III fusion protein was constructed as follows. Plasmid pS0643 was constructed by oligonucleotide-directed mutagenesis of pS0132, which contains pBR322 and f1 origins of replication and expresses an hGH-gene III fusion protein (hGH residues 1-191, followed by a single Giy residue, fused to Pro-198 of gene III) under the control of the E. coli phoA promoter.
  • FIGURE 10 A. Diagram of plasmid pDH188 insert containing the DNA encoding the light chain and heavy chain (variable and constant domain 1 ) of the Fab humanized antibody directed to the HER-2 receptor.
  • _ and VH are the variable regions for the light and heavy chains, respectively.
  • is the constant region of the human kappa light chain.
  • CH1Q1 is the first constant region of the human gamma 1 chain. Both coding regions start with the bacterial st II signal sequence.
  • B A schematic diagram of the entire plasma pDH188 containing the insert described in 5A. After transformation of the plasmid into £ coli SR101 cells and the addition of helper phage, the plasmid is packaged into phage particles. Some of these particles display the Fab-p HI fusion (where p III is the protein encoded by the M13 gene III DNA). The segments in the plasmid figure correspond to the insert shown in5A.
  • FIGURE 11 A through C are collectively referred to here as Figure 11.
  • the amino acid sequence of the light chain is also shown (Seq. ID No.26), as is the amino acid sequence of the heavy chain p ill fusion (Seq. ID No. 27).
  • FIGURE 12 Enrichment of wild-type 4D5 F a b phagemid from variant F a b phagemid.
  • Mixtures of wild- type phagemid and variant 4D5 Fab phagemid in a ratio of 1 :1 ,000 were selected on plates coated with the extra- cellular domain protein of the HER-2 receptor. After each round of selection, a portion of the eluted phagemid were infected into £ coli and plasmid DNA was prepared. This plasmid DNA was then digested with Eco RV and Pst I, separated on a 5% polyacrylamide gel, and stained with ethidium bromide. The bands were visualized under UV light.
  • the bands due to the wild-type and variant plasmids are marked with arrows.
  • the first round of selection was eluted only under acid conditions; subsequent rounds were eluted with either an add elution (left side of Figure) or with a humanized 4D5 antibody wash step prior to acid elution (right side of Figure) using methods described in Example VIII.
  • H91 A amino acid histidine at position 91 on the V chain mutated to alanine; indicated as 'A' lanes in Figure
  • Y49A amino acid tyrosine at position 49 on the V chain mutated to alanine; indicated as 'B' lanes in the Figure
  • Y92A amino acid tyrosine at position 92 on the V chain mutated to alanine; indicated as "C lanes in the Figure.
  • Amino acid position numbering is according to Kabat et al.,(Sequences of proteins of immunological interest, 4th ed., U.S. Dept of Health and Human Services, Public Health Service, Nat'l. Institute of Health, Bethesda, MD [1987]).
  • FIGURE 13 The Scatchard analysis of the RIA affinity determination described in Experimental Protocols is shown here.
  • the amount of labeled ECD antigen that is bound is shown on the x-axis while the amount that is bound divided by the amount that is free is shown on the y-axis.
  • the slope of the line indicates the Ka; the calculated Kd is VK-, DETAILED DESCRIPTION OF THE INVENTION
  • the method of the instant invention comprises a method for selecting novel binding poiypeptides, such as protein ligands, having a desired, usually high, affinity for a target molecule from a library of structurally related binding poiypeptides.
  • the library of structurally related poiypeptides, fused to a phage coat protein, is produced by mutagenesis and, preferably, a single copy of each related polypeptide is displayed on the surface of a phagemid particle containing DNA encoding that polypeptide.
  • These phagemid particles are then contacted with a target molecule and those particles having the highest affinity for the target are separated from those of lower affinity.
  • the high affinity binders are then amplified by infection of a bacterial host and the competitive binding step is repeated. This process is reiterated until poiypeptides of the desired affinity are obtained.
  • novel binding poiypeptides or ligands produced by the method of this invention are useful per se as diagnostics or therapeutics (eg. agonists or antagonists) used in treatment of biological organisms. Structural analysis of the selected poiypeptides may also be used to facilitate rational drug design.
  • binding polypeptide as used herein is meant any polypeptide that binds with a selectable affinity to a target molecule.
  • the polypeptide will be a protein that most preferably contains more than about 100 amino acid residues.
  • the polypeptide will be a hormone or an antibody or a fragment thereof.
  • high affinity * as used herein is meant an affinity constant (Kd ) of ⁇ 10 "5 M and preferably ⁇ 10 "7 M under physiological conditions.
  • target molecule as used herein is meant any molecule, not necessarily a protein, for which it is desirable to produce a ligand.
  • the target will be a protein and most preferably the target will be a receptor, such as a hormone receptor.
  • humanized antibody as used herein is meant an antibody in which the complementarity-determining regions (CDRs) of a mouse or other non-human antibody are grafted onto a human antibody framework.
  • human antibody framework is meant the entire human antibody excluding the CDRs. L Choice of Pohmeptktes for Display on the Surface of a Phage
  • the first step in the method of this invention is to choose a polypeptide having rigid secondary structure exposed to the surface of the polypeptide for display on the surface of a phage.
  • polypeptide as used herein is meant any molecule whose expression can be directed by a specific DNA sequence.
  • the poiypeptides of this invention may comprise more than one subunit, where each subunit is encoded by a separate DNA sequence.
  • rigid secondary structure as used herein is meant any polypeptide segment exhibiting a regular repeated structure such as is found in; ⁇ -helices, 3 ⁇ o helices, ⁇ -helices, parallel and antiparallel ⁇ -sheets, and reverse turns.
  • Certain "non-ordered" structures that lack recognizable geometric order are also included in the definition of rigid secondary structure provided they form a domain or "patch" of amino acid residues capable of interaction with a target and that the overall shape of the structure is not destroyed by replacement of an amino acid within the structure . It is believed that some non-ordered structures are combinations of reverse turns.
  • the geometry of these rigid secondary structures is well defined by ⁇ and ⁇ torsional angles about the ⁇ -carbons of the peptide "backbone”.
  • the requirement that the secondary structure be exposed to the surface of the polypeptide is to provide a domain or 'patch' of amino acid residues that can be exposed to and bind with a target molecule. It is primarily these amino acid residues that are replaced by mutagenesis that form the 'library * of structurally related (mutant) binding poiypeptides that are displayed on the surface of the phage and from which novel polypeptide ligands are selected. Mutagenesis or replacement of amino acid residues directed toward the interior of the polypeptide is generally avoided so that the overall structure of the rigid secondary structure is preserved.
  • Example VIII phagemid selection of hGH was conducted in cycles.
  • amino acids 172, 174, 176 and 178 were mutated and phagemid selected.
  • amino acids 167, 171, 175 and 179 were phagemid selected.
  • hGH amino acids 10, 14, 18 and 21 were phagemid selected.
  • Optimum amino acid changes from a previous cycle may be incorporated into the polypeptide before the next cycle of selection. For example, hGH amino acids substitution 174 (serine) and 176 (tyrosine) were incorporated into the hGH before the phagemid selection of hGH amino acids 167, 171, 175 and 179.
  • the amino acid residues that form the binding domain of the polypeptide will not be sequentially linked and may reside on different subunits of the polypeptide. That is, the binding domain tracks with the particular secondary structure at the binding site and not the primary structure.
  • mutations will be introduced into codons encoding amino acids within a particular secondary structure at sites directed away from the interior of the polypeptide so that they will have the potential to interact with the target.
  • Figure 2 shows the location of residues in hGH that are known to strongly modulate its binding to the hGH-binding protein (Cunningham etal., Science 247:1461 - 1465 [1990]).
  • a glycoprotein hormone such as TSH can be chosen as a ligand for the FSH receptor and a library of mutant TSH molecules are employed in the method of this invention to produce novel drug candidates.
  • Preferred poiypeptides are those that have pharmaceutical utility. More preferred poiypeptides include; a growth hormone, including human growth hormone, des-N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroid stimulating hormone; thyroxine; insulin A-chain; insulin B-chain; proinsulin; follicle stimulating hormone; calcitonin; leutinizing hormone; glucagon; factor VIII; an antibody; lung surfactant; a plasminogen activator, such as urokinase or human tissue-type plasminogen activator (t-PA); bombesin; factor IX, thrombi ⁇ ; hemopoietic growth factor; tumor necrosis factor-alpha and -beta;enkephalinase; a serum albumin such as human serum albumin; mullerian-inhibiting substance; relaxin A-chain; relaxin B-chain
  • one or more predetermined amino acid residues on the polypeptide may be substituted, inserted, or deleted, for example, to produce products with improved biological properties.
  • fragments of these poiypeptides, especially biologically active fragments are included.
  • Yet more preferred poiypeptides of this invention are human growth hormone , and atrial naturetic peptides A, B, and C, endotoxin, subtilisin, trypsin and other serine proteases.
  • polypeptide hormones that can be defined as any amino acid sequence produced in a first cell that binds specifically to a receptor on the same cell type (autocrine hormones) or a second cell type (non-autocrine) and causes a physiological response characteristic of the receptor-bearing cell.
  • polypeptide hormones include cytokines, lymphokines, neurotrophic hormones and adenohypophyseal polypeptide hormones such as growth hormone, proJactin, placental lactogen, luteinizing hormone, follicle-stimulating hormone, thyrotropin, chorionic gonadotropin, cor ⁇ cotropin, ⁇ or ⁇ -melanocyte-stimulating hormone, ⁇ -iipotropin, ⁇ - lipotropin and the endorphins; hypothal ic release-inhibiting hormones such as corticotropin-release factor, growth hormone release-inhibiting hormone, growth hormone-release factor; and other polypeptide hormones such as atrial natriuretic peptides A, B or C.
  • cytokines fGene ii encoding the desired polvpeotide
  • the gene encoding the desired polypeptide i.e., a polypeptide with a rigid secondary structure
  • the DNA encoding the gene may be chemically synthesized (Merrfield, J. Am. Chem. Soc...85 2149 [1963]).
  • the sequence of the gene is not known, or if the gene has not previously been isolated, it may be cloned from a cDNA library (made from RNA obtained from a suitable tissue in which the desired gene is expressed) or from a suitable genomic DNA library.
  • probes include monoclonal or polyclonal antibodies (provided that the cDNA library is an expression library), oligonucleotides, and complementary or homologous cDNAs or fragments thereof.
  • the probes that may be used to isolate the gene of interest from genomic DNA libraries include cDNAs or fragments thereof that encode the same or a similar gene, homologous genomic DNAs or DNA fragments, and oligonucleotides. Screening the cDNA or genomic library with the selected probe is conducted using standard procedures as described in chapters 10-12 of Sambrook etal., supra.
  • PCR polymerase chain reaction methodology
  • Plasmid vectors are the preferred vectors for use herein, as they may be constructed with relative ease, and can be readily amplified. Plasmid vectors generally contain a variety of components including promoters, signal sequences, phenotypic selection genes, origin of replication sites, and other necessary components as are known to those of ordinary skill in tiie art.
  • Promoters most commonly used in prokaryotic vectors include the lac Z promoter system, the alkaline phosphatase ⁇ ⁇ ⁇ A promoter, the bacteriophage ⁇ PL promoter (a temperature sensitive promoter), the lac promoter (a hybrid irj_-J2£ promoter that is regulated by the lac repressor), the tryptophan promoter, and the bacteriophage T7 promoter.
  • the lac Z promoter system the alkaline phosphatase ⁇ ⁇ ⁇ A promoter
  • the bacteriophage ⁇ PL promoter a temperature sensitive promoter
  • the lac promoter a hybrid irj_-J2£ promoter that is regulated by the lac repressor
  • tryptophan promoter a hybrid irj_-J2£ promoter that is regulated by the lac repressor
  • the tryptophan promoter a hybrid irj_-J2£ promoter that is regulated by the lac repressor
  • Preferred promoters tor practicing this invention are those that can be tightly regulated such that expression of the fusion gene can be controlled. It is believed that the problem that went unrecognized in the prior art was that display of multiple copies of the fusion protein on the surface of the phagemid particle lead to multipoint attachment of the phagemid with the target It is believed this effect, referred to as the 'chelate effect", results in selection of false "high affinity" poiypeptides when multiple copies of the fusion protein are displayed on the phagemid particle in close proximity to one another so that the target was "chelated*. When multipoint attachment occurs, the effective or apparent Kd may be as high as the product of the individual Kds for each copy of the displayed fusion protein. This effect may be the reason Cwiria and coworkers supra were unable to separate moderate affinity peptides from higher affinity peptides.
  • Preferred promoters used to practice this invention are the lac Z promoter and the ⁇ ba A promoter.
  • the lac Z promoter is regulated by the lac repressor protein lac >. and thus transcription of the fusion gene can be controlled by manipulation of the level of the lac repressor protein.
  • the phagemid containing the lac Z promoter is grown in a cell strain that contains a copy of the lac i repressor gene, a repressor for the l2£ Z promoter.
  • Exemplary cell strains containing the laci gene include JM 101 and XL1-biue.
  • the host cell can be cotransfected with a plasmid containing both the repressor lac i and the lac Z promoter.
  • phagmide particles containing the lac Z promoter are grown in cell strains containing the lac i gene and the cell strains are cotransfected with a plasmid containing both the lac Z and lac i genes.
  • an inducer such as isopropylthiogalactoside (IPTG).
  • IPTG isopropylthiogalactoside
  • the number of fusion proteins per phagemid particle is about 0.1 (number of bulk fusion proteins number of phagemid particles).
  • the most preferred promoter used to practice this invention is ⁇ A. This promoter is believed to be regulated by the level of inorganic phosphate in the cell where the phosphate acts to down-regulate the activity of the promoter. Thus, by depleting cells of phosphate, the activity of the promoter can be increased. The desired result is achieved by growing cells in a phosphate enriched medium such as 2YT or LB thereby controlling the expression of the gene III fusion.
  • One other useful component of vectors used to practice this invention is a signal sequence.
  • This sequence is typically located immediately 5' to the gene encoding the fusion protein, and will thus be transcribed at the amino terminus of the fusion protein. However, in certain cases, the signal sequence has been demonstrated to be located at positions other 5' to the gene encoding the protein to be secreted. This sequence targets the protein to which it is attached across the inner membrane of the bacterial cell.
  • the DNA encoding the signal sequence may be obtained as a restriction endonuclease fragment from any gene encoding a protein that has a signal sequence.
  • Suitable prokaryotic signal sequences may be obtained from genes encoding, for example, LamB or OmpF (Wong etal., Gene.68:193 [1983]), MalE, PhoA and other genes.
  • a preferred prokaryotic signal sequence for practicing this invention is the £ coli heat-stable enterotoxin II (STII) signal sequence as described by Chang ef al. , Gene. 55: 189 [1987].
  • STII enterotoxin II
  • phenotypic selection genes are those encoding proteins that confer antibiotic resistance upon the host cell.
  • ampicillin resistance gene (amp) the ampicillin resistance gene (amp)
  • lei tetracycline resistance gene
  • Suitable vectors comprising the aforementioned components as well as the gene encoding the desired polypeptide (gene 1) are prepared using standard recombinant DNA procedures as described in Sambrook ef al. supra. Isolated DNA fragments to be combined to form the vector are cleaved, tailored, and ligated together in a specific order and orientation to generate the desired vector.
  • the DNA is cleaved using the appropriate restriction enzyme or enzymes in a suitable buffer.
  • a suitable buffer In general, about 0.2-1 ⁇ g of plasmid or DNA fragments is used with about 1-2 units of the appropriate restriction enzyme in about 20 ⁇ l of buffer solution.
  • Appropriate buffers, DNA concentrations, and incubation times and temperatures are specified by the manufacturers of the restriction enzymes. Generally, incubation times of about one or two hours at 37'C are adequate, although several enzymes require higher temperatures. After incubation, the enzymes and other contaminants are removed by extraction of the digestion solution with a mixture of phenol and chloroform, and the DNA is recovered from the aqueous fraction by precipitation with ethanol.
  • the ends of the DNA fragments must be compatible with each other. In some cases, the ends will be directly compatible after endonuclease digestion. However, it may be necessary to first convert the sticky ends commonly produced by endonuclease digestion to blunt ends to make them compatible for ligation. To blunt the ends, the DNA is treated in a suitable buffer for at least 15 minutes at 15'C with 10 units of of the Klenow fragment of DNA polymerase I (Klenow) in the presence of the four deoxynucleotide triphosphates. The DNA is then purified by phenol-chloroform extraction and ethanol precipitation.
  • the cleaved DNA fragments may be size-separated and selected using DNA gel electrophoresis.
  • the DNA may be electrophoresed through either an agarose or a polyacryiamide matrix. The selection of the matrix will depend on the size of the DNA fragments to be separated.
  • the DNA is extracted from the matrix by electroelution, or, if low-melting agarose has been used as the matrix, by melting the agarose and extracting the DNA from it, as described in sections 6.30-6.33 of Sambrook et al., supra.
  • the DNA fragments that are to be ligated together are put in solution in about equimolar amounts.
  • the solution will also contain ATP, ligase buffer and a ligase such as T4 DNA ligase at about 10 units per 0.5 ⁇ g of DNA.
  • the vector is at first linearized by cutting with the appropriate restriction endonuclease(s).
  • the linearized vector is then treated with alkaline phosphatase or calf intestinal phosphatase. The phosphatasing prevents seiHigation of the vector during the ligation step.
  • Prokaryotes are the preferred host cells for this invention.
  • Suitable prokaryotic host cells include £ coli strain JM101, £ coli K12 strain 294 (ATCC number 31,446), £ coli strain W3110 (ATCC number 27,325), £ coli X1776 (ATCC number 31, 537), E.coli XL-1 Blue (stratagene), and E coli B; however many other strains of £ coli, such as HB101, NM522, NM538, NM539, and many other species and genera of prokaryotes ma be used as well.
  • bacilli such as Bacillus subtilis.
  • enterobacteriaceae such as Salmonella typ mu ⁇ um or Serratia marasa ⁇ s, and various Pseudomonas species mayaii be used as hosts. Transformation of prokaryotic cells is readily accomplished using the calcium chloride method as described in section 1.82 of Sambrook et al., supra. Alternatively, electroporation (Neumann ef al., EMBO J.. 1:841 [1982]) may be used to transform these cells. The transformed cells are selected by growth on an antibiotic, commonly tetracycline (tet) or ampicillin (amp), to which they are rendered resistant due to the presence of tet and/or amp resistance genes on the vector.
  • an antibiotic commonly tetracycline (tet) or ampicillin (amp)
  • Plasmid DNA can be isolated using methods known in the art. Two suitable methods are the small scale preparation of DNA and the large-scale preparation of DNA as described in sections 1.25-1.33 of Sambrook et al, supra. The isolated DNA can be purified by methods known in the art such as that described in section 1.40 of Sambrook ef al., supra. This purified plasmid DNA is then analyzed by restriction mapping andor DNA sequencing. DNA sequencing is generally performed by either the method of Messing et al. Nucleic Acids Res..9 * 309 [1981] or by the method of Maxam etal. Meth. Enzymol..65: 499 [1980]. IV. ⁇ -rf.-.-* ⁇
  • This invention contemplates fusing the gene enclosing the desired polypeptide (gene 1 ) to a second gene (gene 2) such that a fusion protein is generated during transcription.
  • Gene 2 is typically a coat protein gene of a phage, and preferably it is the phage M13 gene III coat protein, or a fragment thereof. Fusion of genes 1 and 2 may be accomplished by inserting gene 2 into a particular site on a plasmid that contains gene 1 , or by inserting gene 1 into a particular site on a plasmid that contains gene 2.
  • Insertion of a gene into a plasmid requires that the plasmid be cut at the precise location that the gene is to be inserted. Thus, there must be a restriction endonuclease site at this location (preferably a unique site such that the plasmid will only be cut at a single location during restriction endonuclease digestion).
  • the plasmid is digested, phosphafased, and purified as described above.
  • the gene is then inserted into this linearized plasmid by ligating the two DNAs together. Ligation can be accomplished if the ends of the plasmid are compatible with the ends of the gene to be inserted.
  • the DNAs can be ligated together directly using a ligase such as bacteriophage T4 DNA ligase and incubating the mixture at 16'C for 14 hours in the presence of ATP and ligase buffer as described in section 1.68 of Sambrook et al., sucia. If the ends are not compatible, they must first be made blunt by using the Klenow fragment of DNA polymerase I or bacteriophage T4 DNA polymerase, both of which require the four deoxyribonucleotide triphosphates to fill-in overhanging single-stranded ends of the digested DNA.
  • a ligase such as bacteriophage T4 DNA ligase
  • the ends may be blunted using a nuclease such as nuclease S1 or mung-bean nuclease, both of which function by cutting back the overhanging single strands of DNA.
  • the DNA is then religated using a ligase as described above.
  • oligonucieotide linkers may be used. The linkers serve as a bridge to connect the plasmid to the gene to be inserted. These linkers can be made synthetically as double stranded or single stranded DNA using standard methods.
  • the linkers have one end that is compatible with the ends of the gene to be inserted; the linkers are first ligated to this gene using ligation methods described above.
  • the other end of the linkers is designed to be compatible with the plasmid for ligation.
  • care must be taken to not destroy the reading frame of the gene to be inserted or the reading frame of the gene contained on the plasmid.
  • it may be necessary to design the linkers such that they code for part of an amino acid, or such that they code for one or more amino acids.
  • termination codons are UAG( amber), UAA (ocher) and UGA (opel). (Microbiology, Davis et al. Harper & Row, New York, 1980, pages 237, 245-47 and 274).
  • the termination codon expressed in a wild type host cell results in the synthesis of the gene 1 protein product without the gene 2 protein attached.
  • growth in a suppressor host cell results in the synthesis of detectable quantities of fused protein.
  • Such suppressor host cells contain a tRNA modified to insert an amino acid in the termination codon position of the mRNA thereby resulting in production of detectible amounts of the fusion protein.
  • suppressor host cells are well known and described, such as E.coli suppressor strain (Bullock et al., BioTechniques 5, 376-379 [1987]). Any acceptable method may be used to place such a termination codon into the mRNA encoding the fusion polypeptide.
  • the suppressible codon may be inserted between the first gene encoding a polypeptide, and a second gene encoding at least a portion of a phage coat protein.
  • the suppressible termination codon may be inserted adjacent to the fusion site by replacing the last amino acid triplet in the polypeptide or the first amino acid in the phage coat protein.
  • the polypeptide When the phagemid is grown in a non-suppressor host cell, the polypeptide is synthesized substantially without fusion to the phage coat protein due to termination at the inserted suppressible triplet encoding UAG, UAA, or UGA. In the non-suppressor cell the polypeptide is synthesized and secreted from the host cell due to the absence of the fused phage coat protein which otherwise anchored it to the host cell. V. Alterationfmutatlon ⁇ of Gene 1 at Selected Positions
  • Gene 1 encoding the desired polypeptide, may be altered at one or more selected codons.
  • An alteration is defined as a substitution, deletion, or insertion of one or more codons in the gene encoding the polypeptide that results in a change in the amino acid sequence of the polypeptide as compared with the unaltered or native sequence of the same polypeptide.
  • the alterations will be by substitution of at least one amino acid with any other amino acid in one or more regions of the molecule.
  • the alterations may be produced be a variety of methods known in the art. These methods include but are not limited to oligonucieotide-mediated mutagenesis and cassette mutagenesis.
  • Oligonucleotide -mediated mutagenesis is preferred method for preparing substitution, deletion, and insertion variants of gene 1. This technique is well known in the art as described by Zoller et al. Nucleic Acids Res. j£: 6487-6504 [1987]. Briefly, gene 1 is altered by hybridizing an oligonucleotide encoding the desired mutation to a DNA template, where the template is the single-stranded form of the plasmid containing the unaltered or native DNA sequence of gene 1. After hybridization, a DNA polymerase is used to synthesize an entire second complementary strand of the template will thus incorporate the oligonucleotide primer, and will code for the selected alteration in gene 1.
  • oligonucleotides of at least 25 nucleotides in length are used.
  • An optimal oligonucleotide will have 12 to 15 nucleotides that are completely complementary to the template on either side of the nudeotide(s) coding for the mutation. This ensures that the oligonucleotide will hybridize properly to the single-stranded DNA template molecule.
  • the oligonucleotides are readily synthesized using techniques known in the art such as that described by Crea ef al. Proc. Natl. Acad. Sci. USA.75: 5765 [1978].
  • the DNA template can only be generated by those vectors that are either derived from bacteriophage M13 vectors (the commercially available M13mp18 and M13mp19 vectors are suitable), or those vectors that contain a single-stranded phage origin of replication as described by Viera etal. Meth. E ⁇ zvmoL 153: 3 [1987].
  • the DNA that is to be mutated must be inserted into one of these vectors in order to generate single- stranded template. Production of the single-stranded template is described in sections 4.214.41 of Sambrook etal., supra.
  • the oligonucleotide is hybridized to the single stranded template under suitable hybridization conditions.
  • a DNA polymerizing enzyme usually the Klenow fragment of DNA polymerase I, is then added to synthesize the complementary strand of the template using the oligonucleotide as a primer for synthesis.
  • a heteroduplex molecule is thus formed such that one strand of DNA encodes the mutated form of gene 1 , and the other strand (the original template) encodes the native, unaltered sequence of gene 1.
  • This heteroduplex molecule is then transformed into a suitable host cell, usually a prokaryote such as £ Coli JM101. After growing the cells, they are plated onto agarose plates and screened using the oligonucleotide primer radiolabelled with 32-Phosphate to identify the bacterial colonies that contain the mutated DNA.
  • the method described immediately above may be modified such that a homoduptex molecule is created wherein both strands of the plasmid contain the mutation(s).
  • the modifications are as follows:
  • the single- stranded oligonucleotide is annealed to the single-stranded template as described above.
  • a mixture of three deoxyribonucleotides, deoxyriboadenosine (dATP), deoxyriboguanosine (dGTP), and deoxyribothymidine (dTTP) is combined with a modified thio-deoxyribocytosine called dCTP-(aS) (which can be obtained from Amersham). This mixture is added to the template-oligonucleotide complex.
  • a strand of DNA identical to the template except for the mutated bases is generated.
  • this new strand of DNA will contain dCTP-(aS) instead of dCTP, which serves to protect it from restriction endonuclease digestion.
  • the template strand can be digested with Exolll nuclease or another appropriate nuclease past the region that contains the site(s) to be mutagenized. The reaction is then stopped to leave a molecule that is only partially single-stranded.
  • a complete double-stranded DNA homodupiex is then formed using DNA polymerase in the presence of all four deoxyribonucleotide triphosphates, ATP, and DNA ligase.
  • This homodupiex molecule can then be transformed into a suitable host cell such as £ coli JM101 , as described above.
  • Mutants with more than one amino acid to be substituted may be generated in one of several ways. If the amino acids are located close together in the polypeptide chain, they may be mutated simultaneously using one oligonucleotide that codes for all of the desired amino acid substitutions. If, however, the amino acids are located some distance from each other (separated by more than about ten amino acids), it is more difficult to generate a single oligonucleotide that encodes all of the desired changes. Instead, one of two alternative methods may be employed.
  • a separate oligonucleotide is generated for each amino acid to be substituted.
  • the oligonucleotides are then annealed to the single-stranded template DNA simultaneously, and the second strand of DNA that is synthesized from the template will encode all of the desired amino acid substitutions.
  • the alternative method involves two or more rounds of mutagenesis to produce the desired mutant.
  • the first round is as described for the single mutants: wild-type DNA is used for the template, an oligonucleotide encoding the first desired amino acid substitution(s) is annealed to this template, and the heteroduplex DNA molecule is then generated.
  • the second round of mutagenesis utilizes the mutated DNA produced in the first round of mutagenesis as the template.
  • this template already contains one or more mutations.
  • the oligonucleotide encoding the additional desired amino acid substitution(s) is then annealed to this template, and the resulting strand of DNA now encodes mutations from both the first and second rounds of mutagenesis.
  • This resultant DNA can be used as a template in a third round of mutagenesis, and so on.
  • This method is also a preferred method for preparing substitution, deletion, and insertion variants of gene l.
  • the method is based on that described by Wells ef al. Gene.34:315 [1985]..
  • the starting material is the plasmid (or other vector) comprising gene 1 , the gene to be mutated.
  • the codon(s) in gene 1 to be mutated are identified. There must be a unique restriction endonuclease site on each side of the identified mutation site(s). If no such restriction sites exist, they may be generated using the above-described oligonucleotide-mediated mutagenesis method to introduce them at appropriate locations in gene 1.
  • the plasmid is cut at these sites to linearize it.
  • a double-stranded oligonucleotide encoding the sequence of the DNA between the restriction sites but containing the desired mufation(s) is synthesized using standard procedures. The two strands are synthesized separately and then hybridized together using standard techniques.
  • This double-stranded oligonucleotide is referred to as the cassette.
  • This cassette is designed to have 3' and 5' ends that are compatible with t e ends of the linearized plasmid, such that it can be directly ligated to the plasmid.
  • This plasmid now contains the mufated DNA sequence of gene 1.
  • mis invention contemplates production of variants of a desired protein containing one or more subunits.
  • Each subunit is typically encoded by separate gene.
  • Each gene encoding each subunit can be obtained by methods known in the art (see, for example, Section II). In some instances, it may be necessary to obtain the gene encoding the various subunits using separate techniques selected from any of the methods described in Section II.
  • all subunits can be regulated by the same promoter, typically located 5' to the DNA encoding the subunits, or each may be regulated by separate promoter suitably oriented in the vector so that each promoter is operabfy linked to the DNA it is intended to regulate . Selection of promoters is carried out as described in Section III above.
  • Figure 10 In constructing a replicable expression vector containing DNA encoding the protein of interest having multiple subunits, the reader is referred to Figure 10 where, by way of illustration, a vector is diagrammed showing DNA encoding each subunit of an antibody fragment.
  • a vector is diagrammed showing DNA encoding each subunit of an antibody fragment.
  • This figure shows that generally, one of the subunits of the protein of interest will be fused to a phage coat protein such as M13 gene III. This gene fusion generally will contain its own signal sequence. A separate gene encodes the other subunit or subunits, and it is apparent that each subunit generally has its own signal sequence.
  • Figure 10 also shows that a single promoter can regulate the expression of both subunits. Alternatively, each subunit may be independently regulated by a different promoter.
  • the protein of interest subunit-phage coat protein fusion construct can be made as described in Section IV above.
  • DNA encoding each subunit in the vector may mutated in one or more positions in each subunit
  • preferred sites of mutagenesis correspond to codons encoding amino acid residues located in the complemenfarity-determining regions (CDR) of either the light chain, the heavy chain, or both chains.
  • CDRs are commonly referred to as the hypervariable regions.
  • Target proteins such as receptors
  • glycoprotein hormone receptors may be prepared by the technique described by McFarland etal., Science 245:494499 [1989], nonglycosylated forms expressed in £ co// are described by Fuh et al. J. Biol. Chem 265:3111-3115 [1990]
  • Other receptors can be prepared by standard methods.
  • the purified target protein may be attached to a suitable matrix such as agarose beads, acrylamide beads, glass beads, cellulose, various acrylic copolymers, hydroxylalkyi methacrylate gels, polyacrylic and polymethacryiic copolymers, nylon, neutral and ionic carriers, and the like. Attachment of the target protein to the matrix may be accomplished by methods described in Methods in Enzvmologv .44 [1976], or by other means known in the art.
  • the immobilized target is contacted with the library of phagemid particles under conditions suitable for binding of at least a portion of the phagemid particles with the immobilized target.
  • the conditions including pH, ionic strength, temperature and the like will mimic physiological conditions.
  • Binders Bound phagemid particles having high affinity for the immobilized target are separated from those having a low affinity (and thus do not bind to the target) by washing. Binders may be dissociated from the immobilized target by a variety of methods. These methods include competitive dissociation using the wild-type ligand, altering pH and/or ionic strength, and methods known in the art.
  • Suitable host cells are infected with the binders and helper phage, and the host cells are cultured under conditions suitable for amplification of the phagemid particles.
  • the phagemid particles are then collected and the selection process is repeated one or more times until binders having the desired affinity for the target molecule are selected.
  • the library of phagemid particles may be sequentially contacted with more than one immobilized target to improve selectivity for a particular target. For example, it is often the case that a ligand such as hGH has more than one natural receptor. In the case of hGH, both the growth hormone receptor and the prolactin receptor bind the hGH ligand.
  • hGH selectivity of hGH for the growth hormone receptor over the prolactin receptor. This can be achieved by first contacting the library of phagemid particles with immobilized prolactin receptor, eluting those with a low affinity (i.e. lower than wild type hGH) for the prolactin receptor and then contacting the low affinity prolactin 'binders * or non-binders with the immobilized growth hormone receptor, and selecting for high affinity growth hormone receptor binders. In this case an hGH mutant having a lower affinity for the prolactin receptor would have therapeutic utility even if the affinity for the growth hormone receptor were somewhat lower than that of wild type hGH. This same strategy may be employed to improve selectivity of a particular hormone or protein for its primary function receptor over its clearance receptor.
  • an improved substrate amino acid sequence can be obtained. These may be useful for making better 'cut sites' for protein linkers, or for better protease substrates/inhibitors.
  • an immobiiizabie molecule e.g. hGH-receptor, biotin-avidin, or one capable of covalent linkage with a matrix
  • the linker will preferably be from 3 to 10 amino acids in length and will act as a substrate for a protease.
  • a phagemid will be constructed as described above where the DNA encoding the linker region is randomly mutated to produce a randomized library of phagemid particles with different amino acid sequences at the linking site.
  • the library cf phagemid particles are then immobilized on a matrix and exposed to a desired protease.
  • Phagemid particles having preferred or better substrate amino add sequences in the liner region for the desired protease will be eluted, first producing an enriched pool of phagemid partides encoding preferred linkers. These phagemid partides are then cyded several more times to produce an enriched pool of particles encoding consense sequence(s) (see examples XIII and XIV).
  • Gi-owthHoiroreVartai-teandMel- ⁇ The cloned gene for hGH has been expressed in a secreted form in Eschericha cola (Chang, C. N>, et al.,
  • the present invention describes novel hGH variants produced using the phagemid selection methods. Human growth hormone variants containing substitutions at positions 10, 14, 18, 21 , 167, 171, 172, 174, 175, 176, 178 and 179 have been described. Those having higher binding affinities are described in Tables VII, XIII and XIV. The amino acid nomenclature for describing the variants is shown below. Growth hormone variants may be administered and formulated in the same manner as regular growth hormone. The growth hormone variants of the present invention may be expressed in any recombinant system which is capable of expressing native or met hGH.
  • Therapeutic formulations of hGH for therapeutic administration are prepared for storage by mixing hGH having the desired degree of purity with optional physiologically acceptable carriers, excipients, or stabilizers (Remington's Pharmaceutical Sdences. 16th edition, Osol, A., Ed., (1980)., in the form of lyophilized cake or aqueous solutions.
  • Acceptable carriers, excipients or stabilizers are nontoxic to redpients at the dosages and concentrations employed, and indude buffers such as phosphate, citrate, and other organic adds; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) poiypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as pdyvinytpyrrolidone; amino adds such as glydne, glufamine, asparagine, arginine, or iysine; monosaccharides, disaccharides, and other carbohydrates induding glucose, mannose, or dextrins; chelating agents such as EDTA; divalent metal ions such as zinc, cobalt or copper; sugar alcohols such as marmitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween, Pluronics or polyethylene glycol
  • Formulations of the present invention may additionally contain a pharmaceutically acceptable buffer, amino add, bulking agent and/or non-ionic surfactant These include, for example, buffers, chelating agents, antioxidants, preservatives, cosolvents, and the like; specific examples of these could indude, bimethylamaine salts (Tris buffer”), and disodiu edetate.
  • the phagemids of the present invention may be used to produce quantities of the hGH variants free of the phage protein.
  • pS0643 and derivatives can simply be grown in a non- suppressor strain such as 16C9. In this case, the amber codon (TAG) leads to termination of translation, which yields free hormone, without the need for an independent DNA construction.
  • the hGH variant is secreted from the host and may be isolated from the culture medium.
  • One or more of the eight hGH amino adds F10, M14, H18, H21, R167, D171,T175 and 1179 may bereped by any amino add other than the one found in that position in naturally occurring hGH as indicated. Therefore, 1 , 2, 3, 4, 5, 6,7, or all 8 of the indicated amino adds, F10, M14, H18, H21, R167, D171, T175 and 1179, maybe replaced by any of the other 19 amino acids out of the 20 amino acids listed below. In apreferred embodiment all eight listed amino acids are replaced by another amino acid. The most preferred eight amino acids to be substituted are indicated in Table XIV in Example XII. Airtno add nomenclature.
  • phGH-M13glll The plasmid phGH-M13glll (Fig. 1), was constructed from M13K07 7 and the hGH producing plasmid, pB0473 (Cunningham, B. C, etal. , Science.243:1330-1336, [1989]).
  • a synthetic oligonucleotide 5'-AGC- TGT-GGC-TTC-GGG-CCC-TTA-GCA-TTT-AAT-GCG-GTA-3' was used to introduce a unique Apal restriction site (underlined) into pB0473 after the final Phe191 codon of hGH.
  • the oligonudeotide 5'-TTC- ACA-AAC-GAA-GGG-CCC-CTA-ATT-AAA-GCC-AGA-3' was used to introduce a unique Apa ⁇ restriction site (underlined), and a Glu197-to-amber stop codon (bold lettering) into M13K07 gene III.
  • the oligonudeotide 5'- CAA-TAA-TAA-CGG-GCT-AGC-CAA-AAG-AAC-TGG-3' introduces a unique Nhe ⁇ site (underlined) after the 3' end of the gene III coding sequence.
  • the resulting 650 base pair (bp) Apa ⁇ -Nhe ⁇ fragment from the doubly mutated M13K07 gene III was cloned into the large Apa ⁇ -Nne ⁇ fragment of pB0473 to create the plasmid, pS0132.
  • This fuses the carboxyl terminus of hGH (Phe191) to the Pro198 residue of the gene III protein with the insertion of a glydne residue encoded from the Apal site and places the fusion protein under control of the £ coli alkaline phosphatase (pft ⁇ A) promoter and stll secretion signal sequence (Chang, C. N., etal. , Q ⁇ , 55:189-196, [1987]).
  • the R64A variant hGH phagemid was constructed as follows: the Nsil-Bglll mutated fragment of hGH (Cu ⁇ ninghamef at supra ) encoding the Arg64 to Ala substitution (R64A) (Cunningham, B. C, Wells, J. A.. Sde ⁇ ce.244:1081-1085. [1989]) was cloned between the corresponding restriction sites in the phGH-M13glll plasmid (Rg. 1) to replace the wild-type hGH sequence.
  • the R64A hGH phagemid partides were propagated and titered as described below for the wild-type hGH-phagemid.
  • Plasmids were transformed into a male strain of £ coli (JM 101) and selected on carbenidllin plates. A single transformant was grown in 2 ml 2YT medium for 4 h at 37'C and infected with 50 ⁇ l of M13K07 helper phage. The infected culture was diluted into 30 ml 2YT, grown overnight and phagemid partides were harvested by predpitation with polyethylene glycol (Vierra, J., Messing, J..Methods in Enzymology.153:3-11, [1987]). Typical phagemid ought ranged from 2 to 5 x 10 11 cfu/ml.
  • hGH or hGH-phagemid partides were serially diluted from 2.0 - 0.002 nM in buffer A (50 mM Tris (pH 7.5), 50 mM NaCl, 2 mM EDTA, 5 mg/ml bovine serum albumin, and 0.05% Tween 20). After 2 hours at room temperature (rt), the plates were washed well and the indicated Mab (Cun ⁇ inghamef a/, supra ) was added at 1 ⁇ g/ml in buffer A for 2 hours at rt. Following washing, horseradish peroxidase conjugated goat anti-mouse IgG antibody was bound at rt for 1 hour. After a final wash, the peroxidase activity was assayed with the substrate, ⁇ -phe ⁇ yienediamine. EXAMPLE 111
  • Oxirane polyacrylamide beads (Sigma) were conjugated to the purified extracellular domain of the hGH receptor (hGHbp) (Fuh, G., etal., J. Biol. Chem.. 265:3111-3115 [1990]) containing an extra cysteine residue introduced by site-directed mutagenesis at position 237 that does not affect binding of hGH (J. Wells, unpublished).
  • the hGHbp was conjugated as recommended by the supplier to a level of 1.7 pmol hGHbp/mg dry oxirane bead, as measured by binding of [ 125 l] hGH to the resin. Subsequently, any unreacted oxirane groups were blocked with BSA and Tris. As a control for non-spedfic binding of phagemid partides, BSA was similarly coupled to the beads. Buffer for adsorption and washing contained 10 mM Tris-HCI (pH 7.5), 1 mM EDTA, 50 mM NaCl, 1 mg/ml BSA, and 0.02% Tween 20.
  • Elution buffers contained wash buffer plus 200 nM hGH or 0.2 M glydne (pH 2.1).
  • Parental phage M13K07 was mixed with hGH phagemid particles at a ratio of nearly 3000:1 (original mixture) and tumbled for 8-12 h with a 5 ⁇ l aliquot (0.2 mg of acrylamide beads) of either absorbent in 50 ⁇ l volume at room temperature.
  • the beads were pelleted by centrifugation and the supernate carefully removed. The beads were resuspended in 200 ⁇ l wash buffer and tumbled at room temperature for 4 hours (wash 1).
  • wash 2 After a second wash (wash 2), the beads were eluted twice with 200 nM hGH for 6-10 hours each (eluate 1 , eluate 2). The final elution was with a glydne buffer (pH 2.1) for 4 hours to remove remaining hGH phagemid partides (eluate 3). Each fraction was diluted appropriately in 2YT media, mixed with fresh JM101, incubated at 37'C for 5 minutes, and plated with 3 ml of 2YT soft agar on LB or LB carbenicillin plates.
  • the gene III protein is composed of 410 residues divided into two domains that are separated by a flexible linker sequence (Armstrong, J., etal., FEBS Lett..135:167-172, [1981]).
  • the amino-terminal domain is required for attachment to the pili of £ coli, while the carboxyl-terminal domain is imbedded in the phage coat and required for proper phage assembly (Crissman, J. W., Smith, G. P., Virology. 132:445455, [1984]).
  • the signal sequence and amino-terminal domain of gene III was replaced with the stll signal and entire hGH gene (Chang et al.
  • hGH-gene III fusion was placed under control of the lac promoter/operator in a plasmid (phGH-M13glll; Fig. 1) containing the pBR322 ⁇ -lactamase gene and Col E1 replication origin, and the phage f 1 intergenic region.
  • the vector can be easily maintained as a small plasmid vector by selection on carbeni iiin, which avoids relying on a functional gene III fusion for propagation.
  • the plasmid can be efficiently packaged into virions (called phagemid partides) by infection with helper phage such as M13K07 (Viera etal.. supra ) which avoids problems of phage assembly.
  • helper phage such as M13K07 (Viera etal.. supra ) which avoids problems of phage assembly.
  • Phagemid infectivity titers based upon transduction to carbenidiiin resistance in this system varied from 2-5 x 10 1 colony forming units (cfuVml.
  • the titer of the M13K07 helper phage in these phagemid stocks is ⁇ 10 1 ⁇ plaque forming units (pfu)/ml.
  • the titer of fusion phage displaying the hGH gene III fusion is about 2 - 5 x 10 1 0/ml. This number is much greater than the titer of £ coli (-10 8 to 10 9 /ml) in the culture from which they are derived. Thus, on average every £ coli cell produces 10-100 copies of phage decorated with an hGH gene III fusion protein.
  • Beads Provides an Enrichment for hGH-phage over M13K07 Phage*
  • ⁇ E ⁇ richments are calculated by dividing the cfu/pfu ratio after each step by cfu/pfu ratio in the original mixture.
  • a fusion phagemid was constructed with an hGH mutant in which Arg64 was substituted with Ala (R64A).
  • the R64A variant hormone is about 20- fold reduced in receptor binding affinity compared to hGH (Kd values of 7.1 nM and 0.34 nM, respectively
  • the titers of the R64A hGH-gene III fusion phagemid were comparable to those of wild-type hGH phagemid. After one round of binding and elution (Table III) the wild-type hGH phagemid was enriched from a mixture of the two phagemids plus M13K07 by 8-fold relative to the phagemid R64A, and ⁇ 10 4 relative to M13K07 helper phage.
  • hGHbp beads as described in Table II and the Materials and Methods After each step, plasmid DNA was isolated(Birnboim, H. C, Doty, J. , Nucleic Adds Res..7:1513-1523, [1979]) from carbenidiiin resistant colonies and analyzed by restriction analysis to determine if it contained the wild-type hGH or the R64A hGH gene ill fusion. TThe enrichment for wild-type hGH phagemid over R64A mutant was calculated from the ratio of hGH phagemid present after each step to that present in the original mixture (8/20), divided by the corresponding ratio for
  • a mutant of the hGH-gene III fusion protein was constructed using the method of KunkeL.ef al. Meth. Enzymol.154, 367-382 [1987].
  • Template DNA was prepared by growing the plasmid pS0132 (containing the natural hGH gene fused to the carboxy-terminal half of M13 gene III, under control of the alkaline phosphatase promoter) in CJ236 cells with M13-K07 phage added as helper.
  • Single-stranded, uradl-containing DNA was prepared for mutagenesis to introduce (1 ) a mutation in hGH which would greatly reduce binding to the hGH binding protein (hGHbp); and (2) a unique restriction site (Kpnl) which could be used for assaying for ⁇ and selecting against - parental background phage.
  • Oligonudeotide-directed mutagenesis was carried out using T7 DNA polymerase and the following oligodeoxy-nucieotide:
  • This oligo introduces the Kpnl site as shown, along with mutations (R178G, I179T) in hGH. These mutations are predicted to reduce binding of hGH to hGHbp by more than 30-fold.
  • Clones from the mutagenesis were screened by Kpnl digestion and confirmed by dideoxy DNA sequendng. The resulting construct, to be used as a template for random mutagenesis, was designated pH0415.
  • Codons 172, 174, 176, 178 were targeted for random mutagenesis in hGH, again using the method of
  • NPS random codons
  • Propagation of the Initial library The mutagenesis products were extracted twice with phenolxhloroform (50:50) and ethanol predpitated with an excess of carrier tRNA to avoid adding salt that would confound the subsequent electroporation step.
  • dsDNA double-stranded DNA
  • phage pool ⁇ 1 The supernatant was spun again to remove any remaining cells, and the phage, designated phage pool ⁇ 1 , were PEG-predpitated and resuspended in 1 mL STE buffer (10 mM Tris, pH 7.6, 1 mM EDTA, 50 mM NaCl). Phage titers were measured as colony-forming units (CFU) for the recombinant phagemid containing hGH-g3p gene III fusion (hGH-g 3 ) plasmid, and plaque-forming units (PFU) for the M13-K07 helper phage.
  • CFU colony-forming units
  • BINDING An aliquot of phage pool ⁇ j>1 (6 x 10 9 CFU, 6 x 10 7 PFU) was diluted 4.5-fold in buffer A (Phosphate-buffered saline, 0.5% BSA, 0.05% Twee ⁇ -20, 0.01% thimerosal) and mixed with a 5 ⁇ L suspension of oxirane-polyacrylamide beads coupled to the hGHbp containing a Ser237 Cys mutation (350 fmols) in a 1.5 mL silated polypropylene tube.
  • buffer A Phosphate-buffered saline, 0.5% BSA, 0.05% Twee ⁇ -20, 0.01% thimerosal
  • an equivalent aliquot of phage were mixed in a separate tube with beads that had been coated with BSA only.
  • the phage were allowed to bind to the beads by incubating 3 hours at room temperature (23°C) with slow rotation (approximately 7 RPM). Sub
  • hGH ELUTION Phage/phagemid binding weakly to the beads were removed by stepwise elution with hGH. In the first step, the beads were rotated with buffer A containing 2 nM hGH. After 17 hours , the beads were pelleted and resuspended in buffer A containing 20 nM hGH and rotated for 3 hours, then pelleted. In the final hGH wash, the beads were suspended in buffer A containing 200 nM hGH and rotated for 3 hours then pelleted.
  • GLYCINE ELUTION To remove the tightest-binding phagemid (i.e. those still bound after the hGH washes), beads were suspended in Glydne buffer (1 M.Gtydne, pH 2.0 with HCl), rotated 2 hours and pelleted. The supernatant (fraction "G"; 200 ⁇ L) was neutralized by adding 30 ⁇ L of 1 M Tris base. Fraction G eluted from the hGHbp-beads (1 x 10 6 CFU, 5 x 10 4 PFU) was not substantially enriched for phagemid over K07 helper phage.
  • PROPAGATION An aliquot (4.3 x 10 5 CFU) of fraction G eluted from the hGHbp-beads was used to Infect log-phase WJM101 cells. Transductions were carried out by mixing 100 ⁇ L fraction G with 1 mL WJM101 cells, incubating 20 min. at 37°C, then adding K07 (multiplicity of infection- *** 1000). Cultures (25 mL 2YT plus carbenidiiin) were grown as described above and the second pool of phage (Library 1G, for first glydne elution) were prepared as described above.
  • Phage from library 1 G (Fig.3) were selected for binding to hGHbp beads as described above. Fraction G eluted from hGHbp beads contained 30 times as many CFU's as fraction G eluted from BSA-beads in this selection. Again, an aliquot of fraction G was propagated in WJM101 cells to yield library 1G 2 (indicating that this library had been twice selected by glydne elution). Double-stranded DNA (pLIB 1G 2 ) was also prepared from this culture.
  • Kpnl assay and restriction-selection of dsDNA To reduce the level of background (Kpnl *1* ) template, an aliquot (about 0.5 ⁇ g) of pLIB 1 G 2 was digested with Kpnl and electroporated into WJM101 cells. These cells were grown in the presence of K07 (multiplicity of infection ⁇ 100) as described for the initial library, and a new phage pool, pLIB 3, was prepared (Fig. 3).
  • phage Library 2 (Fig.3). Successive rounds of selection
  • Phagemid binding, elution, and propagation were carried out in successive rounds for phagemid derived from both pLIB 2 and pLIB 3 (Fig.3) as described above, except that (1) an excess (10-fold over CFU) of purified K07 phage (not displaying hGH) was added in the bead-binding cocktail, and (2) the hGH stepwise elutions were replaced with brief washings of buffer A alone. Also, in some cases, XL1 -Blue cells were used for phagemid propagation.
  • hGH codon 172 174 176 178 5' -AAG GTC TCC ACA TAC CTG AGG ATC-3'
  • Residue 172 in these clones is Lys as in wild- type.
  • the codon selected for 172 is also identical to wild-type hGH. This is not surprising since AAG is the only lysine-codon possible from a degenerate "NNS" codon set.
  • Residue 178-Arg is also the same as wild-type, but here, the codon selected from the library was AAG instead of CGC as is found in wild-type hGH, even though the latter codon is also possible using the "N NS" codon set. Multiplicity of K07 Infection
  • the multiplidty of infection of K07 infection is an important parameter in the propagation of recombinant phagemids.
  • the K07 multiplidty of infection must be high enough to insure that virtually all cells transformed or transfected with phagemid are able to package new phagemid partides.
  • the concentration of wild-type gene III in each cell should be kept high to reduce the possibility of multiple hGH-gene III fusion molecules being displayed on each phagemid moussee, thereby redudng chelate effects in binding.
  • the K07 multiplidty of infection is too high, the packaging of K07 will compete with that of recombinant phagemid. We find that acceptable phagemid yields, with only 1 -10% background K07 phage, are obtained when the K07 multiplidty of infection is 100.
  • Phage pools are labelled as shown (Rg.3).
  • the multiplidty of infection (moi) refers to the multiplidty of K07 infection (PFU/cells) in the propagation of phagemid.
  • the enrichment of CFU over PFU is shown in those cases where purified K07 was added in the binding step.
  • the ratio of CFU eluting from hGHbp-beads over CFU eluting from BSA-beads is shown.
  • the fraction of Kpnl-containi ⁇ g template (i.e., pH0415) remaining in the pool was determined by digesting dsDNA with Kpnl plus EcoRl, running the products on a 1 % agarose gel, and laser- scanning a negative of the ethidium bromide-stained DNA. Receotor-blndinq affinity of the hormone hGH(E174S. F176Y) The fact that a single done was isolated from two different pathways of selection (Rg.3) suggested that the double mutant (E174S.F176Y) binds strongly to hGHbp.
  • this mutant of hGH by site-directed mutagenesis, using a plasmid (pB0720) which contains the wild-type hGH gene as template and the following oligonucleotide which changes codons 174 and 176 : hGH codon: 172 174 176 178 Lys Ser Tyr Arg 5'- ATG GAC AAG GT.1£G ACA T C CTG CGC ATC GTG -3'
  • Human growth hormone variants were produced by the method of the present invention using the phagemid described in figure 9.
  • Plasmid pS0643 was constructed by oligonudeotide-directed mutagenesis (Kunkel et at, Methods
  • pS0643 and derivatives can be grown in a amber- suppressor strain of E. coli. such as JM101 or XL1-Blue (Bullock et al., BioTechniques 5, 376-379 [1987]). Shown above is substitution of Glu at the amber codon which occurs in supE suppressor strains. Suppression with other amino acids is also possible in various available strains of E. coli well known and publically available.
  • pS0643 and derivatives can simply be grown in a non-suppressor strain such as 16C9.
  • the amber codon (TAG) leads to termination of translation, which yields free hormone, without the need for an independent DNA construction.
  • pS0643 was mufated with the oiigonudeotides (1) 5'-CGG- ACT-GGG-CAG-ATA-TTC-AAG-CAG-ACC-3'. which destroys the unique fipjj] site of pS0643; (2) 5'-CTC- AAG-AAC-TAC-GGG-TTA-CCC-TGA-CTG-CTT-CAG-GAA-GG-3'.
  • the BstEII - fifllll segment is cut out of pH0509 and replaced with a DNA cassette, mutated at the codons of interest
  • Other restriction sites for cassette mutagenesis at other locations in hGH have also been introduced into the hor one-phage vector.
  • CassettemutaoenesiswithInhelix4ofhGH Codons 172, 174, 176 and 178 of hGH were targeted for random mutagenesis because they all lie on or near the surface of hGH and contribute significantly to receptor-binding (Cunningham and Wells. Science 244. 1081-1085 [1989]); they all lie within a well-defined structure, occupying 2 turns' on the same side of helix 4; and they are each substituted by at least one amino add among known evolutionary variants of hGH.
  • TAG amber
  • the vector was prepared by digesting pH0509 with BstEII followed by Bglll. The products were run on a 1 % agarose gel and the large fragment exdsed, phenol-extracted, and ethanol predpitated. This fragment was treated with calf intestinal phosphatase (Boehringer), then phenolxhloroform extracted, ethanol predpitated, and resuspended for ligation with the mutagenic cassette.
  • reaction products were again digested with BstEII. then phenol -chloroform extracted, ethanol precipitated and resuspended in water.
  • a BstEjll recognition site (GGTNACC) is created within cassettes which contain a Q. at position 3 of codon 172 and an A££ (Thr) codon at 174.
  • dsDNA double-stranded DNA
  • phage pool ⁇ H0529E the initial library of phage
  • Phage titers were measured as colony-forming units (CFU) for the recombinant phagemid containing hGH-g3p. Approximately 4.5 x 10 13 CFU were obtained from the starting library. Degeneracy of the starting library
  • Codon distribution (per 188 codons) of non-selected hormone phage. Clones were sequenced from the starting library (pH0529E). All codons were tabulated, induding those from dones which contained spurious mutations and/or frameshifts. * Note: the amber stop codon (TAG) is suppressed as Glu in XL1-Blue cells. Highlighted codons were over/under-represented by 50% or more.
  • Non-selected dones with an open reading frame.
  • the notation e.g.TWGS, denotes the hGH mutant 172T/174W/176G/178S.
  • Amber (TAG) codons translated as Glu in XL1 -Blue cells are shown as ⁇ .
  • hGHbp-beads * Immobilized hGHbp
  • Bass et at, Proteins 8. 309-31 [1990] was prepared as described (Bass et at, Proteins 8. 309-31 [1990]), except that wild-type hGHbp (Fuh et al., J. Biol. Chem. 265, 3111-3115 [1990]) was used.
  • hPRLbp-beads Immobilized hPRLbp
  • hPRLbp-beads was prepared as above, using the 211 -residue extracellular domain of the prolactin receptor (Cunningham et at, Science 250.1709-1712 [1990]).
  • Buffer A PBS, 0.5% BSA, 0.05% Tween 20, 0.01% ttiimerosal
  • Buffer B 50 mM tris pH 7.5, 10 mM MgCfe 0.5% BSA, 0.05% Tween 20, 100 mM ZnCfe
  • Buffer C PBS, 0.5% BSA, 0.05% Tween 20, 0.01% thimerosal. 10 mM EDTA) for selections using hPRLbp in the absence of zinc (+ EDTA).
  • Binding selections were carried out according to each of the following paths: (1) binding to blank beads, (2) binding to hGHbp-beads, (3) binding to hPRLbp-beads (+ Zn 2+ ), (4) binding to hPRLbp-beads (+ EDTA), (5) pre-adsorbing twice with hGHbp beads then binding the non-adsorbed fraction to hPRLbp-beads
  • BINDING An aliquot of hormone phage (typically 10 9 -10 t0 CFU) was mixed with an equal amount of non-hormone phage (pCAT), diluted into the appropriate buffer (A, B, or C), and mixed with a 10 mL suspension of hGHbp, hPRLbp or blank beads in a total volume of 200mL in a 1.5 L polypropylene tube. The phage were allowed to bind to the beads by incubating 1 hour at room temperature (23°C) with slow rotation (approximately 7 RPM). Subsequent steps were carried out with a constant volume of 200 ⁇ L and at room temperature.
  • pCAT non-hormone phage
  • WASHES The beads were spun 15 sec, and the supernatant was removed. To reduce the number of phage not spedfically bound, the beads were washed 5 times by resuspending briefly in the appropriate buffer, then pelleting.
  • hGH ELUTION Phage binding weakly to the beads were removed by elution with hGH. The beads were rotated with the appropriate buffer containing 400 nMJiGH for 15-17 hours. The supernatant was saved as the 'hGH elution" and the beads. The beads were washed by resuspending briefly in buffer and pelleting. 4. GLYCINE ELUTION: To remove the tightest-binding phage (i.e. those still bound after the hGH wash), beads were suspended in Glydne buffer (Buffer A plus 0.2 J ⁇ Glydne, pH 2.0 with HCl), rotated 1 hour and pelleted. The supernatant ("Glydne elution"; 200 ⁇ L) was neutralized by adding 30 mL of 1 M Tris base and stored at 4° C.
  • PROPAGATION Aliquots from the hGH elutions and from the Glydne elutions from each set of beads under each set of conditions were used to infect separate cultures of log-phase XL1 -Blue cells.
  • Phage binding, elution, and propagation were carried out in successive rounds, according to the cyde described above.
  • the phage amplified from the hGH elution from hGHbp-beads were again selected on hGHbp-beads and eluted with hGH, then used to infect a new culture of XL1-Blue cells.
  • Three to five rounds of selection and propagation were carried out for each of the selection procedures described above.
  • Mutants of hGH were prepared from osmoticaily shocked cells by ammonium sulfate precipitation as described for hGH (Olson et at, Nature 293, 408-411 [1981]), and protein concentrations were measured by laser densitomoetry of Coomassie-sfained SDS-polyacrylamide gel electrophoresis gels, using hGH as standard (Cunningham and Wells. Science 244. 1081-1085 [1989]). The binding affinity of each mutant was determined by displacement of 125 1 hGH as described (Spencer et al., J. Biol. Chem.263, 7862-7867 [1988] ; Fuh et al., J. Biol. Chem.265, 3111-3115 [1990]), using an anti- receptor monodonal antibody (Mab263).
  • Binding assays may be carried out for mutants selected for hPRLbp-binding.
  • the selected pool in which each mufant was found is indicated as 1 G (first glydne selection), 3G (third glycine selection), 3H (third hGH selection), 3 * (ttiird selection, not binding to hPRLbp, but binding to hGHbp).
  • substitution of a particular amino add has essentially the same effect independent of 0 surrounding residues.
  • substitution of F176Y in the background of 172R/174S reduces binding affinity by 2.0-fold (RSFR vs. RSYR).
  • the binding affinity of the F176Y mutant (KAYR) is 2.9-fold weaker than the corresponding 176F mutant (KAFR; Cunningham and Wells, 1989).
  • the binding constants determined for several selected mutants of hGH demonstrate non-additive effects of some amino add substitutions at residues 172, 174, 176, and 178.
  • Example VIII Using the methods described in Example VIII, we targeted another region of hGH involved in binding to the hGHbp and/or hPRLbp, helix 1 residues 10, 14, 18, 21, for random mutagenesis in the phGHam-g3p vector (also known as pS0643; see Example VIII).
  • phGHam-g3p the "amber" hGH-g3 construct
  • Phage produced from both pS0132 S. Bass, R. Greene, J. A.
  • Phagemid partides from phGHam-g3 reacted much more strongly with antibodies Medix 2, 1B5.G2, and 5B7.C10 than did phagemid particles from pS0132. in particular, binding of pS0132 particles was reduced by >2000-fokl for both Medix 2 and 5B7.C10 and reduced by >25-fold for 1B5.G2 compared to binding to Medix 1.
  • binding of phGHam-g3 phage was weaker by only about 1.5-fold, 1.2-fold, and 2.3- fold for the Medix 2, 1B5.G2, and 5B7.C10 antibodies, respectively, compared with binding to MEDIX 1.
  • This library was constructed by cassette mutagenesis that fully mutated four residues at a time (see Example VIII) which utilized a mutated version of phGHam-g3 into which unique Kpnl (at hGH codon 27)and Xho ⁇ (at hGH codon 6) restriction sites (underiined below) had been inserted by mutagenesis [ T. A. Kunkel, J. D. Roberts, R. A.
  • the later oligo also introduced a +1 frameshift (italicized) to terminate translation from the starting vector and minimize wild-type background in the phagemid library. This strafing vector was designated pH0508B.
  • the helix 1 library which mufated hGH residues 10, 14, 18, 21, was constructed by ligating to the large Xho ⁇ -Kpn ⁇ fragment of pH0508B a cassette made from the complementary oligonucleotides 5'-pTCG AGG CTC NNS GAC AAC GCG NNS CTG CGT GCT NNS CGT CTT NNS CAG CTG GCC TTT GAC ACG TAC-3" and 5'-pGT GTC AAA GGC CAG CTG SNN AAG ACG SNN AGC ACG CAG SNN CGC GTT GTC SNN GAG CC-3'.
  • the Kpnl site was destroyed in the junction of the ligation product so that restriction enzyme digestion could be used for analysis of non-mutated background.
  • the library contained at least 10 7 independent transformants so that if the library were absolutely random (10 6 different combinations of codons) we would have an average of about 10 copies of each possible mutated hGH gene. Restriction analysis using Kpnl indicated that at least 80% of helix 1 library constructs contained the inserted cassette.
  • Binding enrichments of hGH-phage from the libraries was carried out using hGHbp immobilized on oxirane-potyacrylamide beads (Sigma Chemical Co.) as described (Example VIII).
  • Four residues in helix 1 (F10, M14, H18, and H21) were similarly mufated and after 4 and 6 cycles a non-wild-type consensus developed (Table VIII).
  • Position 10 on the hydrophobic face of helix 1 tended to be hydrophobic whereas positions 21 and 18 on the hydrophillic face tended were dominated by Asn; no obvious consensus was evident for position 14 (Table IX).
  • the binding constants for these mutants of hGH to hGHbp was determined by expressing the free hormone variants in the non-suppressor E.
  • Variants of hGH (randomly mutated at residues F10, M14, H18, H21) expressed on phagemid particles were selected by binding to hGHbp-beads and eluting with hGH (0.4 mM) buffer followed by glycine (0.2 M, pH 2) buffer (see Example VIII).
  • Observed frequency is fraction of all clones sequenced with the indicated amino acid.
  • the nominal frequency is calculated on the basis of NNS 32 codon degeneracy.
  • the maximal enrichment factor varies from 11 to 32 depending upon the nominal frequency value for a given residue.
  • Values of [Kd(Ala mut)/K(j(wt hGH)] for single alanine mutations were taken from B. C. Cunningham and J. A. Wells, Science 244, 1081 (1989); B. C. Cunningham, D. J. Henner, J. A. Wells, Science 247, 1461 (1990); B. C. Cunningham and J. A. Wells, Proc. Natl. Acad. Sci. USA 88, 3407 (1991).
  • the helix 4b library was constructed in an attempt to further improve the helix 4 double mufant (E174S/F176Y) selected from the helix 4a library that we found bound tighter to the hGH receptor (see Example VIII). With the E174S/F176Y hGH mufant as the background sfarting hormone, residues were mutated that surrounded positions 174 and 176 on the hydrophilic face of helix 4 (R167, D171, T175 and 1179) . Construction of the helix 4b library bv cassette mutagenesis
  • the binding constants for some of these mutants of hGH to hGHbp was determined by expressing the free hormone variants in the non-suppressor £ coli strain 16C9, purifying the protein, and assaying by competitive displacement of labelled wt-hGH from hGHbp (see Example VIII). As indicated, the binding affinities of several helix-4b mutants for hGHbp were tighter than that of wt-hGH Table XIII). Receptor-selectivity of hGH variants
  • the E174S F176Y mutant binds 200-fold weaker to the hPRLbp than hGH.
  • the E174T/F176Y/R178K and R167N/D171S/E174S/F176Y/I179T mutants each bind >500-fold weaker to the hPRLbp than hGH.
  • Hormone-phagemid selection Identifies the Info ⁇ -natton-contentof particular residues
  • the alanine- scanning information is useful for targeting side-chains that modulate binding, and the phage selection is appropriate for optimizing them and defining the flexibility of each site (and/or combinations of sites) for substitution.
  • the combination of scanning mutationai methods [B. C. Cunningham, P. Jhurani, P. Ng, J. A. Wells, Science 243, 1330 (1989); B. C. Cunningham and J. A. Wells, Science 244, 1081 (1989)] and phage display is a powerful approach to designing receptoNigand interfaces and studying molecular evolution in vitro. Variations on Iterative enrichment of hormone-phaoemid libraries
  • hormone phagemid enrichment can be carried out by one of several variations on the iterative enrichment approach : (1) random DNA libraries can be generated in each of two (or perhaps more) regions of the molecule by cassette or another mutagenesis method.
  • a combined library can be created by ligation of restriction fragments from the two DNA libraries; (2) an hGH variant, optimized for binding by mutation in one region of the molecule, can be randomly mufated in a second region of the molecule as in the helix-4b library example; (3) two or more random libraries can be partially selected for improved binding by hormone-phagemid enrichment; after this "roughing-in" of the optimized binding site, the still-partially-diverse libraries can be recombined by ligation of restriction fragments to generate a single library, partially diverse in two or more regions of the molecules, which in turn can be further selected for optimized binding using hormone-phagemid enrichment.
  • hGH helix 4b mutants (randomly mufated at residues 167, 171, 175, 179), each containing the E174S/F17 double mutant, by binding to hGHbp-beads and eluting with hGH (0.4 M) buffer followed by glydne (0.2 ⁇ f, pH 2) bu One mufant (+) contained the spurious mutation R178H.
  • Plasmid pDH 188 confains the DNA encoding the Fab P° ⁇ - ⁇ l of a humanized IgG antibody, called 4D5, that recognizes the HER-2 receptor. This plasmid is contained in £ co ⁇ strain SR 101, and has been deposited with the ATCC in Rockville, MD.
  • the plasmid was prepared as follows: the starting plasmid was pS0132, containing the alkaline phosphatase promoter as described above.
  • the DNA encoding human growth hormone was exdsed and, after a series of manipulations to make the ends of the plasmid compatible for ligation, the DNA encoding 4D5 was inserted.
  • the 4D5 DNA confains two genes. The first gene encodes the variable and consfant regions of the light chain, and contains at its 5' end the DNA encoding the st II signal sequence. The second gene contains four portions: first, at its 5' end is the DNA encoding the st II signal sequence.
  • PEG polyethylene glycol
  • electroporation Both polyethylene glycol (PEG) and electroporation were used to transform plasmids into SR101 cells.
  • PEG competent cells were prepared and transformed according to the method of Chung and Miller (Nucleic Adds Res.16:3580 [1988]). Cells that were competent for electroporation were prepared, and subsequently transformed via electroporation according to the method of Zabarovsky and Winberg (Nucleic Acids Res.18:5912 [1990]). After pla ⁇ ' ng the cells in 1 ml of the SOC media (described in Sambrook etal., supra), they were grown for 1 hour at 37°C with shaking.
  • the concentration of the cells was determined using light scattering at OD600- A titered K07 phage stock was added to achieve an multiplidty of infection (MOI) of 100, and the phage were allowed to adhere to the cells for 20 minutes at room temperature. This mixture was then diluted into 25 mis of 2YT broth (described in Sambrook ef al., supra) and incubated with shaking at 37°C overnight. The next day, cells were pelleted by centrifugation at 5000 x g for 10 minutes, the supernatant was collected, and the phage partides were predpitated with 0.5 M NaCl and 4% PEG (final concentration) at room temperature for 10 minutes.
  • MOI multiplidty of infection
  • Phage partides were pelleted by centrifugation at 10,000 x g for 10 minutes, resuspended in 1 ml of TEN (10 mM Tris, pH 7.6, 1 mM EDTA, and 150 mM NaCl), and stored at 4°C. Production of antigen coated plates.
  • buffer A PBS, 0.5% BSA, and 0.05% Tween-20
  • Elution of the phage from the plates was done at room temperature by one of two methods: 1) an initial overnight incubation of 0.025 mg/ml purified Mu4D5 antibody (murine) followed by a 30 minute incubation with 0.4 ml of the add elution buffer (0.2 M glydne, pH 2.1 , 0.5% BSA, and 0.05% Tween-20), or 2) an incubation with the acid elution buffer alone. Eluates were then neutralized with 1 M Tris base, and a 0.5 ml aliquot of TEN was added. These samples were then propagated, titered, and stored at 4°C. Phage propagation
  • the affinity of h4D5 F a b fragments and F a b phage for the ECD antigen was determined using a competitive receptor binding RIA (Burt, D. R., Receptor Binding in Drug Research. O'Brien, R.A. (Ed.), pp.3- 29, Dekker, New York [1986]).
  • the ECD antigen was labeled with 125 -k>dine using the sequential chloramine-T method (De Larco, J. E. etal., J. Cell.
  • the labeled ECD-Fab or ECD-F aD phage complex was separated from the unbound labeled antigen by forming an aggregate complex induced by the addition of an anti-human IgG (Fitzgerald 40-GH23) and 6% PEG 8000.
  • the complex was pelleted by centrifugation (15,000 x g for 20 minutes) and the amount of labeled ECD (in cpm) was determined by a gamma counter.
  • the dissociation constant (Kd) was calculated by employing a modified version of the program LIGAND (Munson, P. and Rothbard, D., Ami. Biochem.107 * 220-239 [1980]) which utilizes Scatchard analysis (Scatchard, G.,A ⁇ .
  • hGH-phagemid double-stranded DNA (dsDNA) from each of the one-helix variants was isolated and digested with the restriction enzymes EcoRl and BstX ⁇ . The large fragment from each helix-4b variant was then isolated and ligated with the small fragment from each helix-1 variant to yield the new two-helix variants shown in Table XIII. All of these variants also contained the mufations E174S/F176Y obtained in earlier hGH-phage binding selections (see Example X for details). Construction of selective combinatorial libraries of hGH
  • hGH-phagemid double-stranded DNA from each of the one-helix library pools (selected for 0, 2, or 4 rounds) was isolated and digested with the restriction enzymes Acd and BstX ⁇ .
  • the large fragment from each helix-1 variant pool was then isolated and ligated with the small fragment from each helix-4b variant pool to yield the three combinatorial libraries pH0707A (unselected helix 1 and helix 4b pools, as described in examples IX and X), pH0707B (twice-selected helix-1 pool with twice-selected helix-4b pool), and pH0707C (4-times selected helix-1 pool with 4-times selected helix-4b pool).
  • the ligation products pH0707A-F were processed and electro-transformed into XL1-Blue cells as described (Example VIII). Based on colony-forming units (CFU), the number of transformants obtained from each pool was as follows: 2.4X10 6 from pH0707A, 1.8x10 6 from pH0707B, 1.6x10 6 from pH0707C, 8x10 s from pH0707D, 3x10 s from pH0707E, and 4x10 s from pH0707F.
  • hGH-phagemid partides were prepared and selected for hGHbp-bind ⁇ ng over 2 to 7 cydes as described in Example VIII. Rapfti sorting of hQH-phagemld libraries
  • the pharmacological properties of a protein may be dependent on binding affinity or on kon or koff, depending on the detailed mechanism of action.
  • hGH variants with higher on-rates to investigate the effects of changes in kon-
  • the selection could altemativety be weighted toward koff by increasing the binding time and increasing the wash time and/or concentration with cognate ligand (hGH).
  • phagemid particles from the pH0707B pool were incubated with immobilized hGHbp for only 1 minute, then washed six times with 1 mL of binding buffer; the tiGH-wash step was omitted; and the remaining hGH-phagemid partides were eluted with a pH2 (0.2M glydne in binding buffer) wash. Enrichment of hGH-phagemid partides over non-displaying partides indicated that even with a short binding period and no cognate-ligand (hGH) challenge, hGH-phagemid binding selection sorts tight-binding variants out of a randomized pool. Assay of hGH mutants
  • the binding constants for some of these mutants of hGH to hGHbp was determined by expressing the free hormone variants in the non-suppressor £ coli strain 16C9 or 34B8, purifying the protein, and assaying by competitive displacement of labelled wt-hGH from hGHbp (see Example VIII) in a radio-immunoprecipitation assay.
  • Table XIII -A below, all the variants have glutamatei74 replaced by serinei74 and phenylalaninei76 replaced by tyrosinei76 (E174S and F1176Y) plus the additional substitutions as indicated at hGH amino add positions 10, 14, 18, 21, 167, 171, 175 and 179.
  • hGH variants were selected from combinatorial libraries by the phagemid binding selection process. All hGH variants in Table XIV contain two background mutations (E174S/F176Y). hGH- phagemid pools from the libraries pH0707A (Part A), pH0707B and pH0707E (Part B), or pH0707C (Part C) were sorted for 2 to 7 cydes for binding to hGHbp. The number £ indicates the fractional occurrence of each variant type among the set of clones sequenced from each pool.
  • hGH variants were selected from combinatorial libraries by the phagemid binding selection process. All hGH variants in Table XV contain two background mutations (E174S/F176Y). The number £ is the fractional occurrence of a given variant among all dones sequenced after 4 cycles of rapid-binding selection. Table XV hGH variants from RAPID hGHbp binding selection of an hGH-phagemid combinatorial library
  • t also contained the mutation Y176F (wild-type hGH also contains F176).
  • binding constants were measured by competitive displacement of 12 l-labelled hormone H0650BD or labelled hGH using hGHbp (1-238) and either Mab5 or Mab263.
  • the variant H0650BD appears bind more than 30-fold tighter than wild-type hGH.
  • the plasmid pS0132 contains the gene for hGH fused to the residue Pro198 of the gene III protein with the insertion of an extra glydne residue.
  • This plasmid may be used to produce hGH-phage particles in which the hGH-gene III fusion product is displayed monovalently on the phage surface (Example IV).
  • the fusion protein comprises the entire hGH protein fused to the carboxy terminal domain of gene III via a flexible linker sequence.
  • a genetically engineered variant of subtilisin BPN' was used. (Carter, P.
  • A64SAL subtilisin contains the following mutations: Ser24Cys, His64Ala, Glu156Ser, Gly 169 Ala and Tyr217Leu. Since this enzyme lacks the essential catalytic residue His64, its substrate specificity is greatly restricted so that certain histidine-containing substrates are preferentialty hyrdrolysed (Carter et al., Science 237:394-399 (1987)). Construction of a hGH-substrate-Phage vector
  • the sequence of the linker region in pS0132 was mutated to create a substrate sequence for A64SAL subtilisin, using the oligonucleotide 5'-TTC-GGG-CCC-TTC-GCT-GCT-CAC-TAT-ACG-CGT-CAG-TCG- ACT-GAC-CTG-CCT-3'.
  • the sequence Ala-Ala-His-Tyr-Thr-Agr-GIn is known to be a good substrate for A64SAL subtilisin (Carter et al (1989), supra).
  • the resulting plasmid was designated pS0640.
  • Phagemid particles derived from pS0132 and pS0640 were constructed as described in Example I.
  • a 10 ⁇ l aliquot of each phage pool was separately mixed with 30 ⁇ l of oxirane beads (prepared as described in Example II) in 100 ⁇ J of buffer comprising 20mM Tris-HCI pH 8.6 and 2.5M NaCl.
  • the binding and washing steps were performed as described in example Vll.
  • the beads were then resuspended in 400 ⁇ l of the same buffer, with or without 50nM of A64SAL subtilisin. Following incubation for 10 minutes, the supernatants were collected and the phage titres (cfu) measured.
  • Table XVli shows that approximately 10 times more substrate-containing phagemid particles (pS0640) were eluted in the presence of enzyme than in the absence of enzyme, or than in the case of the non-substrate phagemids (pS0132) in the presence or absence of enzyme. Increasing the enzyme, phagemid or bead concentrations did not improve this ratio.
  • hGH hGH variant used was as described in example XI (pH0650bd) and contains the mutations PhelOAIa, et14Trp, His18Asp, His21Asn, Arg167Asn, Asp171Ser, Glu174Ser, Phe176Tyr and lle179Thr.
  • Table XVII shows that there was a dramatic increase in the ratio of specifically eluted substrate-phagemid particles compared to the method previously described for pS0640 and pS0132. It is likely that this is due to the fact that the tight-binding hGH mutant has a significantly slower off-rate for binding to hGH binding protein compared to wild-type hGH.
  • Colony forming units were estimated by plating out 10 ⁇ l of 10-fold dilutions of phage on 10 ⁇ l spots of XL-1 blue cells, on LB agar plates containing 50 ⁇ g/ml carbeni ⁇ ' llinl
  • pH0650bd mutant hGH gene binding to hGHbp-coated plates phagemid + SQnM AS4SAL no enzyme pDM0411 (substrate) 1.7x10 5 cfu/10 ⁇ i 2x10 3 cfu/10 ⁇ l pDM0390 (non-substrate) 2x10 3 cfu/10 ⁇ l 1x10 3 cfu/10 ⁇ l
  • Example XIII We sought to employ the selective enrichment procedure described in Example XIII to identify good substrate sequences from a library of random substrate sequences.
  • pDM0253 This new construct was designated pDM0253 (The actual sequence of pDM0253 is 5'-AGC-TGT-GGC-TTC-GGG-CCC-GCC-J2CC-GCG-TCG-ACT-GGC-GGT-GGC-TCT-3', where the underiined base substitution is due to a spurious error in the mutagenic oligonucleotide).
  • the tight-binding hGH variant described in example was introduced by exchanging a fragment from pDM0411 (example XIII) The resulting library vector was designated pDM0454.
  • pD 0454 was digested with Apal followed by Sail, then precipitated with 13% PEG 8000+ 10m MgCfc, washed twice in 70% ethanol and resuspended This efficiently precipitates the vector but leaves the small Apa-Sal fragment in solution (Pai thankar, K. R. and Prasad, K. S. N., Nucleic Acids Research 19:1346).
  • the product was run on a 1% agarose gel and the Apal-Sall digested vector excised, purified using a Bandprep kit (Pharmacia) and resuspended for ligation with the mutagenic cassette.
  • the cassette to be inserted contained a DNA sequence similar to that in the linker region of pS0640 and pD 0411 , but with the codons for the histidine and tyrosine residues in the substrate sequence replaced by randomised codons.
  • the oligonucleotides used in the mutagenic cassettes were: 5'-C-TTC-GCT-GCT-NNS-NNS-ACC- CGG-CAA-3' (coding strand) and 5'-T-CGA-TTG-CCG-GGT-SNN-SNN-AGC-AGC-GAA-GGG- CC-3' (non-coding strand).
  • This cassette also destroys the Sail site, so that digestion with Sail may be used to reduce the vector background.
  • the oligonucleotides were not phosphorylated before insertion into the Apa-Sai cassette site, as it was feared that subsequent oligomerisation of a small population of the cassettes may lead to spurious results with multiple cassette inserts.
  • reaction products were phenohchloroform extracted, ethanol precipitated and resuspended in water. Initially, no digestion with Sail to reduce the background vector was performed. Approximately 200 ng was electroporated into XL-1 blue cells and a phagemid library was prepared as described in example VIII.
  • the selection procedure used was identical to that described for pDM0411 and pDM0390 in example XIII. After each round of selection, the eluted phage were propagated by transducing a fresh culture of XL-1 blue cells and propagating a new phagemid library as described for hGH-phage in example VIII. The progress of the selection procedure was monitored by measuring eluted phage titres and by sequencing individual clones after each round of selection.
  • Table A shows the successive phage titres for elution in the presence and absence of enzyme after 1 , 2 and 3 rounds of selection.
  • the ratio of specifically eluted phage: non-specifically eluted phage increases dramatically from round 1 to round 3, suggesting that the population of good substrates is increasing with each round of selection.
  • Sequencing of 10 isolates from the starting library showed them all to consist of the wild-type pD 0464 sequence. This is attributed to the fact that after digestion with Apal, the Sail site is very close to the end of the DNA fragment, thus leading to low efficiency of digestion. Nevertheless, there are only 400 possible sequences in the library, so this population should still be well represented.
  • Tables B1 and B2 shows the sequences of isolates obtained after round 2 and round 3 of selection. After 2 rounds of selection, there is clearly a high incidence of histidine residues. This is exactly what is expected: as described in example XIII, A64SAL subtilisin requires a histidine residue in the substrate as it employs a substrate-assisted catalytic mechanism. After 3 rounds of selection, each of the 10 clones sequenced has a histidine in the randomised cassette. Note, however, that 2 of the sequences are of pDM0411 , which was not present in the starting library and is therefore a contaminant.
  • Colony forming units were estimated by plating out 10 ⁇ l of 10-fold dilutions of phage on 10 ⁇ l spots of XL-1 blue cells, on LB agar plates containing 50 ⁇ g ml carbenidiiin
  • GCT GCT CAC ATG ACC CGG CAA ...
  • GATCTGCACT GCACSNNGCG CAGGTASNNG CTGACCTTSN NCATGTCCTT 50
  • ACGCAAGTTC ACGTAAAAAG GGTATCTAGA GGTTGAGGTG ATTTTATGAA 800 AAAGAATATC GCATTTCTTC TTGCATCTAT GTTCGTTTTT TCTATTGCTA 850
  • Met Lys Lys Asn lie Ala Phe Leu Leu Ala Ser Met Phe Val Phe 1 5 10 15

Abstract

A method for selecting novel proteins such as growth hormone and antibody fragment variants having altered binding properties for their respective receptor molecules is provided. The method comprises fusing a gene encoding a protein of interest to the carboxy terminal domain of the gene III coat protein of the filamentous phage M13. The gene fusion is mutated to form a library of structurally related fusion proteins that are expressed in low quantity on the surface of a phagemid particle. Biological selection and screening are employed to identify novel ligands useful as drug candidates. Disclosed are preferred phagemid expression vectors and selected human growth hormone variants.

Description

ENRICHMENT METHOD FOR VARIANT PROTEINS WTTH ALTERED BINDING PROPERTIES
FIELD OF THE INVENTION This invention relates to the preparation and systematic selection of novel binding proteins having altered binding properties for a target molecule. Specifically, this invention relates to methods for producing foreign poiypeptides mimicking the binding activity of naturally occurring binding partners, in preferred embodiments, the invention is directed to the preparation of therapeutic or diagnostic compounds that mimic proteins or nonpeptidyl molecules such a hormones, drugs and other small molecules, particularly biologically active molecules such as growth hormone.
BACKGROUND OF THE INVENTION Binding partners are substances that specifically bind to one another, usually through noncovalent interactions. Examples of binding partners include iigand-receptor, antibody-antigen, drug-target, and enzyme- substrate interactions. Binding partners are extremely useful in both therapeutic and diagnostic fields. Binding partners have been produced in the past by a variety of methods including; harvesting them from nature (e.g., antibody-antigen, and Iigand-receptor pairings) and by adventitious identification (e.g. traditional drug development employing random screening of candidate molecules). In some instances these two approaches have been combined. For example, variants of proteins or poiypeptides, such as polypeptide fragments, have been made that contain key functional residues that participate in binding. These polypeptide fragments, in turn, have been derivatized by methods akin to traditional drug development. An example of such derivitization would include strategies such as cyclization to conformationally constrain a polypeptide fragment to produce a novel candidate binding partner.
The problem with prior art methods is that naturally occurring ligands may not have proper characteristics for all therapeutic applications. Additionally, polypeptide ligands may not even be available for some target substances. Furthermore, methods for making non-naturally occurring synthetic binding partners are often expensive and difficult, usually requiring complex synthetic methods to produce each candidate. The inability to characterize the structure of the resulting candidate so that rational drug design methods can be applied for further optimization of candidate molecules further hampers these methods.
In an attempt to overcome these problems, Geysen (Geysen, Immun. Today.6:364-369 [1985]); and (Geysen et al., ol. Immun..23:709-715 [1986]) has proposed the use of polypeptide synthesis to provide a framework for systematic iterative binding partner identification and preparation. According to Geysen et al., Ibid, short poiypeptides, such as dipeptides, are first screened for the ability to bind to a target molecule. The most active dipeptides are then selected for an additional round of testing comprising linking, to the starting dipeptide, an additional residue (or by internally modifying the components of the original starting dipeptide) and then screening this set of candidates for the desired activity. This process is reiterated until the binding partner having the desired properties is identified.
The Geysen etal. method suffers from the disadvantage that the chemistry upon which it is based, peptide synthesis, produces molecules with ill-defined or variable secondary and tertiary structure. As rounds of iterative selection progress, random interactions accelerate among the various substituent groups of the polypeptide so that a true random population of interactive molecules having reproducible higher order structure becomes less and less attainable. For example, interactions between side chains of amino acids, which are sequentially widely separated but which are spatially neighbors, freely occur. Furthermore, sequences that do not facilitate conformationally stable secondary structures provide complex peptide-sidechain interactions which may prevent sidechain interactions of a given amino acid with the target molecule. Such complex interactions are facilitated by the flexibility of the polyamide backbone of the polypeptide candidates. Additionally, candidates may exist in numerous conformations making it difficult to identify the conformer that interacts or binds to the target with greatest affinity or specificity complicating rational drug design.
A final problem with the iterative polypeptide method of Geysen is that, at present, there are no practical methods with which a great diversity of different peptides can be produced, screened and analyzed. By using the twenty naturally occurring amino acids, the total number of all combinations of hexapeptides that must be synthesized is 64,000,000. Even having prepared such a diversity of peptides, there are no methods available with which mixtures of such a diversity of peptides can be rapidly screened to select those peptides having a high affinity for the target molecule. At present, each 'adherent* peptide must be recovered in amounts large enough to carry out protein sequencing. To overcome many of the problems inherent in the Geysen approach, biological selection and screening was chosen as an alternative. Biological selections and screens are powerful tools to probe protein function and to isolate variant proteins with desirable properties (Shortle, Protein Engineering. Oxender and Fox, eds., A.R. Liss, Inc., NY, pp.103-108 [1988]) and Bowie ef a/., ≤ciβffi≥, 247:1306-1310 [1990)]. However, a given selection or screen is applicable to only one or a small number of related proteins. Recently, Smith an coworkers (Smith, ≤ΩSDfiS, 228: 1315-1317 [1985]) and Parmley and Smith, Gene.
73:305-318 [1985] have demonstrated that small protein fragments (10-50 amino acids) can be "displayed" efficiently on the surface of filamentous phage by inserting short gene fragments into gene III of the fd phage ("fusion phage"). The gene III minor coat protein (present in about 5 copies atone end of the virion) is important for proper phage assembly and for infection by attachment to the pili of £ coli (see Rasched etal. , ] Rev..50: 401427 [1986]). Recently, "fusion phage" have been shown to be useful for displaying short mutated peptide sequences for identifying peptides that may react with antibodies (Scott et al.. Science 249: 386-390, [1990] )and Cwfrla etal.. Proc. Natl. Acad. U.S.A 87: 6378-6382, [1990]).or a foreign protein (Devlin ef al., ≤CisnC£, 249: 404406 [1990]).
There are, however, several important limitations in using such "fusion phage* to identify altered peptides or proteins with new or enhanced binding properties. First, it has been shown (Parmley et al., Gene.73: 305-318, [1988]) that fusion phage are useful only for displaying proteins of less than 100 and preferably less than 50 amino acid residues, because large inserts presumably disrupt the function of gene ill and therefore phage assembly and infectivity. Second, prior art methods have been unable to select peptides from a library having the highest binding affinity for a target molecule. For example, after exhaustive panning of a random peptide library with an anti-β endorphin monoclonal antibody, Cwiria and co-workers could not separate moderate affinity peptides (KQ* - 10 μM) from higher affinity peptides (K -0.4 μ ) fused to phage. Moreover, the parent β- en orphin peptide sequence which has very high affinity (K - 7nM), was not panned from the epitope library. Ladner WO 9002802 discloses a method for selecting novel binding proteins displayed on the outer surface of cells and viral particles where it is contemplated that the heterologous proteins may have up to 164 amino acid residues . The method contemplates isolating and amplifying the displayed proteins to engineer a new family of binding proteins having desired affinity for a target molecule. More specifically, Ladner discloses a 'fusion phage* displaying proteins having 'initial protein binding domains' ranging from 46 residues (crambin) to 164 residues (T4 lysozyme) fused to the M13 gene III coat protein. Ladner teaches the use of proteins "no larger than necessary" because it is easier to arrange restriction sites in smaller amino acid sequences and prefers the 58 amino acid residue bovine pancreatic trypsin inhibitor (BPTI). Small fusion proteins, such as BPTI, are preferred when the target is a protein or macromolecule, while larger fusion proteins, such as T4 lysozyme, are preferred for small target molecules such as steroids because such large proteins have clefts and grooves into which small molecules can fit. The preferred protein, BPTI, is proposed to be fused to gene III at the site disclosed by Smith et al. or de la Cruz et al., J. Biol. Chem..263: 43184322 [1988], or to one of the terminii, along with a second synthetic copy of gene III so that "some" unaltered gene III protein will be present. Ladner does not address the problem of successfully panning high affinity peptides from the random peptide library which plagues the biological selection and screening methods of the prior ait
Human growth hormone (hGH) participates in much of the regulation of normal human growth and development. This 22,000 dalton pituitary hormone exhibits a multitude of biological effects including linear growth (somatogenesis), lactation, activation of macrophages, insulin-like and diabetogenic effects among others (Chawla, R, K. (I983) Ann. Rev. Med.34.519; Edwards, C. K. et al. (I988) Science 239.769; Thorner, M.0., et al. (1988) J. Clin. Invest.81.745). Growth hormone deficiency in children leads to dwarfis which has been successfully treated for more than a decade by exogenous administration of hGH. hGH is a member of a family of homologous hormones that include placental Iactogens, prolactins, and other genetic and species variants or growth hormone (Nicoll, C. S., etal., (I986) Endocrine Reviews 7. 169). hGH is unusual among these in that it exhibits broad species specificity and binds to either the cloned somatogenic (Leung, D. W., etal., [I987] Nature 330. 537) or prolactin receptor (Boutin, J. M.,ef a/., [I988] Q~ ~~169). The cloned gene for hGH has been expressed in a secreted form in Escherichia &U (Chang, C. N., et al., \\~~~~ Qs~s.55, 189) and its DNA and amino acid sequence has been reported (Goeddel, ef al., [I979] iE£ 2S1 544; Gray, et al., [I985] Gene 3J 247). The three-dimensional structure of hGH is not available. However, the three-dimensional folding pattern for porcine growth hormone (pGH) has been reported at moderate resolution and refinement (Abdel-Meguid, S. S., etal., [1987] Proc. Natl. Acad. Sci. USA 84. 6434). Human growth hormone's receptor and antibody epitopes have been identified by nomolog-scanning mutagenesis (Cunningham etal., Science 243i 1330, 1989). The structure of novel amino terminal methionyl bovine growth hormone containing a spliced-in sequence of human growth hormone including histidine 18 and histidine 21 has been shown (U.S. Patent 4,880,910)
Human growth hormone (hGH) causes a variety of physiological and metabolic effects in various animal models including linear bone growth, lactation, activation of macrophages, insulin-like and diabetogenic effects and others (R. K. Chawla etal., Anna Rev. Med.34, 519 (1983); 0. G. P. Isaksson etal., Amu. Rev. Physiol.47, 483 (1985); C. K. Edwards etal., Science 239, 769 (1988); M.0. Thorner and M. L. Vance, J. Clin. Invest.82, 745 (1988); J. P. Hughes and H. G. Friesen, Ann. Rev. Physiol.47, 469 (1985)). These biological effects derive from the interaction between hGH and specific cellular receptors..
Accordingly, it is an object of this invention to provide a rapid and effective method for the systematic preparation of candidate binding substances. It is another object of this invention to prepare candidate binding substances displayed on surface of a phagemid particle that are conformatioπally stable.
It is another object of this invention to prepare candidate binding substances comprising fusion proteins of a phage coat protein and a heterologous polypeptide where the polypeptide is greater than 100 amino acids in length and may be more than one subunit and is displayed on a phagemid particle where the polypeptide is encoded by the phagemid genome.
It is a further object of this invention to provide a method for the preparation and selection of binding substances that is sufficiently versatile to present, or display, all peptidyl moieties that could potentially participate in a noncovalent binding interaction, and to present these moieties in a fashion that is sterically confined.
Still another object of the invention is the production of growth hormone variants that exhibit stronger affinity for growth hormone receptor and binding protein.
It is yet another object of this invention to produce expression vector phagemids that contain a suppressible termination codon functionally located between the heterologous polypeptide and the phage coat protein such that detectable fusion protein is produced in a host suppressor cell and only the heterologous polypeptide is produced in a non-suppressor host cell.
Finally, it is an object of this invention to produce a phagemid particle that rarely displays more than one copy of candidate binding proteins on the outer surface of the phagemid particle so that efficient selection of high affinity binding proteins can be achieved. These and other objects of this invention will be apparent from consideration of the invention as a whole.
SUMMARY OF THE INVENTION These objectives have been achieved by providing a method for selecting novel binding poiypeptides comprising: (a) constructing a replicable expression vector comprising a first gene encoding a polypeptide, a second gene encoding at least a portion of a natural or wild-type phage coat protein wherein the first and second genes are heterologous, and a transcription regulatory element operabfy linked to the first and second genes, thereby forming a gene fusion encoding a fusion protein; (b) mutating the vector at one or more selected positions within the first gene thereby forming a family of related plasmids; (c) transforming suitable host cells with the plasmids; (d) infecting the transformed host cells with a helper phage having a gene encoding the phage coat protein; (e) culturing the transformed infected host cells under conditions suitable for forming recombinant phagemid particles containing at least a portion of the plasmid and capable of transforming the host, the conditions adjusted so that no more than a minor amount of phagemid particles display more than one copy of the fusion protein on the surface of the particle; (f) contacting the phagemid particles with a target molecule so that at least a portion of the phagemid particles bind to the target molecule; and (g) separating the phagemid particles that bind from those that do not Preferably, the method further comprises transforming suitable host cells with recombinant phagemid particles that bind to the target molecule and repeating steps (d) through (g) one or more times.
Additionally, the method for selecting novel binding proteins where the proteins are composed of more than one subunit is achieved by selecting novel binding peptides comprising constructing a replicable expression vector comprising a transcription regulatory element operabfy linked to DNA encoding a protein of interest containing one or more subunits, wherein the DNA encoding at least one of the subunits is fused to the DNA encoding at least a portion of a phage coat protein;mutating the DNA encoding the protein of interest at one or more selected positions thereby forming a family of related vectors; transforming suitable host cells with the vectors; infecting the transformed host cells with a helper phage having a gene encoding the phage coat protein; culturing the transformed infected host cells under conditions suitable for forming recombinant phagemid particles containing at least a portion of the plasmid and capable of transforming the host, the conditions adjusted so that no more than a minor amount of phagemid particles display more than one copy of the fusion protein on the surface of the particle; contacting the phagemid particles with a target molecule so that at least a portion of the phagemid particles bind to the target molecule; and separating the phagemid particles that bind from those that do not.
Preferably in the method of this invention the plasmid is under tight control of the transcription regulatory element, and the culturing conditions are adjusted so that the amount or number of phagemid particles displaying more than one copy of the fusion protein on the surface of the particle is less than about 1 %. Also preferably, amount of phagemid particles displaying more than one copy of the fusion protein is less than 10% the amount of phagemid particles displaying a single copy of the fusion protein. Most preferably the amount is less than 20%.
Typically, in the method of this invention, the expression vector will further contain a secretory signal sequences fused to the DNA encoding each subunit of the polypeptide, and the transcription regulatory element will be a promoter system. Preferred promoter systems are selected from; Lac Z, λp|_, TAC, T 7 polymerase, tryptophan, and alkaline phosphatase promoters and combinations thereof.
Also typically, the first gene will encode a mammalian protein, preferably the protein will be selected from; human growth hormone(hGH), N-methionyl human growth hormone, bovine growth hormone, parathyroid hormone, thyroxine, insulin A-chain, insulin B-chain, proinsulin, relaxin A-chain, relaxin B-chain, proretaxin, glycoprotein hormones such as follicle stimulating hormone(FSH), thyroid stimulating hormone(TSH), and leutinizing hormone(LH), glycoprotein hormone receptors, calcitonin, glucagon, factor VIII, an antibody, lung surfactant, urokinase, streptokinase, human tissue-type plasminogen activator (t-PA), bo besin, factor IX, thro bin, hemopoiet'ic growth factor, tumor necrosis factor-alpha and -beta, enkephalinase, human serum albumin, mullerian-inhibiting substance, mouse gonadotropin-associated peptide, a microbial protein, such as betalactamase, tissue factor protein, inhibin, activin, vascular endothelial growth factor, receptors for hormones or growth factors; integrin, thrombopoietin, protein A or D, rheumatoid factors, nerve growth factors such as NGF-β, platelet-growth factor, transforming growth factors (TGF) such as TGF-alpha and TGF-beta, insulin¬ like growth factor-l and -II, insulin-like growth factor binding proteins , CD4, DNase, latency associated peptide, erythropoietin, osteoinductive factors, interferons such as interferon-alpha, -beta, and -gamma, colony stimulating factors (CSFs) such as M-CSF, GM-CSF, and G-CSF, interleukins (ILs) such as IL-1, IL-2, IL-3, IL- 4, superoxide dismutase; decay accelerating factor, viral antigen, HIV envelope proteins such as GP120, GP140, atrial natriuretic peptides A, B or C, immunoglobulins, and fragments of any of the above-listed proteins.
Preferably the first gene will encode a polypeptide of one or more subunits containing more than about 100 amino acid residues and will be folded to form a plurality of rigid secondary structures displaying a plurality of amino acids capable of interacting with the target. Preferably the first gene will be mutated at codons corresponding to only the amino acids capable of interacting with the target so that the integrity of the rigid secondary structures will be preserved.
Normally, the method of this invention will employ a helper phage selected from; 13K07, M13R408, M13-VCS, and Phi X 174. The preferred helper phage is M13K07, and the preferred coat protein is the M13 Phage gene III coat protein. The preferred host is £ coli, and protease deficient strains of £ coli. Novel hGH variants selected by the method of the present invention have been detected. Phagemid expression vectors were constructed that contain a suppressible termination codon functionally located between the nucleic acids encoding the polypeptide and the phage coat protein.
BRIEF DESCRIPTION OF THE FIGURES FIGURE 1. Strategy for displaying large proteins on the surface of filamentous phage and enriching for altered receptor binding properties. A plasmid, phGH-M13glll was constructed that fuses the entire coding sequence of hGH to the carboxyl terminal domain of M13 gene III. Transcription of the fusion protein is under control of the lac promoter/operator sequence, and secretion is directed by the stll signal sequence. Phagemid particles are produced by infection with the "helper* phage, M13K07, and particles displaying hGH can be enriched by binding to an affinity matrix containing the hGH receptor. The wild-type gene III (derived from the M13K07 phage) is diagramed by 4-5 copies of the multiple arrows on the tip of the phage, and the fusion protein (derived from the phagemid, phGH-M13glll) is indicated schematically by the folding diagram of hGH replacing the arrowhead.
FIGURE 2. Immunoblot of whole phage particles shows that hGH comigrates with phage. Phagemid particles purified in a cesium chloride gradient were loaded into duplicate wells and electrophoresed through a 1 % agarose gel in 375 M Tris, 40 mM glycine pH 9.6 buffer. The gel was soaked in transfer buffer (25 mM Tris, pH 8.3, 200 mM glycine, 20% methanol) containing 2% SDS and 2% β-mercaptoethanol for 2 hours, then rinsed in transfer buffer for 6 hours. The proteins in the gel were then electrobfotted onto immobilon membranes (Millipore). The membrane containing one set of samples was stained with Coomassie blue to show the position of the phage proteins (A). The duplicate membrane was immuno-stained for hGH by reacting the membrane with polyclonal rabbit anti-hGH antibodies followed by reaction with horseradish peroxidase conjugated goat anti- rabbit IgG antibodies (B). Lane 1 contains the M13K07 parent phage and is visible only in the Coomassie blue stained membrane, since it lacks hGH. Lanes 2 and 3 contain separate preparations of the hormone phagemid particles which is visible both by Coomassie and hGH immuno-staining. The difference in migration distance between the parent M13K07 phage and hormone phagemid particles reflects the different size genomes that are packaged within (8.7 kb vs.5.1 kb, respectively).
FIGURE 3. Summary diagram of steps in the selection process for an hGH-phage library randomized at codons 172, 174, 176, and 178. The template molecules, pH0415, containing a unique Kpnl restriction site and the hGH(R178G,H79T) gene was mutagenized as described in the text and electrofransformed into £ coli strain WJM101 to obtain the initial phagemid library, Library 1. An aliquot (approximately 2%) from Library 1 was used directly in an initial selection round as described in the text to yield Library 1G. Meanwhile, double-stranded DNA (dsDNA) was prepared from Library I, digested with restriction enzyme Kpnl to eliminate template background, and elecuOtraπsformed into WJM101 to yield Library 2. Subsequent rounds of selection (or Kpnl digestion, shaded boxes) followed by phagemid propagation were carried out as indicated by the arrows, according to the procedure described in the text. Four independent clones from Library 4G4 and four independent clones from Library 5G6 were sequenced by dideoxy sequencing. All of these clones had the identical DNA sequence, corresponding to the hGH mutant (Glu 174 Ser, Phe 176 Tyr).
FIGURE 4. Structural model of hGH derived from a 2.8 A folding diagram of porcine growth hormone determined crystallographically. Location of residues in hGH that strongly modulate its binding to the hGH- binding protein are within the shaded circle. Alanine substitutions that cause a greater than tenfold reduction^), a four- to tenfold reduction (•), or increase (O), or a two- to fourfold reduction (•), in binding affinity are indicated. Helical wheel projections in the regions of α-helix reveal their amphipathic quality. Blackened, shaded, or nonshaded residues are charged, polar, or nonpolar, respectively. In helix-4 the most important residues for mutation are on the hydrophilic face.
FIGURE 5. Amino acid substitutions at positions 172, 174, 176 and 178 of hGH (The notation, e.g. KSYR, denotes hGH mutant 172K 174S/176Y/178R.) found after sequencing a number of clones from rounds 1 and 3 of the selection process for the pathways indicated (hGH elution; Glycine elution; or Glycine elution after pre-adsorption). Non-functional sequences (i.e. vector background, or other prematurely terminated and/or frame-shifted mutants) are shown as "NP. Functional sequences which contained a non-silent, spurious mutation (i.e. outside the set of target residues) are marked with a "+". Protein sequences which appeared more than once among all the sequenced clones, but with different DNA sequences, are marked with a "#". Protein sequences which appeared more than once among the sequenced clones and with the same DNA sequence are marked with a "". Note that after three rounds of selection, 2 different contaminating sequences were found; these clones did not correspond to cassette mutants, but to previously constructed hormone phage. The pS0643 contaminant corresponds to wild-type hGH-phage (hGH "KEFR"). The pH0457 contaminant, which dominates the third- round glycine-selected pool of phage, corresponds to a previously identified mutant of hGH, "KSYR." The amplification of these contaminants emphasizes the ability of the hormone-phage selection process to select for rarely occurring mutants. The convergence of sequences is also striking in all three pathways: R or K occurs most often at positions 172 and 178; Y or F occurs most often at position 176; and S, T, A, and other residues occur at position 174.
FIGURE 6. Sequences from phage selected on hPRLbp-beads in the presence of zinc. The notation is as described in Figure.5. Here, the convergence of sequences is not predictable, but there appears to be a bias towards hydrophobic sequences under the most stringent (Glycine) selection conditions; L ,W and P residues are frequently found in this pool.
FIGURE 7. Sequences from phage selected on hPRLbp-beads in the absence of zinc. The notation is as described in Figure 5. In contrast to the sequences of Figure.6, these sequences appear more hydrophilic. After 4 rounds of selection using hGH elution, two clones (ANHQ, and TLDT/171 V) dominate the pool.
FIGURE 8. Sequences from phage selected on blank beads. The notation is as described in Fig.5. After three rounds of selection with glycine elution, no siblings were observed and a background level of non-functional sequences remained.
FIGURE 9. Construction of phagemid fl ori from pH0415. This vector for cassette mutagenesis and expression of the hGH-gene III fusion protein was constructed as follows. Plasmid pS0643 was constructed by oligonucleotide-directed mutagenesis of pS0132, which contains pBR322 and f1 origins of replication and expresses an hGH-gene III fusion protein (hGH residues 1-191, followed by a single Giy residue, fused to Pro-198 of gene III) under the control of the E. coli phoA promoter. Mutagenesis was carried out with the oligonucleotide 5,-GGC-AGC-TGT-GGC-TI£JAi AGT-GGC-GGC-GGC-TCT-GGT-3, I which introduced a Xb l site (underlined) and an amber stop codon (TAG) following Phe-191 of hGH. FIGURE 10. A. Diagram of plasmid pDH188 insert containing the DNA encoding the light chain and heavy chain (variable and constant domain 1 ) of the Fab humanized antibody directed to the HER-2 receptor. V|_ and VH are the variable regions for the light and heavy chains, respectively. C| is the constant region of the human kappa light chain. CH1Q1 is the first constant region of the human gamma 1 chain. Both coding regions start with the bacterial st II signal sequence. B. A schematic diagram of the entire plasma pDH188 containing the insert described in 5A. After transformation of the plasmid into £ coli SR101 cells and the addition of helper phage, the plasmid is packaged into phage particles. Some of these particles display the Fab-p HI fusion (where p III is the protein encoded by the M13 gene III DNA). The segments in the plasmid figure correspond to the insert shown in5A.
FIGURE 11 A through C are collectively referred to here as Figure 11. The nucleotide (Seq. ID No.25) sequence of the DNA encoding the 4D5 Fab molecule expressed on the phagemid surface. The amino acid sequence of the light chain is also shown (Seq. ID No.26), as is the amino acid sequence of the heavy chain p ill fusion (Seq. ID No. 27).
FIGURE 12. Enrichment of wild-type 4D5 Fab phagemid from variant Fab phagemid. Mixtures of wild- type phagemid and variant 4D5 Fab phagemid in a ratio of 1 :1 ,000 were selected on plates coated with the extra- cellular domain protein of the HER-2 receptor. After each round of selection, a portion of the eluted phagemid were infected into £ coli and plasmid DNA was prepared. This plasmid DNA was then digested with Eco RV and Pst I, separated on a 5% polyacrylamide gel, and stained with ethidium bromide. The bands were visualized under UV light. The bands due to the wild-type and variant plasmids are marked with arrows. The first round of selection was eluted only under acid conditions; subsequent rounds were eluted with either an add elution (left side of Figure) or with a humanized 4D5 antibody wash step prior to acid elution (right side of Figure) using methods described in Example VIII. Three variant 4D5 Fab molecules were made: H91 A (amino acid histidine at position 91 on the V chain mutated to alanine; indicated as 'A' lanes in Figure), Y49A (amino acid tyrosine at position 49 on the V chain mutated to alanine; indicated as 'B' lanes in the Figure), and Y92A (amino acid tyrosine at position 92 on the V chain mutated to alanine; indicated as "C lanes in the Figure). Amino acid position numbering is according to Kabat et al.,(Sequences of proteins of immunological interest, 4th ed., U.S. Dept of Health and Human Services, Public Health Service, Nat'l. Institute of Health, Bethesda, MD [1987]).
FIGURE 13. The Scatchard analysis of the RIA affinity determination described in Experimental Protocols is shown here. The amount of labeled ECD antigen that is bound is shown on the x-axis while the amount that is bound divided by the amount that is free is shown on the y-axis. The slope of the line indicates the Ka; the calculated Kd is VK-, DETAILED DESCRIPTION OF THE INVENTION
The following discussion will be best understood by referring to Figure 1. In its simplest form, the method of the instant invention comprises a method for selecting novel binding poiypeptides, such as protein ligands, having a desired, usually high, affinity for a target molecule from a library of structurally related binding poiypeptides. The library of structurally related poiypeptides, fused to a phage coat protein, is produced by mutagenesis and, preferably, a single copy of each related polypeptide is displayed on the surface of a phagemid particle containing DNA encoding that polypeptide. These phagemid particles are then contacted with a target molecule and those particles having the highest affinity for the target are separated from those of lower affinity. The high affinity binders are then amplified by infection of a bacterial host and the competitive binding step is repeated. This process is reiterated until poiypeptides of the desired affinity are obtained.
The novel binding poiypeptides or ligands produced by the method of this invention are useful per se as diagnostics or therapeutics ( eg. agonists or antagonists) used in treatment of biological organisms. Structural analysis of the selected poiypeptides may also be used to facilitate rational drug design.
By 'binding polypeptide" as used herein is meant any polypeptide that binds with a selectable affinity to a target molecule. Preferably the polypeptide will be a protein that most preferably contains more than about 100 amino acid residues. Typically the polypeptide will be a hormone or an antibody or a fragment thereof.
By "high affinity* as used herein is meant an affinity constant (Kd ) of <10"5 M and preferably <10"7M under physiological conditions.
By "target molecule" as used herein is meant any molecule, not necessarily a protein, for which it is desirable to produce a ligand. Preferably, however, the target will be a protein and most preferably the target will be a receptor, such as a hormone receptor.
By "humanized antibody" as used herein is meant an antibody in which the complementarity-determining regions (CDRs) of a mouse or other non-human antibody are grafted onto a human antibody framework. By human antibody framework is meant the entire human antibody excluding the CDRs. L Choice of Pohmeptktes for Display on the Surface of a Phage
The first step in the method of this invention is to choose a polypeptide having rigid secondary structure exposed to the surface of the polypeptide for display on the surface of a phage.
By "polypeptide" as used herein is meant any molecule whose expression can be directed by a specific DNA sequence. The poiypeptides of this invention may comprise more than one subunit, where each subunit is encoded by a separate DNA sequence.
By "rigid secondary structure* as used herein is meant any polypeptide segment exhibiting a regular repeated structure such as is found in; α-helices, 3ιo helices, π-helices, parallel and antiparallel β-sheets, and reverse turns. Certain "non-ordered" structures that lack recognizable geometric order are also included in the definition of rigid secondary structure provided they form a domain or "patch" of amino acid residues capable of interaction with a target and that the overall shape of the structure is not destroyed by replacement of an amino acid within the structure . It is believed that some non-ordered structures are combinations of reverse turns. The geometry of these rigid secondary structures is well defined by φ and ψ torsional angles about the α-carbons of the peptide "backbone". The requirement that the secondary structure be exposed to the surface of the polypeptide is to provide a domain or 'patch' of amino acid residues that can be exposed to and bind with a target molecule. It is primarily these amino acid residues that are replaced by mutagenesis that form the 'library* of structurally related (mutant) binding poiypeptides that are displayed on the surface of the phage and from which novel polypeptide ligands are selected. Mutagenesis or replacement of amino acid residues directed toward the interior of the polypeptide is generally avoided so that the overall structure of the rigid secondary structure is preserved. Some replacement of amino acids on the interior region of the rigid secondary structures, especially with hydrophobe amino acid residues, may be tolerated since these conservative substitutions are unlikely to distort the overall structure of the polypeptide. Repeated cycles of 'polypeptide' selection are used to select for higher and higher affinity binding by the phagemid selection of multiple amino acid changes which are selected by multiple selection cycles. Following a first round of phagemid selection, involving a first region or selection of amino acids in the ligand polypeptide, additional rounds of phagemid selection in other regions or amino acids of the ligand polypeptide are conducted. The cycles of phagemid selection are repeated until the desired affinity properties of the ligand polypeptide are achieved. To illustrate this process, Example VIII phagemid selection of hGH was conducted in cycles. In the first cycle hGH amino acids 172, 174, 176 and 178 were mutated and phagemid selected. In a second cycle hGH amino acids 167, 171, 175 and 179 were phagemid selected. In a third cycle hGH amino acids 10, 14, 18 and 21 were phagemid selected. Optimum amino acid changes from a previous cycle may be incorporated into the polypeptide before the next cycle of selection. For example, hGH amino acids substitution 174 (serine) and 176 (tyrosine) were incorporated into the hGH before the phagemid selection of hGH amino acids 167, 171, 175 and 179.
From the forgoing it will be appreciated that the amino acid residues that form the binding domain of the polypeptide will not be sequentially linked and may reside on different subunits of the polypeptide. That is, the binding domain tracks with the particular secondary structure at the binding site and not the primary structure. Thus, generally, mutations will be introduced into codons encoding amino acids within a particular secondary structure at sites directed away from the interior of the polypeptide so that they will have the potential to interact with the target. By way of illustration, Figure 2 shows the location of residues in hGH that are known to strongly modulate its binding to the hGH-binding protein (Cunningham etal., Science 247:1461 - 1465 [1990]). Thus representative sites suitable for mutagenesis would include residues 172, 174, 176, and 178 on helix-4, as well as residue 64 located in a 'non-ordered' secondary structure. There is no requirement that the polypeptide chosen as a ligand to a target normally bind to that target.
Thus, for example, a glycoprotein hormone such as TSH can be chosen as a ligand for the FSH receptor and a library of mutant TSH molecules are employed in the method of this invention to produce novel drug candidates.
This invention thus contemplates any polypeptide that binds to a target molecule, and includes antibodies. Preferred poiypeptides are those that have pharmaceutical utility. More preferred poiypeptides include; a growth hormone, including human growth hormone, des-N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroid stimulating hormone; thyroxine; insulin A-chain; insulin B-chain; proinsulin; follicle stimulating hormone; calcitonin; leutinizing hormone; glucagon; factor VIII; an antibody; lung surfactant; a plasminogen activator, such as urokinase or human tissue-type plasminogen activator (t-PA); bombesin; factor IX, thrombiπ; hemopoietic growth factor; tumor necrosis factor-alpha and -beta;enkephalinase; a serum albumin such as human serum albumin; mullerian-inhibiting substance; relaxin A-chain; relaxin B-chain; prorelaxin; mouse gonadotropin-associated peptide; a microbiai protein, such as betalactamase; tissue factor protein; inhibin; activin; vascular endothelial growth factor; receptors for hormones or growth factors; integrin; thrombopoietin; protein A or D; rheumatoid factors; nerve growth factor such as NGF-β; platelet-derived growth factor; fibroblast growth factor such as aFGF and bFGF; epidermal growth factor; transforming growth factor (TGF) such as TGF-alpha and TGF-beta; insulin-like growth factor-l and -II; insulin-like growth factor binding proteins; CD4; DNase; latency associated peptide; erythropoietin; osteoinductive factors; an interferon such as interferon-alpha, -beta, and -gamma; colony stimulating factors (CSFs), e.g., M-CSF, GM-CSF, and G-CSF; interieukins (ILs), e.g., IL-1, IL-2, IL-3, IL4, etc.; superoxide dismutase; decay accelerating factor; atrial natriuretic peptides A, B or C; viral antigen such as, for example, a portion of the HIV envelope; immunoglobulins; and fragments of any of the above-listed poiypeptides. In addition, one or more predetermined amino acid residues on the polypeptide may be substituted, inserted, or deleted, for example, to produce products with improved biological properties. Further, fragments of these poiypeptides, especially biologically active fragments, are included. Yet more preferred poiypeptides of this invention are human growth hormone , and atrial naturetic peptides A, B, and C, endotoxin, subtilisin, trypsin and other serine proteases.
Still more preferred are polypeptide hormones that can be defined as any amino acid sequence produced in a first cell that binds specifically to a receptor on the same cell type (autocrine hormones) or a second cell type (non-autocrine) and causes a physiological response characteristic of the receptor-bearing cell. Among such polypeptide hormones are cytokines, lymphokines, neurotrophic hormones and adenohypophyseal polypeptide hormones such as growth hormone, proJactin, placental lactogen, luteinizing hormone, follicle-stimulating hormone, thyrotropin, chorionic gonadotropin, corϋcotropin, α or β-melanocyte-stimulating hormone, β-iipotropin, γ- lipotropin and the endorphins; hypothal ic release-inhibiting hormones such as corticotropin-release factor, growth hormone release-inhibiting hormone, growth hormone-release factor; and other polypeptide hormones such as atrial natriuretic peptides A, B or C. U. Obtaining a Rrst Gene fGene ii encoding the desired polvpeotide
The gene encoding the desired polypeptide (i.e., a polypeptide with a rigid secondary structure) can be obtained by methods known in the art (see generally, Sambrook et al. , Molecular Biology: A Laboratory Manual. Cold Spring Harbor Press, Cold Spring Harbor, New York [1989]). If the sequence of the gene is known, the DNA encoding the gene may be chemically synthesized (Merrfield, J. Am. Chem. Soc...85 2149 [1963]). If the sequence of the gene is not known, or if the gene has not previously been isolated, it may be cloned from a cDNA library (made from RNA obtained from a suitable tissue in which the desired gene is expressed) or from a suitable genomic DNA library. The gene is then isolated using an appropriate probe. For cDNA libraries, suitable probes include monoclonal or polyclonal antibodies (provided that the cDNA library is an expression library), oligonucleotides, and complementary or homologous cDNAs or fragments thereof. The probes that may be used to isolate the gene of interest from genomic DNA libraries include cDNAs or fragments thereof that encode the same or a similar gene, homologous genomic DNAs or DNA fragments, and oligonucleotides. Screening the cDNA or genomic library with the selected probe is conducted using standard procedures as described in chapters 10-12 of Sambrook etal., supra. An alternative means to isolating the gene encoding the protein of interest is to use polymerase chain reaction methodology (PCR) as described in section 14 of Sambrook etal., supra. This method requires the use of oligonucleotides that will hybridize to the gene of interest; thus, at least some of the DNA sequence for this gene must be known in order to generate the oligonucleotides. After the gene has been isolated, it may be inserted into a suitable vector (preferably a plasmid) for amplification, as described generally in Sambrook etal., supra. UL Constructing Replicable Expression Vectors
While several types of vectors are available and may be used to practice this invention, plasmid vectors are the preferred vectors for use herein, as they may be constructed with relative ease, and can be readily amplified. Plasmid vectors generally contain a variety of components including promoters, signal sequences, phenotypic selection genes, origin of replication sites, and other necessary components as are known to those of ordinary skill in tiie art.
Promoters most commonly used in prokaryotic vectors include the lac Z promoter system, the alkaline phosphatase ~ύ~ A promoter, the bacteriophage λPL promoter (a temperature sensitive promoter), the lac promoter (a hybrid irj_-J2£ promoter that is regulated by the lac repressor), the tryptophan promoter, and the bacteriophage T7 promoter. For general descriptions of promoters, see section 17 of Sambrook ef al. supra . While these are the most commonly used promoters, other suitable microbial promoters may be used as well.
Preferred promoters tor practicing this invention are those that can be tightly regulated such that expression of the fusion gene can be controlled. It is believed that the problem that went unrecognized in the prior art was that display of multiple copies of the fusion protein on the surface of the phagemid particle lead to multipoint attachment of the phagemid with the target It is believed this effect, referred to as the 'chelate effect", results in selection of false "high affinity" poiypeptides when multiple copies of the fusion protein are displayed on the phagemid particle in close proximity to one another so that the target was "chelated*. When multipoint attachment occurs, the effective or apparent Kd may be as high as the product of the individual Kds for each copy of the displayed fusion protein. This effect may be the reason Cwiria and coworkers supra were unable to separate moderate affinity peptides from higher affinity peptides.
It has been discovered that by tightly regulating expression of the fusion protein so that no more than a minor amount, i.e. fewer than about 1%, of the phagemid particles contain multiple copies of the fusion protein the "chelate effect" is overcome allowing proper selection of high affinity poiypeptides. Thus, depending on the promoter, culturing conditions of the host are adjusted to maximize the number of phagemid particles containing a single copy of the fusion protein and minimize the number of phagemid particles containing multiple copies of the fusion protein.
Preferred promoters used to practice this invention are the lac Z promoter and the βba A promoter. The lac Z promoter is regulated by the lac repressor protein lac >. and thus transcription of the fusion gene can be controlled by manipulation of the level of the lac repressor protein. By way of illustration, the phagemid containing the lac Z promoter is grown in a cell strain that contains a copy of the lac i repressor gene, a repressor for the l2£ Z promoter. Exemplary cell strains containing the laci gene include JM 101 and XL1-biue. In the alternative, the host cell can be cotransfected with a plasmid containing both the repressor lac i and the lac Z promoter. Occasionally both of the above techniques are used simultaneously, that is, phagmide particles containing the lac Z promoter are grown in cell strains containing the lac i gene and the cell strains are cotransfected with a plasmid containing both the lac Z and lac i genes. Normally when one wishes to express a gene, to the transfected host above one would add an inducer such as isopropylthiogalactoside (IPTG). In the present invention however, this step is omitted to (a) minimize the expression of the gene III fusion protein thereby minimizing the copy number (i.e. the number of gene III fusions per phagemid number) and to (b) prevent poor or improper packaging of the phagemid caused by inducers such as IPTG even at low concentrations. Typically, when no inducer is added, the number of fusion proteins per phagemid particle is about 0.1 (number of bulk fusion proteins number of phagemid particles). The most preferred promoter used to practice this invention is ~ύ~ A. This promoter is believed to be regulated by the level of inorganic phosphate in the cell where the phosphate acts to down-regulate the activity of the promoter. Thus, by depleting cells of phosphate, the activity of the promoter can be increased. The desired result is achieved by growing cells in a phosphate enriched medium such as 2YT or LB thereby controlling the expression of the gene III fusion.
One other useful component of vectors used to practice this invention is a signal sequence. This sequence is typically located immediately 5' to the gene encoding the fusion protein, and will thus be transcribed at the amino terminus of the fusion protein. However, in certain cases, the signal sequence has been demonstrated to be located at positions other 5' to the gene encoding the protein to be secreted. This sequence targets the protein to which it is attached across the inner membrane of the bacterial cell. The DNA encoding the signal sequence may be obtained as a restriction endonuclease fragment from any gene encoding a protein that has a signal sequence. Suitable prokaryotic signal sequences may be obtained from genes encoding, for example, LamB or OmpF (Wong etal., Gene.68:193 [1983]), MalE, PhoA and other genes. A preferred prokaryotic signal sequence for practicing this invention is the £ coli heat-stable enterotoxin II (STII) signal sequence as described by Chang ef al. , Gene. 55: 189 [1987].
Another useful component of the vectors used to practice this invention is phenotypic selection genes. Typical phenotypic selection genes are those encoding proteins that confer antibiotic resistance upon the host cell. By way of illustration, the ampicillin resistance gene (amp), and the tetracycline resistance gene (lei) are readily employed for this purpose.
Construction of suitable vectors comprising the aforementioned components as well as the gene encoding the desired polypeptide (gene 1) are prepared using standard recombinant DNA procedures as described in Sambrook ef al. supra. Isolated DNA fragments to be combined to form the vector are cleaved, tailored, and ligated together in a specific order and orientation to generate the desired vector.
The DNA is cleaved using the appropriate restriction enzyme or enzymes in a suitable buffer. In general, about 0.2-1 μg of plasmid or DNA fragments is used with about 1-2 units of the appropriate restriction enzyme in about 20 μl of buffer solution. Appropriate buffers, DNA concentrations, and incubation times and temperatures are specified by the manufacturers of the restriction enzymes. Generally, incubation times of about one or two hours at 37'C are adequate, although several enzymes require higher temperatures. After incubation, the enzymes and other contaminants are removed by extraction of the digestion solution with a mixture of phenol and chloroform, and the DNA is recovered from the aqueous fraction by precipitation with ethanol.
To ligate the DNA fragments together to form a functional vector, the ends of the DNA fragments must be compatible with each other. In some cases, the ends will be directly compatible after endonuclease digestion. However, it may be necessary to first convert the sticky ends commonly produced by endonuclease digestion to blunt ends to make them compatible for ligation. To blunt the ends, the DNA is treated in a suitable buffer for at least 15 minutes at 15'C with 10 units of of the Klenow fragment of DNA polymerase I (Klenow) in the presence of the four deoxynucleotide triphosphates. The DNA is then purified by phenol-chloroform extraction and ethanol precipitation.
The cleaved DNA fragments may be size-separated and selected using DNA gel electrophoresis. The DNA may be electrophoresed through either an agarose or a polyacryiamide matrix. The selection of the matrix will depend on the size of the DNA fragments to be separated. After electrophoresis, the DNA is extracted from the matrix by electroelution, or, if low-melting agarose has been used as the matrix, by melting the agarose and extracting the DNA from it, as described in sections 6.30-6.33 of Sambrook et al., supra.
The DNA fragments that are to be ligated together (previously digested with the appropriate restriction enzymes such that the ends of each fragment to be ligated are compatible) are put in solution in about equimolar amounts. The solution will also contain ATP, ligase buffer and a ligase such as T4 DNA ligase at about 10 units per 0.5 μg of DNA. If the DNA fragment is to be ligated into a vector, the vector is at first linearized by cutting with the appropriate restriction endonuclease(s). The linearized vector is then treated with alkaline phosphatase or calf intestinal phosphatase. The phosphatasing prevents seiHigation of the vector during the ligation step.
After ligation, the vector with the foreign gene now inserted is transformed into a suitable host cell. Prokaryotes are the preferred host cells for this invention. Suitable prokaryotic host cells include £ coli strain JM101, £ coli K12 strain 294 (ATCC number 31,446), £ coli strain W3110 (ATCC number 27,325), £ coli X1776 (ATCC number 31, 537), E.coli XL-1 Blue (stratagene), and E coli B; however many other strains of £ coli, such as HB101, NM522, NM538, NM539, and many other species and genera of prokaryotes ma be used as well. In addition to the £ coli strains listed above, bacilli such as Bacillus subtilis. other enterobacteriaceae such as Salmonella typ muπum or Serratia marasaπs, and various Pseudomonas species mayaii be used as hosts. Transformation of prokaryotic cells is readily accomplished using the calcium chloride method as described in section 1.82 of Sambrook et al., supra. Alternatively, electroporation (Neumann ef al., EMBO J.. 1:841 [1982]) may be used to transform these cells. The transformed cells are selected by growth on an antibiotic, commonly tetracycline (tet) or ampicillin (amp), to which they are rendered resistant due to the presence of tet and/or amp resistance genes on the vector. After selection of the transformed cells, these cells are grown in culture and the plasmid DNA (or other vector with the foreign gene inserted) is then isolated. Plasmid DNA can be isolated using methods known in the art. Two suitable methods are the small scale preparation of DNA and the large-scale preparation of DNA as described in sections 1.25-1.33 of Sambrook et al, supra. The isolated DNA can be purified by methods known in the art such as that described in section 1.40 of Sambrook ef al., supra. This purified plasmid DNA is then analyzed by restriction mapping andor DNA sequencing. DNA sequencing is generally performed by either the method of Messing et al. Nucleic Acids Res..9*309 [1981] or by the method of Maxam etal. Meth. Enzymol..65: 499 [1980]. IV. ~-rf.-.-*~
This invention contemplates fusing the gene enclosing the desired polypeptide (gene 1 ) to a second gene (gene 2) such that a fusion protein is generated during transcription. Gene 2 is typically a coat protein gene of a phage, and preferably it is the phage M13 gene III coat protein, or a fragment thereof. Fusion of genes 1 and 2 may be accomplished by inserting gene 2 into a particular site on a plasmid that contains gene 1 , or by inserting gene 1 into a particular site on a plasmid that contains gene 2.
Insertion of a gene into a plasmid requires that the plasmid be cut at the precise location that the gene is to be inserted. Thus, there must be a restriction endonuclease site at this location (preferably a unique site such that the plasmid will only be cut at a single location during restriction endonuclease digestion). The plasmid is digested, phosphafased, and purified as described above. The gene is then inserted into this linearized plasmid by ligating the two DNAs together. Ligation can be accomplished if the ends of the plasmid are compatible with the ends of the gene to be inserted. If the restriction enzymes are used to cut the plasmid and isolate the gene to be inserted create blunt ends or compatible sticky ends, the DNAs can be ligated together directly using a ligase such as bacteriophage T4 DNA ligase and incubating the mixture at 16'C for 14 hours in the presence of ATP and ligase buffer as described in section 1.68 of Sambrook et al., sucia. If the ends are not compatible, they must first be made blunt by using the Klenow fragment of DNA polymerase I or bacteriophage T4 DNA polymerase, both of which require the four deoxyribonucleotide triphosphates to fill-in overhanging single-stranded ends of the digested DNA. Alternatively, the ends may be blunted using a nuclease such as nuclease S1 or mung-bean nuclease, both of which function by cutting back the overhanging single strands of DNA. The DNA is then religated using a ligase as described above. In some cases, it may not be possible to blunt the ends of the gene to be inserted, as the reading frame of the coding region will be altered. To overcome this problem, oligonucieotide linkers may be used. The linkers serve as a bridge to connect the plasmid to the gene to be inserted. These linkers can be made synthetically as double stranded or single stranded DNA using standard methods. The linkers have one end that is compatible with the ends of the gene to be inserted; the linkers are first ligated to this gene using ligation methods described above. The other end of the linkers is designed to be compatible with the plasmid for ligation. In designing the linkers, care must be taken to not destroy the reading frame of the gene to be inserted or the reading frame of the gene contained on the plasmid. In some cases, it may be necessary to design the linkers such that they code for part of an amino acid, or such that they code for one or more amino acids.
Between gene 1 and gene 2, DNA encoding a termination codon may be inserted, such termination codons are UAG( amber), UAA (ocher) and UGA (opel). (Microbiology, Davis et al. Harper & Row, New York, 1980, pages 237, 245-47 and 274). The termination codon expressed in a wild type host cell results in the synthesis of the gene 1 protein product without the gene 2 protein attached. However, growth in a suppressor host cell results in the synthesis of detectable quantities of fused protein. Such suppressor host cells contain a tRNA modified to insert an amino acid in the termination codon position of the mRNA thereby resulting in production of detectible amounts of the fusion protein. Such suppressor host cells are well known and described, such as E.coli suppressor strain (Bullock et al., BioTechniques 5, 376-379 [1987]). Any acceptable method may be used to place such a termination codon into the mRNA encoding the fusion polypeptide.
The suppressible codon may be inserted between the first gene encoding a polypeptide, and a second gene encoding at least a portion of a phage coat protein. Alternatively, the suppressible termination codon may be inserted adjacent to the fusion site by replacing the last amino acid triplet in the polypeptide or the first amino acid in the phage coat protein. When the phagemid containing the suppressible codon is grown in a suppressor host cell, it results in the detectable production of a fusion polypeptide containing the polypeptide and the coat protein. When the phagemid is grown in a non-suppressor host cell, the polypeptide is synthesized substantially without fusion to the phage coat protein due to termination at the inserted suppressible triplet encoding UAG, UAA, or UGA. In the non-suppressor cell the polypeptide is synthesized and secreted from the host cell due to the absence of the fused phage coat protein which otherwise anchored it to the host cell. V. Alterationfmutatlonϊ of Gene 1 at Selected Positions
Gene 1 , encoding the desired polypeptide, may be altered at one or more selected codons. An alteration is defined as a substitution, deletion, or insertion of one or more codons in the gene encoding the polypeptide that results in a change in the amino acid sequence of the polypeptide as compared with the unaltered or native sequence of the same polypeptide. Preferably, the alterations will be by substitution of at least one amino acid with any other amino acid in one or more regions of the molecule. The alterations may be produced be a variety of methods known in the art. These methods include but are not limited to oligonucieotide-mediated mutagenesis and cassette mutagenesis.
A. αiqonucleoBde-Medlated Mutagenesis
Oligonucleotide -mediated mutagenesis is preferred method for preparing substitution, deletion, and insertion variants of gene 1. This technique is well known in the art as described by Zoller et al. Nucleic Acids Res. j£: 6487-6504 [1987]. Briefly, gene 1 is altered by hybridizing an oligonucleotide encoding the desired mutation to a DNA template, where the template is the single-stranded form of the plasmid containing the unaltered or native DNA sequence of gene 1. After hybridization, a DNA polymerase is used to synthesize an entire second complementary strand of the template will thus incorporate the oligonucleotide primer, and will code for the selected alteration in gene 1.
Generally, oligonucleotides of at least 25 nucleotides in length are used. An optimal oligonucleotide will have 12 to 15 nucleotides that are completely complementary to the template on either side of the nudeotide(s) coding for the mutation. This ensures that the oligonucleotide will hybridize properly to the single-stranded DNA template molecule. The oligonucleotides are readily synthesized using techniques known in the art such as that described by Crea ef al. Proc. Natl. Acad. Sci. USA.75: 5765 [1978].
The DNA template can only be generated by those vectors that are either derived from bacteriophage M13 vectors (the commercially available M13mp18 and M13mp19 vectors are suitable), or those vectors that contain a single-stranded phage origin of replication as described by Viera etal. Meth. EπzvmoL 153: 3 [1987]. Thus, the DNA that is to be mutated must be inserted into one of these vectors in order to generate single- stranded template. Production of the single-stranded template is described in sections 4.214.41 of Sambrook etal., supra. To alter the native DNA sequence, the oligonucleotide is hybridized to the single stranded template under suitable hybridization conditions. A DNA polymerizing enzyme, usually the Klenow fragment of DNA polymerase I, is then added to synthesize the complementary strand of the template using the oligonucleotide as a primer for synthesis. A heteroduplex molecule is thus formed such that one strand of DNA encodes the mutated form of gene 1 , and the other strand (the original template) encodes the native, unaltered sequence of gene 1. This heteroduplex molecule is then transformed into a suitable host cell, usually a prokaryote such as £ Coli JM101. After growing the cells, they are plated onto agarose plates and screened using the oligonucleotide primer radiolabelled with 32-Phosphate to identify the bacterial colonies that contain the mutated DNA.
The method described immediately above may be modified such that a homoduptex molecule is created wherein both strands of the plasmid contain the mutation(s). The modifications are as follows: The single- stranded oligonucleotide is annealed to the single-stranded template as described above. A mixture of three deoxyribonucleotides, deoxyriboadenosine (dATP), deoxyriboguanosine (dGTP), and deoxyribothymidine (dTTP), is combined with a modified thio-deoxyribocytosine called dCTP-(aS) (which can be obtained from Amersham). This mixture is added to the template-oligonucleotide complex. Upon addition of DNA polymerase to this mixture, a strand of DNA identical to the template except for the mutated bases is generated. In addition, this new strand of DNA will contain dCTP-(aS) instead of dCTP, which serves to protect it from restriction endonuclease digestion. After the template strand of the double-stranded heteroduplex is nicked with an appropriate restriction enzyme, the template strand can be digested with Exolll nuclease or another appropriate nuclease past the region that contains the site(s) to be mutagenized. The reaction is then stopped to leave a molecule that is only partially single-stranded. A complete double-stranded DNA homodupiex is then formed using DNA polymerase in the presence of all four deoxyribonucleotide triphosphates, ATP, and DNA ligase. This homodupiex molecule can then be transformed into a suitable host cell such as £ coli JM101 , as described above.
Mutants with more than one amino acid to be substituted may be generated in one of several ways. If the amino acids are located close together in the polypeptide chain, they may be mutated simultaneously using one oligonucleotide that codes for all of the desired amino acid substitutions. If, however, the amino acids are located some distance from each other (separated by more than about ten amino acids), it is more difficult to generate a single oligonucleotide that encodes all of the desired changes. Instead, one of two alternative methods may be employed.
In the first method, a separate oligonucleotide is generated for each amino acid to be substituted. The oligonucleotides are then annealed to the single-stranded template DNA simultaneously, and the second strand of DNA that is synthesized from the template will encode all of the desired amino acid substitutions. The alternative method involves two or more rounds of mutagenesis to produce the desired mutant. The first round is as described for the single mutants: wild-type DNA is used for the template, an oligonucleotide encoding the first desired amino acid substitution(s) is annealed to this template, and the heteroduplex DNA molecule is then generated. The second round of mutagenesis utilizes the mutated DNA produced in the first round of mutagenesis as the template. Thus, this template already contains one or more mutations. The oligonucleotide encoding the additional desired amino acid substitution(s) is then annealed to this template, and the resulting strand of DNA now encodes mutations from both the first and second rounds of mutagenesis. This resultant DNA can be used as a template in a third round of mutagenesis, and so on. B. Cassette Mutagenesis
This method is also a preferred method for preparing substitution, deletion, and insertion variants of gene l. The method is based on that described by Wells ef al. Gene.34:315 [1985].. The starting material is the plasmid (or other vector) comprising gene 1 , the gene to be mutated. The codon(s) in gene 1 to be mutated are identified. There must be a unique restriction endonuclease site on each side of the identified mutation site(s). If no such restriction sites exist, they may be generated using the above-described oligonucleotide-mediated mutagenesis method to introduce them at appropriate locations in gene 1. After the restriction sites have been introduced into the plasmid, the plasmid is cut at these sites to linearize it. A double-stranded oligonucleotide encoding the sequence of the DNA between the restriction sites but containing the desired mufation(s) is synthesized using standard procedures. The two strands are synthesized separately and then hybridized together using standard techniques. This double-stranded oligonucleotide is referred to as the cassette. This cassette is designed to have 3' and 5' ends that are compatible with t e ends of the linearized plasmid, such that it can be directly ligated to the plasmid. This plasmid now contains the mufated DNA sequence of gene 1. VI. Obtaining DNA encoding the desired protein In an alternative embodiment, mis invention contemplates production of variants of a desired protein containing one or more subunits. Each subunit is typically encoded by separate gene. Each gene encoding each subunit can be obtained by methods known in the art (see, for example, Section II). In some instances, it may be necessary to obtain the gene encoding the various subunits using separate techniques selected from any of the methods described in Section II. When constructing a replicable expression vector where the protein of interest contains more than one subunit, all subunits can be regulated by the same promoter, typically located 5' to the DNA encoding the subunits, or each may be regulated by separate promoter suitably oriented in the vector so that each promoter is operabfy linked to the DNA it is intended to regulate . Selection of promoters is carried out as described in Section III above. In constructing a replicable expression vector containing DNA encoding the protein of interest having multiple subunits, the reader is referred to Figure 10 where, by way of illustration, a vector is diagrammed showing DNA encoding each subunit of an antibody fragment This figure shows that generally, one of the subunits of the protein of interest will be fused to a phage coat protein such as M13 gene III. This gene fusion generally will contain its own signal sequence. A separate gene encodes the other subunit or subunits, and it is apparent that each subunit generally has its own signal sequence. Figure 10 also shows that a single promoter can regulate the expression of both subunits. Alternatively, each subunit may be independently regulated by a different promoter. The protein of interest subunit-phage coat protein fusion construct can be made as described in Section IV above.
When constructing a family of variants of the desired multi-subunit protein, DNA encoding each subunit in the vector may mutated in one or more positions in each subunit When multi-subunit antibody variants are constructed, preferred sites of mutagenesis correspond to codons encoding amino acid residues located in the complemenfarity-determining regions (CDR) of either the light chain, the heavy chain, or both chains. The CDRs are commonly referred to as the hypervariable regions. Methods for mutagenizing DNA encoding each subunit of the protein of interest are conducted essentially as described in Section V above.
VII. Preparing a Target Molecule and Binding wffli Phagemid
Target proteins, such as receptors, may be isolated from natural sources or prepared by recombinant methods by procedures known in the art. B way of illustration, glycoprotein hormone receptors may be prepared by the technique described by McFarland etal., Science 245:494499 [1989], nonglycosylated forms expressed in £ co// are described by Fuh et al. J. Biol. Chem 265:3111-3115 [1990] Other receptors can be prepared by standard methods.
The purified target protein may be attached to a suitable matrix such as agarose beads, acrylamide beads, glass beads, cellulose, various acrylic copolymers, hydroxylalkyi methacrylate gels, polyacrylic and polymethacryiic copolymers, nylon, neutral and ionic carriers, and the like. Attachment of the target protein to the matrix may be accomplished by methods described in Methods in Enzvmologv .44 [1976], or by other means known in the art.
After attachment of the target protein to the matrix, the immobilized target is contacted with the library of phagemid particles under conditions suitable for binding of at least a portion of the phagemid particles with the immobilized target. Normally, the conditions, including pH, ionic strength, temperature and the like will mimic physiological conditions.
Bound phagemid particles ("binders") having high affinity for the immobilized target are separated from those having a low affinity (and thus do not bind to the target) by washing. Binders may be dissociated from the immobilized target by a variety of methods. These methods include competitive dissociation using the wild-type ligand, altering pH and/or ionic strength, and methods known in the art.
Suitable host cells are infected with the binders and helper phage, and the host cells are cultured under conditions suitable for amplification of the phagemid particles. The phagemid particles are then collected and the selection process is repeated one or more times until binders having the desired affinity for the target molecule are selected. Optionally the library of phagemid particles may be sequentially contacted with more than one immobilized target to improve selectivity for a particular target. For example, it is often the case that a ligand such as hGH has more than one natural receptor. In the case of hGH, both the growth hormone receptor and the prolactin receptor bind the hGH ligand. It may be desirable to improve the selectivity of hGH for the growth hormone receptor over the prolactin receptor. This can be achieved by first contacting the library of phagemid particles with immobilized prolactin receptor, eluting those with a low affinity (i.e. lower than wild type hGH) for the prolactin receptor and then contacting the low affinity prolactin 'binders* or non-binders with the immobilized growth hormone receptor, and selecting for high affinity growth hormone receptor binders. In this case an hGH mutant having a lower affinity for the prolactin receptor would have therapeutic utility even if the affinity for the growth hormone receptor were somewhat lower than that of wild type hGH. This same strategy may be employed to improve selectivity of a particular hormone or protein for its primary function receptor over its clearance receptor.
In another embodiment of this invention, an improved substrate amino acid sequence can be obtained. These may be useful for making better 'cut sites' for protein linkers, or for better protease substrates/inhibitors. In this embodiment, an immobiiizabie molecule (e.g. hGH-receptor, biotin-avidin, or one capable of covalent linkage with a matrix) is fused to gene III through a linker. The linker will preferably be from 3 to 10 amino acids in length and will act as a substrate for a protease. A phagemid will be constructed as described above where the DNA encoding the linker region is randomly mutated to produce a randomized library of phagemid particles with different amino acid sequences at the linking site. The library cf phagemid particles are then immobilized on a matrix and exposed to a desired protease. Phagemid particles having preferred or better substrate amino add sequences in the liner region for the desired protease will be eluted, first producing an enriched pool of phagemid partides encoding preferred linkers. These phagemid partides are then cyded several more times to produce an enriched pool of particles encoding consense sequence(s) (see examples XIII and XIV). VIII. Gi-owthHoiroreVartai-teandMel-^ The cloned gene for hGH has been expressed in a secreted form in Eschericha cola (Chang, C. N>, et al.,
[1987] Gene 55. 189) and its DNA and amino acid sequence has been reported (Goeddel, etal. [1979] Nature 281. 544; Gray etal., [1985JfiSD£22, 247). The present invention describes novel hGH variants produced using the phagemid selection methods. Human growth hormone variants containing substitutions at positions 10, 14, 18, 21 , 167, 171, 172, 174, 175, 176, 178 and 179 have been described. Those having higher binding affinities are described in Tables VII, XIII and XIV. The amino acid nomenclature for describing the variants is shown below. Growth hormone variants may be administered and formulated in the same manner as regular growth hormone. The growth hormone variants of the present invention may be expressed in any recombinant system which is capable of expressing native or met hGH.
Therapeutic formulations of hGH for therapeutic administration are prepared for storage by mixing hGH having the desired degree of purity with optional physiologically acceptable carriers, excipients, or stabilizers (Remington's Pharmaceutical Sdences. 16th edition, Osol, A., Ed., (1980)., in the form of lyophilized cake or aqueous solutions. Acceptable carriers, excipients or stabilizers are nontoxic to redpients at the dosages and concentrations employed, and indude buffers such as phosphate, citrate, and other organic adds; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) poiypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as pdyvinytpyrrolidone; amino adds such as glydne, glufamine, asparagine, arginine, or iysine; monosaccharides, disaccharides, and other carbohydrates induding glucose, mannose, or dextrins; chelating agents such as EDTA; divalent metal ions such as zinc, cobalt or copper; sugar alcohols such as marmitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween, Pluronics or polyethylene glycol (PEG). Formulations of the present invention may additionally contain a pharmaceutically acceptable buffer, amino add, bulking agent and/or non-ionic surfactant These include, for example, buffers, chelating agents, antioxidants, preservatives, cosolvents, and the like; specific examples of these could indude, bimethylamaine salts (Tris buffer"), and disodiu edetate. The phagemids of the present invention may be used to produce quantities of the hGH variants free of the phage protein. To express hGH variants free of the gene ill portion of the fusion, pS0643 and derivatives can simply be grown in a non- suppressor strain such as 16C9. In this case, the amber codon (TAG) leads to termination of translation, which yields free hormone, without the need for an independent DNA construction. The hGH variant is secreted from the host and may be isolated from the culture medium.
One or more of the eight hGH amino adds F10, M14, H18, H21, R167, D171,T175 and 1179 may bereped by any amino add other than the one found in that position in naturally occurring hGH as indicated. Therefore, 1 , 2, 3, 4, 5, 6,7, or all 8 of the indicated amino adds, F10, M14, H18, H21, R167, D171, T175 and 1179, maybe replaced by any of the other 19 amino acids out of the 20 amino acids listed below. In apreferred embodiment all eight listed amino acids are replaced by another amino acid. The most preferred eight amino acids to be substituted are indicated in Table XIV in Example XII. Airtno add nomenclature.
Ala (A) Arg (R) Asn (N)
Asp (D) Cys (C) Gin (Q) Glu (E) Gly (G)
His (H) He (I) Leu (L) Lys (K) Met (M)
Phe (F) Pro (P) Ser (S) Thr (T) Trp (W)
Tyr (Y) Val (V) The one letter hGH variant nomendature first gives the hGH amino add deleted, for example glufamate 179; then the amino acid inserted; for example, serine; resulting in (E1795S).
EXAMPLES Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and illustrative examples, make and utilize the present invention to the fullest extent. The following working examples therefore specifically point out preferred embodiments of the present invention, and are not to be construed as limiting in any way of the remainder of the disclosure.
EXAMPLE I Plasmid Constructions and Preparation of hGH-phagemld Partides The plasmid phGH-M13glll (Fig. 1), was constructed from M13K077 and the hGH producing plasmid, pB0473 (Cunningham, B. C, etal. , Science.243:1330-1336, [1989]). A synthetic oligonucleotide 5'-AGC- TGT-GGC-TTC-GGG-CCC-TTA-GCA-TTT-AAT-GCG-GTA-3' was used to introduce a unique Apal restriction site (underlined) into pB0473 after the final Phe191 codon of hGH. The oligonudeotide 5'-TTC- ACA-AAC-GAA-GGG-CCC-CTA-ATT-AAA-GCC-AGA-3' was used to introduce a unique Apa\ restriction site (underlined), and a Glu197-to-amber stop codon (bold lettering) into M13K07 gene III. The oligonudeotide 5'- CAA-TAA-TAA-CGG-GCT-AGC-CAA-AAG-AAC-TGG-3' introduces a unique Nhe\ site (underlined) after the 3' end of the gene III coding sequence. The resulting 650 base pair (bp) Apa\-Nhe\ fragment from the doubly mutated M13K07 gene III was cloned into the large Apa\-Nne\ fragment of pB0473 to create the plasmid, pS0132. This fuses the carboxyl terminus of hGH (Phe191) to the Pro198 residue of the gene III protein with the insertion of a glydne residue encoded from the Apal site and places the fusion protein under control of the £ coli alkaline phosphatase (pftαA) promoter and stll secretion signal sequence (Chang, C. N., etal. , Q~~~\, 55:189-196, [1987]). For indudble expression of the fusion protein in rich media, we replaced the phoA promoter with the lac promoter and operator. A 138 bp EcoRI-Xbal fragment containing the lac promoter, operator, and Cap binding site was produced by PCR of plasmid pUC119 using the oligonudeotides 5'-
CACGACAGAATTCCCGACTGGAAA-3' and 5'-CTGTT ICIA2ΔGTGAAATTGTTA-3' that flank the desired lac sequences and introduce the EcoRl and Xbal restriction sites (underlined). This lac fragment was gel purified and ligated into the large EcoRI-X&al fragment of pS0132 to create the plasmid, phGH-M13glll. The sequences of all tailored DNA junctions were verified by the dideoxy sequence method (Sanger, F., et al. Proc. Natl. Acad. Sd. U.S.A.74:5463-5467. [1977]). The R64A variant hGH phagemid was constructed as follows: the Nsil-Bglll mutated fragment of hGH (Cuπninghamef at supra ) encoding the Arg64 to Ala substitution (R64A) (Cunningham, B. C, Wells, J. A.. Sdeπce.244:1081-1085. [1989]) was cloned between the corresponding restriction sites in the phGH-M13glll plasmid (Rg. 1) to replace the wild-type hGH sequence. The R64A hGH phagemid partides were propagated and titered as described below for the wild-type hGH-phagemid.
Plasmids were transformed into a male strain of £ coli (JM 101) and selected on carbenidllin plates. A single transformant was grown in 2 ml 2YT medium for 4 h at 37'C and infected with 50 μl of M13K07 helper phage. The infected culture was diluted into 30 ml 2YT, grown overnight and phagemid partides were harvested by predpitation with polyethylene glycol (Vierra, J., Messing, J..Methods in Enzymology.153:3-11, [1987]). Typical phagemid partide titers ranged from 2 to 5 x 1011 cfu/ml. The partides were purified to homogeneity by CsCI density cenbrifugatioπ (Day, LA. J. Mol. Biol..39265-277, [1969]) to remove any fusion protein not attached to virions. EXAMPLE II hmuiochejrical Analyses of hGH on the Fusion Phage Rabbit polydoπal antibodies to hGH were purified with protein A, and coated onto microtiter plates (Nunc) at a concentration of 2 μg/ml in 50 M sodium carbonate buffer (pH 10) at 4'C for 16-20 hours. After washing in PBS containing 0.05% Tween 20, hGH or hGH-phagemid partides were serially diluted from 2.0 - 0.002 nM in buffer A (50 mM Tris (pH 7.5), 50 mM NaCl, 2 mM EDTA, 5 mg/ml bovine serum albumin, and 0.05% Tween 20). After 2 hours at room temperature (rt), the plates were washed well and the indicated Mab (Cunπinghamef a/, supra ) was added at 1 μg/ml in buffer A for 2 hours at rt. Following washing, horseradish peroxidase conjugated goat anti-mouse IgG antibody was bound at rt for 1 hour. After a final wash, the peroxidase activity was assayed with the substrate, σ-pheπyienediamine. EXAMPLE 111
Coupling of the hGH Binding Protein to Polyaαylamide Beads and Binding Enrichments Oxirane polyacrylamide beads (Sigma) were conjugated to the purified extracellular domain of the hGH receptor (hGHbp) (Fuh, G., etal., J. Biol. Chem.. 265:3111-3115 [1990]) containing an extra cysteine residue introduced by site-directed mutagenesis at position 237 that does not affect binding of hGH (J. Wells, unpublished). The hGHbp was conjugated as recommended by the supplier to a level of 1.7 pmol hGHbp/mg dry oxirane bead, as measured by binding of [125l] hGH to the resin. Subsequently, any unreacted oxirane groups wer blocked with BSA and Tris. As a control for non-spedfic binding of phagemid partides, BSA was similarly coupled to the beads. Buffer for adsorption and washing contained 10 mM Tris-HCI (pH 7.5), 1 mM EDTA, 50 mM NaCl, 1 mg/ml BSA, and 0.02% Tween 20. Elution buffers contained wash buffer plus 200 nM hGH or 0.2 M glydne (pH 2.1). Parental phage M13K07 was mixed with hGH phagemid particles at a ratio of nearly 3000:1 (original mixture) and tumbled for 8-12 h with a 5 μl aliquot (0.2 mg of acrylamide beads) of either absorbent in 50 μl volume at room temperature. The beads were pelleted by centrifugation and the supernate carefully removed. The beads were resuspended in 200 μl wash buffer and tumbled at room temperature for 4 hours (wash 1). After a second wash (wash 2), the beads were eluted twice with 200 nM hGH for 6-10 hours each (eluate 1 , eluate 2). The final elution was with a glydne buffer (pH 2.1) for 4 hours to remove remaining hGH phagemid partides (eluate 3). Each fraction was diluted appropriately in 2YT media, mixed with fresh JM101, incubated at 37'C for 5 minutes, and plated with 3 ml of 2YT soft agar on LB or LB carbenicillin plates.
EXAMPLE IV Construction of hGH-phagemid Particles with a Mixture of Gene III Products
The gene III protein is composed of 410 residues divided into two domains that are separated by a flexible linker sequence (Armstrong, J., etal., FEBS Lett..135:167-172, [1981]). The amino-terminal domain is required for attachment to the pili of £ coli, while the carboxyl-terminal domain is imbedded in the phage coat and required for proper phage assembly (Crissman, J. W., Smith, G. P., Virology. 132:445455, [1984]). The signal sequence and amino-terminal domain of gene III was replaced with the stll signal and entire hGH gene (Chang et al. supra) by fusion to residue 198 in the carboxyl-terminal domain of gene III (Fig.1). The hGH-gene III fusion was placed under control of the lac promoter/operator in a plasmid (phGH-M13glll; Fig. 1) containing the pBR322 β-lactamase gene and Col E1 replication origin, and the phage f 1 intergenic region. The vector can be easily maintained as a small plasmid vector by selection on carbeni iiin, which avoids relying on a functional gene III fusion for propagation. Alternatively, the plasmid can be efficiently packaged into virions (called phagemid partides) by infection with helper phage such as M13K07 (Viera etal.. supra ) which avoids problems of phage assembly. Phagemid infectivity titers based upon transduction to carbenidiiin resistance in this system varied from 2-5 x 10 1colony forming units (cfuVml. The titer of the M13K07 helper phage in these phagemid stocks is ~101^ plaque forming units (pfu)/ml. With this system we confirmed previous studies (Parmley, Smith supra) that homogeneous expression o large proteins fused to gene III is deleterious to phage production (data not shown). For example, induction of the lac promoter in phGH-M13glll by addition of IPTG produced low phagemid titers. Moreover, phagemid particles produced by co-infection with M13K07 containing an amber mutation in gene III gave very low phagemid titers (<1010 cfu/ml). We believed that multiple copies of the gene III fusion attached to the phagemid surface could lead to multiple point attachment (the "chelate effecf) of the fusion phage to the immobilized target protein. Therefore to control the fusion protein copy number we limited transcription of the hGH-gene III fusion by culturing the plasmid in £ coli JM101 (lac ) which contains a constiturjvely high level of the lac repressor protein. The £ coli JM101 cultures containing phGH-M13glll were best propagated and infected with M13K07 in the absence of the lac operon inducer (IPTG); however, this system is flexible so that co-expression of other gene III fusion proteins can be balanced. We estimate that about 10% of the phagemid partides contain one copy of the hGH gene III fusion protein from the ratio of the amount of hGH per virion (based on hGH immuno-reactive material in CsCI gradient purified phagemid). Therefore, the titer of fusion phage displaying the hGH gene III fusion is about 2 - 5 x 1010/ml. This number is much greater than the titer of £ coli (-108 to 109/ml) in the culture from which they are derived. Thus, on average every £ coli cell produces 10-100 copies of phage decorated with an hGH gene III fusion protein.
EXAMPLE V
Structural Integrity of the hGH-gene II Fusion immunoblot analysis (Fig.2) of the hGH-gene III phagemid show that hGH cross-reactive material comigrates with phagemid partides in agarose gels. This indicates that the hGH is tightly assodated with phagemid partides. The hGH-gene III fusion protein from the phagemid partides runs as a single immuno-stained band showing that there is little degradation of the hGH when it is attached to gene III. Wild-type gene III protein is dearly present because about 25% of the phagemid partides are infectious. This is comparable to specific infectivity estimates made for wild-type M13 phage that are similarly purified (by CsCI density gradients) and concentrations estimated by UV absorbance (Smith, G. P. supra and Parmley, Smith supra) Thus, both wild-type gene III and the hGH-gene III fusion proteins are displayed in the phage pool.
It was important to confirm that the tertiary structure of the displayed hGH was maintained in order to have confidence that results from binding selections will translate to the native protein. We used monodonal antibodies (Mabs) to hGH to evaluate the structural integrity of the displayed hGH gene III fusion protein (Table I).
TABLE L Binding of Eight Different Monoclonal Antibodies (Mab"s) to hGH and hGH Phagemid Particles*
Mab
1 2 3 4 5 6 7 8
Figure imgf000026_0001
Values given represent the concentration (nM) of hGH or hGH-phagemid partides to give half-maximal binding to the particular Mab. Standard errors in these measurements are typically at or below ±30% of the reported value. See Materials and Methods for further details. The epitopes on hGH for these Mabs have been mapped (Cunningham ef al.. supra) and binding for 7 of
8 Mabs requires that hGH be properly folded. The IC50 values for all Mabs were equivalent to wild-type hGH except for Mab 5 and 6. Both Mabs 5 and 6 are known to have binding determinants near the carboxyl-terminus of hGH which is blocked in the gene III fusion protein. The relative IC50 value for Mab1 which reacts with both native and denatured hGH is unchanged compared to the conformationally sensitive Mabs 2-5, 7 and 8. Thus, Mab1 serves as a good internal control for any errors in matching the concentration of the hGH standard to that of the hGH-gene 111 fusion. EXAMPLE VI Binding Enrichments on Receptor Affinity Beads
Previous workers (Parmley, Smith supra ; Scott Smith supra; Cwiria etal. supra; and Devlin etal. supra) have fractionated phage by panning with streptavidin coated polystyrene petri dishes or microtiter plates. However, chromatographic systems would allow more efficient fractionation of phagemid partides displaying mutant proteins with different binding affinities. We chose non-porous oxirane beads (Sigma) to avoid trapping of phagemid partides in the chromatographic resin. Furthermore, these beads have a small particle size (1 μm) to maximize the surface area to mass ratio. The extracellular domain of the hGH receptor (hGHbp) (Fuh etal. , supra) confaining a free cysteino residue was efficientiy coupled to these beads and phagemid particles showed very low non-spedfic binding to beads coupled only to bovine serum albumin (Table II).
TABLE II. Specific Binding of Hormone Phage to hGHbp-coated
Beads Provides an Enrichment for hGH-phage over M13K07 Phage*
Figure imgf000027_0001
*The titers of M13KO7 and hGH-phagemid particles in each fraction was determined by multiplying the number of plaque forming units (pfu) or carbenidiiin resistant colony forming units (cfu) by the dilution factor, respectively. See Example IV for details.
TThe ratio of M13KO7 to hGH-phagemid particles was adjusted to 3000:1 in the original mixture. ^Absorbents were conjugated with BSA or hGHbp.
§Eπrichments are calculated by dividing the cfu/pfu ratio after each step by cfu/pfu ratio in the original mixture.
In a typical enrichment experiment (Table II), one part of hGH phagemid was mixed with >3,000 parts M13K07 phage. After one cycle of binding and elution, 106 phage were recovered and the ratio of phagemid to M13K07 phage was 2 to 1. Thus, a single binding selection step gave >5000-fold enrichment. Additional elutions with free hGH or acid treatment to remove remaining phagemids produced even greater enrichments. The enrichments are comparable to those obtained by Smith and coworkers using batch elution from coated polystyrene plates (Smith, G.P. supra and Parmely, Smith supra ) however much smaller volumes are used on the beads (200 μl vs.6 ml). There was almost no enrichment for the hGH phagemid over M13K07 when we used beads linked only to BSA. The slight enrichment observed for control beads (-10-fold for pH 2.1 elution; Table 2) may result from trace contaminants of bovine growth hormone binding protein present in the BSA linked to the bead. Nevertheless these data show the enrichments for the hGH phage depend upon the presence of the hGHbp on the bead suggesting binding occurs by spedfic interaction between hGH and the hGHbp.
We evaluated the enrichment for wild-type hGH over a weaker binding variant of the hGH on fusion phagemids to further demonstrate enrichment spedfidty, and to link the reduction in binding affinity for the purified hormones to enrichment factors after panning fusion phagemids. A fusion phagemid was constructed with an hGH mutant in which Arg64 was substituted with Ala (R64A). The R64A variant hormone is about 20- fold reduced in receptor binding affinity compared to hGH (Kd values of 7.1 nM and 0.34 nM, respectively
[Cunningham, Wells, supra ]). The titers of the R64A hGH-gene III fusion phagemid were comparable to those of wild-type hGH phagemid. After one round of binding and elution (Table III) the wild-type hGH phagemid was enriched from a mixture of the two phagemids plus M13K07 by 8-fold relative to the phagemid R64A, and ~104 relative to M13K07 helper phage.
TABLE Ul. hGHbf coated Beads Select for hGH Phagemids Over a Weaker Binding hGH Variant Phagemid
Figure imgf000028_0001
*The parent M13K07 phage, wild-type hGH phagemid and R64A phagemid particles were mixed at a ratio of 10 :0.4*0.6. Binding selections were carried out using beads linked with BSA (control beads) or with the hGHbp
(hGHbp beads) as described in Table II and the Materials and Methods After each step, plasmid DNA was isolated(Birnboim, H. C, Doty, J. , Nucleic Adds Res..7:1513-1523, [1979]) from carbenidiiin resistant colonies and analyzed by restriction analysis to determine if it contained the wild-type hGH or the R64A hGH gene ill fusion. TThe enrichment for wild-type hGH phagemid over R64A mutant was calculated from the ratio of hGH phagemid present after each step to that present in the original mixture (8/20), divided by the corresponding ratio for
R64A phagemids. WT = wild-type; ND = not determined.
*The enrichment for phagemid over total M13K07 parental phage was -104 after this step.
Conclusions By displaying a mixture of wild-type gene III and the gene III fusion protein on phagemid particles one can assemble and propagate virions that display a large and proper folded protein as a fusion to gene III. The copy number of the gene III fusion protein can be effectively controlled to avoid 'chelate effects" yet maintained at high enough levels in the phagemid pool to permit panning of large epitope libraries (>1010). We have shown that hGH (a 22 kD protein) can be displayed in its native folded form. Binding selections performed on receptor affinity beads eluted with free hGH, efficientiy enriched for wild-type hGH phagemids over a mutant hGH phagemid shown to have reduced receptor binding affinity. Thus, it is possible to sort phagemid particles whose binding constants are down in the nanomoiar range. Protein-protein and antibody-antigen interactions are dominated by discontinuous epitopes (Janin, J., etal. , J. Mol. Biol- 204:155-164, [1988]; Argos, P., Prot. Enq.. 2:101-113, [1988]; Barlow, D.J.,ef al. , NaiUIS,
322:747-748, [1987]; and Davies, D.R., etal. , J. Biol. Chem.. 263:10541-10544. [1988]); that is the residues directly involved in binding are dose in tertiary structure but separated by residues not involved in binding. The screening system presented here should allow one to analyze more conveniently protein-receptor interactions and isolate discontinuous epitopes in proteins with new and high affinity binding properties.
EXAMPLE VII
Selection of hGH Mutants from a Library Randomized at hGH Codons 172, 174, 176, 178 Construction of template
A mutant of the hGH-gene III fusion protein was constructed using the method of KunkeL.ef al. Meth. Enzymol.154, 367-382 [1987]. Template DNA was prepared by growing the plasmid pS0132 (containing the natural hGH gene fused to the carboxy-terminal half of M13 gene III, under control of the alkaline phosphatase promoter) in CJ236 cells with M13-K07 phage added as helper. Single-stranded, uradl-containing DNA was prepared for mutagenesis to introduce (1 ) a mutation in hGH which would greatly reduce binding to the hGH binding protein (hGHbp); and (2) a unique restriction site (Kpnl) which could be used for assaying for ~ and selecting against - parental background phage. Oligonudeotide-directed mutagenesis was carried out using T7 DNA polymerase and the following oligodeoxy-nucieotide:
Gly Thr hGH codon: 178 179
5'-G ACA TTC CTG fiG A£C GTG CAG T-3'
< Kpnl >
This oligo introduces the Kpnl site as shown, along with mutations (R178G, I179T) in hGH. These mutations are predicted to reduce binding of hGH to hGHbp by more than 30-fold. Clones from the mutagenesis were screened by Kpnl digestion and confirmed by dideoxy DNA sequendng. The resulting construct, to be used as a template for random mutagenesis, was designated pH0415.
Random mutagenesis within hellx-4 of hGH
Codons 172, 174, 176, 178 were targeted for random mutagenesis in hGH, again using the method of
Kunkel. Single-stranded template from pH0415 was prepared as above and mutagenesis was carried out using the following pool of oligos: hGH codon: 172 174
5'- GC TTC AGG AAG GAC ATG GAC MNS. GTC NNS ACA- lie
176 178 179 - HHS. CTG HH≤. A C GTG CAG TGC CGC TCT GTG G-3'
As shown, this oligo pool reverts codon 179 to wild-type (He), destroys the unique Kpnl site of pH0415, and introduces random codons (NNS, where N= A,G,C, or T and S= G or C) at positions 172,174,176, and 178. Using this codon selection in the context of the above sequence, no additional Kpnl sites can be created. The choice of the NNS degenerate sequence yields 32 possible codons (including one "stop" codon, and at least one codon for each amino acid) at 4 sites, for a total of (32)4= 1,048,576 possible nucleotide sequences (12% of which contain at least one stop codon), or (20)4= 160,000 possible polypeptide sequences plus 34,481 prematurely terminated sequences (i.e. sequences containing at least one stop codon). Propagation of the Initial library The mutagenesis products were extracted twice with phenolxhloroform (50:50) and ethanol predpitated with an excess of carrier tRNA to avoid adding salt that would confound the subsequent electroporation step. Approximately 50 ng (15 fmols) of DNA was electroporated into WJM101 cells (2.8 x 1010 cells L) in 45 μL total volume in a 0.2 cm cuvette at a voltage setting of 2.49 kV with a single pulse (time constant = 4.7 msec.).
The cells were allowed to recover 1 hour at 37°C with shaking, then mixed with 25 mL 2YT medium, 100 μg/mL carbenidiiin, and M13-K07 (multiplicity of infection = 1000). Plating of serial dilutions from this culture onto carbenidllin-confaining media indicated that 8.2 x 106 electrotransformants were obtained. After 10' at 23°C, the culture was incubated overnight (15 hours) at37°C with shaking. After overnight incubation, the cells were pelleted, and double-stranded DNA (dsDNA), designated pLIB1 , was prepared by the alkaline lysis method. The supernatant was spun again to remove any remaining cells, and the phage, designated phage pool φ1 , were PEG-predpitated and resuspended in 1 mL STE buffer (10 mM Tris, pH 7.6, 1 mM EDTA, 50 mM NaCl). Phage titers were measured as colony-forming units (CFU) for the recombinant phagemid containing hGH-g3p gene III fusion (hGH-g3) plasmid, and plaque-forming units (PFU) for the M13-K07 helper phage.
Binding selection using hπnoHli-ffid hGHbo
1. BINDING: An aliquot of phage pool <j>1 (6 x 109 CFU, 6 x 107 PFU) was diluted 4.5-fold in buffer A (Phosphate-buffered saline, 0.5% BSA, 0.05% Tweeπ-20, 0.01% thimerosal) and mixed with a 5 μL suspension of oxirane-polyacrylamide beads coupled to the hGHbp containing a Ser237 Cys mutation (350 fmols) in a 1.5 mL silated polypropylene tube. As a control, an equivalent aliquot of phage were mixed in a separate tube with beads that had been coated with BSA only. The phage were allowed to bind to the beads by incubating 3 hours at room temperature (23°C) with slow rotation (approximately 7 RPM). Subsequent steps were carried out with a constant volume of 200μL and at room temperature.
2. WASH: The beads were spun 15 sec., and the supernatant was removed (Sup. 1). To remove phage/phagemid not spedfically bound, the beads were washed twice by resuspending in buffer A, then pelleting. A final wash consisted of rotating the beads in buffer A for 2 hours.
3. hGH ELUTION: Phage/phagemid binding weakly to the beads were removed by stepwise elution with hGH. In the first step, the beads were rotated with buffer A containing 2 nM hGH. After 17 hours , the beads were pelleted and resuspended in buffer A containing 20 nM hGH and rotated for 3 hours, then pelleted. In the final hGH wash, the beads were suspended in buffer A containing 200 nM hGH and rotated for 3 hours then pelleted.
4. GLYCINE ELUTION: To remove the tightest-binding phagemid (i.e. those still bound after the hGH washes), beads were suspended in Glydne buffer (1 M.Gtydne, pH 2.0 with HCl), rotated 2 hours and pelleted. The supernatant (fraction "G"; 200μL) was neutralized by adding 30 μL of 1 M Tris base. Fraction G eluted from the hGHbp-beads (1 x 106 CFU, 5 x 104 PFU) was not substantially enriched for phagemid over K07 helper phage. We believe this resulted from the fact that K07 phage packaged during propagation of the recombinant phagemid display the hGH-g3p fusion. However, when compared with fraction G eluted from the BSA-coated control beads, the hGHbp-beads yielded 14 times as many CFU's. This reflects the enrichment of tight-binding hGH-displaying phagemid over nonspedfically-binding phagemid.
5. PROPAGATION: An aliquot (4.3 x 105 CFU) of fraction G eluted from the hGHbp-beads was used to Infect log-phase WJM101 cells. Transductions were carried out by mixing 100 μL fraction G with 1 mL WJM101 cells, incubating 20 min. at 37°C, then adding K07 (multiplicity of infection-*** 1000). Cultures (25 mL 2YT plus carbenidiiin) were grown as described above and the second pool of phage (Library 1G, for first glydne elution) were prepared as described above.
Phage from library 1 G (Fig.3) were selected for binding to hGHbp beads as described above. Fraction G eluted from hGHbp beads contained 30 times as many CFU's as fraction G eluted from BSA-beads in this selection. Again, an aliquot of fraction G was propagated in WJM101 cells to yield library 1G2 (indicating that this library had been twice selected by glydne elution). Double-stranded DNA (pLIB 1G2) was also prepared from this culture.
Kpnl assay and restriction-selection of dsDNA To reduce the level of background (Kpnl*1*) template, an aliquot (about 0.5 μg) of pLIB 1 G2 was digested with Kpnl and electroporated into WJM101 cells. These cells were grown in the presence of K07 (multiplicity of infection^ 100) as described for the initial library, and a new phage pool, pLIB 3, was prepared (Fig. 3).
In addition, an aliquot (about 0.5 μg) of dsDNA from the initial library (pLIB1) was digested with Kpnl and electroporated directly into WJM101 cells. Transformants were allowed to recover as above, infected with M13-K07, and grown overnight to obtain a new library of phage, designated phage Library 2 (Fig.3). Successive rounds of selection
Phagemid binding, elution, and propagation were carried out in successive rounds for phagemid derived from both pLIB 2 and pLIB 3 (Fig.3) as described above, except that (1) an excess (10-fold over CFU) of purified K07 phage (not displaying hGH) was added in the bead-binding cocktail, and (2) the hGH stepwise elutions were replaced with brief washings of buffer A alone. Also, in some cases, XL1 -Blue cells were used for phagemid propagation.
An additional digestion of dsDNA with Kpnl was carried out on pLIB 2G3 and on pLIB 3G5 before the final round of bead-binding selection (Rg. 3). DNA Seαuendnα of selected phagemids
Four independently isolated dones from LIB 4G4 and four independently isolated clones from LIB 5G6 were sequenced by dideoxy sequencing. All eight of these clones had identical DNA sequences:
hGH codon: 172 174 176 178 5' -AAG GTC TCC ACA TAC CTG AGG ATC-3'
Thus, all these encode the same mutant of hGH: (E174S, F176Y). Residue 172 in these clones is Lys as in wild- type. The codon selected for 172 is also identical to wild-type hGH. This is not surprising since AAG is the only lysine-codon possible from a degenerate "NNS" codon set. Residue 178-Arg is also the same as wild-type, but here, the codon selected from the library was AAG instead of CGC as is found in wild-type hGH, even though the latter codon is also possible using the "N NS" codon set. Multiplicity of K07 Infection
The multiplidty of infection of K07 infection is an important parameter in the propagation of recombinant phagemids. The K07 multiplidty of infection must be high enough to insure that virtually all cells transformed or transfected with phagemid are able to package new phagemid partides. Furthermore, the concentration of wild-type gene III in each cell should be kept high to reduce the possibility of multiple hGH-gene III fusion molecules being displayed on each phagemid partide, thereby redudng chelate effects in binding. However, if the K07 multiplidty of infection is too high, the packaging of K07 will compete with that of recombinant phagemid. We find that acceptable phagemid yields, with only 1 -10% background K07 phage, are obtained when the K07 multiplidty of infection is 100.
Table IV.
Figure imgf000032_0001
Figure imgf000032_0002
Phage pools are labelled as shown (Rg.3). The multiplidty of infection (moi) refers to the multiplidty of K07 infection (PFU/cells) in the propagation of phagemid. The enrichment of CFU over PFU is shown in those cases where purified K07 was added in the binding step. The ratio of CFU eluting from hGHbp-beads over CFU eluting from BSA-beads is shown. The fraction of Kpnl-containiπg template (i.e., pH0415) remaining in the pool was determined by digesting dsDNA with Kpnl plus EcoRl, running the products on a 1 % agarose gel, and laser- scanning a negative of the ethidium bromide-stained DNA. Receotor-blndinq affinity of the hormone hGH(E174S. F176Y) The fact that a single done was isolated from two different pathways of selection (Rg.3) suggested that the double mutant (E174S.F176Y) binds strongly to hGHbp. To determine the affinity of this mutant of hGH for hGHbp, we constructed this mutant of hGH by site-directed mutagenesis, using a plasmid (pB0720) which contains the wild-type hGH gene as template and the following oligonucleotide which changes codons 174 and 176 : hGH codon: 172 174 176 178 Lys Ser Tyr Arg 5'- ATG GAC AAG GT.1£G ACA T C CTG CGC ATC GTG -3'
The resulting construct, pH0458B, was transformed into E. coli strain 16C9 for expression of the mutant hormone. Scatchard analysis of competitive binding of hGH(E174S.F176Y) versus 125l-hGH to hGHbp indicated that the (E174S.F176Y) mutant has a binding affinity at least 5.0-fold tighter than that of wild-type hGH. EXAMPLE VIII
SELECTION OF hGH VARIANTS FROM A HEUX-4 RANDOM CASSETTE UBRARY OF HORMONE-PHAGE
Human growth hormone variants were produced by the method of the present invention using the phagemid described in figure 9.
Construction of a de-fiffirøff PnflWff-tfttCI? -ΨM"
We designed a vector for cassette mutagenesis (Wells et al., Q~~- 34, 315-323 [1985]) and expression of the hGH-gene III fusion protein with the objectives of (1 ) improving the linkage between hGH and the gene III moiety to more favorably display the hGH moiety on the phage (2) limiting expression of the fusion protein to obtain essentially "monovalent display," (3) allowing for restriction nudease selection against the starting vector, (4) eliminating expression of fusion protein from the starting vector, and (5) achieving facile expression of the corresponding free hormone from a given hGH-gene III fusion mufant. Plasmid pS0643 was constructed by oligonudeotide-directed mutagenesis (Kunkel et at, Methods
Eπzymol.154, 367-382 [1987]) of pS0132, which contains pBR322 and f1 origins of replication and expresses an hGH-gene III fusion protein (hGH residues 1-191, followed by a single Gly residue, fused to Pro-198 of gene III) under the control of the E. coli phoA promoter (Bass et al., Proteins 8, 309-314 [1990])(Figure 9). Mutagenesis was carried out with the oligonudeotide 5'-GGC-AGC-TGT-GGC-TTC-TAG-AGT-GGC-GGC-GGC-TCT- GGT-3', which introduces a Xbal site (underiined) and an amber stop codon (TAG) following Phe-191 of hGH. In the resulting construct, pS0643, a portion of gene III was deleted, and two silent mutations (underiined) occurred, yielding the following junction between hGH and gene III:
Figure imgf000033_0001
This shortens the total size of the fusion protein from 401 residues in pS0132 to 350 residues in pS0643. Experiments using monodonal antibodies against hGH have demonstrated that the hGH portion of the new fusion protein, assembled on a phage particle, is more accessible than was the previous, longer fusion.
For propagation of hormone-displaying phage, pS0643 and derivatives can be grown in a amber- suppressor strain of E. coli. such as JM101 or XL1-Blue (Bullock et al., BioTechniques 5, 376-379 [1987]). Shown above is substitution of Glu at the amber codon which occurs in supE suppressor strains. Suppression with other amino acids is also possible in various available strains of E. coli well known and publically available.
To express hGH (or mutants) free of the gene III portion of the fusion, pS0643 and derivatives can simply be grown in a non-suppressor strain such as 16C9. In this case, the amber codon (TAG) leads to termination of translation, which yields free hormone, without the need for an independent DNA construction.
To create sites for cassette mutagenesis, pS0643 was mufated with the oiigonudeotides (1) 5'-CGG- ACT-GGG-CAG-ATA-TTC-AAG-CAG-ACC-3'. which destroys the unique fipjj] site of pS0643; (2) 5'-CTC- AAG-AAC-TAC-GGG-TTA-CCC-TGA-CTG-CTT-CAG-GAA-GG-3'. which inserts a unique BstEII site, a single-base frameshift, and a non-amber stop codon (TGA); and (3) 5'-CGC-ATC-GTG-CAG-TGC-AGA-TCT- GTG-GAG-GGC-3', which introduces a new βglll site, to yield the starting vector, pH0509. The addition of a frameshift along with a TGA stop codon insures that no genelll-fusion can be produced from the starting vector. The BstEII - fifllll segment is cut out of pH0509 and replaced with a DNA cassette, mutated at the codons of interest Other restriction sites for cassette mutagenesis at other locations in hGH have also been introduced into the hor one-phage vector. CassettemutaoenesiswithInhelix4ofhGH Codons 172, 174, 176 and 178 of hGH were targeted for random mutagenesis because they all lie on or near the surface of hGH and contribute significantly to receptor-binding (Cunningham and Wells. Science 244. 1081-1085 [1989]); they all lie within a well-defined structure, occupying 2 turns' on the same side of helix 4; and they are each substituted by at least one amino add among known evolutionary variants of hGH.
We chose to substitute NNS (N=A/G/C T; S=G/C) at each of the target residues. The choice of the NNS degenerate sequence yields 32 possible codons (induding at least one codon for each amino acid) at 4 sites, for a total of (32) = 1,048,576 possible nucleotide sequences, or (20)4= 160,000 possible polypeptide sequences. Only one stop codon, amber (TAG), is allowed by this choice of codons, and this codon is suppressible as Glu in supE strains of E. coli.
Two degenerate oligonucleotides, with NNS at codons 172, 174, 176, and 178, were synthesized, phosphoryiated, and annealed to construct the mutagenic cassette: 5'-GT-TAC-TCT-ACT-GCT-TTC-AGG- AAG-GAC-ATG-GAC-NNS-GTC-NNS-ACA-NNS-CTG-NNS-ATC-GTG-CAG-TGC-A-3', and 5'-GA-TCT- GCA-CTG-CAC-GAT-SNN-CAG-SNN-TGT-SNN-GAC-SNN-GTC-CAT-GTC-CTT-CCT-GAA-GCA-GTA- GA-3'.
The vector was prepared by digesting pH0509 with BstEII followed by Bglll. The products were run on a 1 % agarose gel and the large fragment exdsed, phenol-extracted, and ethanol predpitated. This fragment was treated with calf intestinal phosphatase (Boehringer), then phenolxhloroform extracted, ethanol predpitated, and resuspended for ligation with the mutagenic cassette.
Propagation of the inlffl library \~ XU-Blue cells
Following ligation, the reaction products were again digested with BstEII. then phenol -chloroform extracted, ethanol precipitated and resuspended in water. (A BstEjll recognition site (GGTNACC) is created within cassettes which contain a Q. at position 3 of codon 172 and an A££ (Thr) codon at 174. However, treatment with BstEII at this step should not select against any of the possible mutagenic cassettes, because virtually all cassettes will be heteroduplexes, which cannot be deaved by the enzyme.) Approximately 150 ng (45 fmols) of DNA was electroporated into XL1 -Blue cells (1.8 x 109 cells in 0.045 mL) in a 0.2 cm cuvette at a voltage setting of 2.49 kV with a single pulse (time constant = 4.7 msec).
The cells were allowed to recover 1 hour at 37°C in S.O.C media with shaking, then mixed with 25 mL 2YT medium, 100 mg/mL carbenidiiin, and M13-K07 (moi= 100). After 10' at 23°C, the culture was incubated overnight (15 hours) at 37°C with shaking. Plating of serial dilutions from this culture onto carbenidllin- containing media indicated that 3.9 x 107 electrotransformants were obtained. After overnight incubation, the cells were pelleted, and double-stranded DNA (dsDNA), designated pH0529E (the initial library), was prepared by the alkaline lysis method. The supernatant was spun again to remove any remaining cells, and the phage, designated phage pool φH0529E (the initial library of phage), were PEG-precipitated and resuspended in 1 mL STE buffer (10 mM Tris, pH 7.6, 1 mM EDTA, 50 mM NaCl). Phage titers were measured as colony-forming units (CFU) for the recombinant phagemid containing hGH-g3p. Approximately 4.5 x 1013 CFU were obtained from the starting library. Degeneracy of the starting library
From the pool of electrotransformants, 58 dones were sequenced in the region of the BstEH-Bglll cassette. Of these, 17% corresponded to the starting vector, 17% contained at least one frame shift, and 7% contained a non-silent (non-terminating) mutation outside the four target codons. We conclude that 41% of the clones were defedive by one of the above measures, leaving a total functional pool of 2.0 x 107 initial transformants. This number still exceeds the possible number of DNA sequences by nearly 20-fold. Therefore, we are confident of having all possible sequences represented in the sfarting library.
We examined the sequences of non-selected phage to evaluate the degree of codon bias in the mutagenesis (Table V). The results indicated that, although some codons (and amino adds) are under- or over- represented relative to the random expectation, the library is extremely diverse, with no evidence of large-scale
"sibling" degeneracy (Table VI).
Table V.
Codon distribution (per 188 codons) of non-selected hormone phage. Clones were sequenced from the starting library (pH0529E). All codons were tabulated, induding those from dones which contained spurious mutations and/or frameshifts. * Note: the amber stop codon (TAG) is suppressed as Glu in XL1-Blue cells. Highlighted codons were over/under-represented by 50% or more.
Figure imgf000035_0001
Table VI.
Non-selected (pH0529E) dones with an open reading frame.
The notation, e.g.TWGS, denotes the hGH mutant 172T/174W/176G/178S. Amber (TAG) codons, translated as Glu in XL1 -Blue cells are shown as ε.
Kε NT KTEQ CVLQ
TWGS NNCR EASL
Pε ER FPCL SSKE LPPS NSDF ALLL
SLOP HRPS PSHP
QQSN LSLε SYAP
GSKT NGSK ASNG
TPVT LTTE EANN RSRA PSGG KNA
LCGL LWFP SRGK
TGRL PAGS GLDG
AKAS GRAK NDPI
GNDD GTNG
Preparation of Immobilized hGHbp and hPRLbp
Immobilized hGHbp ("hGHbp-beads*) was prepared as described (Bass et at, Proteins 8. 309-31 [1990]), except that wild-type hGHbp (Fuh et al., J. Biol. Chem. 265, 3111-3115 [1990]) was used. Competitive binding experiments with [125l] hGH indicated that 58 fmols of functional hGHbp were coupled per μL of bead suspension.
Immobilized hPRLbp ("hPRLbp-beads") was prepared as above, using the 211 -residue extracellular domain of the prolactin receptor (Cunningham et at, Science 250.1709-1712 [1990]). Competitive binding experiments with [1251] hGH in the presence of 50 μM zinc indicated that 2.1 fmols of functional hPRLbp were coupled per μL of bead suspension.
"Blank beads" were prepared by treating the oxirane-acrylamide beads with 0.6 M ethanolamine (pH 9.2) for 15 hours at 4°C. Binding selection using immobilized hGHbp and hPRLbp
Binding of hor one-phage to beads was carried out in one of the following buffers: Buffer A (PBS, 0.5% BSA, 0.05% Tween 20, 0.01% ttiimerosal) for selections using hGHbp and blank beads; Buffer B (50 mM tris pH 7.5, 10 mM MgCfe 0.5% BSA, 0.05% Tween 20, 100 mM ZnCfe) for selections using hPRLbp in the presence of zinc (+ Zn2+); or Buffer C (PBS, 0.5% BSA, 0.05% Tween 20, 0.01% thimerosal. 10 mM EDTA) for selections using hPRLbp in the absence of zinc (+ EDTA). Binding selections were carried out according to each of the following paths: (1) binding to blank beads, (2) binding to hGHbp-beads, (3) binding to hPRLbp-beads (+ Zn2+), (4) binding to hPRLbp-beads (+ EDTA), (5) pre-adsorbing twice with hGHbp beads then binding the non-adsorbed fraction to hPRLbp-beads
('-hGHbp, +hPRLbp" selection), or (6) pre-adsorbing twice with hPRLbp-beads then binding the non-adsorbed fraction to hGHbp-beads ("-hPRLbp, +hGHbp" selection). The latter two procedures are expected to enrich for mutants binding hPRLbp but not hGHbp, or for mutants binding hGHbp but not hPRLbp, respectively. Binding and elution of phage was carried out in each cyde as follows:
1. BINDING: An aliquot of hormone phage (typically 109 -10t0 CFU) was mixed with an equal amount of non-hormone phage (pCAT), diluted into the appropriate buffer (A, B, or C), and mixed with a 10 mL suspension of hGHbp, hPRLbp or blank beads in a total volume of 200mL in a 1.5 L polypropylene tube. The phage were allowed to bind to the beads by incubating 1 hour at room temperature (23°C) with slow rotation (approximately 7 RPM). Subsequent steps were carried out with a constant volume of 200μL and at room temperature.
2. WASHES: The beads were spun 15 sec, and the supernatant was removed. To reduce the number of phage not spedfically bound, the beads were washed 5 times by resuspending briefly in the appropriate buffer, then pelleting.
3. hGH ELUTION: Phage binding weakly to the beads were removed by elution with hGH. The beads were rotated with the appropriate buffer containing 400 nMJiGH for 15-17 hours. The supernatant was saved as the 'hGH elution" and the beads. The beads were washed by resuspending briefly in buffer and pelleting. 4. GLYCINE ELUTION: To remove the tightest-binding phage (i.e. those still bound after the hGH wash), beads were suspended in Glydne buffer (Buffer A plus 0.2 JϋGlydne, pH 2.0 with HCl), rotated 1 hour and pelleted. The supernatant ("Glydne elution"; 200μL) was neutralized by adding 30 mL of 1 M Tris base and stored at 4° C.
5. PROPAGATION: Aliquots from the hGH elutions and from the Glydne elutions from each set of beads under each set of conditions were used to infect separate cultures of log-phase XL1 -Blue cells.
Transductions were carried out by mixing phage with 1 L XL1-Blue cells, incubating 20 min. at 37°C, then adding K07 (moi= 100). Cultures (25 mL 2YT plus carbenidiiin) were grown as described above and the next pool of phage was prepared as described above.
Phage binding, elution, and propagation were carried out in successive rounds, according to the cyde described above. For example, the phage amplified from the hGH elution from hGHbp-beads were again selected on hGHbp-beads and eluted with hGH, then used to infect a new culture of XL1-Blue cells. Three to five rounds of selection and propagation were carried out for each of the selection procedures described above. DNA Sequendng of selected phagemids
From the hGH and Glydne elution steps of each cyde, an aliquot of phage was used to inoculate XL1-Biue cells, which were plated on LB media containing carbenidiiin and tefracydine to obtain independent clones from each phage pool. Single-stranded DNA was prepared from isolated colony and sequenced in the region of the mutagenic cassette. The results of DNA sequencing are summarized in terms of the deduced amino acid sequences in Figures 5, 6, 7, and 8.
Expression and t{ fff IffiH IT1 Hants
To determine the binding affinity of some of the selected hGH mutants for the hGHbp, we transformed DNA from sequenced clones into E. coli strain 16C9. As described above, this is a non-suppressor strain which terminates translation of protein after the final Phe-191 residue of hGH. Single-stranded DNA was used for these transformations, but double-stranded DNA or even whole phage can be easily electroporated into a non- suppressor strain for expression of free hormone.
Mutants of hGH were prepared from osmoticaily shocked cells by ammonium sulfate precipitation as described for hGH (Olson et at, Nature 293, 408-411 [1981]), and protein concentrations were measured by laser densitomoetry of Coomassie-sfained SDS-polyacrylamide gel electrophoresis gels, using hGH as standard (Cunningham and Wells. Science 244. 1081-1085 [1989]). The binding affinity of each mutant was determined by displacement of 1251 hGH as described (Spencer et al., J. Biol. Chem.263, 7862-7867 [1988] ; Fuh et al., J. Biol. Chem.265, 3111-3115 [1990]), using an anti- receptor monodonal antibody (Mab263).
The results for a number of hGH mutants, selected by different pathways (Fig.6) are shown in Table VII. Many of these mutants have a tighter binding affinity for hGHbp than wild-type hGH. The most improved mutant KSYR, has a binding affinity 5.6 times greater than that of wild-type hGH. The weakest selected mutant among those assayed was only about 10-fold tower in binding affinity than hGH.
Binding assays may be carried out for mutants selected for hPRLbp-binding.
10 Table VII. Competitive binding to hGHbp
The selected pool in which each mufant was found is indicated as 1 G (first glydne selection), 3G (third glycine selection), 3H (third hGH selection), 3* (ttiird selection, not binding to hPRLbp, but binding to hGHbp).
15 The number of times each mutant occurred among all sequenced clones is shown ().
Figure imgf000038_0001
At some residues, substitution of a particular amino add has essentially the same effect independent of 0 surrounding residues. For example, substitution of F176Y in the background of 172R/174S reduces binding affinity by 2.0-fold (RSFR vs. RSYR). Similarly, in the background of 172K 174A the binding affinity of the F176Y mutant (KAYR) is 2.9-fold weaker than the corresponding 176F mutant (KAFR; Cunningham and Wells, 1989). On the other hand, the binding constants determined for several selected mutants of hGH demonstrate non-additive effects of some amino add substitutions at residues 172, 174, 176, and 178. For example, in the background of 172K/176Y, the substitution E174S results in a mutant (KSYR) which binds hGHbp 3.7-fold tighter than the corresponding mutant containing E174A (KAYR). However, in the background of 172R/176Y, the effects of these E174 substitutions are reversed. Here, the E174A mutant (RAYR) binds 1.5-fold tighter than the E174S mutant (RSYR).
Such non-additive effects on binding for substitutions at proximal residues illustrate the utility of protein-phage binding selection as a means of selecting optimized mutants from a library randomized at several positions. In the absence of detailed structural information, without such a selection process, many combinations of substitutions might be tried before finding the optimum mutant.
EXAMPLE IX
SELECTION OF hGH VARIANTS FROM A HELIX-1 RANDOM CASSETTE LIBRARY OF HORMONE-PH AGE
Using the methods described in Example VIII, we targeted another region of hGH involved in binding to the hGHbp and/or hPRLbp, helix 1 residues 10, 14, 18, 21, for random mutagenesis in the phGHam-g3p vector (also known as pS0643; see Example VIII). We chose to use the "amber" hGH-g3 construct (called phGHam-g3p) because it appears to make the target protein, hGH, more accessible for binding. This is supported by data from comparative ELISA assays of monodonal antibody binding. Phage produced from both pS0132 (S. Bass, R. Greene, J. A. Wells, Proteins 8, 309 (1990).) and phGHam-g3 were tested with three antibodies (Medix 2, 1B5.G2, and 5B7.C10) that are known to have binding determinants near the carboxyl-terminus of hGH [B. C. Cunningham, P. Jhurani, P. Ng, J. A. Wells, Science 243, 1330 (1989); B. C. Cunningham and J. A. Wells, Science 244, 1081 (1989); L. Jin and J. Wells, unpublished results], and one antibody (Medix 1) that recognizes determinants in helices 1 and 3 ([B. C. Cunningham, P. Jhurani, P. Ng, J. A. Wells, Science 243, 1330 (1989); B. C. Cunningham and J. A. Wells, Science 244, 1081 (1989)]). Phagemid partides from phGHam-g3 reacted much more strongly with antibodies Medix 2, 1B5.G2, and 5B7.C10 than did phagemid particles from pS0132. in particular, binding of pS0132 particles was reduced by >2000-fokl for both Medix 2 and 5B7.C10 and reduced by >25-fold for 1B5.G2 compared to binding to Medix 1. On the other hand, binding of phGHam-g3 phage was weaker by only about 1.5-fold, 1.2-fold, and 2.3- fold for the Medix 2, 1B5.G2, and 5B7.C10 antibodies, respectively, compared with binding to MEDIX 1. Construction of the helix 1 library bv cassette mutioenesls
We mutated residues in helix 1 that were previously identified by alanine-scanning mutagenesis [B. C. Cunningham, P. Jhurani, P. Ng, J. A. Wells, Science 243, 1330 (1989); B. C. Cunningham and J. A. Wells, Science 244, 1081 (1989), 15, 16) to modulate the binding of the extracellular domains of the hGH and/or hPRL receptors (called hGHbp and hPRLbp, respectively). Cassette mutagenesis was carried out essentially as described [J. A. Wells, M. Vasser, D. B. Powers, Gene 34, 315 (1985)]. This library was constructed by cassette mutagenesis that fully mutated four residues at a time (see Example VIII) which utilized a mutated version of phGHam-g3 into which unique Kpnl (at hGH codon 27)and Xho\ (at hGH codon 6) restriction sites (underiined below) had been inserted by mutagenesis [ T. A. Kunkel, J. D. Roberts, R. A. Zakour, Methods Enzymol.154, 367- 382] with the oligonucleotides 5'-GCC TTT GAC AGG TAC CAG GAG TTT G-3' and 5'-CCA ACT ATA CCA CTC TCG AGG TCT ATT CGA TAA C-3", respectively. The later oligo also introduced a +1 frameshift (italicized) to terminate translation from the starting vector and minimize wild-type background in the phagemid library. This strafing vector was designated pH0508B. The helix 1 library, which mufated hGH residues 10, 14, 18, 21, was constructed by ligating to the large Xho\-Kpn\ fragment of pH0508B a cassette made from the complementary oligonucleotides 5'-pTCG AGG CTC NNS GAC AAC GCG NNS CTG CGT GCT NNS CGT CTT NNS CAG CTG GCC TTT GAC ACG TAC-3" and 5'-pGT GTC AAA GGC CAG CTG SNN AAG ACG SNN AGC ACG CAG SNN CGC GTT GTC SNN GAG CC-3'. The Kpnl site was destroyed in the junction of the ligation product so that restriction enzyme digestion could be used for analysis of non-mutated background. The library contained at least 107 independent transformants so that if the library were absolutely random (106 different combinations of codons) we would have an average of about 10 copies of each possible mutated hGH gene. Restriction analysis using Kpnl indicated that at least 80% of helix 1 library constructs contained the inserted cassette.
Binding enrichments of hGH-phage from the libraries was carried out using hGHbp immobilized on oxirane-potyacrylamide beads (Sigma Chemical Co.) as described (Example VIII). Four residues in helix 1 (F10, M14, H18, and H21) were similarly mufated and after 4 and 6 cycles a non-wild-type consensus developed (Table VIII). Position 10 on the hydrophobic face of helix 1 tended to be hydrophobic whereas positions 21 and 18 on the hydrophillic face tended were dominated by Asn; no obvious consensus was evident for position 14 (Table IX). The binding constants for these mutants of hGH to hGHbp was determined by expressing the free hormone variants in the non-suppressor E. coli strain 16C9, purifying the protein, and assaying by competitive displacement of labelled wt-hGH from hGHbp (see Example VIII). As indicated, several mutants bind tighter to hGHbp than does wt-hGH.
Table VIII. Selection of hGH helix 1 mutants
Variants of hGH (randomly mutated at residues F10, M14, H18, H21) expressed on phagemid particles were selected by binding to hGHbp-beads and eluting with hGH (0.4 mM) buffer followed by glycine (0.2 M, pH 2) buffer (see Example VIII).
Figure imgf000041_0001
Table IX Consensus sequences from the selected hefa! library
Observed frequency is fraction of all clones sequenced with the indicated amino acid. The nominal frequency is calculated on the basis of NNS 32 codon degeneracy. The maximal enrichment factor varies from 11 to 32 depending upon the nominal frequency value for a given residue. Values of [Kd(Ala mut)/K(j(wt hGH)] for single alanine mutations were taken from B. C. Cunningham and J. A. Wells, Science 244, 1081 (1989); B. C. Cunningham, D. J. Henner, J. A. Wells, Science 247, 1461 (1990); B. C. Cunningham and J. A. Wells, Proc. Natl. Acad. Sci. USA 88, 3407 (1991).
Figure imgf000042_0001
Table X Binding of purified hGH helix 1 mutants to hGHbp
Competition binding experiments were performed using [1 5l]hGH (wild-type), hGHbp (confaining the extracellular receptor domain, residues 1-238), and Mab263 [B. C. Cunningham, P. Jhurani, P. Ng, J. A. Wells, Science 243, 1330 (1989)];. The number P indicates the fractional occurrence of each mutant among all the clones sequenced after one or more rounds of selection.
Figure imgf000043_0001
EXAMPLE X
SELECTION OF hGH VARIANTS FROM A HELIX-4 RANDOM CASSETTE UBRARY CONTAINING PREVIOUSLY FOUND MUTATIONS BY ENRICHMENT OF HORMONE-PHAGE Design of mufant proteins with improved binding properties bv Iterative seiection using hoπτκme--phage
Our experience with recruiting non-binding homologs of hGH evolutionary variants suggests that many individual amino acid substitutions can be combined to yield cumulatively improved mutants of hGH with respect to binding a particular receptor [B. C. Cunningham, D. J. Henner, J. A. Wells, Science 247, 1461 (1990); B. C. Cunningham and J. A. Wells, Proc. Natl. Acad. Sci. USA 88, 3407 (1991); H. B. Lowman, B. C. Cunningham, J. A. Wells, J. Biol. Chem.266, in press (1991)].
The helix 4b library was constructed in an attempt to further improve the helix 4 double mufant (E174S/F176Y) selected from the helix 4a library that we found bound tighter to the hGH receptor (see Example VIII). With the E174S/F176Y hGH mufant as the background sfarting hormone, residues were mutated that surrounded positions 174 and 176 on the hydrophilic face of helix 4 (R167, D171, T175 and 1179) . Construction of the helix 4b library bv cassette mutagenesis
Cassette mutagenesis was carried out essentially as described [J. A. Wells, M. Vasser, D. B. Powers, Gene 34, 315 (1985)]. The helix 4b library, which mutated residues 167, 171, 175 and 179 within the E174S/F176Y background, was constructed using cassette mutagenesis that fully mutated four residues at a time (see Example VIII) and which utilized a mutated version of phGHam-g3 into which unique BstEM and Bg'\ restriction sites had been inserted previously (Example VIII). Into the BstEU-BglU sites of the vector was inserted a cassette made from the complementary oligonudeotides 5'-pG TTA CTC TAC TGC TTC NNS AAG GAC ATG NNS AAG GTC AGC NNS TAC CTG CGC NNS GTG CAG TGC A-3' and 5'-pGA TCT GCA CTG CAC SNN GCG CAG GTA SNN GCT GAC CTT SNN CAT GTC CTT SNN GAA GCA GTA GA-3'. The BstB\ site was eliminated in the ligated cassette. From the helix 4b library, 15 unselected dones were sequenced. Of these, none lacked a cassette insert, 20% were frame-shifted, and 7% had a non-silent mutation. Results of HGHbo enrichment
Binding enrichments of hGH-phage from the libraries was carried out using hGHbp immobilized on oxirane-polyacryiamide beads (Sigma Chemical Co.) as described (Example VIII). After 6 cydes of binding a reasonably dear consensus developed (Table XI). Interestingly, all positions tended to contain polar residues, notably Ser, Thr and Asn (XII). Assay of hGH mutants
The binding constants for some of these mutants of hGH to hGHbp was determined by expressing the free hormone variants in the non-suppressor £ coli strain 16C9, purifying the protein, and assaying by competitive displacement of labelled wt-hGH from hGHbp (see Example VIII). As indicated, the binding affinities of several helix-4b mutants for hGHbp were tighter than that of wt-hGH Table XIII). Receptor-selectivity of hGH variants
Finally, we have begun to analyze the binding affinity of several of the tighter hGHbp binding mutants for their ability to bind to the hPRLbp. The E174S F176Y mutant binds 200-fold weaker to the hPRLbp than hGH. The E174T/F176Y/R178K and R167N/D171S/E174S/F176Y/I179T mutants each bind >500-fold weaker to the hPRLbp than hGH. Thus, it is possible to use the produce new receptor selective mutants of hGH by phage display technology. Hormone-phagemid selection Identifies the Infoπ-natton-contentof particular residues
Of the 12 residues mutated in three hGH-phagemid libraries (Examples VIII, IX, X), 4 showed a strong, although not exclusive, conservation of the wild-type residues (K172, T175, F176, and R178). Not surprisingly, these were residues that when converted to Ala caused the largest disruptions (4- to 60-fold) in binding affinity to the hGHbp. There was a dass of 4 other residues (F10, M14, D171 , and 1179) where Ala substitutions caused weaker effects on binding (2- to 7-fold) and these positions exhibited little wild-type consensus. Finally the other 4 residues (H18, H21, R167, and E174), that promote binding to he hPRLbp but not the hGHbp, did not exhibit any consensus for the wild-type hGH sequence by selection on hGHbp-beads. In fact two residues (E174 and
H21), where Ala substitutions enhance binding affinity to the hGHbp by 2- to 4-fold [B. C. Cunningham, P. Jhurani, P. Ng, J. A. Wells, Science 243, 1330 (1989); B. C. Cunningham and J. A. Wells, Science 244, 1081 (1989); B. C. Cunningham, D. J. Henner, J. A. Wells, Science 247, 1461 (1990); B. C. Cunningham and J. A. Wells, Proc. Naϋ. Acad. Sci. USA 88, 3407 (1991)]. Thus, the alanine-scanning mutagenesis data correlates reasonably well with the flexibility to substitute each position. In fact , the reduction in binding affinity caused by alanine substitutions [B. C. Cunningham, P. Jhurani, P. Ng, J. A. Wells, Science 243, 1330 (1989); B. C. Cunningham and J. A. Wells, Science 244, 1081 (1989)], B. C. Cunningham, D. J. Henner, J. A. Wells, Science 247, 1461 (1990); B. C. Cunningham and J. A. Wells, Proc. Naϋ. Acad. Sci. USASS, 3407 (1991)] is a reasonable predictor of the percentage that the wild-type residue is found in the phagemid pool after 3-6 rounds of selection. The alanine- scanning information is useful for targeting side-chains that modulate binding, and the phage selection is appropriate for optimizing them and defining the flexibility of each site (and/or combinations of sites) for substitution. The combination of scanning mutationai methods [B. C. Cunningham, P. Jhurani, P. Ng, J. A. Wells, Science 243, 1330 (1989); B. C. Cunningham and J. A. Wells, Science 244, 1081 (1989)] and phage display is a powerful approach to designing receptoNigand interfaces and studying molecular evolution in vitro. Variations on Iterative enrichment of hormone-phaoemid libraries
In cases where combined mutations in hGH have additive effects on binding affinity to receptor, mutations learned through hormone-phagemid enrichment to improve binding can be combined by simple cutting and ligation of restriction fragments or mutagenesis to yield cumulatively optimized mutants of hGH. On the other hand, mutations in one region of hGH which optimize receptor binding may be structurally or functionally incompatible with mutations in an overlapping or another region of the molecule. In these cases, hormone phagemid enrichment can be carried out by one of several variations on the iterative enrichment approach : (1) random DNA libraries can be generated in each of two (or perhaps more) regions of the molecule by cassette or another mutagenesis method. Thereafter, a combined library can be created by ligation of restriction fragments from the two DNA libraries; (2) an hGH variant, optimized for binding by mutation in one region of the molecule, can be randomly mufated in a second region of the molecule as in the helix-4b library example; (3) two or more random libraries can be partially selected for improved binding by hormone-phagemid enrichment; after this "roughing-in" of the optimized binding site, the still-partially-diverse libraries can be recombined by ligation of restriction fragments to generate a single library, partially diverse in two or more regions of the molecules, which in turn can be further selected for optimized binding using hormone-phagemid enrichment.
Table XI. Mutant phagemids of hGH selected from helix 4b library after 4 and 6 cycles of enrichment
Selection of hGH helix 4b mutants (randomly mufated at residues 167, 171, 175, 179), each containing the E174S/F17 double mutant, by binding to hGHbp-beads and eluting with hGH (0.4 M) buffer followed by glydne (0.2 λf, pH 2) bu One mufant (+) contained the spurious mutation R178H.
Figure imgf000046_0001
Table XII Consensus sequences from the selected library.
Observed frequency is fraction of all clones sequenced with the indicated amino add. The nominal frequency is calculated on the basis of NNS 32 codon degeneracy. The maximal enrichment factor varies from 11 to 16 to 32 depending upon the nominal frequency value for a given residue. Values of [K<j(Ala mut)/Kd(wt hGH)] for single alanine mutations were taken from refs. below; for position 175 we only have a value for the T175S mufant [B. C.
Cunningham, P. Jhurani, P. Ng, J. A. Wells, Science 243, 1330 (1989); B. C. Cunningham and J. A. Wells, Science 244,
1081 (1989); B. C. Cunningham, D. J. Henner, J. A. Wells, Science 2A7, 1461 (1990); B. C. Cunningham and J. A. Wells,
Proc. Natl. Acad. Sci. USA 88, 3407 (1991).].
Figure imgf000047_0001
Table XIII Binding of purified hGH mutants to hGHbp.
Competition binding experiments were performed using [1 5l]hGH (wild-type), hGHbp (containing the extracellular receptor domain, residues 1-238), and Mab263 (11). The number P indicates the fractional occurrence of each mufant among all the clones sequenced after one or more rounds of selection. Note that the helix 4b mutations (*) are in the background of hGH(E174S/F176Y). In the list of helix 4b mutants,, the E174S/F176Y mutant (*), with wt residues at 167, 171 , 175, 179, is shown in bold.
Kd(Alamut)
Sequence position Wntø(wt hGH)
Figure imgf000047_0002
Assembly of F-f- Molecule on the Phagemid Surface Cons icBon of plasmids
Plasmid pDH 188 confains the DNA encoding the Fab P°~-~~l of a humanized IgG antibody, called 4D5, that recognizes the HER-2 receptor. This plasmid is contained in £ coø strain SR 101, and has been deposited with the ATCC in Rockville, MD.
Briefly, the plasmid was prepared as follows: the starting plasmid was pS0132, containing the alkaline phosphatase promoter as described above. The DNA encoding human growth hormone was exdsed and, after a series of manipulations to make the ends of the plasmid compatible for ligation, the DNA encoding 4D5 was inserted. The 4D5 DNA confains two genes. The first gene encodes the variable and consfant regions of the light chain, and contains at its 5' end the DNA encoding the st II signal sequence. The second gene contains four portions: first, at its 5' end is the DNA encoding the st II signal sequence. This is followed by the DNA encoding the variable domain of the heavy chain, which is followed by the DNA encoding the first domain of the heavy chain constant region, which in turn is followed by the DNA encoding the M13 gene III. The salient features of this construct are shown in Figure 10. The sequence of the DNA encoding 4D5 is shown in Figure 11.
£ coff transformation and phage production,
Both polyethylene glycol (PEG) and electroporation were used to transform plasmids into SR101 cells. (PEG competent cells were prepared and transformed according to the method of Chung and Miller (Nucleic Adds Res.16:3580 [1988]). Cells that were competent for electroporation were prepared, and subsequently transformed via electroporation according to the method of Zabarovsky and Winberg (Nucleic Acids Res.18:5912 [1990]). After plaα'ng the cells in 1 ml of the SOC media (described in Sambrook etal., supra), they were grown for 1 hour at 37°C with shaking. At this time, the concentration of the cells was determined using light scattering at OD600- A titered K07 phage stock was added to achieve an multiplidty of infection (MOI) of 100, and the phage were allowed to adhere to the cells for 20 minutes at room temperature. This mixture was then diluted into 25 mis of 2YT broth (described in Sambrook ef al., supra) and incubated with shaking at 37°C overnight. The next day, cells were pelleted by centrifugation at 5000 x g for 10 minutes, the supernatant was collected, and the phage partides were predpitated with 0.5 M NaCl and 4% PEG (final concentration) at room temperature for 10 minutes. Phage partides were pelleted by centrifugation at 10,000 x g for 10 minutes, resuspended in 1 ml of TEN (10 mM Tris, pH 7.6, 1 mM EDTA, and 150 mM NaCl), and stored at 4°C. Production of antigen coated plates.
Aliquots of 0.5 ml from a solution of 0.1 mg/ml of the extra-cellular domain of the HER-2 antigen (ECD) or a solution of 0.5 mg/ml of BSA (control antigen) in 0.1 M sodium bicarbonate, pH 8.5 were used to coat one well of a Falcon 12 well tissue culture plate. Once the solution was applied to the wells, the plates were incubated at 4°C on a rocking platform overnight. The plates were then blocked by removing the initial solution, applying 0.5 ml of blocking buffer (30 mg/ml BSA in 0.1 M sodium bicarbonate), and incubating at room temperature for one hour. Finally, the blocking buffer was removed, 1 ml of buffer A (PBS, 0.5% BSA, and 0.05% Tween-20) was added, and the plates were stored up to 10 days at 4°C before being used for phage selection. Approximately 109 phage particles were mixed with a 100-fold excess of K07 helper phage and 1 ml of buffer A . This mixture was divided into two 05 ml aliquots; one of which was applied to ECD coated wells, and the other was applied to BSA coated wells. The plates were incubated at room temperature while shaking for one to three hours, and were then washed three times over a period of 30 minutes with 1 ml aliquots of buffer A. Elution of the phage from the plates was done at room temperature by one of two methods: 1) an initial overnight incubation of 0.025 mg/ml purified Mu4D5 antibody (murine) followed by a 30 minute incubation with 0.4 ml of the add elution buffer (0.2 M glydne, pH 2.1 , 0.5% BSA, and 0.05% Tween-20), or 2) an incubation with the acid elution buffer alone. Eluates were then neutralized with 1 M Tris base, and a 0.5 ml aliquot of TEN was added. These samples were then propagated, titered, and stored at 4°C. Phage propagation
Aliquots of eluted phage were added to 0.4 ml of 2YT broth and mixed with approximately 108 mid-log phase male £ coli strain SR101. Phage were allowed to adhere to the cells for 20 minutes at room temperature and then added to 5 ml of 2YT broth that contained 50 μg/ml of carbenidiiin and 5 μg/ml of tefracydine. These cells were grown at 37°C for 4 to 8 hours until they reached mid-log phase. The ODβoo was determined, and the cells were superinfected with K07 helper phage for phage production. Once phage partides were obtained, they were titered in order to determine the number of colony forming units (cfu). This was done by taking aliquots of serial dilutions of a given phage stock, allowing them to infect mid-fog phase SR101 , and plating on LB plates containing 50 υg/ml carbenidiiin. RIA affinity determination.
The affinity of h4D5 Fab fragments and Fab phage for the ECD antigen was determined using a competitive receptor binding RIA (Burt, D. R., Receptor Binding in Drug Research. O'Brien, R.A. (Ed.), pp.3- 29, Dekker, New York [1986]). The ECD antigen was labeled with 125-k>dine using the sequential chloramine-T method (De Larco, J. E. etal., J. Cell. Physiol.109:143-152 [1981]) which produced a radioactive tracer with a spedfic activity of 14μCi/μg and incorporation of 0.47 moles of Iodine per mole of receptor. A series of 0.2 ml solutions confaining 0.5 ng (by ELISA) of Fab or Fab phage, 50 nCi of 125l ECD tracer, and a range of unlabeled ECD amounts (6.4 ng to 3277ng) were prepared and incubated at room temperature overnight. The labeled ECD-Fab or ECD-FaD phage complex was separated from the unbound labeled antigen by forming an aggregate complex induced by the addition of an anti-human IgG (Fitzgerald 40-GH23) and 6% PEG 8000. The complex was pelleted by centrifugation (15,000 x g for 20 minutes) and the amount of labeled ECD (in cpm) was determined by a gamma counter. The dissociation constant (Kd) was calculated by employing a modified version of the program LIGAND (Munson, P. and Rothbard, D., Ami. Biochem.107*220-239 [1980]) which utilizes Scatchard analysis (Scatchard, G.,Aππ. N.Y. Acad. Sci. 51*660-672 [1949]). The Kd values are shown in Figure 13. fampfffitiYft ~~\\ Mng ~s Murine 4D5 antibody was labeled with 125-1 to a spedfic activity of 40-50 μCi/μg using the lodogen procedure. Solutions confaining a constant amount of labeled antibody and increasing amounts of unlabeled variant Fab were prepared and added to near confluent cultures of SK-BR-3 cells grown in 96-well microtiter dishes (final concentration of labeled antibody was 0.1 nM). After an overnight incubation at 4°C, the supernatant was removed, the cells were washed and the cell assodated radioactivity was determined in a gamma counter. Kd values were determined by analyzing the data using a modified version of the program LIGAND (Munson, P. and Rothbard, D., supra)
This deposit of plasmid pDH188 ATCC no.68663 was made under the provisions of the Budapest Treaty on the Intemationai Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable culture for 30 years from the date of deposit. The organisms will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures permanent and unrestricted availability of the progeny of the cultures to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U. S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U. S. Commissioner of Patents and Trademarks to be entitied thereto according to 35 USC §122 and the Commissioner's rules pursuant thereto (induding 37 CFR §1.14 with particular reference to 886 OG 638).
The assignee of the present application has agreed that if the cultures on deposit should die or be lost or destroyed when cultivated under suitable conditions, they will be promptly replaced on notification with a viable spedmen of the same culture. Availability of the deposited cultures is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.
The foregoing written spedfication is considered to be suffident to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the cultures deposited, since the deposited embodiments are intended as separate illustrations of certain aspects of the invention and any cultures that are functionally equivalent are within the scope of this invention. The deposit of material herein does not constitute an admission that the written description herein contained is inadequate to enable the practice of any aspect of the invention, induding the best mode thereof, nor is it to be construed as limiting the scope of the daims to the spedfic illustrations that it represents. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.
While the invention has necessarily been described in conjunction with preferred embodiments, one of ordinary skill, after reading the foregoing spedfication, will be able to effect various changes, substitutions of equivalents, and alterations to the subject matter set forth herein, without departing from the spirit and scope thereof. Hence, the invention can be practiced in ways other than those spedfically described herein. It is therefore intended that the protection granted by Letters Patent hereon be limited only by the appended daims and equivalents thereof. EXAMPLE XII SELECTION OF hGH VARIANTS FROM COMBINATIONS OF HEUX-1 AND HEUX-4 HORMONE-PHAGE
VARIANTS
Construction of additive variants of hGH
According to additivity principles [J. A. Wells, Biochemistry 29, 8509 (1990)], mutations in different parts of a protein, if they are not mutually interacting, are expected to combine to produce additive changes in the free energy of binding to another molecule (changes are additive in terms of ΔΔGbinding- or multiplicative in terms of Kd = exp(-ΔG/RT] ). Thus a mutation produdng a 2-fold increase in binding affinity, when combined with a second mutation causing a 3-fold increase, would be predicted to yield a double mutant with a 6-fold increased affinity over the starting variant.
To test whether multiple mutations obtained from hGH-phage selections would produce cumulatively favorable effects on hGHbp (hGH-binding protein; the extracellular domain of the hGH receptor) binding, we combined mutations found in the three tightest-binding variants of hGH from the helix- 1 library (Example IX: F10A M14W/H18D/H21N, F10H/M14G/H18N/H21N, and F10F/M14S/H18F/H21L) with those found in the three tightest binding variants found in the helix-4b library (Example X: R167N/D171S T175/1179T, R167E/D171S/T175/I179, and R167N/D171N/T175/I179T). hGH-phagemid double-stranded DNA (dsDNA) from each of the one-helix variants was isolated and digested with the restriction enzymes EcoRl and BstX\. The large fragment from each helix-4b variant was then isolated and ligated with the small fragment from each helix-1 variant to yield the new two-helix variants shown in Table XIII. All of these variants also contained the mufations E174S/F176Y obtained in earlier hGH-phage binding selections (see Example X for details). Construction of selective combinatorial libraries of hGH
Although additivity principles appear to hold for a number of combinations of mutations, some combinations (e.g. E174S with F176Y) are dearly non-additive (see examples VIII and X). In order to identity with certainty the tightest binding variant with, for example, 4 mutations in helix-1 and 4 mutations in helix-4, one would ideally mutate all 8 residues at once and then sort the pool for the globally tightest binding variant. However, such a pool would consist of 1.1 x 1012 DNA sequences (utilizing NNS codon degeneracy) encoding 2.6 x 1010 different poiypeptides. Obtaining a random phagemid library large enough to assure representation of all variants (perhaps 1013 transformants) is not practical using current transformation technology.
We have addressed this difficulty first by utilizing successive rounds of mutagenesis, taking the tightest binding variant from one library, then mutating other residues to further improve binding (Example X). In a second method, we have utilized the principle of additivity to combine the best mutations from two independently sorted libraries to create multiple mutants with improved binding (described above). Here, we further searched through the possible combinations of mufations at positions 10, 14, 18, 21 , 167, 171 , 175, and 179 in hGH, by creating combinatorial libraries of random or partially-random mutants. We constructed three different combinatorial libraries of hGH-phagemids, using the pooled phagemids from the helix 1 library (independently sorted for 0, 2, or 4 cycles; Example IX) and the pool from the helix-4b library (independently sorted for 0, 2, or 4 cycles; Example X) and sorted the combined variant pool for hGHbp binding. Since some amount of sequence diversity exists in each of these pools, the resulting combinatorial library can explore more sequence combinations than what we might construct manually (e.g. Table XIII). hGH-phagemid double-stranded DNA (dsDNA) from each of the one-helix library pools (selected for 0, 2, or 4 rounds) was isolated and digested with the restriction enzymes Acd and BstX\. The large fragment from each helix-1 variant pool was then isolated and ligated with the small fragment from each helix-4b variant pool to yield the three combinatorial libraries pH0707A (unselected helix 1 and helix 4b pools, as described in examples IX and X), pH0707B (twice-selected helix-1 pool with twice-selected helix-4b pool), and pH0707C (4-times selected helix-1 pool with 4-times selected helix-4b pool). Duplicate legations were also set up with less DNA and designated as pH0707D, pH0707E, and pH0707F, corresponding to the 0-.2-, and 4-round starting libraries respectively. All of these variant pools also contained the mutations E174S F176Y obtained in earlier hGH-phage binding selections (see Example X for details). Sorting combinatorial ltt)rartes of hGH-phaoe variants
The ligation products pH0707A-F were processed and electro-transformed into XL1-Blue cells as described (Example VIII). Based on colony-forming units (CFU), the number of transformants obtained from each pool was as follows: 2.4X106 from pH0707A, 1.8x106 from pH0707B, 1.6x106 from pH0707C, 8x10s from pH0707D, 3x10s from pH0707E, and 4x10s from pH0707F. hGH-phagemid partides were prepared and selected for hGHbp-bindϊng over 2 to 7 cydes as described in Example VIII. Rapfti sorting of hQH-phagemld libraries
In addition to sorting phagemid libraries for tight-binding protein variants, as measured by equilibrium binding affinity, it is of interest to sort for variants which are altered in either the on-rate (kon) or the off-rate (koff) of binding to a receptor or other molecule. From thermodynamics, these rates are related to the equilibrium dissodatfon consfant, Kd = (koff kon)- We envision that certain variants of a particular protein have similar Kd's for binding while having very different kon's and koff's. Conversely, changes in Kd from one variant to another may be due to effects on kon. effects on koff, or both. The pharmacological properties of a protein may be dependent on binding affinity or on kon or koff, depending on the detailed mechanism of action. Here, we sought to identify hGH variants with higher on-rates to investigate the effects of changes in kon- We envision that the selection could altemativety be weighted toward koff by increasing the binding time and increasing the wash time and/or concentration with cognate ligand (hGH).
From time-course analysis of wild-type hGH-phagemid binding to immobilized hGHbp, it appears that, of the total hGH-phagemid particles that can be eluted in the final pH 2 wash (see Example VIII for the complete binding and elution protocol), less than 10% are bound after 1 minute of incubation, while greater than 90% are bound after 15 minutes of incubation.
For "rapid-binding selection," phagemid particles from the pH0707B pool (twice-selected for helices 1 and 4 independently) were incubated with immobilized hGHbp for only 1 minute, then washed six times with 1 mL of binding buffer; the tiGH-wash step was omitted; and the remaining hGH-phagemid partides were eluted with a pH2 (0.2M glydne in binding buffer) wash. Enrichment of hGH-phagemid partides over non-displaying partides indicated that even with a short binding period and no cognate-ligand (hGH) challenge, hGH-phagemid binding selection sorts tight-binding variants out of a randomized pool. Assay of hGH mutants
The binding constants for some of these mutants of hGH to hGHbp was determined by expressing the free hormone variants in the non-suppressor £ coli strain 16C9 or 34B8, purifying the protein, and assaying by competitive displacement of labelled wt-hGH from hGHbp (see Example VIII) in a radio-immunoprecipitation assay. In Table XIII -A below, all the variants have glutamatei74 replaced by serinei74 and phenylalaninei76 replaced by tyrosinei76 (E174S and F1176Y) plus the additional substitutions as indicated at hGH amino add positions 10, 14, 18, 21, 167, 171, 175 and 179.
Table Xlll-A hGH variants from addition of hellx-1 and helix-4b mutations
Figure imgf000053_0001
In Table XIV below, hGH variants were selected from combinatorial libraries by the phagemid binding selection process. All hGH variants in Table XIV contain two background mutations (E174S/F176Y). hGH- phagemid pools from the libraries pH0707A (Part A), pH0707B and pH0707E (Part B), or pH0707C (Part C) were sorted for 2 to 7 cydes for binding to hGHbp. The number £ indicates the fractional occurrence of each variant type among the set of clones sequenced from each pool.
Table XIV hGH variants from ho ione-phagemid bindng selection of combinatorial libraries.
Figure imgf000054_0001
* = also contained the mufations L15R, K168R.
In Table XV below, hGH variants were selected from combinatorial libraries by the phagemid binding selection process. All hGH variants in Table XV contain two background mutations (E174S/F176Y). The number £ is the fractional occurrence of a given variant among all dones sequenced after 4 cycles of rapid-binding selection. Table XV hGH variants from RAPID hGHbp binding selection of an hGH-phagemid combinatorial library
Figure imgf000055_0001
t = also contained the mutation Y176F (wild-type hGH also contains F176).
In table XVI below, binding constants were measured by competitive displacement of 12 l-labelled hormone H0650BD or labelled hGH using hGHbp (1-238) and either Mab5 or Mab263. The variant H0650BD appears bind more than 30-fold tighter than wild-type hGH.
Table XVI Equilibrium binding constants of selected hGH variants.
Figure imgf000056_0001
EXAMPLE XIII
Selective enrichment erf hGH-phage containing a protease substrate sequence versus non-substrate phage
As described in Example I, the plasmid pS0132 contains the gene for hGH fused to the residue Pro198 of the gene III protein with the insertion of an extra glydne residue. This plasmid may be used to produce hGH-phage particles in which the hGH-gene III fusion product is displayed monovalently on the phage surface (Example IV). The fusion protein comprises the entire hGH protein fused to the carboxy terminal domain of gene III via a flexible linker sequence. To investigate the feasibility of using phage display technology to select favourable substrate sequences for a given proteolytic enzyme, a genetically engineered variant of subtilisin BPN' was used. (Carter, P. et al., Proteins: Structure, function and genetics 6:240-248 (1989)). This variant (hereafter referred to as A64SAL subtilisin) contains the following mutations: Ser24Cys, His64Ala, Glu156Ser, Gly 169 Ala and Tyr217Leu. Since this enzyme lacks the essential catalytic residue His64, its substrate specificity is greatly restricted so that certain histidine-containing substrates are preferentialty hyrdrolysed (Carter et al., Science 237:394-399 (1987)). Construction of a hGH-substrate-Phage vector
The sequence of the linker region in pS0132 was mutated to create a substrate sequence for A64SAL subtilisin, using the oligonucleotide 5'-TTC-GGG-CCC-TTC-GCT-GCT-CAC-TAT-ACG-CGT-CAG-TCG- ACT-GAC-CTG-CCT-3'. This resulted in the introduction of the protein sequence Phe-Gly-Pro-Phe-Ala-Ala- His-Tyr-Thr-Arg-Gln-Ser-Thr-Asp in the linker region between hGH and the carboxy terminal domain of gene III, where the first Phe residue in the above sequence is Phe191 of hGH. The sequence Ala-Ala-His-Tyr-Thr-Agr-GIn is known to be a good substrate for A64SAL subtilisin (Carter et al (1989), supra). The resulting plasmid was designated pS0640.
Selective enrichment of hGH-substrate-Phaoe
Phagemid particles derived from pS0132 and pS0640 were constructed as described in Example I. In initial experiments, a 10μl aliquot of each phage pool was separately mixed with 30μl of oxirane beads (prepared as described in Example II) in 100μJ of buffer comprising 20mM Tris-HCI pH 8.6 and 2.5M NaCl. The binding and washing steps were performed as described in example Vll. The beads were then resuspended in 400μl of the same buffer, with or without 50nM of A64SAL subtilisin. Following incubation for 10 minutes, the supernatants were collected and the phage titres (cfu) measured. Table XVli shows that approximately 10 times more substrate-containing phagemid particles (pS0640) were eluted in the presence of enzyme than in the absence of enzyme, or than in the case of the non-substrate phagemids (pS0132) in the presence or absence of enzyme. Increasing the enzyme, phagemid or bead concentrations did not improve this ratio.
Improvement of the selective enrichment procedure in an attempt to decrease the non-specific elution of immobilised phagemids, a tight- binding variant of hGH was introduced in place of the wild-type hGH gene in pS0132 and pS0640. The hGH variant used was as described in example XI (pH0650bd) and contains the mutations PhelOAIa, et14Trp, His18Asp, His21Asn, Arg167Asn, Asp171Ser, Glu174Ser, Phe176Tyr and lle179Thr. This resulted in the construction of two new phagemids: pDM0390 (containing tight-binding hGH and no substrate sequence) and pDM0411 (containing tight- binding hGH and the substrate sequence Ala-Ala-His-Tyr-Thr-Agr-GIn). The binding washing and elution protocol was also changed as follows:
(i) Binding: COSTAR 12 -well tissue culture plates were coated for 16 hours with
0.5ml/well 2ug/ml hGHbp in sodium carbonate buffer pH 10.0. The plates were then incubated with 1 ml/well of blocking buffer (phosphate buffered saline (PBS) containing 0.1%w/v bovine serum albumen) for 2 hours and washed in an assay buffer containing 10mM Tris-HCI pH 7.5, 1mM EDTA and 100mM NaCl. Phagemids were again prepared as described in Example I: the phage pool was diluted 1 :4 in the above assay buffer and 0.5ml of phage incubated per well for 2 hours. (ii) Washing: The plates were washed thoroughly with PBS + 0.05% Tween 20 and incubated for 30 minuted with 1ml of this wash buffer. This washing step was repeated three times.
(ii) Eution: The plates were incubated for 10 minutes in an elution buffer consisting of 20m Tris-HCI pH 8.6 + 10OmM NaCl, then the phage were eluted with 0.5ml of the above buffer with or without 500nM of A64SAL subtilisin.
Table XVII shows that there was a dramatic increase in the ratio of specifically eluted substrate-phagemid particles compared to the method previously described for pS0640 and pS0132. It is likely that this is due to the fact that the tight-binding hGH mutant has a significantly slower off-rate for binding to hGH binding protein compared to wild-type hGH.
Table XVII
Specific elution of substrate-phagemlds by A64SAL subtilisin
Colony forming units (cfu) were estimated by plating out 10μl of 10-fold dilutions of phage on 10μl spots of XL-1 blue cells, on LB agar plates containing 50μg/ml carbeniα'llinl
(i) Wild-type hGH gene: binding to hGHbp-oxirane beads phagemid + 50nM A64SAL no eπzvme pS0640 (substrate) 9x106cfu/10μl 1.5x106cfu/1 Oμl pS0132 (non-substrate) 6x105cfu/10μl 3x105cfu/10μl
(ii) pH0650bd mutant hGH gene: binding to hGHbp-coated plates phagemid + SQnM AS4SAL no enzyme pDM0411 (substrate) 1.7x105cfu/10μi 2x103cfu/10μl pDM0390 (non-substrate) 2x103cfu/10μl 1x103cfu/10μl
Example XIV
Identification of preferred substrates for A64SAL subtilisin using selective enrichment of a library of substrate sequences.
We sought to employ the selective enrichment procedure described in Example XIII to identify good substrate sequences from a library of random substrate sequences.
Construction of a vector for insertion of randomised substrate cassettes
We designed a vector suitable for introduction of randomised substrate cassettes, and subsequent expression of a library of substrate sequences. The starting point was the vector pS0643, described in Example VIII. Site-directed mutagenesis was carried out using the olioonucleotide 5'-AGC^TGT-GGC-TTC-GGG-CCC-GCC-GCC-GCG-TCG-ACT-GGC-GGT-GGπ- TCT-3', which introduces Aβal (GGGCCC) and Sail (GTCGAC) restriction sites between hGH and Gene ill. This new construct was designated pDM0253 (The actual sequence of pDM0253 is 5'-AGC-TGT-GGC-TTC-GGG-CCC-GCC-J2CC-GCG-TCG-ACT-GGC-GGT-GGC-TCT-3', where the underiined base substitution is due to a spurious error in the mutagenic oligonucleotide). In addition, the tight-binding hGH variant described in example was introduced by exchanging a fragment from pDM0411 (example XIII) The resulting library vector was designated pDM0454.
Preparation of the library cassette vector and insertion of the mutagenic
-ass-US.
To introduce a library cassette, pD 0454 was digested with Apal followed by Sail, then precipitated with 13% PEG 8000+ 10m MgCfc, washed twice in 70% ethanol and resuspended This efficiently precipitates the vector but leaves the small Apa-Sal fragment in solution (Paithankar, K. R. and Prasad, K. S. N., Nucleic Acids Research 19:1346). The product was run on a 1% agarose gel and the Apal-Sall digested vector excised, purified using a Bandprep kit (Pharmacia) and resuspended for ligation with the mutagenic cassette.
The cassette to be inserted contained a DNA sequence similar to that in the linker region of pS0640 and pD 0411 , but with the codons for the histidine and tyrosine residues in the substrate sequence replaced by randomised codons. We chose to substitute NNS (N=G/A/T/C; S=G/C) at each of the randomised positions as described in example VIII. The oligonucleotides used in the mutagenic cassettes were: 5'-C-TTC-GCT-GCT-NNS-NNS-ACC- CGG-CAA-3' (coding strand) and 5'-T-CGA-TTG-CCG-GGT-SNN-SNN-AGC-AGC-GAA-GGG- CC-3' (non-coding strand). This cassette also destroys the Sail site, so that digestion with Sail may be used to reduce the vector background. The oligonucleotides were not phosphorylated before insertion into the Apa-Sai cassette site, as it was feared that subsequent oligomerisation of a small population of the cassettes may lead to spurious results with multiple cassette inserts. Following annealing and ligation, the reaction products were phenohchloroform extracted, ethanol precipitated and resuspended in water. Initially, no digestion with Sail to reduce the background vector was performed. Approximately 200 ng was electroporated into XL-1 blue cells and a phagemid library was prepared as described in example VIII.
Selection of highly cleavable substrates from the substrate library
The selection procedure used was identical to that described for pDM0411 and pDM0390 in example XIII. After each round of selection, the eluted phage were propagated by transducing a fresh culture of XL-1 blue cells and propagating a new phagemid library as described for hGH-phage in example VIII. The progress of the selection procedure was monitored by measuring eluted phage titres and by sequencing individual clones after each round of selection.
Table A shows the successive phage titres for elution in the presence and absence of enzyme after 1 , 2 and 3 rounds of selection. Clearly, the ratio of specifically eluted phage: non-specifically eluted phage (ie phage eluted with enzyme phage eluted without enzyme) increases dramatically from round 1 to round 3, suggesting that the population of good substrates is increasing with each round of selection. Sequencing of 10 isolates from the starting library showed them all to consist of the wild-type pD 0464 sequence. This is attributed to the fact that after digestion with Apal, the Sail site is very close to the end of the DNA fragment, thus leading to low efficiency of digestion. Nevertheless, there are only 400 possible sequences in the library, so this population should still be well represented.
Tables B1 and B2 shows the sequences of isolates obtained after round 2 and round 3 of selection. After 2 rounds of selection, there is clearly a high incidence of histidine residues. This is exactly what is expected: as described in example XIII, A64SAL subtilisin requires a histidine residue in the substrate as it employs a substrate-assisted catalytic mechanism. After 3 rounds of selection, each of the 10 clones sequenced has a histidine in the randomised cassette. Note, however, that 2 of the sequences are of pDM0411 , which was not present in the starting library and is therefore a contaminant.
Table A
Titration of Initial phage pools and eluted phage from 3 rounds of selective enrichment
Colony forming units (cfu) were estimated by plating out 10μl of 10-fold dilutions of phage on 10μl spots of XL-1 blue cells, on LB agar plates containing 50μg ml carbenidiiin
ROUND 1
Figure imgf000061_0001
Table B1
Sequences of eluted phage after 2 rounds of selective enrichment.
All protein sequences should be of the form AA**TRQ, where * represents a randomised codon. In the table below, the randomised codons and amino acids are underlined and in bold.
After round 2:
Sequence NO, Of occurrences
A A fl ~~ T R Q GCT GCT CAC TAC ACC CGG CAA
A A fl H T R Q
... GCT GCT CAC ATG ACC CGG CAA ...
A A i fi T R Q
... GCT GCT CTC CAC ACC CGG CAA ...
A A fl T R Q
... GCT GCT CTG CAC ACC CGG CAA ...
A A fl ~ R Q
, .. GCT GCT CAC ACC CGG CAA ...
A A 2 H T R Q
.. GCT GCT ~-~ CAC ACC CGG CAA ##
.. wild-type pDM0454
# - spurious deletion of 1 codon within the cassette ## - ambiguous sequence
labi£_B2
Sequences of eluted nhaαe after 3 rounds of selective enrichment.
All protein sequences should be of the form AA**TRQ, where * represents a randomised codon. In the table below, the randomised codons and amino acids are underlined and in bold.
After round 3:
Sequence No. of occurrences
A A fl X T R Q GCT GCT CAC TAT ACG CGT CAG
A A i fl T R Q GCT GCT CTC CAC ACC CGG CAA
A A Q, H T R Q GCT GCT CAG CAC ACC CGG CAA
A A I H T R Q GCT GCT ACG CAC ACC CGG CAA
A A fl £ R Q GCT GCT CAC TCC CGG CAA
A A fl fl T R Q ... GCT GCT CAT CAT ACC CGG CAA 1 ##
A A fl £ R Q ... GCT GCT CAC TTC CGG CAA ... 1 A A fl I R Q
... GCT GCT CAC ACC CGG CAA ... 1
# - contaminating sequence from pDM0411
## - contains the "illegal" codon CAT - T should not appear in the 3rd position of a codon.
SEQUENCE LISTING
(1) GENERAL INFORMATION: (i) APPLICANT: Genentech, Inc.
Garrard, Lisa J. Henner, Dennis J. Bass, Steven Greene, Ronald Lowman, Henry B.
Wells, James A. Matthews, David J.
(ii) TITLE OF INVENTION: Enrichment Method For Variant Proteins With Altered Binding Properties
(iii) NUMBER OF SEQUENCES: 27
(iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Genentech, Inc.
(B) STREET: 460 Point San Bruno Blvd
(C) CITY: South San Francisco
(D) STATE: California
(E) COUNTRY: USA (F) ZIP: 94080
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
(B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: patin (Genentech)
(vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: 03-DEC-91
(C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/743614 (B) APPLICATION DATE: 09-Aug-91
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/715300
(B) APPLICATION DATE: 14-June-91
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/683400
(B) APPLICATION DATE: 10-Apr-91 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/621667
(B) APPLICATION DATE: 03-Dec-1990
(viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Benson, Robert H.
(B) REGISTRATION NUMBER: 30,446
(C) REFERENCE/DOCKET NUMBER: 645P4
(ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 415/266-1489
(B) TELEFAX: 415/952-9881
(C) TELEX: 910/371-7168
(2) INFORMATION FOR SEQ ID NO:l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 bases
(B) TYPE: nucleic acid (C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:l:
GGCAGCTGTG GCTTCTAGAG TGGCGGCGGC TCTGGT 36
(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 bases
(B) TYPE: nucleic acid (C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
AGCTGTGGCT TCGGGCCCTT AGCATTTAAT GCGGTA 36
(2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single (D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
TTCACAAACG AAGGGCCCCT AATTAAAGCC AGA 33
(2) INFORMATION FOR SEQ ID NO: : (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
CAATAATAAC GGGCTAGCCA AAAGAACTGG 30
(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
CACGACAGAA TTCCCGACTG GAAA 24
(2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
CTGTTTCTAG AGTGAAATTG TTA 23
(2) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
ACATTCCTGG GTACCGTGCA G 21
(2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 63 bases (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
GCTTCAGGAA GGACATGGAC NNSGTCNNSA CANNSCTGNN SATCGTGCAG 50
TGCCGCTCTG TGG 63
(2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
AAGGTCTCCA CATACCTGAG GATC 24
(2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
ATGGACAAGG TGTCGACATA CCTGCGCATC GTG 33 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
GGCAGCTGTG GCTTCTAGAG TGGCGGCGGC TCTGGT 36
(2) INFORMATION FOR SEQ ID NO:12:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
GGCAGCTGTG GATTCTAGAG TGGCGGTGGC TCTGGT 36
(2) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 12 amino acids (B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: Gly Ser Cys Gly Phe Glu Ser Gly Gly Gly Ser Gly 1 5 10 12
(2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:
CGGACTGGGC AGATATTCAA GCAGACC 27
(2) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 38 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
CTCAAGAACT ACGGGTTACC CTGACTGCTT CAGGAAGG 38 (2) INFORMATION FOR SEQ ID NO:16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:
CGCATCGTGC AGTGCAGATC TGTGGAGGGC 30
(2) INFORMATION FOR SEQ ID NO:17:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 66 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:
GTTACTCTAC TGCTTTCAGG AAGGACATGG ACNNSGTCNN SACANNSCTG 50
NNSATCGTGC AGTGCA 66
(2) INFORMATION FOR SEQ ID NO:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 64 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single (D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
GATCTGCACT GCACGATSNN CAGSNNTGTS NNGACSNNGT CCATGTCCTT 50
CCTGAAGCAG TAGA 64
(2) INFORMATION FOR SEQ ID NO:19:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 bases (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:
GCCTTTGACA GGTACCAGGA GTTTG 25
(2) INFORMATION FOR SEQ ID NO:20:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 bases (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
CCAACTATAC CACTCTCGAG GTCTATTCGA TAA 33
(2) INFORMATION FOR SEQ ID NO:21:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 66 bases (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
TCGAGGCTCN NSGACAACGC GNNSCTGCGT GCTNNSCGTC TTNNSCAGCT 50
GGCCTTTGAC ACGTAC 66
(2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 58 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:
GTGTCAAAGG CCAGCTGSNN AAGACGSNNA GCACGCAGSN NCGCGTTGTC 50
SNNGAGCC 58
(2) INFORMATION FOR SEQ ID NO:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 65 bases
(B) TYPE: nucleic acid (C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:
GTTACTCTAC TGCTTCNNSA AGGACATGNN SAAGGTCAGC NNSTACCTGC 50
GCNNSGTGCA GTGCA 65
(2) INFORMATION FOR SEQ ID NO:24:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 64 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:
GATCTGCACT GCACSNNGCG CAGGTASNNG CTGACCTTSN NCATGTCCTT 50
SNNGAAGCAG TAGA 64
(2) INFORMATION FOR SEQ ID NO:25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2178 bases
(B) TYPE: nucleic acid (C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:
ATGAAAAAGA ATATCGCATT TCTTCTTGCA TCTATGTTCG TTTTTTCTAT 50
TGCTACAAAC GCGTACGCTG ATATCCAGAT GACCCAGTCC CCGAGCTCCC 100
TGTCCGCCTC TGTGGGCGAT AGGGTCACCA TCACCTGCCG TGCCAGTCAG 150
GATGTGAATA CTGCTGTAGC CTGGTATCAA CAGAAACCAG GAAAAGCTCC 200
GAAACTACTG ATTTACTCGG CATCCTTCCT CTACTCTGGA GTCCCTTCTC 250
GCTTCTCTGG ATCCAGATCT GGGACGGATT TCACTCTGAC CATCAGCAGT 300
CTGCAGCCGG AAGACTTCGC AACTTATTAC TGTCAGCAAC ATTATACTAC 350
TCCTCCCACG TTCGGACAGG GTACCAAGGT GGAGATCAAA CGAACTGTGG 400
CTGCACCATC TGTCTTCATC TTCCCGCCAT CTGATGAGCA GTTGAAATCT 450
GGAACTGCCT CTGTTGTGTG CCTGCTGAAT AACTTCTATC CCAGAGAGGC 500
CAAAGTACAG TGGAAGGTGG ATAACGCCCT CCAATCGGGT AACTCCCAGG 550
AGAGTGTCAC AGAGCAGGAC AGCAAGGACA GCACCTACAG CCTCAGCAGC 600
ACCCTGACGC TGAGCAAAGC AGACTACGAG AAACACAAAG TCTACGCCTG 650
CGAAGTCACC CATCAGGGCC TGAGCTCGCC CGTCACAAAG AGCTTCAACA 700
GGGGAGAGTG TTAAGCTGAT CCTCTACGCC GGACGCATCG TGGCCCTAGT 750
ACGCAAGTTC ACGTAAAAAG GGTATCTAGA GGTTGAGGTG ATTTTATGAA 800 AAAGAATATC GCATTTCTTC TTGCATCTAT GTTCGTTTTT TCTATTGCTA 850
CAAACGCGTA CGCTGAGGTT CAGCTGGTGG AGTCTGGCGG TGGCCTGGTG 900
CAGCCAGGGG GCTCACTCCG TTTGTCCTGT GCAGCTTCTG GCTTCAACAT 950
TAAAGACACC TATATACACT GGGTGCGTCA GGCCCCGGGT AAGGGCCTGG 1000
AATGGGTTGC AAGGATTTAT CCTACGAATG GTTATACTAG ATATGCCGAT 1050
AGCGTCAAGG GCCGTTTCAC TATAAGCGCA GACACATCCA AAAACACAGC 1100
CTACCTGCAG ATGAACAGCC TGCGTGCTGA GGACACTGCC GTCTATTATT 1150
GTTCTAGATG GGGAGGGGAC GGCTTCTATG CTATGGACTA CTGGGGTCAA 1200
GGAACCCTGG TCACCGTCTC CTCGGCCTCC ACCAAGGGCC CATCGGTCTT 1250
CCCCCTGGCA CCCTCCTCCA AGAGCACCTC TGGGGGCACA GCGGCCCTGG 1300
GCTGCCTGGT CAAGGACTAC TTCCCCGAAC CGGTGACGGT GTCGTGGAAC 1350
TCAGGCGCCC TGACCAGCGG CGTGCACACC TTCCCGGCTG TCCTACAGTC 1400
CTCAGGACTC TACTCCCTCA GCAGCGTGGT GACTGTGCCC TCTAGCAGCT 1450
TGGGCACCCA GACCTACATC TGCAACGTGA ATCACAAGCC CAGCAACACC 1500
AAGGTGGACA AGAAAGTTGA GCCCAAATCT TGTGACAAAA CTCACACAGG 1550
GCCCTTCGTT TGTGAATATC AAGGCCAATC GTCTGACCTG CCTCAACCTC 1600
CTGTCAATGC TGGCGGCGGC TCTGGTGGTG GTTCTGGTGG CGGCTCTGAG 1650
GGTGGTGGCT CTGAGGGTGG CGGTTCTGAG GGTGGCGGCT CTGAGGGAGG 1700
CGGTTCCGGT GGTGGCTCTG GTTCCGGTGA TTTTGATTAT GAAAAGATGG 1750
CAAACGCTAA TAAGGGGGCT ATGACCGAAA ATGCCGATGA AAACGCGCTA 1800
CAGTCTGACG CTAAAGGCAA ACTTGATTCT GTCGCTACTG ATTACGGTGC 1850
TGCTATCGAT GGTTTCATTG GTGACGTTTC CGGCCTTGCT AATGGTAATG 1900
GTGCTACTGG TGATTTTGCT GGCTCTAATT CCCAAATGGC TCAAGTCGGT 1950 GACGGTGATA ATTCACCTTT AATGAATAAT TTCCGTCAAT ATTTACCTTC 2000
CCTCCCTCAA TCGGTTGAAT GTCGCCCTTT TGTCTTTAGC GCTGGTAAAC 2050
CATATGAATT TTCTATTGAT TGTGACAAAA TAAACTTATT CCGTGGTGTC 2100
TTTGCGTTTC TTTTATATGT TGCCACCTTT ATGTATGTAT TTTCTACGTT 2150
TGCTAACATA CTGCGTAATA AGGAGTCT 2178
(2) INFORMATION FOR SEQ ID NO:26:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 237 amino acids (B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: Met Lys Lys Asn lie Ala Phe Leu Leu Ala Ser Met Phe Val Phe 1 5 10 15
Ser lie Ala Thr Asn Ala Tyr Ala Asp lie Gin Met Thr Gin Ser 20 25 30
Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr lie Thr 35 40 45
Cys Arg Ala Ser Gin Asp Val Asn Thr Ala Val Ala Trp Tyr Gin 50 55 60
Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu lie Tyr Ser Ala Ser 65 70 75 Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Arg Ser
80 85 90
Gly Thr Asp Phe Thr Leu Thr lie Ser Ser Leu Gin Pro Glu Asp 95 100 105
Phe Ala Thr Tyr Tyr Cys Gin Gin His Tyr Thr Thr Pro Pro Thr 110 115 120
Phe Gly Gin Gly Thr Lys Val Glu lie Lys Arg Thr Val Ala Ala 125 130 135
Pro Ser Val Phe lie Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser 140 145 150 Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
155 160 165
Glu Ala Lys Val Gin Trp Lys Val Asp Asn Ala Leu Gin Ser Gly 170 175 180
Asn Ser Gin Glu Ser Val Thr Glu Gin Asp Ser Lys Asp Ser Thr 185 190 195
Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 200 205 210
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser 215 220 225 Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 230 235 237
(2) INFORMATION FOR SEQ ID NO:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 461 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:
Met Lys Lys Asn lie Ala Phe Leu Leu Ala Ser Met Phe Val Phe 1 5 10 15
Ser lie Ala Thr Asn Ala Tyr Ala Glu Val Gin Leu Val Glu Ser 20 25 30
Gly Gly Gly Leu Val Gin Pro Gly Gly Ser Leu Arg Leu Ser Cys 35 40 45
Ala Ala Ser Gly Phe Asn lie Lys Asp Thr Tyr lie His Trp Val 50 55 60
Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg lie Tyr 65 70 75
Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val Lys Gly Arg 80 85 90
Phe Thr lie Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu Gin 95 100 105
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ser 110 115 120
Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gin
125 130 135 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
140 145 150
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 155 160 165
Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 170 175 180
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 185 190 195
Phe Pro Ala Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser 200 205 210 Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr He
215 220 225
Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys
230 235 240
Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Gly Pro Phe Val
245 250 255
Cys Glu Tyr Gin Gly Gin Ser Ser Asp Leu Pro Gin Pro Pro Val 260 265 270
Asn Ala Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Glu
275 280 285 Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu 290 295 300
Gly Gly Gly Ser Gly Gly Gly Ser Gly Ser Gly Asp Phe Asp Tyr 305 310 315
Glu Lys Met Ala Asn Ala Asn Lys Gly Ala Met Thr Glu Asn Ala 320 325 330 Asp Glu Asn Ala Leu Gin Ser Asp Ala Lys Gly Lys Leu Asp Ser
335 340 345
Val Ala Thr Asp Tyr Gly Ala Ala He Asp Gly Phe He Gly Asp 350 355 360
Val Ser Gly Leu Ala Asn Gly Asn Gly Ala Thr Gly Asp Phe Ala 365 370 375
Gly Ser Asn Ser Gin Met Ala Gin Val Gly Asp Gly Asp Asn Ser 380 385 390
Pro Leu Met Asn Asn Phe Arg Gin Tyr Leu Pro Ser Leu Pro Gin 395 400 405 Ser Val Glu Cys Arg Pro Phe Val Phe Ser Ala Gly Lys Pro Tyr
410 415 420
Glu Phe Ser He Asp Cys Asp Lys He Asn Leu Phe Arg Gly Val 425 430 435
Phe Ala Phe Leu Leu Tyr Val Ala Thr Phe Met Tyr Val Phe Ser 440 445 450
Thr Phe Ala Asn He Leu Arg Asn Lys Glu Ser 455 460 461

Claims

What is claimed is:
1. A method for selecting novel binding poiypeptides comprising:
(a) constructing a replicable expression vector comprising a transcription regulatory element operably linked to a gene fusion encoding a fusion protein wherein the gene fusion comprises a first gene encoding a polypeptide, and a second gene encoding at least a portion of a phage coat protein;
( b ) mutating the vector at one or more selected positions within the first gene thereby forming a family of related plasmids;
(c) transforming suitable host cells with the plasmids;
( d ) infecting the transformed host cells with a helper phage having a gene encoding the phage coat protein;
( e ) culturing the transformed infected host cells under conditions suitable for forming recombinant phagemid partides containing at least a portion of the plasmid and capable of transforming the host, the conditions adjusted so that no more than a minor amount of phagemid partides display more than one copy of the fusion protein on the surface of the particle;
( f ) contacting the phagemid particles with a target molecule so that at least a portion of the phagemid partides bind to the target molecule; and
( g ) separating the phagemid partides that bind from those that do not.
2. The method of daim 1 further comprising infecting a suitable host cells with the phagemid particles that bind and repeating steps (d) through (g).
3. The method of daim 2 wherein the steps are repeated one or more times.
4. The method of claim 1 wherein the expression vector further comprises a secretory signal sequence.
5. The method of daim 1 wherein the transcription regulatory element is a promoter system selected from the group; lad, pho A, tryptophan, tac, λpι_, bacteriophage T7, and combinations thereof.
6. The method of claim 1 wherein the first gene encodes a mammalian protein.
7. The method of daim 6 wherein the protein is selected from the group; growth hormone, human growth hormone(hGH), des-N-methioπyi human growth hormone, bovine growth hormone, parathyroid hormone, thyroxine, insulin A-chain, insulin B-chain, proinsulin, relaxin A-chain, relaxin B-chain, prorelaxin, follicle stimulating hormone(FSH), thyroid stimulating hormone(TSH), leutinizing hormone(LH), glycoprotein hormone receptors, caldtonin, glucagon, factor VIII, an antibody, lung surfactant, urokinase, streptokiπase, human tissue-type plasminogen activator (t-PA), bombesin, factor IX, thrombin, hemopoietic growth factor, tumor necrosis factor-alpha and -beta, enkephalinase, human serum albumin, mullerian- inhibiting substance, mouse gonadotropin-assodated peptide, β-lactamase, tissue factor protein, inhibin, activin, vascular endothelial growth factor, integrin receptors, thrombopoietin, protein A or D, rheumatoid factors, NGF-β, platelet-growth factor, transforming growth factor ; TGF-alp a and TGF-beta, insulin-like growth factor-l and -II, insulin-like growth factor binding proteins , CD-4, DNase, latency assodated peptide, erythropoietin, HER2 ligands, osteoinductive factors, interferon-alpha, -beta, and -gamma, colony stimulating factors (CSFs), M-CSF, GM-CSF, and G-CSF, interieukins (ILs), IL-1, IL-2, IL-3, IL-4, superoxide dismutase; decay accelerating factor, viral antigen, HIV envelope proteins GP120 and GP140, atrial natriuretic peptides A, B, or C, or immuno globulins, and fragments of the above-listed proteins.
8. The method of claim 7 wherein the protein is a human protein.
9. The method of daim 8 wherein the protein comprises more than about 100 amino acid residues.
10. The method of daim 1 wherein the protein comprises a plurality of rigid secondary structures displaying amino acids capable of interacting with the target, and the mutations are primarily produced at positions corresponding to codons encoding the amino acids.
11. The method of daim 10 wherein the rigid secondary structures comprise structures selected from the group; α-(3.6i3)helix, 3*ιo helix, π-(4.4i6)helix, parallel and anti-parallel β-pleated sheets, reverse turns, and non-ordered structures.
12. The method of daim 10 wherein the mutations are produced at more than one codon.
13. The method of claim 12 wherein the mutations are produced on more than one rigid secondary structure.
14. The method of claim 1 wherein the helper phage is selected from the group M13K07, M13R408, M13-
VCS, and Phi X 174.
15. The method of daim 14 wherein the helper phage is M13K07 and the coat protein is the M13 phage gene
III coat protein.
16. The method of claim 15 wherein the host is £ coli.
17. The method of daim 16 wherein the plasmid is under tight control of the transcription regulatory element.
18. The method of claim 17 wherein the amount is less than about 1%.
19. The method of daim 18 wherein the amount is less than 20% the amount of phagemid particles displaying a single copy of the fusion protein.
20. The method of claim 19 wherein the amount is less than 10%.
21. The method of daim 1 further comprising in step (a), inserting a DNA triplet, encoding an mRNA suppressible terminator codon between said first gene encoding a polypeptide, and said second gene encoding at least a portion of a phage coat protein.
22. The method of claim 21 wherein said mRNA suppressible terminator codon is selected from the following: UAG (amber), UAA (ocher) and UGA (opel).
23. The method of daim 22 wherein said suppressible mutation results in the detectable production of a fusion polypeptide containing sadi polypeptide and said coat protein when said expression vector is grown in a suppressor host cell; and, when grown in a non-suppressor host cell said polypeptide is synthesized substantially without fusion to said phage coat protein.
24. A human growth hormone variant wherein hGH amino acids 172, 174, 176 and 178 respectively are as a group sequentially selected from one of the following: (1)R,S,F,R; (2)R,A,Y,R; (3)K,T,Y,K; (4)R,S,Y,R; (5)K,A,Y,R; (6)R,F,F,R; (7)K,Q,Y,R; (8) R.T.Y.H; (9)Q,R,Y,R; (10)K,K,Y,K; (11)R,S,F,S; and (12)K,S,N,R.
25. A phagemid comprising a replicable expression vector comprising a transcription regulatory element operably linked to a gene fusion encoding a fusion protein wherein the gene fusion comprises a first gene encoding a polypeptide, and a second gene encoding at least a portion of a phage coat protein, wherein a DNA triplet codon encoding an mRNA suppressible terminator codon selected from UAG, UAA and UGA is inserted between the fused ends of the first and second genes, or is substituted for an amino add encoding triplet codon adjacent to the gene fusion junction.
26. The phagemid of daim 25 wherein said first gene encodes a mammalian protein.
27. The phagemid of daim 26 wherein the protein is selected from the group: growth hormone, human growth hormone (hGH), des-N-methionyi human growth hormone, bovine growth hormone, parathyroid hormone, thyroxine, insulin A-chain, insulin B-chain, proinsulin, relaxin A-chain, relaxin B-chain, prorelaxin, follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), leutinizing hormone (LH), glycoprotein hormone receptors, caldtonin, glucagon, factor
VIII, an antibody, lung surfactant, urokinase, streptokinase, human tissue-type plasminogen activator (t-PA), bombesin, factor IX, thrombin, hemopoietic growth factor, tumor necrosis factor-alpha and-beta, enkephalinase, human serum albumin, mullerian-inhibiting substance, mouse gonadotropin-assodated peptide, β-lactamase, tissue factor protein, inhibin, acϋ'vin, vascular endothelial growth factor, integrin receptors, thrombopoϊetin, protein A or D, rheumatoid factors, NGF-β, platelet-growth factor, transforming growth factor; TGF-alpha and TGF-beta, insulin-like growth-l and -II, insulin-like growth factor binding proteins, CD-4, DNase, latency associated peptide, erythropoietin, osteoinductive factors, interferon-alpha, - beta, and -gamma, colony stimulating factors (CSFs), M-CSF, GM-CSF, and G-CSF, interleukins (ILs), IL-1, IL-2, IL-3, IL-4, superoxide dismutase; decay accelerating factor, viral antigen, HIV envelope proteins GP120 and GP140, atrial natriuretic peptides A, B or C immune- globulins, and fragments of the above-listed proteins.
28. The phagemid of claim 27 wherein said protein is a human protein.
29. The phagemid of claim 28 wherein the protein comprises more than about 100 amino acid residues.
30. The phagemid of daim 25 wherein said protein comprises a plurality of rigid secondary structures displaying amino adds capable of interacting with the target
31. The phagemid of daim 30 wherein said rigid secondary structures comprises structures selected from the group; α-(3.6-|3)helix, 3*ιo helix, π-(4.4-*6)helix, parallel and anti-parallel β-pleated sheets, reverse turns, and non-ordered structures.
32. The phagemid of daim 25 wherein the helper phage is selected from the group M13K07, M13R408, M13-VCS, and Phi X 174.
33. The phagemid of claim 32 wherein the helper phage is M13K07and the coat protein is the M13 phage gene III coat protein.
34. The phagemid of claim 33 wherein the host is the £. co// wild type or suppressor type.
35. The phagemid of daim 34 wherein the plasmid is under tight control of the transcription regulatory element.
36. The phagemid of claim 35 wherein the number of phagemid partides displaying more than one copy of the fusion protein on the surface of the particles is less than 1%.
37. The phagemid of claim 36 wherein said number of phagemid particles is less than about 10%.
38. The phagemid of claim 37 wherein the number of phagemid partides is less than about 20%.
39. A human growth variant wherein hGH amino adds 10, 14, 18, and 21 respedively are as a group sequentially selected from one of the following:
(1)H,G,N,N; (2)A,W,D,N; (3)F,S,F,L; (4)Y,T,V,N and (5)I,N,I,N.
40. A human growth variant wherein hGH amino acids 174 is serine and 176 is tyrosine and hGH amino adds
167, 171 , 175 and 179 respectively are as a group sequentially selected from one of the following:
(1)N,S,T,T; (2)E,S,T,I; (3)K,S,T,L; (4)N,N,T,T; (5) R.D.I.I; and (6)N,S,T,Q.
41. A method for selecting novel binding poiypeptides comprising
( a ) constructing a replicable expression vector comprising a transcription regulatory element operably linked to DNA encoding a protein of interest containing one or more subunits, wherein the DNA encoding at least one of the subunits is fused to the DNA encoding at least a portion of a phage coat protein;
( b ) mutating the DNA encoding the protein of interest at one or more selected positions thereby forming a family of related vectors;
( c ) transforming suitable host cells with the vectors;
( d ) infecting the transformed host cells with a helper phage having a gene encoding the phage coat protein;
(e) culturing the transformed infected host cells under conditions suitable for forming recombinant phagemid particles containing at least a portion of the plasmid and capable of transforming the host, the conditions adjusted so that no more than a minor amount of phagemid partides display more than one copy of the fusion protein on the surface of the particle;
( f ) contacting the phagemid partides with a target molecule so that at least a portion of the phagemid partides bind to the target molecule; and
(g ) separating the phagemid partides that bind from those that do not
42. The method of claim 41 wherein the expression vector further comprises a secretory signal sequence operably linked to the DNA encoding each subunit of the protein of interest.
43. The method of claim 42 wherein the protein of interest is a mammalian protein.
44. The method of daim 43 wherein the protein of interest is selected from the group; insulin, relaxin, follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), leufc'nizing hormone (LH), glycoprotein hormone receptors, monoclonal and polyclonal antibodies, lung surfactant, integrin receptors, insulin-like growth factor-l and -II, and fragments of the above-listed proteins.
45. The method of daim 44 wherein the protein of interest is a humanized antibody.
46. The method of claim 45 wherein the protein of interest is a humanized Fab fragment capable of binding to the HER-2 receptor (human epidermal growth factor receptor-2).
47 A human growth hormone (hGH) variant wherein hGH amino acid glutamate-174 is replaced by seriπe-174 and phenylalaπine*i76 is replaced by tyrosinei 7 and one or more of the eight naturally occurring hGH amino adds F10, M14, H18, H21 , R167, D171, T175 and 1179 are replaced by another natural amino add.
48 The hGH variant of daim 47 wherein the eight naturally occurring hGH amino adds F10, M14, H18, H21 , R167, D171 , T175 and 1179 respectively are as a group replaced with a corresponding amino add sequentially selected from one of the following groups:
(I) H, G, N, N, N, S , T, T (2 ) H, G, N, N, E, S, T, I; (3) H, G, N, N, N, N, T, T (4) A, W, D, N, N, S, T, T;
(5) A, W, D, N, E, S , T, I ( 6) A, , D, N, N, N, T, T;
(7 ) F, S, F, L, N, S , T, T ( 8 ) F, S, F, L, E, S , T, I ;
(9 ) F, S, F, L, N, N, T, T (10 ) H, G, N, N, N, S, T, N;
(II) A, N, D, A, N, N, T, N (12) F, S , F, G, H, S , T, T; (13) H, Q, T, S, A, D, N, S (14) H, G, N, N, N, A, T, T;
(15) F, S, F, L, S , D, T, T (16) A, S , T, N, R, D, T, I;
(17 ) Q, Y, N, N, H, S , T, T (18 ) W, G, S , S , R, D , T , I ;
(19) F, L, S, S, K, N, T, (20 ) W, N, N, S , H, S, T, T; (21) A, N, A, S, N, S, T, T; (22) P, S, D, N, R, D, T, I;
(23) H, G, N, N, N, N, T, S; (24) F, S, T, G, R, D, T, I;
(25) M, T, S, N, Q, S, T, T; (26) F, S, F, L, T, S, T, S;
(27) A, W, D, N, R, D, T, I; (28) A, , D, N, H, S, T, N; (29) M, Q, M, N, N, S, T, T; (30) H, Y, D, H, R, D, T, T;
(31) L, N, S, H, R, D, T, I; (32) L, N, S, H, T, S, T, T;
(33) A, W, D, N, N, A, T, T; (34) F, S, T, G, R, D, T, I;
(35) A, W, D, N, R, D, T, I; (36) I, Q, E, H, N, S, T, T;
(37) F, S, L, A, N, S, T, V; (38) F, S, F, L, K, D, T, T; (39) M, A, D, N, N, S, T, T; (40) A, W, D, N, S, S, V, T;
(41) H, Q, Y, S, R, D, T, I.
49. The method of claim 48 wherein said human growth hormone variant (11) further contains leudne-|5 replaced by arginine-|5 and lysine-|68 replaced by arginine*i68-
50. The method of claim 48 wherein said human growth hormone variant (40) further contains phenylalaninei76
51. A method for selecting novel binding poiypeptides comprising:
(a) constructing a replicable expression vector comprising a transcription regulatory element operabfy linked to a gene fusion encoding a fusion protein wherein the gene fusion comprises a first gene encoding a polypeptide operable connedted to a linking amino acid sequence, and a second gene encoding at least a portion of a phage coat protein;
( b ) mutating the vector at one or more selected positions within the amino acid linking sequence of the first gene thereby forming a family of related plasmids;
(c) transforming suitable host cells with the plasmids;
( d ) infecting the transformed host cells with a helper phage having a gene encoding the phage coat protein;
( e ) culturing the transformed infected host cells under conditions suitable for forming recombinant phagemid partides containing at least a portion of the plasmid and capable of transforming the host, the conditions adjusted so that no more than a minor amount of phagemid partides display more than one copy of the fusion protein on the surface of the particle;
( f ) contacting the phagemid partides with a target molecule so that at least a portion of the phagemid particles bind to the target molecule; and (g ) contacting the bound phagemid particles with a protease capable of hydrolysing the linking a amink) add sequence of at least a portion of the bound phagmid partides, and
(h) isolating the hydrolyzed phagmid partides.
52. The method of daim 51 further comprising infecting suitable host cells with the hydrolyzed phagemid particles and repeating steps (d) through (h).
PCT/US1991/009133 1990-12-03 1991-12-03 Enrichment method for variant proteins with altered binding properties WO1992009690A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
EP92902109A EP0564531B1 (en) 1990-12-03 1991-12-03 Enrichment method for variant proteins with altered binding properties
JP50271092A JP3267293B2 (en) 1990-12-03 1991-12-03 Methods for enriching mutant proteins with altered binding
CA002095633A CA2095633C (en) 1990-12-03 1991-12-03 Enrichment method for variant proteins with altered binding properties
ES92902109T ES2113940T3 (en) 1990-12-03 1991-12-03 ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
DK92902109T DK0564531T3 (en) 1990-12-03 1991-12-03 Enrichment procedure for variant proteins with altered binding properties
US08/050,058 US5750373A (en) 1990-12-03 1991-12-03 Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
DE69129154T DE69129154T2 (en) 1990-12-03 1991-12-03 METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES
US08/463,667 US5834598A (en) 1990-12-03 1995-06-05 Human growth hormone variants
US08/463,587 US5821047A (en) 1990-12-03 1995-06-05 Monovalent phage display
GR980400652T GR3026468T3 (en) 1990-12-03 1998-03-27 Enrichment method for variant proteins with altered binding properties
US11/199,062 US20060115874A1 (en) 1990-12-03 2005-08-08 Enrichment method for variant proteins with altered binding properties
US11/761,180 US20080038717A1 (en) 1990-12-03 2007-06-11 Enrichment method for variant proteins with altered binding properties
US12/508,859 US20100035236A1 (en) 1990-12-03 2009-07-24 Enrichment method for variant proteins with altered binding properties

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US743,614 1976-11-22
US62166790A 1990-12-03 1990-12-03
US68340091A 1991-04-10 1991-04-10
US71530091A 1991-06-14 1991-06-14
US621,667 1991-06-14
US683,400 1991-06-14
US715,300 1991-06-14
US74361491A 1991-08-08 1991-08-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US74361491A Continuation-In-Part 1988-10-28 1991-08-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US08/463,587 Division US5821047A (en) 1990-12-03 1995-06-05 Monovalent phage display

Publications (2)

Publication Number Publication Date
WO1992009690A2 true WO1992009690A2 (en) 1992-06-11
WO1992009690A3 WO1992009690A3 (en) 1992-12-10

Family

ID=27505166

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/009133 WO1992009690A2 (en) 1990-12-03 1991-12-03 Enrichment method for variant proteins with altered binding properties

Country Status (9)

Country Link
US (7) US5750373A (en)
EP (1) EP0564531B1 (en)
AT (1) ATE164395T1 (en)
CA (2) CA2405246A1 (en)
DE (1) DE69129154T2 (en)
DK (1) DK0564531T3 (en)
ES (1) ES2113940T3 (en)
GR (1) GR3026468T3 (en)
WO (1) WO1992009690A2 (en)

Cited By (740)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001288A1 (en) * 1991-07-08 1993-01-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Phagemide for screening antibodies
US5432018A (en) * 1990-06-20 1995-07-11 Affymax Technologies N.V. Peptide library and screening systems
WO1995018856A1 (en) 1993-12-30 1995-07-13 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing hedgehog-like proteins
US5498530A (en) * 1991-10-16 1996-03-12 Affymax Technologies, N.V. Peptide library and screening method
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
WO1997011178A1 (en) * 1995-09-21 1997-03-27 Genentech, Inc. Human growth hormone variants
WO1997017614A1 (en) * 1995-11-10 1997-05-15 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
WO1997035194A2 (en) * 1996-03-21 1997-09-25 President And Fellows Of Harvard College Enantiomeric screening process, and compositions therefor
US5681809A (en) * 1989-10-12 1997-10-28 Ohio University Growth hormone antagonists
US5688666A (en) * 1988-10-28 1997-11-18 Genentech, Inc. Growth hormone variants with altered binding properties
US5733731A (en) * 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5763575A (en) * 1993-07-26 1998-06-09 Cor Therapeutics, Inc. Agonist and antagonist peptides of the C140 receptor
US5858657A (en) * 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) * 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5885793A (en) * 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1999026069A1 (en) * 1997-11-14 1999-05-27 Generic Biologicals Limited Improvements in or relating to detection of molecules in samples
US5962255A (en) * 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US5969108A (en) * 1990-07-10 1999-10-19 Medical Research Council Methods for producing members of specific binding pairs
WO2000006717A2 (en) * 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
WO2000018933A1 (en) * 1998-09-30 2000-04-06 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
US6140471A (en) * 1992-03-24 2000-10-31 Cambridge Antibody Technology, Ltd. Methods for producing members of specific binding pairs
WO2001000810A1 (en) 1999-06-30 2001-01-04 Millennium Pharmaceuticals, Inc. Glycoprotein vi and uses thereof
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
WO2001058956A2 (en) 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
WO2001064954A1 (en) 2000-03-02 2001-09-07 Promega Corporation Method of reverse transcription using bacillus steraothermophilus or thermoactinomyces vulgaris dna polymerase
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
US6335319B1 (en) * 1994-11-15 2002-01-01 Metabolic Pharmaceuticals, Inc. Treatment of obesity
WO2002000730A2 (en) 2000-06-28 2002-01-03 Genetics Institute, Llc. Pd-l2 molecules: novel pd-1 ligands and uses therefor
US6361938B1 (en) 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
WO2002028893A2 (en) 2000-07-14 2002-04-11 Cropdesign N.V. Plant cyclin-dependent kinase inhibitors
US6420110B1 (en) 1998-10-19 2002-07-16 Gpc Biotech, Inc. Methods and reagents for isolating biologically active peptides
US6485972B1 (en) 1998-10-15 2002-11-26 President And Fellows Of Harvard College WNT signalling in reproductive organs
GB2375765A (en) * 1997-11-14 2002-11-27 Kymed Gb Ltd Tagged growth hormone molecules
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO2002100330A2 (en) 2001-06-08 2002-12-19 Abbott Biotechnology Ltd METHODS OF ADMINISTERING ANTI-TNFα ANTIBODIES
US6497874B1 (en) 1997-02-05 2002-12-24 Maardh Sven Recombinant phages
WO2003040170A2 (en) 2001-11-09 2003-05-15 Pfizer Products Inc. Antibodies to cd40
US6573370B1 (en) 2000-05-19 2003-06-03 Regents Of The University Of Michigan PON3 and uses thereof
US6616926B1 (en) 1999-03-03 2003-09-09 Curis, Inc. Methods of modulating lipid metabolism and storage
WO2003082914A1 (en) 2002-04-03 2003-10-09 The University Of Queensland Prothrombin activating protein
US6632645B1 (en) 2000-03-02 2003-10-14 Promega Corporation Thermophilic DNA polymerases from Thermoactinomyces vulgaris
US6667150B1 (en) 1997-08-01 2003-12-23 Morphosys Ag Method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly) peptide complex
US6777194B1 (en) 1999-04-01 2004-08-17 Dakocytomation Denmark A/S Monoclonal antibodies against human protein Mcm3, process for their production, and their use
US6800740B1 (en) 1991-05-10 2004-10-05 Genentech, Inc. Variants of native growth hormones having non naturally occurring amino acid sequences or covalent modifications
US6806079B1 (en) 1990-07-10 2004-10-19 Medical Research Council Methods for producing members of specific binding pairs
US6878861B2 (en) 2000-07-21 2005-04-12 Washington State University Research Foundation Acyl coenzyme A thioesterases
WO2004094476A3 (en) * 2003-04-16 2005-06-16 Genentech Inc Compositions and methods relating to stop-1
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6951839B1 (en) 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
EP1592777A2 (en) * 2003-02-01 2005-11-09 Tanox, Inc. A method for generating high affinity antibodies
WO2006014744A2 (en) 2004-07-23 2006-02-09 University Of Massachusetts Compounds that inhibit hsp90 protein-protein interactions with iap proteins
EP1626056A2 (en) 1999-12-30 2006-02-15 President And Fellows of Harvard College Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or T cell subset activity by modulation of XBP-1 activity
US7037498B2 (en) 2001-01-05 2006-05-02 Abgenix, Inc. Antibodies to insulin-like growth factor I receptor
US7056517B2 (en) 1998-04-13 2006-06-06 The Forsyth Institute Glucosyltransferase immunogens
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
US7087418B2 (en) 2001-12-19 2006-08-08 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
US7101549B2 (en) 1999-06-30 2006-09-05 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
EP1714661A2 (en) 2000-05-19 2006-10-25 The Center for Blood Research, INC. Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
WO2006116442A2 (en) 2005-04-27 2006-11-02 Tripath Imaging, Inc. Monoclonal antibodies and methods for their use in the detection of cervical disease
US7151169B2 (en) 1999-04-30 2006-12-19 Cambridge Antibody Technology Limited Specific binding members for TGFβ1
US7163682B2 (en) 1998-04-13 2007-01-16 The Forsyth Institute Glucan binding protein and glucosyltransferase immunogens
WO2007024715A2 (en) 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
WO2007024705A2 (en) 2005-08-19 2007-03-01 Abbott Biotechnology Ltd. Method of treating depression using a tnf-alpha antibody
US7250551B2 (en) 2002-07-24 2007-07-31 President And Fellows Of Harvard College Transgenic mice expressing inducible human p25
WO2007089303A2 (en) 2005-11-01 2007-08-09 Abbott Biotechnology Ltd. Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
US7323175B2 (en) 2002-03-07 2008-01-29 The Forsyth Institute Immunogenicity of glucan binding protein
US7326414B2 (en) 2003-09-10 2008-02-05 Warner-Lambert Company Llc Antibodies to M-CSF
WO2008052187A2 (en) 2006-10-27 2008-05-02 Genentech. Inc. Antibodies and immunoconjugates and uses therefor
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
US7378506B2 (en) 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US7396905B1 (en) 1999-05-21 2008-07-08 Mckeon Frank Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto
WO2008083174A2 (en) 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
EP1944322A2 (en) 2002-07-19 2008-07-16 Abbott Biotechnology Ltd. Treatment of TNF alpha related disorders
US7405276B2 (en) 2000-11-01 2008-07-29 Elusys Therapeutics, Inc. Method of producing bispecific molecules by protein trans-splicing
EP1958966A2 (en) 1994-07-01 2008-08-20 Dana-Farber Cancer Institute Methods for modulating T cell responses by manipulating a common cytokine receptor gamma chain
EP1975620A2 (en) 2001-03-02 2008-10-01 GPC Biotech AG Three hybrid assay system
EP1990409A2 (en) 1999-07-20 2008-11-12 MorphoSys AG Bacteriophage
US7455989B2 (en) 2002-08-20 2008-11-25 Yeda Research And Development Co. Ltd. AKAP84 and its use for visualization of biological structures
US7465705B2 (en) 2002-08-10 2008-12-16 Yale University Nogo receptor antagonists
WO2008151819A2 (en) 2007-06-15 2008-12-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Treatment of tumors using specific anti-l1 antibody
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
US7488807B2 (en) 2006-11-22 2009-02-10 3M Innovative Properties Company Antibody with protein A selectivity
US7491516B2 (en) 2000-06-29 2009-02-17 Abbott Laboratories Dual specificity antibodies and methods of making and using
WO2009024593A1 (en) 2007-08-21 2009-02-26 Morphosys Ag Improved methods for the formation of disulphide bonds
US7498420B2 (en) 2003-08-04 2009-03-03 Amgen Fremont Inc. Antibodies to c-Met
EP2033662A1 (en) 2004-01-21 2009-03-11 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
EP2051077A2 (en) 2003-10-07 2009-04-22 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
EP2060628A1 (en) 2002-02-13 2009-05-20 XOMA Technology Ltd. Eukaryotic signal sequences for polypeptide expression and polypeptide display libraries
US7537762B2 (en) 2005-09-07 2009-05-26 Amgen Fremont, Inc. Human monoclonal antibodies to activin receptor-like kinase-1
EP2065402A1 (en) 2007-11-30 2009-06-03 Industrial Technology Research Institut Trimeric collagen scaffold antibodies
EP2065467A2 (en) 2001-02-22 2009-06-03 Genentech, Inc. Anti-interferon-alpha antibodies
US7550280B2 (en) 2002-08-19 2009-06-23 Dsm Ip Assets B.V. Lipases and uses thereof
EP2077324A2 (en) 2001-02-23 2009-07-08 DSM IP Assets B.V. Genes encoding proteolytic enzymes from aspargilli
WO2009086003A1 (en) 2007-12-20 2009-07-09 Xoma Technology Ltd. Methods for the treatment of gout
WO2009086539A2 (en) 2007-12-28 2009-07-09 Elan Pharmaceuticals, Inc. Treatment and prophylaxis of amyloidosis
US7572886B2 (en) 2001-12-18 2009-08-11 Centre National De La Recherche Scientifique Death associated proteins, and THAP1 and PAR4 pathways in apoptosis control
WO2009109572A2 (en) * 2008-03-03 2009-09-11 Ablynx Nv Monovalent phage display of single variable domains
US7588925B2 (en) 2002-05-21 2009-09-15 Dsm Ip Assets B.V. Phospholipases and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
EP2116556A1 (en) 2008-05-09 2009-11-11 Abbott GmbH & Co. KG Antibodies to receptor of advanced glycation end products (rage) and uses thereof
US7618626B2 (en) 2004-07-16 2009-11-17 Pfizer Inc Combination treatment for non-hematologic malignancies
WO2009149185A2 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
EP2133427A1 (en) 2004-01-14 2009-12-16 Ohio University Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
US7667099B2 (en) 2002-06-20 2010-02-23 Board Of Trustees Of Michigan State University Plastid division and related genes and proteins, and methods of use
EP2168984A1 (en) 1999-03-25 2010-03-31 Abbott GmbH & Co. KG Human antibodies that bind human IL-12 and methods for producing
WO2010039533A2 (en) 2008-09-23 2010-04-08 Wyeth Methods for predicting production of activating signals by cross-linked binding proteins
WO2010039536A2 (en) 2008-09-23 2010-04-08 President And Fellows Of Harvard College Sirt4 and uses thereof
US7700739B2 (en) 2005-06-30 2010-04-20 Abbott Laboratories IL-12/p40 binding proteins
EP2177537A2 (en) 2004-01-09 2010-04-21 Pfizer Inc. Antibodies to MAdCAM
WO2010045315A1 (en) 2008-10-14 2010-04-22 Dyax Corp. Use of igf-ii/igf-iie binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis
EP2181711A1 (en) 2002-09-04 2010-05-05 Biopolymer Engineering, Inc. Cancer therapy using whole glucan particles and antibodies
WO2010062995A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2
WO2010063011A2 (en) 2008-11-28 2010-06-03 Emory University Methods for the treatment of infections and tumors
EP2196218A2 (en) 2002-04-26 2010-06-16 Abbott Biotechnology Ltd Use of anti-TNFalpha antibodies and another drug
US7745391B2 (en) 2001-09-14 2010-06-29 Compugen Ltd. Human thrombospondin polypeptide
US7744890B2 (en) 2006-10-12 2010-06-29 Wyeth Llc Methods and compositions with reduced opalescence
WO2010080985A1 (en) 2009-01-08 2010-07-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
WO2010084173A1 (en) 2009-01-22 2010-07-29 Novo Nordisk Health Care Ag Stable growth hormone compounds
EP2216653A1 (en) 2005-08-02 2010-08-11 XBiotech, Inc Diagnosis, treatment and prevention of vascular disorders using il-1alpha autoantibodies
US7776331B1 (en) 2007-01-16 2010-08-17 Abbott Laboratories Methods of treating plaque psoriasis
WO2010099079A1 (en) 2009-02-24 2010-09-02 Abbott Laboratories Antibodies to troponin i and methods of use thereof
WO2010102177A1 (en) 2009-03-06 2010-09-10 Becton, Dickinson And Company Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer
WO2010102167A1 (en) 2009-03-05 2010-09-10 Becton, Dickinson And Company Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer
US7795494B2 (en) 2001-03-22 2010-09-14 Abbott Laboratories Transgenic mice expressing antibodies specific for genes of interest and uses thereof
US7803377B2 (en) 2006-06-06 2010-09-28 Genentech, Inc. Anti-DLL4 antibodies and methods using same
WO2010111367A1 (en) 2009-03-25 2010-09-30 Genentech, Inc. Anti-fgfr3 antibodies and methods using same
US7807790B2 (en) 2005-11-14 2010-10-05 Metamol Theranostics, Llc Peptide sequence that promotes tumor invasion
WO2010120561A1 (en) 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
EP2251026A1 (en) 2000-06-08 2010-11-17 Immune Disease Institute, Inc. Methods and compositions for inhibiting immunoglobulin-mediated reperfusion injury
US7846439B2 (en) 2006-02-01 2010-12-07 Cephalon Australia Pty Ltd Domain antibody construct
EP2258718A1 (en) 2001-04-16 2010-12-08 Wyeth Holdings Corporation Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
EP2261242A1 (en) 2009-06-10 2010-12-15 Universite Catholique De Louvain Aspartate-N-acetyltransferase enzyme, diagnostic method and therapeutic method
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
EP2270188A2 (en) 2001-06-22 2011-01-05 Pioneer Hi-Bred International, Inc. Defensin polynucleotides and methods of use
EP2270034A2 (en) 2004-06-03 2011-01-05 Athlomics Pty Ltd Agents and methods for diagnosing stress
US7867494B2 (en) 2007-04-02 2011-01-11 Amgen Fremont Inc. Anti-IgE antibodies
EP2272979A1 (en) 2009-06-30 2011-01-12 Centre National de la Recherche Scientifique (CNRS) Method for testing a subject thought to be predisposed to having cancer
WO2011003996A1 (en) 2009-07-09 2011-01-13 F. Hoffmann-La Roche Ag In vivo tumor vasculature imaging
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
EP2290107A1 (en) 2003-01-07 2011-03-02 Dyax Corporation Kunitz domain library
EP2290086A2 (en) 2004-12-22 2011-03-02 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
EP2289909A1 (en) 2005-11-30 2011-03-02 Abbott Laboratories Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
EP2290077A2 (en) 2004-03-01 2011-03-02 Immune Disease Institute, Inc. Natural IGM antibodies and inhibitors thereof
WO2011025964A2 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
EP2293069A2 (en) 2004-03-24 2011-03-09 Tripath Imaging, Inc. Methods and compositions for the detection of cervical disease
WO2011028950A1 (en) 2009-09-02 2011-03-10 Genentech, Inc. Mutant smoothened and methods of using the same
EP2295466A2 (en) 2005-04-25 2011-03-16 Pfizer Inc. Antibodies to myostatin
EP2295606A1 (en) 2000-11-28 2011-03-16 Wyeth LLC Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
EP2298899A2 (en) 1997-04-16 2011-03-23 Millennium Pharmaceuticals, Inc. CRSP proteins (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
EP2301947A2 (en) 1999-02-26 2011-03-30 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
WO2011038301A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
WO2011038290A2 (en) 2009-09-25 2011-03-31 The U. S. A., As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
WO2011038302A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Novel modulators
WO2011036555A1 (en) 2009-09-25 2011-03-31 University Of Oslo Multivalent phage display systems and methods
US7919257B2 (en) 2003-05-30 2011-04-05 Merus Biopharmaceuticals, B.V.I.O. Method for selecting a single cell expressing a heterogeneous combination of antibodies
EP2305836A1 (en) 2002-08-20 2011-04-06 Millennium Pharmaceuticals, Inc. Compositions, kits and methods for identification, assessment, prevention and therapy of cervical cancer
EP2305713A1 (en) 1996-02-09 2011-04-06 Abbott Biotechnology Ltd Human antibodies that bind human TNFalpha
WO2011041584A2 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
US7927834B2 (en) 2002-07-18 2011-04-19 Merus B.V. Recombinant production of mixtures of antibodies
WO2011050188A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Anti-hepsin antibodies and methods using same
EP2316969A1 (en) 2003-03-13 2011-05-04 Fujirebio America, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
EP2316976A1 (en) 2000-11-28 2011-05-04 Wyeth LLC Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
WO2011053538A1 (en) 2009-10-27 2011-05-05 Exxonmobil Research And Engineering Company Multi-stage processes and control thereof
WO2011057120A1 (en) 2009-11-05 2011-05-12 Genentech, Inc. Methods and composition for secretion of heterologous polypeptides
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011058087A1 (en) 2009-11-11 2011-05-19 Gentian As Immunoassay for assessing related analytes of different origin
EP2325208A1 (en) 2005-12-15 2011-05-25 Genentech, Inc. Polyubiquitin antibodies
EP2327423A2 (en) 2006-02-21 2011-06-01 Wyeth LLC Human antibodies against human interleukin-22 (IL-22)
WO2011070045A1 (en) 2009-12-08 2011-06-16 Abbott Gmbh & Co. Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
WO2011071577A1 (en) 2009-12-11 2011-06-16 Genentech, Inc. Anti-vegf-c antibodies and methods using same
US7964708B2 (en) 2006-11-15 2011-06-21 Limin Li Anti-TSG101 antibodies and their uses for treatment of viral infections
EP2335731A2 (en) 2004-04-09 2011-06-22 Abbott Biotechnology Ltd Multiple-variable dose regimen for treating TNF-alpha-related disorders
EP2336170A2 (en) 2005-12-15 2011-06-22 Industrial Technology Research Institute Recombinant triplex scaffold-based polypeptides
EP2336160A2 (en) 2003-01-31 2011-06-22 Abbott GmbH & Co. KG Amyloid-beta(1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use thereof.
WO2011079185A1 (en) 2009-12-23 2011-06-30 Genentech, Inc. Anti-bv8 antibodies and uses thereof
WO2011084750A1 (en) 2009-12-21 2011-07-14 Genentech, Inc. Antibody formulation
WO2011085103A2 (en) 2010-01-06 2011-07-14 Dyax Corp. Plasma kallikrein binding proteins
WO2011088163A1 (en) 2010-01-14 2011-07-21 President And Fellows Of Harvard College Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
WO2011089250A2 (en) 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Stable growth hormone compounds
WO2011091134A2 (en) 2010-01-22 2011-07-28 Dana-Farber Cancer Institute, Inc. Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
WO2011097301A2 (en) 2010-02-02 2011-08-11 Abbott Biotechnology Ltd. METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR
WO2011095894A2 (en) 2010-02-04 2011-08-11 Jichi Medical University Identification, assessment, and therapy of cancers with innate or acquired resistance to alk inhibitors
EP2360254A1 (en) 1999-08-23 2011-08-24 Dana-Farber Cancer Institute, Inc. Assays for screening anti-pd-1 antibodies and uses thereof
EP2363711A1 (en) 2006-01-27 2011-09-07 Tripath Imaging, Inc. Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
EP2385070A1 (en) 2003-11-12 2011-11-09 Abbott Laboratories Il-18 binding proteins
EP2386318A1 (en) 2003-05-15 2011-11-16 Iogenetics, Inc. Targeted biocides
WO2011143562A2 (en) 2010-05-14 2011-11-17 Abbott Laboratories Il-1 binding proteins
EP2388274A1 (en) 2005-06-17 2011-11-23 Janssen Alzheimer Immunotherapy Methods of purifying anti A Beta antibodies
EP2388590A1 (en) 2001-04-02 2011-11-23 Dana Farber Cancer Institute PD-1, a receptor for B7-4, and uses thereof
EP2392353A1 (en) 2005-01-28 2011-12-07 Janssen Alzheimer Immunotherapy Anti A beta antibody formulation
WO2011153346A1 (en) 2010-06-03 2011-12-08 Genentech, Inc. Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
WO2011153477A2 (en) 2010-06-03 2011-12-08 Abbott Biotechnology Ltd. Uses and compositions for treatment of hidradenitis suppurativa (hs)
EP2395077A1 (en) 2006-11-03 2011-12-14 Wyeth LLC Glycolysis-inhibiting substances in cell culture
EP2402438A2 (en) 2006-07-05 2012-01-04 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
EP2402373A2 (en) 2006-01-05 2012-01-04 Genentech, Inc. Anti-EphB4 Antibodies and Methods Using Same
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
WO2012007880A2 (en) 2010-07-16 2012-01-19 Ablynx Nv Modified single domain antigen binding molecules and uses thereof
EP2410335A1 (en) 2005-11-30 2012-01-25 Massachusetts Institute of Technology (MIT) Pathogen detection biosensor
WO2012010516A1 (en) 2010-07-22 2012-01-26 Novo Nordisk Health Care Ag Growth hormone conjugates
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
WO2012020072A1 (en) 2010-08-12 2012-02-16 Westfälische Wilhelms-Universität Muenster Anti-syndecan-4 antibodies
WO2012024650A2 (en) 2010-08-19 2012-02-23 Abbott Laboratories Anti-ngf antibodies and their use
WO2012027723A1 (en) 2010-08-27 2012-03-01 Stem Centrx, Inc Notum protein modulators and methods of use
WO2012031273A2 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
EP2431392A1 (en) 2006-02-21 2012-03-21 Wyeth LLC Antibodies against human IL-22 and uses therefor
WO2012040041A1 (en) 2010-09-20 2012-03-29 Abbott Laboratories Purification of antibodies using simulated moving bed chromatography
WO2012044921A1 (en) 2010-10-01 2012-04-05 St. Jude Children's Research Hospital Methods and compositions for typing molecular subgroups of medulloblastoma
WO2012041981A2 (en) 2010-09-30 2012-04-05 Laboratorios Del Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
WO2012047324A2 (en) 2010-06-10 2012-04-12 President And Fellows Of Harvard College Systems and methods for amplification and phage display
WO2012047968A2 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
EP2441474A1 (en) 2003-10-17 2012-04-18 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
EP2444421A1 (en) 2005-04-26 2012-04-25 Pfizer Inc. P-Cadherin antibodies
EP2444805A2 (en) 2004-01-21 2012-04-25 Fujirebio America, Inc. Detection of mesothelin-/megakaryocyte potentiating factor-related peptides in peritoneal fluid for assessment of the peritoneum and the peritoneal cavity
WO2012052391A1 (en) 2010-10-19 2012-04-26 Glaxo Group Limited Polypeptide with jmjd3 catalytic activity
US8168178B2 (en) 1999-11-30 2012-05-01 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US8168760B2 (en) 2007-03-29 2012-05-01 Abbott Laboratories Crystalline anti-human IL-12 antibodies
EP2446904A2 (en) 2006-05-30 2012-05-02 Genentech, Inc. Anti-CD22 antibodies, their immunoconjugates and uses thereof
US8178579B2 (en) 2001-05-09 2012-05-15 President And Fellows Of Harvard College Dioxanes and uses thereof
US8178092B2 (en) 2008-03-18 2012-05-15 Abbott Laboratories Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23
EP2455395A1 (en) 2005-12-19 2012-05-23 Tripath Imaging, Inc. MCM6 monoclonal antibodies and methods for their use in the detection of cervical disease
WO2012068463A2 (en) 2010-11-18 2012-05-24 Beth Israel Deaconess Medicall Center, Inc. Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
EP2460832A2 (en) 2005-05-27 2012-06-06 Biogen Idec MA Inc. TWEAK binding antibodies
WO2012078813A2 (en) 2010-12-08 2012-06-14 Stem Centrx, Inc. Novel modulators and methods of use
EP2468772A2 (en) 2006-03-16 2012-06-27 Genentech, Inc. Antibodies to EGFL7 and methods for their use
WO2012088094A2 (en) 2010-12-21 2012-06-28 Abbott Laboratories Il-1 binding proteins
WO2012089814A1 (en) 2010-12-30 2012-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigen binding formats for use in therapeutic treatments or diagnostic assays
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
WO2012092323A1 (en) 2010-12-28 2012-07-05 Xoma Technology Ltd. Cell surface display using pdz domains
EP2474557A2 (en) 2007-07-16 2012-07-11 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
US8222423B2 (en) 2006-02-14 2012-07-17 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
EP2476761A2 (en) 2005-07-07 2012-07-18 Athlomics Pty Ltd Polynucleotide marker genes and their expression, for diagnosis of endotoxemia
EP2481797A1 (en) 2007-04-13 2012-08-01 Catalyst Biosciences, Inc. Modified factor VII polypeptides and uses thereof
WO2012112943A1 (en) 2011-02-18 2012-08-23 Stem Centrx, Inc. Novel modulators and methods of use
WO2012119129A1 (en) 2011-03-02 2012-09-07 Berg Biosystems, Llc Interrogatory cell-based assays and uses thereof
WO2012121775A2 (en) 2010-12-21 2012-09-13 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
US8268756B2 (en) 2004-01-20 2012-09-18 Merus B.V. Mixture of binding proteins
EP2500355A2 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500037A2 (en) 2005-05-16 2012-09-19 Abbott Biotechnology Ltd Use of TNF alpha inhibitor for treatment of erosive polyarthritis
WO2012125735A1 (en) 2011-03-15 2012-09-20 Abott Laboratories An integrated approach to the isolation and purification of antibodies
WO2012128810A1 (en) 2011-03-23 2012-09-27 Abbott Laboratories Methods and systems for the analysis of protein samples
US8278421B2 (en) 2006-03-20 2012-10-02 Xoma Techolology Ltd. Human antibodies specific for gastrin materials and methods
WO2012134813A1 (en) 2011-03-31 2012-10-04 St. Jude Children's Research Hospital Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
WO2012131053A1 (en) 2011-03-30 2012-10-04 Ablynx Nv Methods of treating immune disorders with single domain antibodies against tnf-alpha
EP2508608A1 (en) 2003-06-09 2012-10-10 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
WO2012139058A1 (en) 2011-04-08 2012-10-11 Biogen Idec Ma Inc. BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO IFNβ AND USES THEREOF
EP2511301A2 (en) 2006-08-04 2012-10-17 Medimmune Limited Human antibodies to ERBB2
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
US8304451B2 (en) 2006-05-03 2012-11-06 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
US8313942B2 (en) 2008-09-26 2012-11-20 Wyeth Llc Compatible display vector systems
EP2526968A2 (en) 2006-01-27 2012-11-28 Biogen Idec MA Inc. Nogo receptor antagonists
US8324350B2 (en) 2006-12-29 2012-12-04 Abbott Laboratories Dual-specific IL-1α/IL-1β antibodies
WO2012167143A1 (en) 2011-06-03 2012-12-06 Xoma Technology Ltd. Antibodies specific for tgf-beta
US8329945B2 (en) 1996-03-26 2012-12-11 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
EP2535355A2 (en) 2005-03-23 2012-12-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
EP2535425A1 (en) 2007-05-25 2012-12-19 Decode Genetics EHF. Variantes génétiques sur les chr 10q26 utilisées comme marqueurs dans l'évaluation, le diagnostic, le pronostic et le traitement d'un risque de cancer du sein
US8383778B2 (en) 2009-01-29 2013-02-26 Abbvie Inc. IL-1 binding proteins
WO2013028817A1 (en) 2011-08-23 2013-02-28 Foundation Medicine , Inc. Novel kif5b-ret fusion molecules and uses thereof
WO2013040142A2 (en) 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2013039996A1 (en) 2011-09-13 2013-03-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using fndc5
EP2573563A1 (en) 2007-12-20 2013-03-27 Heptares Therapeutics Limited Screening
US8420083B2 (en) 2009-10-31 2013-04-16 Abbvie Inc. Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
WO2013054200A2 (en) 2011-10-10 2013-04-18 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
WO2013063114A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against tnf
WO2013063095A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against sclerostin
US8435780B2 (en) 2000-03-03 2013-05-07 President And Fellows Of Harvard College Class II human histone deacetylases, and uses related thereto
WO2013067268A1 (en) 2011-11-03 2013-05-10 Tripath Imaging, Inc. Methods and compositions for preparing samples for immunostaining
WO2013067451A2 (en) 2011-11-04 2013-05-10 Population Diagnostics Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
US8440716B2 (en) 2008-07-23 2013-05-14 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
WO2013068902A1 (en) 2011-11-08 2013-05-16 Pfizer Inc. Methods of treating inflammatory disorders using anti-m-csf antibodies
WO2013078377A1 (en) 2011-11-23 2013-05-30 Igenica, Inc. Anti-cd98 antibodies and methods of use thereof
WO2013080050A2 (en) 2011-11-30 2013-06-06 Universitaetsklinikum Erlangen Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
WO2013090633A2 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
WO2013090635A2 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
WO2013096516A1 (en) 2011-12-19 2013-06-27 Xoma Technology Ltd. Methods for treating acne
WO2013106485A2 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
WO2013106489A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
WO2013112922A1 (en) 2012-01-27 2013-08-01 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
WO2013119960A2 (en) 2012-02-08 2013-08-15 Stem Centrx, Inc. Novel modulators and methods of use
EP2641618A2 (en) 2007-07-16 2013-09-25 Genentech, Inc. Humanized anti-CD79B antibodies and immunoconjugates and methods of use
WO2013148373A1 (en) 2012-03-28 2013-10-03 Genentech, Inc. Anti-hcmv idiotypic antibodies and uses thereof
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
WO2013151577A1 (en) 2012-04-02 2013-10-10 Berg Pharma Llc Interrogatory cell-based assays and uses thereof
US8557239B2 (en) 2009-09-14 2013-10-15 Abbvie Inc. Methods for treating psoriasis using antibodies that bind to the P40 subunit of IL-12 and/or IL-23
WO2013158275A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
EP2657253A2 (en) 2008-01-31 2013-10-30 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
US8586714B2 (en) 2009-09-01 2013-11-19 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
EP2666478A2 (en) 2006-04-10 2013-11-27 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriasis
EP2666480A2 (en) 2006-04-10 2013-11-27 Abbott Biotechnology Ltd Uses and compositions for treatment of Crohn's desease
EP2666472A2 (en) 2006-04-10 2013-11-27 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
WO2013177115A2 (en) 2012-05-21 2013-11-28 Abbvie Inc. Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
US8623812B2 (en) 2004-04-19 2014-01-07 Ohio University Cross-linkable glycoproteins and methods of making the same
US8637244B2 (en) 2006-12-05 2014-01-28 Decode Genetics Ehf. Genetic markers for risk management of atrial fibrillation, atrial flutter, and stroke
WO2014043519A1 (en) 2012-09-14 2014-03-20 Population Diagnostics Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
US8697360B2 (en) 2007-11-30 2014-04-15 Decode Genetics Ehf. Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition
US8697374B2 (en) 2008-02-28 2014-04-15 3M Innovative Properties Company Antibodies to Clostridium difficile spores and uses thereof
WO2014058875A2 (en) 2012-10-09 2014-04-17 Biogen Idec Ma Inc. Combination therapies and uses for treatment of demyelinating disorders
WO2014059028A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
US8703915B2 (en) 2009-06-22 2014-04-22 Heptares Therapeutics Limited Mutant proteins and methods for producing them
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
US8716450B2 (en) 2009-10-15 2014-05-06 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2014071358A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
US8722855B2 (en) 2009-10-28 2014-05-13 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2014074905A1 (en) 2012-11-08 2014-05-15 Eleven Biotherapeutics, Inc. Il-6 antagonists and uses thereof
WO2014074942A1 (en) 2012-11-08 2014-05-15 Illumina, Inc. Risk variants of alzheimer's disease
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
EP2738179A1 (en) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
US8748182B2 (en) 2007-12-08 2014-06-10 Heptares Therapeutics Limited Mutant proteins and methods for producing them
WO2014093396A1 (en) 2012-12-10 2014-06-19 Biogen Idec Ma Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof
WO2014100542A1 (en) 2012-12-21 2014-06-26 Abbvie, Inc. High-throughput antibody humanization
US8779109B2 (en) 2010-01-22 2014-07-15 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
US8785135B2 (en) 2007-03-22 2014-07-22 Heptares Therapeutics Limited Mutant G-protein coupled receptors and methods for selecting them
WO2014113729A2 (en) 2013-01-18 2014-07-24 Foundation Mecicine, Inc. Methods of treating cholangiocarcinoma
US8796182B2 (en) 2009-07-10 2014-08-05 Decode Genetics Ehf. Genetic markers associated with risk of diabetes mellitus
US8795963B2 (en) 2009-04-03 2014-08-05 Decode Genetics Ehf. Genetic markers for risk management of atrial fibrillation and stroke
WO2014123696A1 (en) 2013-01-25 2014-08-14 Thymon, Llc Compositions for selective reduction of circulating bioactive soluble tnf and methods for treating tnf-mediated disease
US8809285B2 (en) 2009-07-31 2014-08-19 Wayne State University Monophosphorylated lipid A derivatives
US8808985B2 (en) 2008-04-01 2014-08-19 Decode Genetics Ehf. Susceptibility variants for peripheral arterial disease and abdominal aortic aneurysm
WO2014130879A2 (en) 2013-02-22 2014-08-28 Stem Centrx, Inc. Novel antibody conjugates and uses thereof
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
EP2772269A2 (en) 2009-03-05 2014-09-03 Abbvie Inc. IL-17 binding proteins
US8828657B2 (en) 2008-02-14 2014-09-09 Decode Genetics Ehf. Susceptibility variants for lung cancer
WO2014145098A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
WO2014142882A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
WO2014144292A2 (en) 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
WO2014144355A2 (en) 2013-03-15 2014-09-18 Abbott Laboratories Anti-gp73 monoclonal antibodies and methods of obtaining the same
WO2014139994A1 (en) * 2013-03-11 2014-09-18 Novo Nordisk Health Care Ag Growth hormone compounds
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
WO2014151680A1 (en) 2013-03-15 2014-09-25 Biogen Idec Ma Inc. Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
WO2014153056A2 (en) 2013-03-14 2014-09-25 Parkash Gill Cancer treatment using antibodies that bing cell surface grp78
WO2014160497A1 (en) 2013-03-13 2014-10-02 Genentech, Inc. Formulations with reduced oxidation
WO2014160495A1 (en) 2013-03-13 2014-10-02 Genentech, Inc. Formulations with reduced oxidation
WO2014158231A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
WO2014159554A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
WO2014160490A1 (en) 2013-03-13 2014-10-02 Genetech, Inc. Antibody formulations
US8865868B2 (en) 2008-08-06 2014-10-21 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy
US8865400B2 (en) 2007-02-07 2014-10-21 Decode Genetics Ehf. Genetic variants contributing to risk of prostate cancer
US8871468B2 (en) 1997-07-21 2014-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
EP2799453A1 (en) 2009-04-29 2014-11-05 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. ERG monoclonal antibodies
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
EP2810654A1 (en) 2008-07-08 2014-12-10 AbbVie Inc. Prostaglandin E2 binding proteins and uses thereof
WO2014197885A2 (en) 2013-06-07 2014-12-11 Duke University Inhibitors of complement factor h
US8921279B2 (en) 2007-06-26 2014-12-30 F-Star Biotechnologische Forschungs—und Entwicklungsges. m.b.H Display of binding agents
WO2015010100A2 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
WO2015017529A2 (en) 2013-07-31 2015-02-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
US8951735B2 (en) 2008-07-07 2015-02-10 Decode Genetics Ehf. Genetic variants for breast cancer risk assessment
US8957187B2 (en) 2005-12-02 2015-02-17 Genentech, Inc. Binding polypeptides and uses thereof
WO2015026846A1 (en) 2013-08-19 2015-02-26 Biogen Idec Ma Inc. Control of protein glycosylation by culture medium supplementation and cell culture process parameters
US8986972B2 (en) 2012-02-24 2015-03-24 Stem Centrx, Inc. Nucleic acid encoding DLL3 antibodies
US8987418B2 (en) 2013-03-15 2015-03-24 Abbvie Inc. Dual specific binding proteins directed against IL-1β and/or IL-17
EP2851372A1 (en) 2007-11-30 2015-03-25 Genentech, Inc. Anti-VEGF antibodies
WO2015048520A1 (en) 2013-09-27 2015-04-02 Genentech, Inc. Anti-pdl1 antibody formulations
US8999289B2 (en) 2005-03-22 2015-04-07 President And Fellows Of Harvard College Treatment of protein degradation disorders
EP2862867A2 (en) 2005-10-25 2015-04-22 The Johns Hopkins University Methods and compositions for the treatment of Marfan syndrome and associated disorders
WO2015057939A1 (en) 2013-10-18 2015-04-23 Biogen Idec Ma Inc. Anti-s1p4 antibodies and uses thereof
US9017287B2 (en) 2004-06-23 2015-04-28 Abbvie Biotechnology Ltd Automatic injection devices
US9023594B2 (en) 2008-09-05 2015-05-05 President And Fellows Of Harvard College Continuous directed evolution of proteins and nucleic acids
WO2015066190A1 (en) 2013-10-29 2015-05-07 President And Fellows Of Harvard College Methods and compositions for inhibting oxidative stress
US9029508B2 (en) 2008-04-29 2015-05-12 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2015070068A1 (en) 2013-11-07 2015-05-14 Abbvie Inc. Isolation and purification of antibodies
US9035027B2 (en) 2008-06-03 2015-05-19 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2015071759A1 (en) 2013-11-15 2015-05-21 Institut Pasteur A molecular marker of plasmodium falciparum artemisinin resistance
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9045551B2 (en) 2012-11-01 2015-06-02 Abbvie Inc. Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2015090230A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
WO2015095809A1 (en) 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
EP2891722A1 (en) 2013-11-12 2015-07-08 Population Diagnostics, Inc. Methods and compositions for diagnosing, prognosing, and treating endometriosis
US9081020B2 (en) 2008-02-11 2015-07-14 Heptares Therapeutics Limited Mutant proteins and methods for selecting them
WO2015109180A2 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015120075A2 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
WO2015122995A1 (en) 2014-02-11 2015-08-20 Visterra, Inc. Antibody moleules to dengue virus and uses thereof
US9115195B2 (en) 2010-03-02 2015-08-25 Abbvie Inc. Therapeutic DLL4 binding proteins
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
EP2921501A1 (en) 2008-10-20 2015-09-23 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
EP2921177A2 (en) 2010-07-09 2015-09-23 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
US9170262B2 (en) 2010-06-16 2015-10-27 Abbvie, Inc. Comparison of protein samples
WO2015175340A1 (en) 2014-05-13 2015-11-19 Bavarian Nordic, Inc. Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3
WO2015187779A1 (en) 2014-06-03 2015-12-10 Xbiotech, Inc. Compositions and methods for treating and preventing staphylococcus aureus infections
EP2960252A1 (en) 2014-06-26 2015-12-30 Institut Pasteur Phospholipase for treatment of immunosuppression
CN105229035A (en) * 2013-03-11 2016-01-06 诺和诺德保健股份有限公司 Growth hormone compound
EP2966089A1 (en) 2011-06-02 2016-01-13 Dyax Corp. Fc receptor binding proteins
US9260520B2 (en) 2008-04-25 2016-02-16 Dyax Corp. Antibodies to FeRn and uses thereof
US9259476B2 (en) 2009-07-31 2016-02-16 Wayne State University Monophosphorylated lipid A derivatives
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
US9266950B2 (en) 2009-10-20 2016-02-23 Abbvie Inc. Isolation and purification of anti-IL-13 antibodies using protein a affinity chromatography
WO2016040880A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
WO2016042412A1 (en) 2014-09-16 2016-03-24 Symphogen A/S Anti-met antibodies and compositions
WO2016054555A2 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
WO2016061424A1 (en) 2014-10-17 2016-04-21 Biogen Ma Inc. Copper supplementation for control of glycosylation in mammalian cell culture process
EP3011953A1 (en) 2008-10-29 2016-04-27 Ablynx N.V. Stabilised formulations of single domain antigen binding molecules
WO2016070152A1 (en) 2014-10-31 2016-05-06 Biogen Ma Inc. Hypotaurine, gaba, beta-alanine, and choline for control of waste byproduct accumulation in mammalian cell culture process
WO2016073685A1 (en) 2014-11-05 2016-05-12 Annexon, Inc. Humanized anti-complement factor c1q antibodies and uses thereof
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
WO2016081835A2 (en) 2014-11-21 2016-05-26 University Of Maryland, Baltimore Targeted structure-specific particulate delivery systems
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
US9383364B2 (en) 2011-03-07 2016-07-05 University Of Louisville Research Foundation, Inc. Predictive marker of DNMT1 inhibitor therapeutic efficacy and methods of using the marker
US9394537B2 (en) 2010-12-22 2016-07-19 President And Fellows Of Harvard College Continuous directed evolution
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2016118961A1 (en) 2015-01-24 2016-07-28 Academia Sinica Cancer markers and methods of use thereof
WO2016123593A1 (en) 2015-01-30 2016-08-04 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
WO2016126972A1 (en) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened and methods of using the same
WO2016141111A1 (en) 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
US9441035B2 (en) 2013-03-15 2016-09-13 Genentech, Inc. Cell culture media and methods of antibody production
WO2016144917A1 (en) 2015-03-10 2016-09-15 University Of Massachusetts Targeting gdf6 and bmp signaling for anti-melanoma therapy
WO2016161410A2 (en) 2015-04-03 2016-10-06 Xoma Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
WO2016170022A1 (en) 2015-04-21 2016-10-27 Institut Gustave Roussy Therapeutic methods, products and compositions inhibiting znf555
US9486584B2 (en) 2006-06-30 2016-11-08 Abbvie Biotechnology Ltd. Automatic injection device
US9499621B2 (en) 2013-04-08 2016-11-22 Cytodyn, Inc. Felinized antibodies and methods of treating retroviral infections in felines
EP3124045A2 (en) 2006-12-20 2017-02-01 Xoma (Us) Llc Treatment of il-1 beta related diseases
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
US9561328B2 (en) 2009-04-29 2017-02-07 Abbvie Biotechnology Ltd Automatic injection device
WO2017040342A1 (en) 2015-08-28 2017-03-09 Genentech, Inc. Anti-hypusine antibodies and uses thereof
WO2017049011A1 (en) 2015-09-15 2017-03-23 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
US9605069B2 (en) 2008-02-29 2017-03-28 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM a protein and uses thereof
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
US9617597B2 (en) 2007-02-21 2017-04-11 Decode Genetics Ehf Genetic susceptibility variants associated with cardiovascular disease
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
WO2017075329A2 (en) 2015-10-29 2017-05-04 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
WO2017077275A1 (en) * 2015-11-02 2017-05-11 Imperial Innovations Limited Phagemid vector
EP3168232A1 (en) 2009-11-13 2017-05-17 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
WO2017083515A2 (en) 2015-11-10 2017-05-18 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
WO2017091683A1 (en) 2015-11-25 2017-06-01 Visterra, Inc. Antibody molecules to april and uses thereof
US9670276B2 (en) 2012-07-12 2017-06-06 Abbvie Inc. IL-1 binding proteins
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2017106810A2 (en) 2015-12-17 2017-06-22 Novartis Ag Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
WO2017117304A1 (en) 2015-12-30 2017-07-06 Genentech, Inc. Use of tryptophan derivatives for protein formulations
WO2017117311A1 (en) 2015-12-30 2017-07-06 Genentech, Inc. Formulations with reduced degradation of polysorbate
WO2017120523A2 (en) 2016-01-08 2017-07-13 Scholar Rock, Inc. Anti-pro/latent myostatin antibodies and methods of use thereof
EP3199553A1 (en) 2008-10-29 2017-08-02 China Synthetic Rubber Corporation Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
WO2017136558A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same
US9737493B2 (en) 2012-09-07 2017-08-22 University Of Louisville Research Foundation, Inc. Compositions and methods for modulating DNMT1 inhibitor activity
US9745375B2 (en) 2008-07-09 2017-08-29 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
US9758805B2 (en) 2012-04-20 2017-09-12 Merus N.V. Methods and means for the production of Ig-like molecules
WO2017156500A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgfb1-binding immunoglobulins and use thereof
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
WO2017158436A1 (en) 2016-03-17 2017-09-21 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2017165736A1 (en) 2016-03-25 2017-09-28 Visterra, Inc. Formulation of antibody molecules to dengue virus
WO2017177199A2 (en) 2016-04-08 2017-10-12 Iti Health, Inc. Plectin-1 binding antibodies and uses thereof
US9790478B2 (en) 2013-03-14 2017-10-17 Abbott Laboratories HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
WO2017181098A2 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
US9841427B2 (en) 2013-03-14 2017-12-12 Abbott Laboratories HCV antigen-antibody combination assay and methods and compositions for use therein
US9840554B2 (en) 2015-06-15 2017-12-12 Abbvie Inc. Antibodies against platelet-derived growth factor (PDGF)
US9856311B2 (en) 2005-01-05 2018-01-02 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
EP3263581A1 (en) 2005-05-17 2018-01-03 University of Connecticut Compositions and methods for immunomodulation in an organism
WO2018005556A1 (en) 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Mhc-e restricted epitopes, binding molecules and related methods and uses
WO2018005559A1 (en) 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
WO2018013918A2 (en) 2016-07-15 2018-01-18 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
WO2018013714A1 (en) 2016-07-13 2018-01-18 Biogen Ma Inc. Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
US9879042B2 (en) 2014-09-08 2018-01-30 Academia Sinica Human iNKT cell activation using glycolipids
US9878102B2 (en) 2011-01-24 2018-01-30 Abbvie Biotechnology Ltd. Automatic injection devices having overmolded gripping surfaces
WO2018022479A1 (en) 2016-07-25 2018-02-01 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
WO2018026748A1 (en) 2016-08-01 2018-02-08 Xoma (Us) Llc Parathyroid hormone receptor 1 (pth1r) antibodies and uses thereof
EP3293275A1 (en) 2013-06-06 2018-03-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
WO2018052556A1 (en) 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof
WO2018057955A1 (en) 2016-09-23 2018-03-29 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
WO2018064255A2 (en) 2016-09-28 2018-04-05 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
WO2018067474A1 (en) 2016-10-03 2018-04-12 Abbott Laboratories Improved methods of assessing gfap status in patient samples
WO2018067992A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
WO2018071576A1 (en) 2016-10-14 2018-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of tumors by inhibition of cd300f
US9951125B2 (en) 2006-11-30 2018-04-24 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9957506B2 (en) 2013-09-25 2018-05-01 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
US9956236B2 (en) 2011-02-07 2018-05-01 Cornell University Methods for increasing immune responses using agents that directly bind to and activate IRE-1
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
EP3335728A1 (en) 2008-10-10 2018-06-20 Children's Medical Center Corporation Biochemically stabilized hiv-1 env trimer vaccine
US10005847B2 (en) 2014-05-27 2018-06-26 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
EP3339445A1 (en) 2006-09-08 2018-06-27 AbbVie Bahamas Ltd. Interleukin -13 binding proteins
EP3338793A1 (en) 2013-08-28 2018-06-27 AbbVie Stemcentrx LLC Novel sez6 modulators and methods of use
WO2018119402A1 (en) 2016-12-23 2018-06-28 Visterra, Inc. Binding polypeptides and methods of making the same
WO2018129395A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
WO2018129329A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF
US10023892B2 (en) 2014-05-27 2018-07-17 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
WO2018130660A1 (en) 2017-01-13 2018-07-19 Academia Sinica Reloadable hydrogel system for treating myocardial infarction
WO2018130661A1 (en) 2017-01-13 2018-07-19 Academia Sinica Reloadable hydrogel system for treating brain conditions
WO2018136626A1 (en) 2017-01-18 2018-07-26 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
WO2018136553A1 (en) 2017-01-18 2018-07-26 Genentech, Inc. Idiotypic antibodies against anti-pd-l1 antibodies and uses thereof
US10035853B2 (en) 2013-08-28 2018-07-31 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
US10059997B2 (en) 2010-08-02 2018-08-28 Population Bio, Inc. Compositions and methods for discovery of causative mutations in genetic disorders
WO2018158719A1 (en) 2017-03-02 2018-09-07 Novartis Ag Engineered heterodimeric proteins
WO2018175942A1 (en) 2017-03-23 2018-09-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
WO2018176019A1 (en) 2017-03-24 2018-09-27 The Regents Of The University Of California Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
WO2018187227A1 (en) 2017-04-03 2018-10-11 Concologie, Inc. Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
WO2018189611A1 (en) 2017-04-12 2018-10-18 Pfizer Inc. Antibodies having conditional affinity and methods of use thereof
WO2018191531A1 (en) 2017-04-15 2018-10-18 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
WO2018195283A1 (en) 2017-04-19 2018-10-25 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
US10111951B2 (en) 2013-09-06 2018-10-30 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
WO2018197859A1 (en) * 2017-04-24 2018-11-01 Imperial Innovations Limited Cancer treatment
WO2018201047A1 (en) 2017-04-28 2018-11-01 Elstar Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
WO2018200823A1 (en) 2017-04-28 2018-11-01 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
US10119972B2 (en) 2014-03-27 2018-11-06 Academia Sinica Reactive labelling compounds and uses thereof
US10118962B2 (en) 2008-10-29 2018-11-06 Ablynx N.V. Methods for purification of single domain antigen binding molecules
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2018218169A1 (en) 2017-05-25 2018-11-29 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
WO2018215535A1 (en) 2017-05-23 2018-11-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
WO2018222783A1 (en) 2017-05-30 2018-12-06 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i and early biomarkers
WO2018222901A1 (en) 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2018226336A1 (en) 2017-06-09 2018-12-13 Providence Health & Services - Oregon Utilization of cd39 and cd103 for identification of human tumor reactive cells for treatment of cancer
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019006007A1 (en) 2017-06-27 2019-01-03 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
WO2019010131A1 (en) 2017-07-03 2019-01-10 Abbott Laboratories Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
US10179911B2 (en) 2014-01-20 2019-01-15 President And Fellows Of Harvard College Negative selection and stringency modulation in continuous evolution systems
WO2019014572A1 (en) 2017-07-14 2019-01-17 Pfizer, Inc. Antibodies to madcam
EP3431496A1 (en) 2017-07-19 2019-01-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti- isoasp7 amyloid beta antibodies and uses thereof
WO2019018730A1 (en) 2017-07-20 2019-01-24 Novartis Ag Dosage regimens of anti-lag-3 antibodies and uses thereof
WO2019023661A1 (en) 2017-07-28 2019-01-31 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
US10197573B2 (en) 2013-03-14 2019-02-05 Abbott Laboratories HCV core lipid binding domain monoclonal antibodies
US10210306B2 (en) 2006-05-03 2019-02-19 Population Bio, Inc. Evaluating genetic disorders
US10208120B2 (en) 2014-11-05 2019-02-19 Genentech, Inc. Anti-FGFR2/3 antibodies and methods using same
US10208109B2 (en) 2005-11-30 2019-02-19 Abbvie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Multispecific molecules that bind to bcma and uses thereof
US10214765B2 (en) 2012-08-18 2019-02-26 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US10233495B2 (en) 2012-09-27 2019-03-19 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
EP3461841A1 (en) 2017-10-02 2019-04-03 Certest Biotec, S.L. Antibodies and test devices for the detection of bacteria of the genus campylobacter
US10253101B2 (en) 2015-08-06 2019-04-09 Xoma (Us) Llc Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
WO2019070161A2 (en) 2017-10-04 2019-04-11 Opko Pharmaceuticals, Llc Articles and methods directed to personalized therapy of cancer
WO2019070726A1 (en) 2017-10-02 2019-04-11 Visterra, Inc. Antibody molecules to cd138 and uses thereof
WO2019077165A1 (en) 2017-10-20 2019-04-25 Institut Curie Dap10/12 based cars adapted for rush
WO2019077132A1 (en) 2017-10-19 2019-04-25 Debiopharm International S.A. Combination product for the treatment of cancer
US10274488B2 (en) 2008-07-15 2019-04-30 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
WO2019099838A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
US10308721B2 (en) 2014-02-21 2019-06-04 Abbvie Stemcentrx Llc Anti-DLL3 antibodies and drug conjugates for use in melanoma
WO2019108755A1 (en) 2017-11-30 2019-06-06 Genentech, Inc. Anti-pd-l1 antibodies and methods of using the same for detection of pd-l1
US10317393B2 (en) 2007-03-23 2019-06-11 Academia Sinica Alkynyl sugar analogs for labeling and visualization of glycoconjugates in cells
WO2019112860A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
WO2019113464A1 (en) 2017-12-08 2019-06-13 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
WO2019113525A2 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
US10336784B2 (en) 2016-03-08 2019-07-02 Academia Sinica Methods for modular synthesis of N-glycans and arrays thereof
US10342858B2 (en) 2015-01-24 2019-07-09 Academia Sinica Glycan conjugates and methods of use thereof
EP3511413A1 (en) 2014-07-25 2019-07-17 Theravectys Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
EP3514179A1 (en) 2014-01-24 2019-07-24 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
WO2019152810A1 (en) 2018-02-02 2019-08-08 Bio-Techne Corporation Compounds that modulate the interaction of vista and vsig3 and methods of making and using
US10392674B2 (en) 2015-07-22 2019-08-27 President And Fellows Of Harvard College Evolution of site-specific recombinases
US10400037B2 (en) 2014-09-30 2019-09-03 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Binding molecules, especially antibodies, binding to L1CAM (CD171)
US10407724B2 (en) 2012-02-09 2019-09-10 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
WO2019178364A2 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019180272A1 (en) 2018-03-23 2019-09-26 Fundación Instituto De Investigación Sanitaria De Santiago De Compostela Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases
US10428145B2 (en) 2015-09-29 2019-10-01 Celgene Corporation PD-1 binding proteins and methods of use thereof
WO2019185515A1 (en) 2018-03-26 2019-10-03 Glycanostics S.R.O. Means and methods for glycoprofiling of a protein
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
WO2019200229A1 (en) 2018-04-13 2019-10-17 Novartis Ag Dosage regimens for anti-pd-l1 antibodies and uses thereof
EP3569245A1 (en) 2006-09-26 2019-11-20 Genmab A/S Combination treatment of cd38-expressing tumors
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
EP3574919A1 (en) 2011-07-13 2019-12-04 AbbVie Inc. Methods and compositions for treating asthma using anti-il-13 antibodies
WO2019229658A1 (en) 2018-05-30 2019-12-05 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
WO2019246293A2 (en) 2018-06-19 2019-12-26 Atarga, Llc Antibody molecules to complement component 5 and uses thereof
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
WO2020008083A1 (en) 2018-07-05 2020-01-09 Consejo Superior De Investigaciones Científicas Therapeutic target in chemokine receptors for the screening of compounds useful for the treatment of pathological processes involving chemokine signaling
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020014460A1 (en) 2018-07-11 2020-01-16 Scholar Rock, Inc. HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF
WO2020014473A1 (en) 2018-07-11 2020-01-16 Scholar Rock, Inc. TGFβ1 INHIBITORS AND USE THEREOF
US10538592B2 (en) 2016-08-22 2020-01-21 Cho Pharma, Inc. Antibodies, binding fragments, and methods of use
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
WO2020033485A1 (en) 2018-08-08 2020-02-13 Genentech, Inc. Use of tryptophan derivatives and l-methionine for protein formulation
EP3613765A1 (en) 2012-08-03 2020-02-26 Dana-Farber Cancer Institute, Inc. Antibody against repulsive guidance molecule b (rgmb)
EP3626744A1 (en) 2015-05-29 2020-03-25 AbbVie Inc. Anti-cd40 antibodies and uses thereof
WO2020065594A1 (en) 2018-09-28 2020-04-02 Kyowa Kirin Co., Ltd. Il-36 antibodies and uses thereof
WO2020069372A1 (en) 2018-09-27 2020-04-02 Elstar Therapeutics, Inc. Csf1r/ccr2 multispecific antibodies
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
US10612011B2 (en) 2015-07-30 2020-04-07 President And Fellows Of Harvard College Evolution of TALENs
EP3632931A1 (en) 2014-11-07 2020-04-08 Sesen Bio, Inc. Improved il-6 antibodies
WO2020070303A1 (en) 2018-10-05 2020-04-09 Bavarian Nordic A/S Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
WO2020079580A1 (en) 2018-10-15 2020-04-23 Novartis Ag Trem2 stabilizing antibodies
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
WO2020086736A1 (en) 2018-10-23 2020-04-30 Scholar Rock, Inc. Rgmc-selective inhibitors and use thereof
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
WO2020104531A1 (en) 2018-11-20 2020-05-28 Bavarian Nordic A/S Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l
WO2020128898A1 (en) 2018-12-20 2020-06-25 Novartis Ag Pharmaceutical combinations
WO2020128927A1 (en) 2018-12-20 2020-06-25 Kyowa Kirin Co., Ltd. Fn14 antibodies and uses thereof
EP3677278A1 (en) 2018-07-11 2020-07-08 Scholar Rock, Inc. Isoform selective tgfbeta1 inhibitors and use thereof
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
US10724096B2 (en) 2014-09-05 2020-07-28 Population Bio, Inc. Methods and compositions for inhibiting and treating neurological conditions
EP3689905A2 (en) 2019-01-30 2020-08-05 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf-beta and uses thereof
EP3693063A1 (en) 2019-02-06 2020-08-12 Diaccurate Methods and compositions for treating cancer
EP3696191A1 (en) 2019-02-14 2020-08-19 Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) Car t-cells for the treatment of cd1a-positive cancer
WO2020165868A1 (en) 2019-02-15 2020-08-20 Perkinelmer Cellular Technologies Germany Gmbh Low-power microscope-objective pre-scan and high-power microscope-objective scan in x,y and z-direction for imaging objects such as cells using a microscope
US10751414B2 (en) 2016-09-19 2020-08-25 Celgene Corporation Methods of treating psoriasis using PD-1 binding antibodies
US10752689B2 (en) 2017-06-26 2020-08-25 Bio-Techne Corporation Hybridoma clones, monoclonal antibodies to VSIG-4, and methods of making and using
WO2020172596A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and thereof
WO2020172601A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020172598A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
WO2020172571A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
EP3712171A1 (en) 2014-08-19 2020-09-23 Novartis AG Treatment of cancer using a cd123 chimeric antigen receptor
WO2020205523A1 (en) 2019-03-29 2020-10-08 Atarga, Llc Anti fgf23 antibody
EP3722316A1 (en) 2014-07-21 2020-10-14 Novartis AG Treatment of cancer using a cd33 chimeric antigen receptor
WO2020213724A1 (en) 2019-04-19 2020-10-22 中外製薬株式会社 Chimeric receptor recognizing modification site of antibody
EP3738981A1 (en) 2014-01-24 2020-11-18 NGM Biopharmaceuticals, Inc. Antibodies binding beta klotho domain 2 and methods of use thereof
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
WO2020257289A2 (en) 2019-06-17 2020-12-24 Visterra, Inc. Humanized antibody molecules to cd138 and uses thereof
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2021010326A1 (en) 2019-07-12 2021-01-21 中外製薬株式会社 Anti-mutation type fgfr3 antibody and use therefor
WO2021021606A1 (en) 2019-07-26 2021-02-04 Visterra, Inc. Interleukin-2 agents and uses thereof
WO2021023860A1 (en) 2019-08-07 2021-02-11 Db Biotech, As Improved horseradish peroxidase polypeptides
WO2021023721A1 (en) 2019-08-02 2021-02-11 Fundacio Clinic Per A La Recerca Biomedica Car t-cells against bcma for the treatment of multiple myeloma
US10920208B2 (en) 2014-10-22 2021-02-16 President And Fellows Of Harvard College Evolution of proteases
US10927342B2 (en) 2015-08-04 2021-02-23 Regeneran Pharmaceuticals, Inc. Taurine supplemented cell culture medium and methods of use
US10935544B2 (en) 2015-09-04 2021-03-02 Obi Pharma, Inc. Glycan arrays and method of use
WO2021044009A1 (en) 2019-09-04 2021-03-11 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Herv inhibitors for use in treating tauopathies
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
WO2021053560A1 (en) 2019-09-18 2021-03-25 Novartis Ag Combination therapy with entpd2 and cd73 antibodies
US10961585B2 (en) 2018-08-08 2021-03-30 Pml Screening, Llc Methods for assessing risk of developing a viral of disease using a genetic test
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US10982002B2 (en) 2018-03-12 2021-04-20 Zoetis Services Llc Anti-NGF antibodies and methods thereof
WO2021079188A1 (en) 2019-10-21 2021-04-29 Novartis Ag Combination therapies with venetoclax and tim-3 inhibitors
WO2021079195A1 (en) 2019-10-21 2021-04-29 Novartis Ag Tim-3 inhibitors and uses thereof
US11000601B2 (en) 2016-11-21 2021-05-11 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
WO2021099586A1 (en) 2019-11-20 2021-05-27 Bavarian Nordic A/S Recombinant mva viruses for intratumoral and/or intravenous administration for treating cancer
US11041017B2 (en) 2016-03-29 2021-06-22 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
WO2021123902A1 (en) 2019-12-20 2021-06-24 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
WO2021142427A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. TGFβ INHIBITORS AND USE THEREOF
WO2021142448A2 (en) 2020-01-11 2021-07-15 Scholar Rock,Inc. Tgf-beta inhibitors and use thereof
WO2021144657A1 (en) 2020-01-17 2021-07-22 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
WO2021146320A1 (en) 2020-01-13 2021-07-22 Visterra, Inc. Antibody molecules to c5ar1 and uses thereof
WO2021159024A1 (en) 2020-02-05 2021-08-12 Larimar Therapeutics, Inc. Tat peptide binding proteins and uses thereof
WO2021180890A1 (en) 2020-03-11 2021-09-16 Fundació Institut De Recerca Contra La Leucèmia Josep Carreras Cd22 targeting-moiety for the treatment of b-cell acute lymphoblastic leukemia (b-all)
US11124760B2 (en) 2014-03-24 2021-09-21 Biogen Ma Inc. Methods for overcoming glutamine deprivation during mammalian cell culture
WO2021203024A1 (en) 2020-04-03 2021-10-07 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
WO2021211331A1 (en) 2020-04-13 2021-10-21 Abbott Point Of Care Inc. METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE
WO2021217085A1 (en) 2020-04-24 2021-10-28 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
WO2021220218A1 (en) 2020-05-01 2021-11-04 Novartis Ag Immunoglobulin variants
WO2021220215A1 (en) 2020-05-01 2021-11-04 Novartis Ag Engineered immunoglobulins
WO2021222333A1 (en) 2020-04-30 2021-11-04 Genentech, Inc. Kras specific antibodies and uses thereof
WO2021239666A1 (en) 2020-05-26 2021-12-02 Diaccurate Therapeutic methods
WO2021247908A1 (en) 2020-06-03 2021-12-09 Bionecure Therapeutics, Inc. Trophoblast cell-surface antigen-2 (trop-2) antibodies
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
US11208452B2 (en) 2015-06-02 2021-12-28 Novo Nordisk A/S Insulins with polar recombinant extensions
WO2021262999A1 (en) 2020-06-24 2021-12-30 Visterra, Inc. Antibody molecules to april and uses thereof
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
US11237165B2 (en) 2008-06-27 2022-02-01 Merus N.V. Antibody producing non-human animals
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
WO2022031804A1 (en) 2020-08-04 2022-02-10 Abbott Laboratories Improved methods and kits for detecting sars-cov-2 protein in a sample
WO2022046920A2 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022046922A2 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022047046A1 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Methods of detecting trbc1 or trbc2
US11292825B2 (en) 2015-10-01 2022-04-05 Novo Nordisk A/S Protein conjugates
US11299729B2 (en) 2015-04-17 2022-04-12 President And Fellows Of Harvard College Vector-based mutagenesis system
WO2022081718A1 (en) 2020-10-14 2022-04-21 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
US11332523B2 (en) 2014-05-28 2022-05-17 Academia Sinica Anti-TNF-alpha glycoantibodies and uses thereof
WO2022115538A1 (en) 2020-11-24 2022-06-02 Bio-Techne Corporation Anti-severe acute respiratory syndrome coronavirus antibodies
WO2022119841A1 (en) 2020-12-01 2022-06-09 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2022120224A1 (en) 2020-12-04 2022-06-09 Visterra, Inc. Methods of using interleukin-2 agents
WO2022133191A2 (en) 2020-12-18 2022-06-23 Kiniksa Pharmaceuticals, Ltd. Protein compositions and methods for producing and using the same
US11370833B2 (en) 2014-09-15 2022-06-28 Genentech, Inc. Antibody formulations
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2022147463A2 (en) 2020-12-31 2022-07-07 Alamar Biosciences, Inc. Binder molecules with high affinity and/ or specificity and methods of making and use thereof
WO2022147147A1 (en) 2020-12-30 2022-07-07 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
WO2022159590A1 (en) 2021-01-20 2022-07-28 Visterra, Inc. Interleukin-2 mutants and uses thereof
WO2022162569A1 (en) 2021-01-29 2022-08-04 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
WO2022182872A2 (en) 2021-02-24 2022-09-01 Alladapt Immunotherapeutics, Inc. Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
WO2022187440A1 (en) 2021-03-03 2022-09-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services La protien as a novel regulator of osteoclastogenesis
US11447809B2 (en) 2017-07-06 2022-09-20 President And Fellows Of Harvard College Evolution of tRNA synthetases
WO2022195551A1 (en) 2021-03-18 2022-09-22 Novartis Ag Biomarkers for cancer and methods of use thereof
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022215011A1 (en) 2021-04-07 2022-10-13 Novartis Ag USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof
US11471537B2 (en) 2017-04-05 2022-10-18 Novo Nordisk A/S Oligomer extended insulin-Fc conjugates
WO2022245920A1 (en) 2021-05-18 2022-11-24 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
US11524983B2 (en) 2015-07-23 2022-12-13 President And Fellows Of Harvard College Evolution of Bt toxins
WO2022261018A1 (en) 2021-06-07 2022-12-15 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
WO2022266034A1 (en) 2021-06-14 2022-12-22 Abbott Laboratories Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
WO2022271867A1 (en) 2021-06-23 2022-12-29 Scholar Rock, Inc. A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
WO2023288267A1 (en) 2021-07-14 2023-01-19 2Seventy Bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
WO2023018803A1 (en) 2021-08-10 2023-02-16 Byomass Inc. Anti-gdf15 antibodies, compositions and uses thereof
US11583577B2 (en) 2016-04-22 2023-02-21 Obi Pharma, Inc. Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
WO2023025927A1 (en) 2021-08-26 2023-03-02 Glycanostics S.R.O Glycoprotein biomarkers for diagnosing cancer
US11596620B2 (en) 2013-03-13 2023-03-07 F. Hoffmann-La Roche Ag Formulations with reduced oxidation
WO2023034777A1 (en) 2021-08-31 2023-03-09 Abbott Laboratories Methods and systems of diagnosing brain injury
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023044094A1 (en) 2021-09-20 2023-03-23 Alnylam Pharmaceuticals, Inc. Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
WO2023041565A1 (en) 2021-09-14 2023-03-23 Glycanostics S.R.O Use of lectins to determine mammaglobin-a glycoforms in breast cancer
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2023056268A1 (en) 2021-09-30 2023-04-06 Abbott Laboratories Methods and systems of diagnosing brain injury
US11623945B2 (en) 2017-02-06 2023-04-11 The United States Of America, As Represented By The Secretary Of Agriculture Immunostimulating compositions and uses therefore
US11624130B2 (en) 2017-09-18 2023-04-11 President And Fellows Of Harvard College Continuous evolution for stabilized proteins
WO2023069421A1 (en) 2021-10-18 2023-04-27 Byomass Inc. Anti-activin a antibodies, compositions and uses thereof
US11642400B2 (en) 2016-07-27 2023-05-09 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
US11643456B2 (en) 2016-07-29 2023-05-09 Obi Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
US11649285B2 (en) 2016-08-03 2023-05-16 Bio-Techne Corporation Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
WO2023097254A1 (en) 2021-11-24 2023-06-01 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2023102463A1 (en) 2021-12-01 2023-06-08 Visterra, Inc. Methods of using interleukin-2 agents
WO2023114978A1 (en) 2021-12-17 2023-06-22 Abbott Laboratories Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
WO2023129942A1 (en) 2021-12-28 2023-07-06 Abbott Laboratories Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
EP4218817A2 (en) 2017-01-06 2023-08-02 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
WO2023147107A1 (en) 2022-01-31 2023-08-03 Byomass Inc. Myeloproliferative conditions
WO2023150652A1 (en) 2022-02-04 2023-08-10 Abbott Laboratories Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
WO2023150778A1 (en) 2022-02-07 2023-08-10 Visterra, Inc. Anti-idiotype antibody molecules and uses thereof
US11725247B2 (en) 2016-02-29 2023-08-15 Foundation Medicine, Inc. Methods of treating cancer
US11738050B2 (en) 2019-02-01 2023-08-29 Regents Of The University Of Minnesota Compounds binding to fibroblast activation protein alpha
WO2023212518A1 (en) 2022-04-25 2023-11-02 Visterra, Inc. Antibody molecules to april and uses thereof
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
US11827720B2 (en) 2006-07-05 2023-11-28 F-Star Therapeutics Limited Multivalent immunoglobulins
WO2023239803A1 (en) 2022-06-08 2023-12-14 Angiex, Inc. Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
EP4296279A1 (en) 2022-06-23 2023-12-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-transthyretin (ttr) binding proteins and uses thereof
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
US11884739B2 (en) 2014-05-27 2024-01-30 Academia Sinica Anti-CD20 glycoantibodies and uses thereof
WO2024030976A2 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier
EP4324518A2 (en) 2014-01-31 2024-02-21 Novartis AG Antibody molecules to tim-3 and uses thereof
US11913044B2 (en) 2018-06-14 2024-02-27 President And Fellows Of Harvard College Evolution of cytidine deaminases

Families Citing this family (1434)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE164395T1 (en) * 1990-12-03 1998-04-15 Genentech Inc METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES
CA2108147C (en) 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
US6800738B1 (en) * 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5837458A (en) * 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US6475806B1 (en) 1995-06-07 2002-11-05 Praecis Pharmaceuticals, Inc. Anchor libraries and identification of peptide binding sequences
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
CA2309358A1 (en) 1997-11-21 1999-06-03 Genentech, Inc. A-33 related antigens and their pharmacological uses
AU3072799A (en) 1998-03-19 1999-10-11 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
ES2316194T3 (en) * 1998-10-28 2009-04-01 Cornell Research Foundation, Inc. METHODS FOR THE REGULATION OF ANGIOGENESIS AND VASCULAR INTEGRITY USING THE BDNF, NT-3 AND NT-4 LIGANDS.
US6927024B2 (en) 1998-11-30 2005-08-09 Genentech, Inc. PCR assay
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
WO2000039302A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
JP2003523721A (en) 1998-12-31 2003-08-12 カイロン コーポレイション Polynucleotides encoding antigenic HIVC-type polypeptides, polypeptides, and uses thereof
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
DK1141315T3 (en) 1998-12-31 2008-05-19 Novartis Vaccines & Diagnostic Modified HIV Env polypeptides
EP1141014B1 (en) 1999-01-06 2004-12-08 Genentech, Inc. Insulin-like growth factor (igf) i mutant variant
WO2000040612A1 (en) * 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
CA2363779A1 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
AU4057600A (en) * 1999-03-31 2000-10-16 Rosetta Inpharmatics, Inc. Methods for the identification of reporter and target molecules using comprehensive gene expression profiles
US7270969B2 (en) 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
US7803765B2 (en) * 1999-05-05 2010-09-28 Phylogica Limited Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
CA2372464C (en) 1999-05-05 2012-07-31 Tvw Telethon Institute For Child Health Research Isolating biological modulators from biodiverse gene fragment libraries
US6200803B1 (en) 1999-05-21 2001-03-13 Rosetta Inpharmatics, Inc. Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
US6197517B1 (en) 1999-05-21 2001-03-06 Rosetta Inpharmatics, Inc. Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
US6221597B1 (en) 1999-05-21 2001-04-24 Rosetta Inpharmatics, Inc. Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
US20030166003A1 (en) * 1999-06-14 2003-09-04 Cochran Andrea G. Structured peptide scaffold for displaying turn libraries on phage
ES2242620T3 (en) 1999-06-14 2005-11-16 Genentech, Inc. PEPTIDIC STRUCTURES TO DISPLAY LIBRARIES OF TURNS OF A PAYMENT.
DE19943743C2 (en) * 1999-09-03 2002-02-07 Jerini Biotools Gmbh Procedure for the identification of binding partners with position-specific arrays
CN1279054C (en) * 1999-10-20 2006-10-11 杰南技术公司 Type I cytokine receptor TCCR
US20060073509A1 (en) * 1999-11-18 2006-04-06 Michael Kilpatrick Method for detecting and quantitating multiple subcellular components
AU784983B2 (en) * 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
US20020004247A1 (en) * 1999-12-23 2002-01-10 Genentech, Inc. Assay method
CA2403425C (en) 2000-04-11 2013-08-27 Genentech, Inc. Multivalent antibodies and uses therefor
ES2529300T3 (en) 2000-04-12 2015-02-18 Novozymes Biopharma Dk A/S Albumin fusion proteins
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US20040029113A1 (en) * 2000-04-17 2004-02-12 Ladner Robert C. Novel methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins
US7297762B2 (en) * 2000-04-24 2007-11-20 Yale University Modified avian pancreatic polypeptide miniature binding proteins
US7495070B2 (en) * 2000-04-24 2009-02-24 Yale University Protein binding miniature proteins
WO2001087323A2 (en) 2000-05-16 2001-11-22 Genentech, Inc. Method for treating cartilage disorders
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
EP1294949A4 (en) 2000-06-15 2004-08-25 Human Genome Sciences Inc Human tumor necrosis factor delta and epsilon
KR101287395B1 (en) 2000-06-16 2014-11-04 휴먼 게놈 사이언시즈, 인코포레이티드 Antibodies that immunospecifically bind to BLyS
BR0111298A (en) * 2000-06-28 2005-05-10 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification, design and use
US6951947B2 (en) * 2000-07-13 2005-10-04 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
US7176037B2 (en) * 2000-07-13 2007-02-13 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
DE60136816D1 (en) 2000-07-27 2009-01-15 Genentech Inc SEQUENTIAL ADMINISTRATION OF CPT-11 AND APO-2L POLYPEPTIDE
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
TWI283182B (en) 2000-08-07 2007-07-01 Nektar Therapeutics Inhalable spray dried 4-helix bundle protein powders having minimized aggregation
UA81743C2 (en) 2000-08-07 2008-02-11 Центокор, Инк. HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
ATE552859T1 (en) * 2000-09-13 2012-04-15 Praecis Pharm Inc PHARMACEUTICAL FORMULATIONS FOR CONTINUOUS DELIVERY OF PEPTIDES
GB0022978D0 (en) 2000-09-19 2000-11-01 Oxford Glycosciences Uk Ltd Detection of peptides
ATE402958T1 (en) 2000-09-26 2008-08-15 Genentech Inc ANTAGONISTS OF THE IGE RECEPTOR
US7393532B1 (en) 2000-10-18 2008-07-01 Genentech, Inc. Modulation of T cell differentiation for the treatment of T helper cell mediated diseases
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US6841359B2 (en) * 2000-10-31 2005-01-11 The General Hospital Corporation Streptavidin-binding peptides and uses thereof
TWI327600B (en) 2000-11-28 2010-07-21 Medimmune Llc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
DE60136656D1 (en) 2000-12-05 2009-01-02 Alexion Pharma Inc Rationally designed antibodies
US9249229B2 (en) * 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20060057651A1 (en) 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
EP1341902A2 (en) * 2000-12-08 2003-09-10 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
EP2357187A1 (en) 2000-12-12 2011-08-17 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
AU2002249854B2 (en) 2000-12-18 2007-09-20 Dyax Corp. Focused libraries of genetic packages
ATE519783T1 (en) * 2000-12-22 2011-08-15 Grad Carole Legal Representative Of Kaplan Howard ßPHAGE DISPLAYß LIBRARY OF HUMAN VH FRAGMENTS
EP1355666B1 (en) 2000-12-22 2012-06-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (RGM) and its modulators
CA2437811A1 (en) 2001-02-09 2002-08-22 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
US20030044406A1 (en) * 2001-03-02 2003-03-06 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
CA2342376C (en) * 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) * 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US20090081199A1 (en) * 2001-03-20 2009-03-26 Bioxell S.P.A. Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6914123B2 (en) * 2001-04-17 2005-07-05 Genentech, Inc. Hairpin peptides with a novel structural motif and methods relating thereto
EP1572874B1 (en) 2001-05-25 2013-09-18 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US20060239533A1 (en) * 2001-06-04 2006-10-26 Triantafyllos Tafas Method for detecting infectious agents using computer controlled automated image analysis
US20030148380A1 (en) * 2001-06-05 2003-08-07 Belcher Angela M. Molecular recognition of materials
US20050164515A9 (en) * 2001-06-05 2005-07-28 Belcher Angela M. Biological control of nanoparticle nucleation, shape and crystal phase
US20030113714A1 (en) * 2001-09-28 2003-06-19 Belcher Angela M. Biological control of nanoparticles
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US7803915B2 (en) * 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
US20050107595A1 (en) * 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
ATE522623T1 (en) 2001-06-20 2011-09-15 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF LUNG TUMORS
EP1409694A4 (en) * 2001-07-05 2006-02-08 Chiron Corp Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
CA2452015C (en) 2001-07-05 2012-07-03 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
DE10135039C1 (en) * 2001-07-18 2003-03-13 Nemod Immuntherapie Ag Method for isolating large variances of specific molecules for a target molecule from phagemid gene libraries
US6867189B2 (en) * 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
KR100458083B1 (en) * 2001-08-29 2004-11-18 주식회사 아이지세라피 Method for the construction of phage display library using helper phage variants
JP2005521380A (en) * 2001-08-31 2005-07-21 カイロン コーポレイション Polynucleotide encoding antigenic type B HIV polypeptide, polypeptide and use thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
EP1425040A2 (en) * 2001-09-14 2004-06-09 Cytos Biotechnology AG In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
EP2153843B1 (en) 2001-09-18 2012-08-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20030073104A1 (en) * 2001-10-02 2003-04-17 Belcher Angela M. Nanoscaling ordering of hybrid materials using genetically engineered mesoscale virus
WO2005049075A2 (en) 2003-11-17 2005-06-02 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
JP2005525095A (en) 2002-01-02 2005-08-25 ジェネンテック・インコーポレーテッド Compositions and methods for tumor diagnosis and treatment
AU2003207459A1 (en) * 2002-01-03 2003-07-24 The Scripps Research Institute Cancer-associated epitope
US20060046249A1 (en) * 2002-01-18 2006-03-02 Fei Huang Identification of polynucleotides and polypetide for predicting activity of compounds that interact with protein tyrosine kinase and or protein tyrosine kinase pathways
EP1573316B1 (en) 2002-03-01 2009-08-26 Siemens Healthcare Diagnostics Inc. Assays for cancer patient monitoring based on levels of epidermal growth factor receptor (egfr) extracellular domain (ecd) analyte, alone or in combination with other analytes, in body fluid samples
EP1489968B1 (en) * 2002-03-01 2009-02-18 Siemens Healthcare Diagnostics Inc. Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples
AU2003218456A1 (en) * 2002-04-01 2003-10-20 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
GB0207533D0 (en) 2002-04-02 2002-05-08 Oxford Glycosciences Uk Ltd Protein
WO2003086458A1 (en) 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
EP2011886A3 (en) 2002-04-16 2009-02-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP4753578B2 (en) * 2002-06-03 2011-08-24 ジェネンテック, インコーポレイテッド Synthetic antibody phage library
CN100418981C (en) * 2002-06-10 2008-09-17 瓦西尼斯公司 Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US9321992B2 (en) * 2002-06-14 2016-04-26 Case Western Reserve University Cell targeting methods and compositions
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040067532A1 (en) * 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
PT1534335E (en) 2002-08-14 2012-02-28 Macrogenics Inc Fcgammariib-specific antibodies and methods of use thereof
DE10238846A1 (en) * 2002-08-20 2004-03-04 Nemod Immuntherapie Ag Active fusion proteins and processes for their production
KR20050057047A (en) * 2002-08-29 2005-06-16 제넨테크, 인크. Achaete-scute like-2 polypeptides and encoding nucleic acids and methods for the diagnosis and treatment of tumor
ATE466085T1 (en) * 2002-09-09 2010-05-15 Hanall Pharmaceutical Co Ltd PROTEASE-RESISTANT MODIFIED INTERFERON ALPHA POLYPEPTIDES
US20050064508A1 (en) * 2003-09-22 2005-03-24 Semzyme Peptide mediated synthesis of metallic and magnetic materials
ZA200502612B (en) 2002-10-08 2007-07-25 Rinat Neuroscience Corp Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
AU2003304238A1 (en) 2002-10-08 2005-01-13 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
BR0315157A (en) * 2002-10-09 2005-08-09 Rinat Neuroscience Corp Methods of treating alzheimer's disease by employing antibodies directed against amyloid beta peptide and compositions thereof
PT2301965E (en) 2002-10-16 2015-05-20 Purdue Pharma Lp Antibodies that bind cell-associated ca 125/o722p and methods of use thereof
EP1578799B8 (en) * 2002-12-02 2011-03-23 Amgen Fremont Inc. Antibodies directed to tumor necrosis factor and uses thereof
US7056702B2 (en) * 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
US20050089521A1 (en) * 2002-12-23 2005-04-28 Shelton David L. Methods for treating taxol-induced sensory neuropathy
AU2003293958A1 (en) * 2002-12-23 2004-07-22 Apalexo Biotechnologie Gmbh Purification of recombinant filamental bacteriophages by means of affinity chromatography to increase the immunogenicity and efficacy of phagic vaccines
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
DK2270048T3 (en) 2002-12-24 2016-01-18 Rinat Neuroscience Corp Anti-NGF antibodies and methods for their use
WO2004065416A2 (en) * 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
JP2006518997A (en) * 2003-01-21 2006-08-24 ブリストル−マイヤーズ スクイブ カンパニー Novel acyl coenzyme A: polynucleotide encoding monoacylglycerol acyltransferase-3 (MGAT3) and uses thereof
US7429472B2 (en) 2003-01-31 2008-09-30 Promega Corporation Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
EP2455458B1 (en) 2003-01-31 2015-01-07 Promega Corporation Covalent tethering of functional groups to proteins
EP1594441B1 (en) 2003-02-19 2010-12-15 Rinat Neuroscience Corp. Method for treating pain by administering a nerve growth factor antagonist and an nsaid and composition containing the same
CA2516455C (en) 2003-02-20 2012-05-01 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
MXPA05009913A (en) * 2003-03-19 2005-11-04 Biogen Idec Inc Nogo receptor binding protein.
WO2004084836A2 (en) * 2003-03-20 2004-10-07 Rinat Neuroscience Corp. Methods for treating taxol-induced gut disorder
US7294701B2 (en) * 2003-04-02 2007-11-13 Technion Research & Development Foundation Ltd. Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
KR20110094361A (en) 2003-04-11 2011-08-23 메디뮨 엘엘씨 Recombinant il-9 antibodies and uses thereof
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CN1829741A (en) 2003-05-30 2006-09-06 健泰科生物技术公司 Treatment with anti-VEGF antibodies
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
CA2528343A1 (en) 2003-06-06 2005-01-06 Genentech, Inc. Modulating the interaction between hgf beta chain and c-met
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
SI1641822T1 (en) 2003-07-08 2013-08-30 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
WO2005010163A2 (en) * 2003-07-15 2005-02-03 Barros Research Institute Compositions and methods for immunotherapy of human immunotherapy of human immunodeficiency virus (hiv)
AU2004259727A1 (en) * 2003-07-15 2005-02-03 Barros Research Institute Compositions and methods for immunotherapy of cancer and infectious diseases.
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
EP1668111A4 (en) 2003-08-08 2008-07-02 Genenews Inc Osteoarthritis biomarkers and uses thereof
JP4934426B2 (en) 2003-08-18 2012-05-16 メディミューン,エルエルシー Antibody humanization
BRPI0414093A (en) 2003-09-05 2006-10-31 Scripps Res Insittute cholesterol ozonation products for the treatment and prevention of atherosclerosis and / or cardiovascular disease
MXPA06002563A (en) * 2003-09-05 2006-06-20 Scripps Research Inst Detection of cholesterol ozonation products.
IL158287A0 (en) 2003-10-07 2004-05-12 Yeda Res & Dev Antibodies to nik, their preparation and use
US7329725B1 (en) * 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
GB0325836D0 (en) * 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
AU2004290070A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
DK1983000T3 (en) * 2003-11-21 2015-12-07 Ucb Biopharma Sprl A method for the treatment of multiple sclerosis by inhibiting IL-17 activity
WO2005055936A2 (en) * 2003-12-04 2005-06-23 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
CA2548282A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
GB0329825D0 (en) * 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
JP4503617B2 (en) 2003-12-23 2010-07-14 ライナット ニューロサイエンス コーポレイション Agonist anti-trkC antibody and method using the antibody
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
JP4782700B2 (en) 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド Transfer of antibody specificity using minimally required binding determinants
CN103755800B (en) * 2004-02-02 2016-02-24 Ambrx公司 Modified human interferon polypeptides and its purposes
US20050232927A1 (en) * 2004-02-03 2005-10-20 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
SI1729795T1 (en) 2004-02-09 2016-04-29 Human Genome Sciences, Inc. Albumin fusion proteins
ATE452147T1 (en) 2004-02-19 2010-01-15 Genentech Inc ANTIBODIES WITH CORRECTED CDR
EP1735453A2 (en) * 2004-03-12 2006-12-27 The Scripps Research Institute Fluorescent signal emitting live cell biosensor molecules and dyes for detection and quantification of protein activities
US7973139B2 (en) * 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
JP5128935B2 (en) 2004-03-31 2013-01-23 ジェネンテック, インコーポレイテッド Humanized anti-TGF-β antibody
ATE456580T1 (en) * 2004-04-07 2010-02-15 Rinat Neuroscience Corp METHOD FOR PAIN TREATMENT IN BONE CANCER BY ADMINISTRATION OF A NGF ANTAGONIST
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US7785903B2 (en) * 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
CA2955027A1 (en) 2004-04-15 2005-11-10 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
CA2558963A1 (en) * 2004-04-16 2005-12-15 Genentech, Inc. Omi pdz modulators
ES2442386T3 (en) 2004-04-23 2014-02-11 Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr Method for the treatment of conditions mediated by T cells by the decrease of positive ICOS cells in vivo.
US20060292554A1 (en) * 2004-05-18 2006-12-28 Genentech, Inc. Major coat protein variants for C-terminal and bi-terminal display
EP1602928A1 (en) * 2004-06-01 2005-12-07 Universiteit Maastricht Process and kit for determining binding parameters of bioaffinity binding reactions
DK1754052T3 (en) * 2004-06-03 2015-09-28 Phylogica Ltd Modulators with biochemical properties
US7604947B2 (en) * 2004-06-09 2009-10-20 Cornell Research Foundation, Inc. Detection and modulation of cancer stem cells
CN102603895B (en) * 2004-06-18 2016-09-28 Ambrx公司 Novel antigen-binding polypeptides and its purposes
PT1776136E (en) 2004-06-24 2012-12-05 Biogen Idec Inc Treatment of conditions involving demyelination
US6986264B1 (en) * 2004-07-15 2006-01-17 Carrier Corporation Economized dehumidification system
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
DE602005019167D1 (en) * 2004-07-20 2010-03-18 Genentech Inc ANGIOPOIETIN-LIKE 4 PROTEIN HEMMER COMBINATIONS AND THEIR USE
AU2005327906B2 (en) * 2004-07-21 2010-05-13 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US20070087400A1 (en) * 2004-07-30 2007-04-19 Aldis Darzins Covalent tethering of functional groups to proteins and substrates therefor
KR20070040824A (en) 2004-07-30 2007-04-17 리나트 뉴로사이언스 코퍼레이션 Antibodies directed against amyloid-beta peptide and methods using same
US7425436B2 (en) * 2004-07-30 2008-09-16 Promega Corporation Covalent tethering of functional groups to proteins and substrates therefor
EP1789070B1 (en) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in neuronal function
HUE058817T2 (en) 2004-09-03 2022-09-28 Genentech Inc Humanized anti-beta7 antagonists and uses therefor
JP2008513540A (en) 2004-09-21 2008-05-01 メディミューン,インコーポレーテッド Antibody to respiratory syncytial virus and method for producing vaccine for the virus
WO2006047417A2 (en) 2004-10-21 2006-05-04 University Of Florida Research Foundation, Inc. Detection of cannabinoid receptor biomarkers and uses thereof
NZ590132A (en) 2004-10-21 2012-03-30 Genentech Inc Dosage regime for treating intraocular neovascular diseases with VEGF
JP2008518023A (en) 2004-10-27 2008-05-29 メディミューン,インコーポレーテッド Regulation of antibody specificity by altering affinity for cognate antigens
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
KR20070095949A (en) * 2004-12-16 2007-10-01 제넨테크, 인크. Methods for treating autoimmune disorders
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
JP2008525032A (en) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド Methods for expressing and purifying recombinant human growth hormone
SG160437A1 (en) 2004-12-22 2010-04-29 Ambrx Inc Modified human growth hormone
AU2005319518B2 (en) * 2004-12-22 2010-09-09 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
WO2006074397A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Cripto binding molecules
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
WO2006086242A2 (en) 2005-02-07 2006-08-17 Genenews, Inc. Mild osteoarthritis biomarkers and uses thereof
JP5651285B2 (en) 2005-02-15 2015-01-07 デューク ユニバーシティ Anti-CD19 antibodies and use in oncology
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
EP1858545A2 (en) * 2005-03-04 2007-11-28 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
CN101175769A (en) 2005-03-10 2008-05-07 健泰科生物技术公司 Methods and compositions for modulating vascular integrity
AU2006227377B2 (en) 2005-03-18 2013-01-31 Medimmune, Llc Framework-shuffling of antibodies
GB0506912D0 (en) 2005-04-05 2005-05-11 Celltech R&D Ltd Biological products
AU2006236439B2 (en) 2005-04-15 2012-05-03 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2012018687A1 (en) 2010-08-02 2012-02-09 Macrogenics, Inc. Covalent diabodies and uses thereof
US20060269556A1 (en) * 2005-04-18 2006-11-30 Karl Nocka Mast cell activation using siglec 6 antibodies
AU2006236225C1 (en) 2005-04-19 2013-05-02 Seagen Inc. Humanized anti-CD70 binding agents and uses thereof
AR054260A1 (en) * 2005-04-26 2007-06-13 Rinat Neuroscience Corp METHODS OF TREATMENT OF DISEASES OF THE LOWER MOTOR NEURONE AND COMPOSITIONS USED IN THE SAME
UY29504A1 (en) 2005-04-29 2006-10-31 Rinat Neuroscience Corp DIRECTED ANTIBODIES AGAINST BETA AMYLOID PEPTIDE AND METHODS USING THE SAME.
PA8672101A1 (en) 2005-04-29 2006-12-07 Centocor Inc ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES
EP2295066B1 (en) * 2005-05-25 2016-04-27 CureDM Group Holdings, LLC Peptides, derivatives and analogs thereof, and methods of using same
CA2609205A1 (en) * 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
NZ563341A (en) 2005-06-06 2009-10-30 Genentech Inc Methods for identifying agents that modulate a gene that encodes for a PRO1568 polypeptide
WO2006135886A2 (en) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
KR20080025174A (en) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 Antibody formulations having optimized aggregation and fragmentation profiles
US7491391B2 (en) 2005-06-30 2009-02-17 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
PT1904104E (en) 2005-07-08 2013-11-21 Biogen Idec Inc Sp35 antibodies and uses thereof
EP1904652A2 (en) * 2005-07-08 2008-04-02 Brystol-Myers Squibb Company Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
CN101282994B (en) * 2005-07-22 2013-09-18 Y's治疗有限公司 Anti-CD26 antibodies and methods of use thereof
EP1920057A4 (en) 2005-08-03 2009-03-18 Grains Res & Dev Corp Polysaccharide synthases
EP1995321A2 (en) 2005-08-15 2008-11-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US7632823B2 (en) 2005-08-18 2009-12-15 Ambrx, Inc. Compositions of tRNA and uses thereof
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US20070202512A1 (en) * 2005-08-19 2007-08-30 Bristol-Myers Squibb Company Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
ATE546160T1 (en) * 2005-09-14 2012-03-15 Ucb Pharma Sa ANTIBODY COMB POLYMER CONJUGATE
KR101176830B1 (en) 2005-10-17 2012-08-27 주식회사 아이지세라피 Novel method for phage display
US8249814B2 (en) 2005-10-21 2012-08-21 Genenews Inc. Method, computer readable medium, and system for determining a probability of colorectal cancer in a test subject
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP2009513708A (en) 2005-10-31 2009-04-02 オンコメッド ファーマシューティカルズ インコーポレイテッド Compositions and methods for diagnosis and treatment of cancer
AU2006308847C1 (en) * 2005-10-31 2012-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
AU2006311828B2 (en) 2005-11-04 2013-07-11 Biogen Ma Inc. Methods for promoting neurite outgrowth and survival of dopaminergic neurons
AU2006311661B2 (en) 2005-11-07 2011-05-26 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
ES2577292T3 (en) 2005-11-07 2016-07-14 Genentech, Inc. Binding polypeptides with diversified VH / VL hypervariable sequences and consensus
CN101400646A (en) * 2005-11-08 2009-04-01 Ambrx公司 Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
UA96139C2 (en) 2005-11-08 2011-10-10 Дженентек, Інк. Anti-neuropilin-1 (nrp1) antibody
KR20080068062A (en) 2005-11-14 2008-07-22 리나트 뉴로사이언스 코퍼레이션 Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
EP1951890A4 (en) 2005-11-16 2009-06-24 Ambrx Inc Methods and compositions comprising non-natural amino acids
US20090293137A1 (en) 2005-11-21 2009-11-26 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
DK1963369T3 (en) 2005-11-28 2013-06-03 Zymogenetics Inc IL-21 Antagonists
CA2631181A1 (en) 2005-12-02 2007-06-07 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
WO2007126439A2 (en) 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
WO2007064919A2 (en) * 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
SI1960430T1 (en) * 2005-12-09 2015-01-30 Ucb Pharma, S.A. Antibody molecules having specificity for human il-6
NZ568578A (en) * 2005-12-14 2011-10-28 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
CA2635692C (en) 2005-12-29 2013-06-18 Centocor, Inc. Human anti-il-23 antibodies, compositions, methods and uses
SG10201400426XA (en) 2006-01-12 2014-07-30 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
EP1987361A4 (en) * 2006-01-30 2009-03-04 Invitrogen Corp Compositions and methods for detecting and quantifying toxic substances in disease states
US20070175313A1 (en) * 2006-01-31 2007-08-02 Kevin Vandervliet MP3 player holder assembly
ZA200807714B (en) 2006-02-17 2010-01-27 Genentech Inc Gene disruptions, compositions and methods relating thereto
AU2007218045B2 (en) * 2006-02-20 2011-11-10 Phylogica Limited Method of constructing and screening libraries of peptide structures
US20070243192A1 (en) * 2006-02-21 2007-10-18 Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
WO2008121102A2 (en) * 2006-02-21 2008-10-09 The Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
US8021839B2 (en) * 2006-02-24 2011-09-20 Investigen, Inc. Methods and compositions for detecting polynucleotides
WO2007103469A2 (en) 2006-03-06 2007-09-13 Aeres Biomedical Ltd. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CA2647277A1 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
AU2007238186B2 (en) 2006-04-10 2014-01-09 Genentech, Inc. Disheveled PDZ modulators
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
TW200812616A (en) * 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
US20090142259A1 (en) * 2006-05-12 2009-06-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
ES2718952T3 (en) 2006-06-07 2019-07-05 Bioalliance Cv Antibodies that recognize an epitope that contains carbohydrates on CD-43 and CEA expressed in cancer cells and methods that use them
SG10201504662WA (en) 2006-06-14 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
EP2505209A1 (en) 2006-06-26 2012-10-03 MacroGenics, Inc. Fcgamma-RIIB-specific antibodies and methods of the use thereof
DE102006030028A1 (en) * 2006-06-29 2008-02-14 Forschungszentrum Jülich GmbH A method for finding bait-binding specific molecules and bait-binding molecules and their use
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
KR101528939B1 (en) * 2006-07-18 2015-06-15 사노피 Antagonist antibody against epha2 for the treatment of cancer
EP2057465A4 (en) 2006-08-09 2010-04-21 Homestead Clinical Corp Organ-specific proteins and methods of their use
MY162024A (en) 2006-08-28 2017-05-31 La Jolla Inst Allergy & Immunology Antagonistic human light-specific human monoclonal antibodies
CA2662629C (en) 2006-09-07 2019-08-13 University Of Otago Bnp signal peptide fragments for acute cardiac disorders
NZ574960A (en) * 2006-09-08 2012-02-24 Ambrx Inc Suppressor trna transcription in vertebrate cells
PT2061878E (en) * 2006-09-08 2014-04-22 Ambrx Inc Hybrid suppressor trna for vertebrate cells
WO2008030558A2 (en) * 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
CA2662236A1 (en) 2006-09-12 2008-03-20 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
EP2074138A4 (en) * 2006-09-19 2009-12-30 Phylogica Ltd Neuroprotective peptide inhibitors of ap-1 signaling and uses therefor
DK2066694T3 (en) 2006-09-29 2016-02-08 Oncomed Pharm Inc Compositions and Methods for Diagnosing and Treating Cancer
JP5298021B2 (en) * 2006-10-12 2013-09-25 ジェネンテック, インコーポレイテッド Antibodies against lymphotoxin-α
US20100143254A1 (en) 2006-10-16 2010-06-10 Medimmune, Llc Molecules with reduced half-lives, compositions and uses thereof
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US20080096193A1 (en) * 2006-10-24 2008-04-24 Charles Robert Bupp Methods and compositions for detecting polynucleotides
WO2008054821A2 (en) 2006-10-30 2008-05-08 Promega Corporation Mutant hydrolase proteins with enhanced kinetics and functional expression
US8785400B2 (en) * 2006-11-22 2014-07-22 Curedm Group Holdings, Llc Methods and compositions relating to islet cell neogenesis
CA2671264C (en) * 2006-11-30 2015-11-24 Research Development Foundation Improved immunoglobulin libraries
ES2523915T5 (en) 2006-12-01 2022-05-26 Seagen Inc Variant Target Binding Agents and Uses Thereof
EP2687232A1 (en) 2006-12-06 2014-01-22 MedImmune, LLC Methods of treating systemic lupus erythematosus
KR20140031996A (en) 2006-12-19 2014-03-13 제넨테크, 인크. Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
EP2913341A1 (en) 2006-12-22 2015-09-02 University of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
US20090068110A1 (en) * 2006-12-22 2009-03-12 Genentech, Inc. Antibodies to insulin-like growth factor receptor
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
UA99120C2 (en) 2007-01-09 2012-07-25 Байоджэн Айдэк Ма Инк. Sp35 antibodies and uses thereof
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
EP2629094A1 (en) 2007-01-24 2013-08-21 Carnegie Mellon University Optical biosensors
CN101652389A (en) 2007-02-09 2010-02-17 健泰科生物技术公司 Anti-ROBO4 antibodies and uses therefor
US8114606B2 (en) * 2007-02-16 2012-02-14 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies
US8685666B2 (en) * 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
KR101508397B1 (en) 2007-02-22 2015-04-08 제넨테크, 인크. Methods for detecting inflammatory bowel disease
WO2008103702A2 (en) * 2007-02-23 2008-08-28 Investigen, Inc. Methods and compositions for rapid light-activated isolation and detection of analytes
EP3118221B1 (en) 2007-02-26 2019-08-21 Oxford BioTherapeutics Ltd Proteins
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
SI2125894T1 (en) 2007-03-22 2019-05-31 Biogen Ma Inc. Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
JP5456658B2 (en) 2007-03-30 2014-04-02 メディミューン,エルエルシー Antibody preparation
CA2682147C (en) * 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
US20100291562A1 (en) * 2007-04-04 2010-11-18 Michael Adler Method for the detection of an analyte in biological matrix
US7807168B2 (en) * 2007-04-10 2010-10-05 Vaccinex, Inc. Selection of human TNFα specific antibodies
BRPI0810622A2 (en) 2007-05-02 2020-10-13 Ambrx, Inc. modified interferon beta polypeptides and their uses
SG194368A1 (en) 2007-05-04 2013-11-29 Technophage Investigacao E Desenvolvimento Em Biotecnologia Sa Engineered rabbit antibody variable domains and uses thereof
EP2703011A3 (en) 2007-05-07 2014-03-26 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CN103223167B (en) 2007-05-14 2015-06-17 米迪缪尼有限公司 Methods of reducing eosinophil levels
AU2007353779B2 (en) * 2007-05-17 2013-11-07 Genentech, Inc. Crystal structures of neuropilin fragments and neuropilin-antibody complexes
US7906149B2 (en) * 2007-05-25 2011-03-15 Boval Company, L.P. Method for treating allergic dermatitis
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
PE20090329A1 (en) * 2007-05-30 2009-03-27 Abbott Lab HUMANIZED ANTIBODIES AGAINST GLOBULOMER AB (20-42) AND ITS USES
WO2008154700A1 (en) * 2007-06-20 2008-12-24 Phylogica Limited Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith
KR101799337B1 (en) 2007-06-21 2017-12-20 마크로제닉스, 인크. Covalent diabodies and uses thereof
PT2173379E (en) 2007-07-02 2015-11-24 Oncomed Pharm Inc Compositions and methods for treating and diagnosing cancer
JP2010534664A (en) 2007-07-23 2010-11-11 セントコア・オーソ・バイオテツク・インコーポレーテツド Methods and compositions for treatment of fibrosis related diseases using IL-17 antagonists
BRPI0814645A2 (en) * 2007-07-25 2015-01-27 Alexion Pharma Inc METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASE.
WO2009020477A1 (en) * 2007-08-06 2009-02-12 Yale University Modified miniature proteins
ES2534434T3 (en) * 2007-08-30 2015-04-22 Curedm Group Holdings, Llc Compositions and methods of using proislot peptides and analogs thereof
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
JP5933894B2 (en) 2007-09-14 2016-06-15 アディマブ, エルエルシー Rationally designed synthetic antibody libraries and their use
US8877688B2 (en) * 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
TWI464262B (en) 2007-09-26 2014-12-11 中外製藥股份有限公司 Antibody constant region mutant
CA2700714C (en) 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
NZ584330A (en) * 2007-10-04 2013-01-25 Bionomics Ltd Markers of endothelial cells and uses thereof
RU2530561C2 (en) 2007-11-05 2014-10-10 Медиммун, Ллк Method of treating scleroderma
RU2503460C2 (en) 2007-11-07 2014-01-10 Дженентек Инк. Using antimicrobial polypeptide for treating microbial disorders
JP5580205B2 (en) 2007-11-19 2014-08-27 セレラ コーポレーション Lung cancer markers and their use
JP5547083B2 (en) 2007-11-20 2014-07-09 アンブルックス,インコーポレイテッド Modified insulin polypeptides and their use
WO2009070642A1 (en) * 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
US8426153B2 (en) 2007-12-03 2013-04-23 Carnegie Mellon University Linked peptides fluorogenic biosensors
RU2570559C2 (en) 2007-12-17 2015-12-10 Пфайзер Лимитед Treatment of interstitial cystitis
CA2706502C (en) 2007-12-18 2018-08-07 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
CN101932333A (en) 2007-12-26 2010-12-29 瓦西尼斯公司 Anti-c 35 antibody combination therapies and method
GB0800277D0 (en) 2008-01-08 2008-02-13 Imagination Tech Ltd Video motion compensation
US8821863B2 (en) 2008-01-11 2014-09-02 Gene Techno Science Co., Ltd. Humanized anti-α 9 integrin antibodies and the uses thereof
BRPI0907046A2 (en) 2008-01-18 2015-07-28 Medimmune Llc Engineered cysteine antibody, isolated nucleic acid, vector, host cell, antibody conjugate, pharmaceutical composition, methods of detecting cancer, autoimmune, inflammatory or infectious disorders in an individual and inhibiting proliferation of a target cell
MX2010008632A (en) 2008-02-08 2010-08-30 Ambrx Inc Modified leptin polypeptides and their uses.
AU2009212273B2 (en) 2008-02-08 2014-07-31 Astrazeneca Ab Anti-IFNAR1 antibodies with reduced Fc ligand affinity
CN107296957A (en) 2008-03-04 2017-10-27 梯瓦制药国际有限责任公司 The method for treating chronic ache
MX2010009724A (en) 2008-03-04 2010-09-28 Pfizer Ltd Methods of treating inflammatory pain.
WO2009111644A2 (en) * 2008-03-05 2009-09-11 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating pancreatic cancer
AU2009224113B2 (en) * 2008-03-12 2013-02-21 Otago Innovation Limited Biomarkers
US8507209B2 (en) 2008-03-12 2013-08-13 Otago Innovation Limited Biomarkers
WO2009114815A1 (en) 2008-03-13 2009-09-17 Dyax Corp Libraries of genetic packages comprising novel hc cdr3 designs
US20110020368A1 (en) 2008-03-25 2011-01-27 Nancy Hynes Treating cancer by down-regulating frizzled-4 and/or frizzled-1
EP2271770B1 (en) * 2008-03-31 2018-08-22 Genentech, Inc. Compositions and methods for treating and diagnosing asthma
AU2009231991B2 (en) 2008-04-02 2014-09-25 Macrogenics, Inc. HER2/neu-specific antibodies and methods of using same
EP2252631B1 (en) 2008-04-02 2016-04-13 MacroGenics, Inc. Bcr-complex-specific antibodies and methods of using same
WO2009126934A2 (en) 2008-04-11 2009-10-15 Seattle Genetics, Inc. Detection and tratment of pancreatic, ovarian and other cancers
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
WO2009132287A2 (en) * 2008-04-24 2009-10-29 Dyax Corp. Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
AU2009238897B2 (en) 2008-04-24 2015-03-19 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof
US20090269786A1 (en) * 2008-04-25 2009-10-29 The Board Of Trustees Of The University Of Illinois RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies
PL2282773T3 (en) 2008-05-02 2014-08-29 Seattle Genetics Inc Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
ES2605471T3 (en) 2008-05-06 2017-03-14 Genentech, Inc. Variants of matured affinity CRIg
SI2279004T1 (en) * 2008-05-16 2015-05-29 F. Hoffmann-La Roche Ag Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
US8093018B2 (en) 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
WO2009148896A2 (en) 2008-05-29 2009-12-10 Nuclea Biotechnologies, LLC Anti-phospho-akt antibodies
WO2010033279A2 (en) 2008-06-04 2010-03-25 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
JP5560270B2 (en) 2008-07-08 2014-07-23 オンコメッド ファーマシューティカルズ インコーポレイテッド NOTCH binding agents and antagonists and methods of use thereof
NZ591235A (en) * 2008-07-23 2012-07-27 Ambrx Inc Modified bovine g-csf polypeptides comprising non natural amino acid and their uses treating infections such as mastitis
US9182406B2 (en) * 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
US8652843B2 (en) 2008-08-12 2014-02-18 Oncomed Pharmaceuticals, Inc. DDR1-binding agents and methods of use thereof
EA026110B1 (en) 2008-08-14 2017-03-31 Сефалон Острэйлиа Пти Лтд. Anti-il-12/il-23 antibodies
TWI445716B (en) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Pcsk9 antagonists
US20100081575A1 (en) * 2008-09-22 2010-04-01 Robert Anthony Williamson Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules
AU2009293640A1 (en) * 2008-09-22 2010-03-25 Calmune Corporation Methods and vectors for display of 2G12 -derived domain exchanged antibodies
NO2337846T3 (en) 2008-09-26 2018-06-16
BRPI0919473A2 (en) 2008-09-26 2017-08-29 Oncomed Pharm Inc FRIZZLED BINDING AGENTS AND THEIR USES
NZ592250A (en) 2008-09-26 2012-11-30 Lilly Co Eli Modified animal erythropoietin polypeptides and their uses
WO2010047515A2 (en) 2008-10-20 2010-04-29 광주과학기술원 Bipodal peptide binder
US20120251502A1 (en) 2008-10-24 2012-10-04 The Government of the US as Represented by the Secretary of the Dept. of health Human Ebola Virus Species and Compositions and Methods Thereof
JP5848607B2 (en) 2008-10-31 2016-01-27 ヤンセン バイオテツク,インコーポレーテツド Scaffold compositions, methods and uses based on fibronectin type 3 domains
US9221902B2 (en) 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
DK2894165T3 (en) 2008-11-10 2023-03-20 Alexion Pharma Inc Methods and compositions for treating complement-related disorders
SI2356462T1 (en) 2008-11-11 2017-05-31 The Regents Of The University Of Michigan Anti-cxcr1 compositions and methods
CN102438652B (en) 2008-11-12 2014-08-13 米迪缪尼有限公司 Antibody formulation
ATE523603T1 (en) * 2008-11-21 2011-09-15 Chimera Biotec Gmbh CONJUGATE COMPLEXES FOR ANALYTE DETECTION
DK2752189T3 (en) 2008-11-22 2017-01-16 Hoffmann La Roche APPLICATION OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMOTHERY TO TREAT CANCER CANCER
NZ593314A (en) * 2008-12-04 2013-03-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2740806C (en) 2008-12-09 2021-07-20 Bryan Irving Anti-pd-l1 antibodies and their use to enhance t-cell function
MX2011006416A (en) 2008-12-19 2011-07-12 Macrogenics Inc Covalent diabodies and uses thereof.
BRPI0918211A2 (en) 2008-12-23 2015-12-08 Genentech Inc patient identification methods, patient responsiveness prediction methods, monitoring methods, therapeutic efficacy optimization methods, and p1gf expression level detection kit
AU2009334498A1 (en) 2008-12-31 2011-07-21 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
GB0900425D0 (en) 2009-01-12 2009-02-11 Ucb Pharma Sa Biological products
WO2010082134A1 (en) 2009-01-14 2010-07-22 Iq Therapeutics Bv Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
WO2010085510A1 (en) 2009-01-20 2010-07-29 Zadeh Homayoun H Antibody mediated osseous regeneration
AU2010207552A1 (en) 2009-01-21 2011-09-01 Oxford Biotherapeutics Ltd. PTA089 protein
WO2010088393A2 (en) * 2009-01-28 2010-08-05 Antigen Express, Inc. Li-kay hybrid peptides that modulate the immune response to influenza
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
WO2010093993A2 (en) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
CN102596992B (en) 2009-02-12 2015-09-09 詹森生物科技公司 Based on the holder combination thing of III type fibronectin domain, method and purposes
AR075504A1 (en) 2009-02-17 2011-04-06 Ucb Pharma Sa MOLECULES OF ANTIBODIES THAT HAVE SPECIFICITY FOR THE HUMAN OX40
EP2398860B1 (en) 2009-02-18 2013-11-20 Carnegie Mellon University Quenched dendrimeric dyes for fluorescence detection
US20110311521A1 (en) 2009-03-06 2011-12-22 Pico Caroni Novel therapy for anxiety
EP2406285B1 (en) 2009-03-10 2016-03-09 Gene Techno Science Co., Ltd. Generation, expression and characterization of the humanized k33n monoclonal antibody
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
KR101523127B1 (en) 2009-03-25 2015-05-26 제넨테크, 인크. Novel anti-alpha5beta1 antibodies and uses thereof
EP2241323A1 (en) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W and brain cancers
MX2011011075A (en) 2009-04-20 2011-11-04 Oxford Biotherapeutics Ltd Antibodies specific to cadherin-17.
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
KR101224468B1 (en) 2009-05-20 2013-01-23 주식회사 파멥신 Bispecific antibody having a novel form and use thereof
CA2762837C (en) * 2009-05-20 2021-08-03 Novimmune S.A. Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
US8680055B2 (en) 2009-06-03 2014-03-25 University Of Southern California Methods for decreasing steroidogenesis in prostate cancer cells
US8748386B2 (en) 2009-06-10 2014-06-10 New York University Immunological targeting of pathological Tau proteins
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
AU2010270979B2 (en) 2009-06-22 2015-04-23 Medimmune, Llc Engineered Fc regions for site-specific conjugation
US20110027275A1 (en) 2009-07-31 2011-02-03 Napoleone Ferrara Inhibition of tumor metastasis
PT2464725T (en) 2009-08-11 2020-05-21 Hoffmann La Roche Production of proteins in glutamine-free cell culture media
WO2011020079A1 (en) * 2009-08-13 2011-02-17 Calmune Corporation Antibodies against human respiratory syncytial virus (rsv) and methods of use
CN102573909A (en) 2009-08-15 2012-07-11 霍夫曼-拉罗奇有限公司 Anti-angiogenesis therapy for the treatment of previously treated breast cancer
EP2292266A1 (en) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Treating cancer by modulating copine III
CN102740884A (en) 2009-08-28 2012-10-17 瑞纳神经科学公司 Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
US20110059111A1 (en) 2009-09-01 2011-03-10 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
EP2478136A4 (en) * 2009-09-14 2013-09-25 Dyax Corp Libraries of genetic packages comprising novel hc cdr3 designs
MX2012002909A (en) 2009-09-17 2012-04-19 Hoffmann La Roche Methods and compositions for diagnostics use in cancer patients.
US20120244170A1 (en) 2009-09-22 2012-09-27 Rafal Ciosk Treating cancer by modulating mex-3
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
AR078470A1 (en) 2009-10-02 2011-11-09 Sanofi Aventis ANTIBODIES THAT SPECIFICALLY JOIN THE EPHA2 RECEIVER
WO2011047083A1 (en) 2009-10-13 2011-04-21 Oxford Biotherapeutics Ltd. Antibodies against epha10
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
DK2488204T3 (en) 2009-10-16 2016-06-06 Oncomed Pharm Inc Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents
CA2778442A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
US8734798B2 (en) 2009-10-27 2014-05-27 Ucb Pharma S.A. Function modifying NAv 1.7 antibodies
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
US20120282177A1 (en) 2009-11-02 2012-11-08 Christian Rohlff ROR1 as Therapeutic and Diagnostic Target
US20120277144A1 (en) 2009-11-04 2012-11-01 Henricus Johannes Duckers Novel compounds for modulating neovascularisation and methods of treatment using these compounds
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
MX2012006072A (en) 2009-11-30 2012-07-23 Genentech Inc Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 ).
WO2011070443A1 (en) 2009-12-09 2011-06-16 Institut National De La Sante Et De La Recherche Medicale Monoclonal antibodies that bind b7h6 and uses thereof
WO2011084496A1 (en) * 2009-12-16 2011-07-14 Abbott Biotherapeutics Corp. Anti-her2 antibodies and their uses
CN104017063A (en) 2009-12-21 2014-09-03 Ambrx公司 Modified porcine somatotropin polypeptides and their uses
CN107674121A (en) 2009-12-21 2018-02-09 Ambrx 公司 Bovine somatotropin polypeptide and its purposes by modification
WO2011079283A1 (en) * 2009-12-23 2011-06-30 Bioalliance C.V. Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same
US9180186B2 (en) 2010-01-11 2015-11-10 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-CD200 antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
CN102958534B (en) 2010-01-13 2014-11-05 昂考梅德药品有限公司 Notch1 binding agents and methods of use thereof
CA2789629A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc. Cd20 antibodies and uses thereof
US10393754B2 (en) 2010-02-17 2019-08-27 Cedars-Sinai Medical Center Methods of diagnosing and treating heart failure
SG183333A1 (en) 2010-02-18 2012-09-27 Genentech Inc Neuregulin antagonists and use thereof in treating cancer
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
BR112012020373A8 (en) 2010-02-23 2018-01-02 Genentech Inc isolated antibody, cell, isolated nucleic acid, method of identification, cell proliferation inhibition, therapeutic treatment, determination of the presence of a tat419 protein, diagnosis of the presence of cancer and distribution of cytotoxic agent
KR101839161B1 (en) 2010-02-23 2018-03-16 제넨테크, 인크. Anti-angiogenesis therapy for the treatment of ovarian cancer
SA114360064B1 (en) 2010-02-24 2016-01-05 رينات نيوروساينس كوربوريشن Antagonist anti-il-7 receptor antibodies and methods
TWI672318B (en) 2010-02-24 2019-09-21 美商免疫遺傳股份有限公司 Folate receptor 1 antibodies and immunoconjugates and uses thereof
US20130004519A1 (en) 2010-03-05 2013-01-03 Ruth Chiquet-Ehrismann Smoci, tenascin-c and brain cancers
AU2011225716A1 (en) 2010-03-11 2012-09-27 Pfizer Inc. Antibodies with pH dependent antigen binding
EP2544719B1 (en) 2010-03-12 2019-07-03 Debiopharm International S.A. Cd37-binding molecules and immunoconjugates thereof
EP2547359B1 (en) 2010-03-15 2016-03-09 The Board of Trustees of the University of Illionis Inhibitors of beta integrin-g protein alpha subunit binding interactions
EP2548030B1 (en) * 2010-03-18 2015-05-27 Cornell University Engineering correctly folded antibodies using inner membrane display of twin-arginine translocation intermediates
BR112012022044A2 (en) 2010-03-24 2020-08-25 Genentech Inc ''antibody, immunoconjugate, pharmaceutical formulation, antibody use, treatment method, isolated bispecific antibody and host cell''.
WO2011117653A1 (en) 2010-03-25 2011-09-29 Ucb Pharma S.A. Disulfide stabilized dvd-lg molecules
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
EP2561076A1 (en) 2010-04-19 2013-02-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulating xrn1
EP2380909A1 (en) 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PTK-7 protein involved in breast cancer
ES2552954T3 (en) 2010-04-30 2015-12-03 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for the use of antibodies
CN102958941A (en) 2010-05-03 2013-03-06 霍夫曼-拉罗奇有限公司 Compositions and methods for the diagnosis and treatment of tumor
ES2606017T3 (en) 2010-05-03 2017-03-17 University Of Rochester Passive anti-glucosaminidase immunization for Staphylococcus aureus infections
EP2569335B1 (en) 2010-05-14 2018-08-22 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
EP2577309B1 (en) 2010-05-25 2016-11-23 Carnegie Mellon University Targeted probes of cellular physiology
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
US20130089538A1 (en) 2010-06-10 2013-04-11 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh Treating cancer by modulating mammalian sterile 20-like kinase 3
CA2794731C (en) 2010-06-18 2019-03-19 Genentech, Inc. Anti-axl antibodies and methods of use
NZ603488A (en) 2010-07-09 2015-02-27 Crucell Holland Bv Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
WO2012006633A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Chimeric clotting factors
KR20130120439A (en) 2010-07-09 2013-11-04 제넨테크, 인크. Anti-neuropilin antibodies and methods of use
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
US9354228B2 (en) 2010-07-16 2016-05-31 Adimab, Llc Antibody libraries
WO2012012469A2 (en) 2010-07-19 2012-01-26 Otago Innovation Limited Signal biomarkers
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
WO2012012750A1 (en) 2010-07-23 2012-01-26 Trustees Of Boston University ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY
WO2012015758A2 (en) 2010-07-30 2012-02-02 Saint Louis University Methods of treating pain
CN103153341B (en) 2010-08-03 2015-05-27 霍夫曼-拉罗奇有限公司 Chronic lymphocytic leukemia (Cll) biomarkers
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
KR20130049196A (en) 2010-08-05 2013-05-13 에프. 호프만-라 로슈 아게 Anti-mhc antibody anti-viral cytokine fusion protein
MX2013001336A (en) 2010-08-13 2013-03-08 Roche Glycart Ag Anti-tenascin-c a2 antibodies and methods of use.
US9011847B2 (en) 2010-08-13 2015-04-21 Roche Glycart, AG Anti-FAP antibodies and methods of use
WO2012024452A2 (en) 2010-08-17 2012-02-23 Ambrx, Inc. Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
ES2555864T3 (en) 2010-08-19 2016-01-11 F. Hoffmann-La Roche Ag Assay for measuring antibody binding to a therapeutic monoclonal antibody
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
KR20130103734A (en) 2010-08-31 2013-09-24 제넨테크, 인크. Biomarkers and methods of treatment
WO2012032143A1 (en) 2010-09-10 2012-03-15 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Phosphorylated twist1 and metastasis
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
TWI480288B (en) 2010-09-23 2015-04-11 Lilly Co Eli Formulations for bovine granulocyte colony stimulating factor and variants thereof
KR20140008308A (en) 2010-10-29 2014-01-21 이뮤노젠 아이엔씨 Novel egfr-binding molecules and immunoconjugates thereof
CN105399831A (en) 2010-10-29 2016-03-16 伊缪诺金公司 Non-antagonistic egfr-binding molecules and immunoconjugates thereof
WO2012064836A1 (en) 2010-11-10 2012-05-18 Genentech, Inc. Methods and compositions for neural disease immunotherapy
US20140093506A1 (en) 2010-11-15 2014-04-03 Marc Buehler Anti-fungal-agents
EP2640831A1 (en) 2010-11-17 2013-09-25 Sea Lane Biotechnologies,llc. Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
CN103619879A (en) 2010-12-01 2014-03-05 奥尔德生物控股有限责任公司 Anti-ngf compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
MX371228B (en) 2010-12-16 2020-01-10 Genentech Inc Diagnosis and treatments relating to th2 inhibition.
EP2655418B1 (en) 2010-12-20 2017-10-04 F. Hoffmann-La Roche AG Anti-mesothelin antibodies and immunoconjugates
WO2012087943A2 (en) 2010-12-20 2012-06-28 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
CN103429261A (en) 2010-12-22 2013-12-04 塞法隆澳大利亚股份有限公司 Modified antibody with improved half-life
BR112013015687A2 (en) 2010-12-22 2016-10-11 Genentech Inc anti-pcsk9 antibody or an antibody fragment that binds to pcsk9, isolated nucleic acid, vector, host cell, method for making an anti-pcsk9 antibody, pharmaceutical composition, method of lowering ldl cholesterol level in a subject and method of treatment of hypercholesterolemia in a subject
EP2661282A1 (en) 2011-01-03 2013-11-13 F.Hoffmann-La Roche Ag A pharmaceutical composition of a complex of an anti-dig antibody and digoxigenin that is conjugated to a peptide
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
AU2012206431B2 (en) 2011-01-14 2015-04-30 UCB Biopharma SRL Antibody molecules which bind IL-17A and IL-17F
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
WO2012106634A1 (en) 2011-02-03 2012-08-09 Alexion Pharmaceuticals, Inc. Use of an anti-cd200 antibody for prolonging the survival of allografts
WO2012129347A1 (en) 2011-03-21 2012-09-27 Biodesy, Llc Classification of kinase inhibitors using nonlinear optical techniques
SG10201602394QA (en) 2011-03-29 2016-05-30 Roche Glycart Ag Antibody FC Variants
MX342240B (en) 2011-04-07 2016-09-21 Genentech Inc Anti-fgfr4 antibodies and methods of use.
US10352936B2 (en) 2011-04-14 2019-07-16 Apoplogic Pharmaceuticals, Inc. Use of tumor Fas expression to determine response to anti-cancer therapy
EP2699264B1 (en) 2011-04-20 2018-03-14 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
JP6038121B2 (en) 2011-04-21 2016-12-07 ガーバン インスティテュート オブ メディカル リサーチ Modified variable domain molecules and methods for their production and use B
JP2014518624A (en) 2011-05-12 2014-08-07 ザ・ジョンズ・ホプキンス・ユニバーシティー Assay reagent for neurogranin diagnostic kit
US8679767B2 (en) 2011-05-12 2014-03-25 Genentech, Inc. Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
EA030462B1 (en) 2011-05-16 2018-08-31 Дженентек, Инк. Fgfr1 agonists and methods of use thereof
NZ618016A (en) 2011-05-21 2015-05-29 Macrogenics Inc Deimmunized serum-binding domains and their use for extending serum half-life
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
WO2012168259A1 (en) 2011-06-06 2012-12-13 Novartis Forschungsstiftung, Zweigniederlassung Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
JP6058645B2 (en) 2011-06-10 2017-01-11 メディミューン,エルエルシー Anti-Pseudomonas Psl binding molecules and uses thereof
AU2012267786B2 (en) 2011-06-10 2017-08-03 Oregon Health & Science University CMV glycoproteins and recombinant vectors
MY166974A (en) 2011-06-15 2018-07-27 Hoffmann La Roche Anti-human epo receptor antibodies and method of use
MY160826A (en) 2011-06-28 2017-03-31 Berlin-Chemie Ag Antibodies to bone marrow stromal antigen 1
PT2726094T (en) 2011-06-28 2017-02-10 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
CN103781493A (en) 2011-06-30 2014-05-07 霍夫曼-拉罗奇有限公司 Anti-c-met antibody formulations
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
MX2014000578A (en) 2011-07-14 2014-04-30 Pfizer Treatment with anti-pcsk9 antibodies.
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
CN106167526A (en) 2011-07-15 2016-11-30 昂考梅德药品有限公司 RSPO bonding agent and its application
US20130022551A1 (en) 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
CN103842030B (en) 2011-08-01 2018-07-31 霍夫曼-拉罗奇有限公司 Use the method for PD-1 axis binding antagonists and mek inhibitor treating cancer
CA2845536A1 (en) 2011-08-15 2013-02-21 Amplimmune, Inc. Anti-b7-h4 antibodies and their uses
CN103890007A (en) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 Neuregulin antibodies and uses thereof
EP2747781B1 (en) 2011-08-23 2017-11-15 Roche Glycart AG Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
RU2014109038A (en) 2011-08-23 2015-09-27 Рош Гликарт Аг ANTIBODIES TO CHONDROITINSULFATE PROTEOGLYCAN MELANOMA
RU2617970C2 (en) 2011-08-23 2017-04-28 Рош Гликарт Аг ANTIBODIES WITHOUT Fc-FRAGMENT INCLUDING TWO FAB-FRAGMENT AND METHODS OF APPLICATION
EP2753697A1 (en) 2011-09-05 2014-07-16 ETH Zürich Biosynthetic gene cluster for the production of peptide/protein analogues
ES2908046T3 (en) 2011-09-09 2022-04-27 Medimmune Ltd Anti-siglec-15 antibodies and uses thereof.
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
CN103930781A (en) 2011-09-15 2014-07-16 霍夫曼-拉罗奇有限公司 Methods of promoting differentiation
KR20140064971A (en) 2011-09-19 2014-05-28 제넨테크, 인크. Combination treatments comprising c-met antagonists and b-raf antagonists
PL3485903T3 (en) 2011-09-23 2023-06-12 Mereo Biopharma 5, Inc. Vegf/dll4 binding agents and uses thereof
CA2849011A1 (en) 2011-10-05 2013-04-11 Genentech, Inc. Methods of treating liver conditions using notch2 antagonists
CA2851261A1 (en) 2011-10-06 2013-04-11 The Board Of Trustees Of The University Of Illinois Myosin binding protein-c for use in methods relating to diastolic heart failure
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
JP6190813B2 (en) 2011-10-14 2017-08-30 ジェネンテック, インコーポレイテッド Zymogen activator
EP2766028B1 (en) 2011-10-14 2017-08-16 F. Hoffmann-La Roche AG Peptide inhibitors of bace1
MX2014004022A (en) 2011-10-14 2014-04-30 Genentech Inc ANTI-HtrA1 ANTIBODIES AND METHODS OF USE.
RU2014119426A (en) 2011-10-15 2015-11-20 Дженентек, Инк. WAYS OF APPLICATION OF SCD1 ANTAGONISTS
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
BR112014009953A2 (en) 2011-10-28 2017-12-05 Genentech Inc tumor growth inhibition method, melanoma treatment, industrialized article and use
AU2012332593B2 (en) 2011-11-01 2016-11-17 Bionomics, Inc. Anti-GPR49 antibodies
WO2013067057A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
EP2773373B1 (en) 2011-11-01 2018-08-22 Bionomics, Inc. Methods of blocking cancer stem cell growth
CN104053671A (en) 2011-11-01 2014-09-17 生态学有限公司 Antibodies and methods of treating cancer
CA2853943C (en) 2011-11-02 2015-12-08 University Of Rochester Anti-glucosaminidase passive immunization for staphylococcus aureus infections
AU2012336028A1 (en) 2011-11-07 2014-06-26 Medimmune, Llc Combination therapies using anti- Pseudomonas Psl and PcrV binding molecules
US20140294732A1 (en) 2011-11-08 2014-10-02 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Early diagnostic of neurodegenerative diseases
US20140314787A1 (en) 2011-11-08 2014-10-23 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Treatment for neurodegenerative diseases
WO2013071233A1 (en) 2011-11-10 2013-05-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for detecting infectious agents and a novel virus detected thereby
LT2776466T (en) 2011-11-11 2017-11-27 Ucb Biopharma Sprl Albumin binding antibodies and binding fragments thereof
JP5936702B2 (en) 2011-11-11 2016-06-22 ライナット ニューロサイエンス コーポレイション Antibodies specific for TROP-2 and uses thereof
KR20140105765A (en) 2011-11-21 2014-09-02 이뮤노젠 아이엔씨 Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
RU2014124842A (en) 2011-11-21 2015-12-27 Дженентек, Инк. CLEANING ANTI-C-MET ANTIBODIES
DK2797957T3 (en) 2011-11-23 2019-09-23 Medimmune Llc BINDING MOLECULES SPECIFIC TO HER3 AND APPLICATIONS THEREOF
EP2788024A1 (en) 2011-12-06 2014-10-15 F.Hoffmann-La Roche Ag Antibody formulation
SG11201403223PA (en) 2011-12-22 2014-07-30 Hoffmann La Roche Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
CN107119073A (en) 2011-12-22 2017-09-01 弗·哈夫曼-拉罗切有限公司 The combination of expression vector element, new Cells for production production method and its purposes in restructuring produces polypeptide
RU2625033C2 (en) 2011-12-22 2017-07-11 Ф. Хоффманн-Ля Рош Аг Display system based on full length antibody for eukaryotic cells, and its application
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
EP3539982A3 (en) 2011-12-23 2020-01-15 Pfizer Inc Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
WO2013102825A1 (en) 2012-01-02 2013-07-11 Novartis Ag Cdcp1 and breast cancer
EP2802606B1 (en) 2012-01-10 2018-04-25 Biogen MA Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
CN104168920A (en) 2012-01-18 2014-11-26 霍夫曼-拉罗奇有限公司 Methods of using FGF19 modulators
TW201335187A (en) 2012-01-18 2013-09-01 Genentech Inc Anti-LRP5 antibodies and methods of use
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
EP3575794A1 (en) 2012-02-10 2019-12-04 Seattle Genetics, Inc. Detection and treatment of cd30+ cancers
JP6545959B2 (en) 2012-02-11 2019-07-17 ジェネンテック, インコーポレイテッド R-Spondin rearrangement and method of using the same
SI2814842T1 (en) 2012-02-15 2018-10-30 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
EP2814587B1 (en) 2012-02-15 2018-05-02 F.Hoffmann-La Roche Ag Fc-receptor based affinity chromatography
JP6411218B2 (en) 2012-02-15 2018-10-24 ノヴォ ノルディスク アー/エス Antibodies that bind to and block trigger receptor 1 (TREM-1) expressed in bone marrow cells
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
PE20141909A1 (en) 2012-03-13 2014-11-29 Hoffmann La Roche COMBINED THERAPY FOR THE TREATMENT OF OVARIAN CANCER
RU2014141018A (en) 2012-03-16 2016-05-10 Ф. Хоффманн-Ля Рош Аг METHODS OF TREATING MELANOMA WITH CANCER INHIBITORS
KR20140142293A (en) 2012-03-16 2014-12-11 제넨테크, 인크. Engineered conformationally-stabilized proteins
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
DK2828282T3 (en) 2012-03-20 2018-03-05 Otago Innovation Ltd Biomarkers
WO2013139956A1 (en) 2012-03-22 2013-09-26 Thrombogenics Nv Antibodies abrogating cell binding to lactadherin
WO2013142808A1 (en) 2012-03-23 2013-09-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pathogenic phlebovirus isolates and compositions and methods of use
MX2014011500A (en) 2012-03-27 2014-12-05 Genentech Inc Diagnosis and treatments relating to her3 inhibitors.
US20150266961A1 (en) 2012-03-29 2015-09-24 Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
AR090549A1 (en) 2012-03-30 2014-11-19 Genentech Inc ANTI-LGR5 AND IMMUNOCATE PLAYERS
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
MX2014012843A (en) 2012-04-24 2017-01-23 Thrombogenics Nv Anti-pdgf-c antibodies.
EP2841951B1 (en) 2012-04-25 2019-12-11 Biodesy, Inc. Methods for detecting allosteric modulators of proteins
TW201402609A (en) 2012-05-01 2014-01-16 Genentech Inc Anti-PMEL17 antibodies and immunoconjugates
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
JP6122948B2 (en) 2012-05-15 2017-04-26 モルフォテック, インコーポレイテッド Methods for the treatment of gastric cancer
EP2852840B1 (en) 2012-05-23 2019-10-09 F.Hoffmann-La Roche Ag Selection method for therapeutic agents
KR102129636B1 (en) 2012-05-31 2020-07-03 제넨테크, 인크. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
CA2875980A1 (en) 2012-06-06 2013-12-12 Oncomed Pharmaceuticals, Inc. Binding agents that modulate the hippo pathway and uses thereof
JP2015530867A (en) 2012-06-15 2015-10-29 ジェネンテック, インコーポレイテッド Anti-PCSK9 antibodies, formulations, dosing and methods of use
ES2631608T3 (en) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Env-glycoprotein variant of HIV-1
EP2867674B1 (en) 2012-06-28 2018-10-10 UCB Biopharma SPRL A method for identifying compounds of therapeutic interest
WO2014001482A1 (en) 2012-06-29 2014-01-03 Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research Treating diseases by modulating a specific isoform of mkl1
PL2869837T3 (en) 2012-07-04 2017-03-31 F.Hoffmann-La Roche Ag Anti-theophylline antibodies and methods of use
KR20150030755A (en) 2012-07-04 2015-03-20 에프. 호프만-라 로슈 아게 Anti-biotin antibodies and methods of use
PL2869848T3 (en) 2012-07-04 2017-04-28 F.Hoffmann-La Roche Ag Covalently linked antigen-antibody conjugates
CN110042114A (en) 2012-07-05 2019-07-23 弗·哈夫曼-拉罗切有限公司 Expression and excretory system
WO2014006114A1 (en) 2012-07-05 2014-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
US20150224190A1 (en) 2012-07-06 2015-08-13 Mohamed Bentires-Alj Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
CN104540524A (en) 2012-07-09 2015-04-22 基因泰克公司 Immunoconjugates comprising anti-CD22 antibodies
AU2013288932A1 (en) 2012-07-09 2014-12-11 Genentech, Inc. Immunoconjugates comprising anti - CD79b antibodies
CA2874904A1 (en) 2012-07-09 2014-01-16 Genentech, Inc. Immunoconjugates comprising anti-cd22 antibodies
IN2014DN10652A (en) 2012-07-09 2015-09-11 Genentech Inc
MA37794B1 (en) 2012-07-13 2017-07-31 Roche Glycart Ag Anti-vegf / anti-ang-2 bispecific antibodies and their use in the treatment of ocular vascular pathologies
US9297806B2 (en) 2012-08-01 2016-03-29 The Johns Hopkins University 5-hydroxymethylcytosine in human cancer
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
WO2014025813A1 (en) 2012-08-07 2014-02-13 Genentech, Inc. Combination therapy for the treatment of glioblastoma
CN104755498B (en) 2012-08-31 2019-06-18 伊缪诺金公司 For detecting the diagnostic assay and kit of folacin receptor 1
AR092745A1 (en) 2012-10-01 2015-04-29 Univ Pennsylvania COMPOSITIONS THAT INCLUDE AN ANTI-FAP UNION DOMAIN AND METHODS TO MAKE WHITE IN STROMAL CELLS FOR THE TREATMENT OF CANCER
MX2015003616A (en) 2012-10-08 2015-06-05 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use.
BR112015008118A2 (en) 2012-10-12 2017-12-05 Brigham & Womens Hospital Inc immune response booster
JP2015536933A (en) 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Methods of treating neuroendocrine tumors using Wnt pathway binding agents
WO2014071018A1 (en) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist
SG11201502989XA (en) 2012-11-05 2015-05-28 Genzyme Corp Compositions and methods for treating proteinopathies
US9725512B2 (en) 2012-11-08 2017-08-08 Hoffmann-La Roche Inc. HER3 antibodies binding to the beta-hairpin of HER3
CN104968367B (en) 2012-11-13 2018-04-13 弗·哈夫曼-拉罗切有限公司 Antihemagglutinin antibody and application method
WO2014085821A2 (en) 2012-11-30 2014-06-05 The Regents Of The University Of California Fully human antibodies and fragments recognizing human c-met
RU2691428C2 (en) 2012-12-21 2019-06-13 МЕДИММЬЮН, ЭлЭлСи Antibodies to h7cr
AU2013364065B2 (en) 2012-12-21 2018-10-04 Altrubio Inc. Hydrophilic self-immolative linkers and conjugates thereof
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
AU2013202668B2 (en) 2012-12-24 2014-12-18 Adelaide Research & Innovation Pty Ltd Inhibition of cancer growth and metastasis
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
CN105073195A (en) 2013-02-04 2015-11-18 昂科梅德制药有限公司 Methods and monitoring of treatment with a Wnt pathway inhibitor
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
WO2014129895A1 (en) 2013-02-19 2014-08-28 Stichting Vu-Vumc Means and method for increasing the sensitivity of cancers for radiotherapy
JP2016509045A (en) 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト How to treat cancer and prevent drug resistance
CN105247072B (en) 2013-02-25 2019-10-15 基因泰克公司 The method and composition of detection and treatment drug resistance AKT mutant
RU2015140921A (en) 2013-02-26 2017-04-03 Роше Гликарт Аг ANTIBODIES TO MCSP
CA2902263A1 (en) 2013-03-06 2014-09-12 Genentech, Inc. Methods of treating and preventing cancer drug resistance
EP2968565A2 (en) 2013-03-14 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
KR20150127199A (en) 2013-03-14 2015-11-16 제넨테크, 인크. Anti-b7-h4 antibodies and immunoconjugates
CA2903480A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
JP6456356B2 (en) 2013-03-15 2019-01-23 ジェネンテック, インコーポレイテッド IL-22 polypeptides and IL-22 Fc fusion proteins and methods of use
RU2661111C2 (en) 2013-03-15 2018-07-11 Ац Иммуне С.А. Anti-tau antibodies and methods of use
EP2970471A2 (en) 2013-03-15 2016-01-20 F. Hoffmann-La Roche AG Anti-crth2 antibodies and their use
EP2972373B1 (en) 2013-03-15 2019-10-09 F.Hoffmann-La Roche Ag Biomarkers and methods of treating pd-1 and pd-l1 related conditions
SG11201507432XA (en) 2013-03-15 2015-10-29 Abbvie Inc Antibody drug conjugate (adc) purification
EA201890895A1 (en) 2013-03-15 2019-02-28 Зинджения, Инк. MULTIVALENT AND MONOVALENT MULTIS-SPECIFIC COMPLEXES AND THEIR APPLICATION
CN105339001A (en) 2013-03-15 2016-02-17 基因泰克公司 Methods of treating cancer and preventing cancer drug resistance
JP6382935B2 (en) 2013-03-15 2018-08-29 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー Anti-EGFR antibody drug complex preparation
AR095527A1 (en) 2013-03-15 2015-10-21 Biogen Idec Inc FC-FACTOR IX POLYPEPTIDE FORMULATIONS IX
WO2014151866A1 (en) 2013-03-15 2014-09-25 Genentech, Inc. Compositions and methods for diagnosis and treatment of hepatic cancers
SG11201508910WA (en) 2013-04-29 2015-11-27 Hoffmann La Roche Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
EA201501063A1 (en) 2013-04-29 2016-05-31 Ф. Хоффманн-Ля Рош Аг CONNECTING HUMAN FcRn MODIFIED ANTIBODIES AND METHODS OF THEIR APPLICATION
JP6618893B2 (en) 2013-04-29 2019-12-11 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Asymmetric antibodies with altered FC receptor binding and methods of use
US10501802B2 (en) 2013-04-30 2019-12-10 Universite De Montreal Biomarkers for acute myeloid leukemia
SG10201913751RA (en) 2013-05-06 2020-03-30 Scholar Rock Inc Compositions and methods for growth factor modulation
KR102293064B1 (en) 2013-05-20 2021-08-23 제넨테크, 인크. Anti-transferrin receptor antibodies and methods of use
BR112015029395A2 (en) 2013-05-24 2017-09-19 Medimmune Llc ANTI-B7-H5 ANTIBODIES AND THEIR USES
ES2891755T3 (en) 2013-06-06 2022-01-31 Pf Medicament Anti-C10orf54 antibodies and uses thereof
CN105636984A (en) 2013-06-13 2016-06-01 法斯特弗沃德制药有限公司 CD40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an TGR5-receptor agonist, an FXR agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
BR112016000853A2 (en) 2013-07-16 2017-12-12 Genentech Inc methods for treating or delaying, reducing or inhibiting cancer relapse or progression and the progression of an immune-related disease in an individual, to increase, improve or stimulate an immune response or function in an individual and kit.
KR101809072B1 (en) 2013-08-02 2017-12-14 화이자 인코포레이티드 Anti-cxcr4 antibodies and antibody-drug conjugates
ES2761587T3 (en) 2013-08-07 2020-05-20 Friedrich Miescher Institute For Biomedical Res New screening method for the treatment of Friedreich's ataxia
KR102553717B1 (en) 2013-08-26 2023-07-11 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 Nucleic acids encoding human antibodies to sialyl-lewis a
AU2014312086B2 (en) 2013-08-30 2020-03-12 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
WO2015042108A1 (en) 2013-09-17 2015-03-26 Genentech, Inc. Methods of using anti-lgr5 antibodies
US10414818B2 (en) 2013-09-27 2019-09-17 Roche Diagnostics Operations, Inc. Thermus thermophilus SlyD FKBP domain specific antibodies
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US20150132323A1 (en) 2013-10-08 2015-05-14 Immunogen, Inc. Anti-FOLR1 Immunoconjugate Dosing Regimens
KR20160068855A (en) 2013-10-11 2016-06-15 제넨테크, 인크. Nsp4 inhibitors and methods of use
BR112016008477A2 (en) 2013-10-18 2017-10-03 Genentech Inc BODIES, NUCLEIC ACID, HOST CELL, METHOD OF PRODUCING AN ANTIBODY, IMMUNOCONJUGATE, PHARMACEUTICAL FORMULATION AND USES OF THE ANTIBODY
CN105849280B (en) 2013-10-23 2020-11-06 豪夫迈·罗氏有限公司 Methods of diagnosing and treating eosinophilic disorders
WO2015066027A2 (en) 2013-10-28 2015-05-07 Dots Devices, Inc. Allergen detection
LT3071597T (en) 2013-11-21 2020-10-12 F. Hoffmann-La Roche Ag Anti-alpha-synuclein antibodies and methods of use
EP3074035B1 (en) 2013-11-25 2020-05-13 FameWave Ltd. Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy
WO2015085311A1 (en) 2013-12-07 2015-06-11 Case Western Reserve University Compositions and methods of treating thrombosis
BR112016013514B1 (en) 2013-12-13 2022-04-19 Stora Enso Oyj (Fi) MULTI-LAYER CARDBOARD
EP3080611B1 (en) 2013-12-13 2018-11-14 The General Hospital Corporation Soluble high molecular weight (hmw) tau species and applications thereof
WO2015089344A1 (en) 2013-12-13 2015-06-18 Genentech, Inc. Anti-cd33 antibodies and immunoconjugates
US20150190506A1 (en) 2013-12-17 2015-07-09 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
HUE050159T2 (en) 2013-12-17 2020-11-30 Genentech Inc Anti-cd3 antibodies and methods of use
MX2016007885A (en) 2013-12-17 2017-01-11 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody.
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
AU2014364601A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Methods of treating HER2-positive cancers using PD-1 axis binding antagonists and anti-HER2 antibodies
TWI670283B (en) 2013-12-23 2019-09-01 美商建南德克公司 Antibodies and methods of use
KR102344991B1 (en) 2013-12-24 2021-12-28 잔센파마슈티카엔.브이. Anti-vista antibodies and fragments
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
RU2694981C2 (en) 2014-01-03 2019-07-18 Ф. Хоффманн-Ля Рош Аг Covalently linked conjugates chelicar-antibody against chelicar and use thereof
CA2933384A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
BR112016014945A2 (en) 2014-01-03 2018-01-23 F. Hoffmann-La Roche Ag conjugate, pharmaceutical formulation and use
KR102381685B1 (en) 2014-01-06 2022-04-01 에프. 호프만-라 로슈 아게 Monovalent blood brain barrier shuttle modules
MX2016008539A (en) 2014-01-15 2016-09-26 Hoffmann La Roche Fc-region variants with modified fcrn- and maintained protein a-binding properties.
MX2016009515A (en) 2014-01-24 2016-10-26 Genentech Inc Methods of using anti-steap1 antibodies and immunoconjugates.
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
US11648335B2 (en) 2014-01-31 2023-05-16 Wake Forest University Health Sciences Organ/tissue decellularization, framework maintenance and recellularization
WO2015120187A1 (en) 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
JP6685912B2 (en) 2014-02-08 2020-04-22 ジェネンテック, インコーポレイテッド Alzheimer's disease treatment method
SG10201901076WA (en) 2014-02-08 2019-03-28 Genentech Inc Methods of treating alzheimer's disease
KR102030891B1 (en) 2014-02-12 2019-10-11 제넨테크, 인크. Anti-jagged1 antibodies and methods of use
KR20160124165A (en) 2014-02-21 2016-10-26 제넨테크, 인크. Anti-il-13/il-17 bispecific antibodies and uses thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
AU2015229035B2 (en) 2014-03-14 2021-08-05 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
US20170107294A1 (en) 2014-03-21 2017-04-20 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
EP4324481A2 (en) 2014-03-21 2024-02-21 Teva Pharmaceuticals International GmbH Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
JP2017516458A (en) 2014-03-24 2017-06-22 ジェネンテック, インコーポレイテッド Cancer treatment with c-met antagonist and correlation with HGF expression of c-met antagonist
AU2015241037B2 (en) 2014-03-31 2020-10-15 Genentech, Inc. Anti-OX40 antibodies and methods of use
RU2016142476A (en) 2014-03-31 2018-05-07 Дженентек, Инк. COMBINED THERAPY, INCLUDING ANTI-ANGIOGENESIS AGENTS AND AGONISTS BINDING OX40
SG10202107077QA (en) 2014-04-02 2021-07-29 Hoffmann La Roche Method for detecting multispecific antibody light chain mispairing
US9546214B2 (en) 2014-04-04 2017-01-17 Bionomics, Inc. Humanized antibodies that bind LGR5
MA50678A (en) 2014-04-08 2020-08-05 Boston Pharmaceuticals Inc IL-21 SPECIFIC BINDING MOLECULES AND THEIR USES
US10160812B2 (en) 2014-04-11 2018-12-25 Medimmune, Llc Bispecific HER2 antibodies
MX2016013635A (en) 2014-04-18 2017-02-02 Acceleron Pharma Inc Methods for increasing red blood cell levels and treating sickle-cell disease.
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
MX366359B (en) 2014-04-27 2019-07-05 Ccam Biotherapeutics Ltd Humanized antibodies against ceacam1.
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
US9753036B2 (en) 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
SG11201608953WA (en) 2014-04-30 2016-11-29 Pfizer Anti-ptk7 antibody-drug conjugates
MA51519A (en) 2014-05-05 2020-11-11 Regeneron Pharma HUMANIZED C5 AND C3 ANIMALS
WO2015175874A2 (en) 2014-05-16 2015-11-19 Medimmune, Llc Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
EP3145952A2 (en) 2014-05-22 2017-03-29 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
RU2016144405A (en) 2014-05-23 2018-06-26 Дженентек, Инк. MiT BIOMARKERS AND WAYS OF THEIR APPLICATION
SG10201912986PA (en) 2014-05-28 2020-02-27 Agenus Inc Anti-gitr antibodies and methods of use thereof
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
WO2015187811A2 (en) 2014-06-04 2015-12-10 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside gd2
CA2949982A1 (en) 2014-06-11 2015-12-17 Genentech, Inc. Anti-lgr5 antibodies and uses thereof
WO2015189816A1 (en) 2014-06-13 2015-12-17 Friedrich Miescher Institute For Biomedical Research New treatment against influenza virus
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
WO2015192111A1 (en) 2014-06-13 2015-12-17 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
CN106661124A (en) 2014-06-20 2017-05-10 荷商台医(有限合伙)公司 Anti-folate receptor aplha (FRA) antibody-drug conjugates and methods of using thereof
EP3157535A1 (en) 2014-06-23 2017-04-26 Friedrich Miescher Institute for Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
TW201623329A (en) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 Vaccines and monoclonal antibodies targeting truncated variants of osteopontin and uses thereof
WO2016001830A1 (en) 2014-07-01 2016-01-07 Friedrich Miescher Institute For Biomedical Research Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
CA2954687A1 (en) 2014-07-10 2016-01-14 Affiris Ag Substances and methods for the use in prevention and/or treatment in huntington's disease
BR112017000130A2 (en) 2014-07-11 2018-01-09 Genentech Inc method for mitigating toxicity associated with notch pathway inhibition and cancer treatment method
CN106460067A (en) 2014-07-14 2017-02-22 豪夫迈·罗氏有限公司 Diagnostic methods and compositions for treatment of glioblastoma
EP3169361B1 (en) 2014-07-15 2019-06-19 F.Hoffmann-La Roche Ag Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
PE20170192A1 (en) 2014-07-17 2017-03-16 Novo Nordisk As MUTAGENESIS TARGETED TO THE TRIGGERING RECEPTOR ANTIBODY SITE EXPRESSED IN TYPE 1 MELOID (TREM-1) TO REDUCE VISCOSITY
CA2956991A1 (en) 2014-08-06 2016-02-11 Rinat Neuroscience Corp. Methods for reducing ldl-cholesterol
WO2016020799A1 (en) 2014-08-06 2016-02-11 Rinat Neuroscience Corp. Methods for reducing ldl-cholesterol
US11219670B2 (en) 2014-09-05 2022-01-11 The Johns Hopkins University Targeting CAPN9/CAPNS2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
SG10201804931QA (en) 2014-09-12 2018-07-30 Genentech Inc Anti-cll-1 antibodies and immunoconjugates
CN114106185A (en) 2014-09-12 2022-03-01 基因泰克公司 anti-HER 2 antibodies and immunoconjugates
EP3191518B1 (en) 2014-09-12 2020-01-15 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
EP3197500A1 (en) 2014-09-17 2017-08-02 Genentech, Inc. Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
WO2016044697A1 (en) 2014-09-19 2016-03-24 The Johns Hopkins University Biomarkers of cognitive dysfunction
AU2015320678B2 (en) 2014-09-23 2021-07-22 Genentech, Inc. Method of using anti-CD79b immunoconjugates
US10472424B2 (en) 2014-09-23 2019-11-12 Pfizer Inc. Treatment with anti-PCSK9 antibodies
US20170298360A1 (en) 2014-09-24 2017-10-19 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
RU2021125449A (en) 2014-10-01 2021-09-16 Медиммьюн Лимитед ANTIBODIES TO TICAGRELOR AND METHODS OF APPLICATION
WO2016061389A2 (en) 2014-10-16 2016-04-21 Genentech, Inc. Anti-alpha-synuclein antibodies and methods of use
WO2016061460A1 (en) 2014-10-17 2016-04-21 Carnegie Mellon University Enhanced biomolecule detection assays based on tyramide signal amplification and gammapna probes
EP3209697A4 (en) 2014-10-23 2018-05-30 La Trobe University Fn14-binding proteins and uses thereof
UY36370A (en) 2014-10-24 2016-04-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware MODIFIED FGF-21 POLIPEPTIDES AND ITS USES
US10626176B2 (en) 2014-10-31 2020-04-21 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind B7-H4
EP3212233B1 (en) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
SG11201703521UA (en) 2014-11-03 2017-05-30 Genentech Inc Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
EP3215850B1 (en) 2014-11-03 2019-07-03 F. Hoffmann-La Roche AG Assays for detecting t cell immune subsets and methods of use thereof
WO2016073791A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Methods of producing two chain proteins in bacteria
KR102544705B1 (en) 2014-11-05 2023-06-15 제넨테크, 인크. Methods of producing two chain proteins in bacteria
EP3611188B1 (en) 2014-11-06 2022-05-04 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn-binding and methods of use
MX2017005150A (en) 2014-11-06 2017-08-08 Hoffmann La Roche Fc-region variants with modified fcrn- and protein a-binding properties.
RU2017119428A (en) 2014-11-06 2018-12-06 Дженентек, Инк. COMBINED THERAPY, INCLUDING THE USE OF OX40-CONNECTING AGONISTS AND TIGIT INHIBITORS
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
BR112017009728A2 (en) 2014-11-10 2018-02-06 Genentech, Inc. isolated antibodies, isolated nucleic acid, vector, host cell, method for producing antibody, composition, uses of an antibody and methods of treating a disorder
EP3552488A1 (en) 2014-11-10 2019-10-16 F. Hoffmann-La Roche AG Animal model for nephropathy and agents for treating the same
HUE054339T2 (en) 2014-11-10 2021-08-30 Medimmune Ltd Binding molecules specific for cd73 and uses thereof
GB2538120A (en) 2014-11-11 2016-11-09 Medimmune Ltd Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
US20170306046A1 (en) 2014-11-12 2017-10-26 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US10160795B2 (en) 2014-11-14 2018-12-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to Ebola virus glycoprotein and their use
US10434177B2 (en) 2014-11-17 2019-10-08 Carnegie Mellon University Activatable two-component photosensitizers
CA2967368A1 (en) 2014-11-17 2016-05-26 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
WO2016081643A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
WO2016081640A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
EP3845565A3 (en) 2014-11-19 2021-09-08 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
LT3789402T (en) 2014-11-20 2022-09-26 F. Hoffmann-La Roche Ag Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
MA41119A (en) 2014-12-03 2017-10-10 Acceleron Pharma Inc METHODS OF TREATMENT OF MYELODYSPLASIC SYNDROMES AND SIDEROBLASTIC ANEMIA
CN107206088A (en) 2014-12-05 2017-09-26 豪夫迈·罗氏有限公司 It is used for the method and composition for the treatment of cancer using the axle antagonists of PD 1 and HPK1 antagonists
CA2966362A1 (en) 2014-12-05 2016-06-09 Genentech, Inc. Anti-cd79b antibodies and methods of use
BR112017011234A2 (en) 2014-12-10 2018-03-27 Genentech Inc antibodies to the blood-brain barrier receptor and methods of use
ES2934940T3 (en) 2014-12-11 2023-02-28 Pf Medicament Anti-C10orf54 antibodies and uses thereof
EP3233921B1 (en) 2014-12-19 2021-09-29 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
CA2972048C (en) 2014-12-22 2023-03-07 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
WO2016106286A1 (en) 2014-12-23 2016-06-30 Biodesy, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
SG11201705583XA (en) 2015-01-09 2017-08-30 Adalta Pty Ltd Cxcr4 binding molecules
JP2018511557A (en) 2015-01-22 2018-04-26 中外製薬株式会社 Combination and use of two or more anti-C5 antibodies
JP6912386B2 (en) 2015-01-26 2021-08-04 ザ ユニバーシティー オブ シカゴ CAR T cells that recognize cancer-specific IL13Rα2
WO2016123142A1 (en) 2015-01-26 2016-08-04 The University Of Chicago IL13RAα2 BINDING AGENTS AND USE THEREOF IN CANCER TREATMENT
EP3253793A4 (en) 2015-02-02 2018-11-14 i2 Pharmaceuticals, Inc. Anti-surrogate light chain antibodies
AU2016215155A1 (en) 2015-02-04 2017-08-17 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
WO2016127000A1 (en) 2015-02-04 2016-08-11 Bristol-Myers Squibb Company Methods of selecting therapeutic molecules
KR102605798B1 (en) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
HUE061070T2 (en) 2015-03-03 2023-05-28 Kymab Ltd Antibodies, uses & methods
CN107430117A (en) 2015-03-16 2017-12-01 豪夫迈·罗氏有限公司 Detection and quantitative IL 13 method and the purposes in diagnosing and treating Th2 relevant diseases
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3271389B8 (en) 2015-03-20 2020-04-22 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to gp120 and their use
SI3273992T1 (en) 2015-03-23 2020-09-30 Jounce Therapeutics, Inc. Antibodies to icos
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2016154629A1 (en) 2015-03-26 2016-09-29 Woman & Infants' Hospital Of Rhode Island Therapy for malignant disease
EP3273994B1 (en) 2015-03-27 2021-12-01 University of Southern California Car t-cell therapy directed to lhr for the treatment of solid tumors
RU2754041C2 (en) 2015-04-03 2021-08-25 Еурека Терапьютикс, Инк. Structures aimed at afp/mhc peptide complexes and types of their use
MA41919A (en) 2015-04-06 2018-02-13 Acceleron Pharma Inc ALK4 HETEROMULTIMERS: ACTRIIB AND THEIR USES
EP3828199A1 (en) 2015-04-06 2021-06-02 Acceleron Pharma Inc. Alk7: actriib heteromultimers and uses thereof
CA2982115A1 (en) 2015-04-06 2016-10-13 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
IL254887B2 (en) 2015-04-07 2023-11-01 Alector Llc Anti-sortilin antibodies and methods of use thereof
CN107709364A (en) 2015-04-07 2018-02-16 豪夫迈·罗氏有限公司 Antigen binding complex and application method with agonist activity
KR102528825B1 (en) 2015-04-13 2023-05-08 화이자 인코포레이티드 Chimeric antigen receptors targeting b-cell maturation antigen
CN108136002B (en) 2015-04-13 2022-05-31 辉瑞公司 Therapeutic antibodies and their use
ES2870991T3 (en) 2015-04-17 2021-10-28 Alpine Immune Sciences Inc Immunomodulatory proteins with adjustable affinities
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
PL3286315T3 (en) 2015-04-24 2021-11-02 F. Hoffmann-La Roche Ag Methods of identifying bacteria comprising binding polypeptides
US10814012B2 (en) 2015-04-29 2020-10-27 University Of South Australia Compositions and methods for administering antibodies
CN107709363A (en) 2015-05-01 2018-02-16 基因泰克公司 Shelter anti-cd 3 antibodies and application method
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
CN107847594B (en) 2015-05-06 2022-04-15 詹森生物科技公司 Prostate Specific Membrane Antigen (PSMA) bispecific binding agents and uses thereof
US10259882B2 (en) 2015-05-07 2019-04-16 Agenus Inc. Anti-OX40 antibodies
EP3736287A1 (en) 2015-05-11 2020-11-11 The Johns Hopkins University Autoimmune antibodies for use in inhibiting cancer cell growth
EP3936524A3 (en) 2015-05-11 2022-06-15 F. Hoffmann-La Roche AG Compositions and methods of treating lupus nephritis
MX2017014381A (en) 2015-05-12 2018-03-02 Genentech Inc Therapeutic and diagnostic methods for cancer.
EP3718569B1 (en) 2015-05-22 2023-05-03 Translational Drug Development, LLC Benzamide and active compound compositions and methods of use
EA039951B1 (en) 2015-05-27 2022-03-31 Юсб Биофарма Спрл Inhibitor of csf-1r activity for use in the treatment or prophylaxis of epilepsy or parkinson's disease and pharmaceutical composition thereof
MX2017015046A (en) 2015-05-29 2018-05-17 Agenus Inc Anti-ctla-4 antibodies and methods of use thereof.
ES2789500T5 (en) 2015-05-29 2023-09-20 Hoffmann La Roche Therapeutic and diagnostic procedures for cancer
WO2016196343A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Humanized anti-ebola virus glycoprotein antibodies and methods of use
AR105618A1 (en) 2015-05-29 2017-10-25 Genentech Inc METHODATION OF THE PROMOTER OF THE BINDING TO THE PROGRAMMED DEATH RECEIVER (PD-L1) IN CANCER
JP2018516933A (en) 2015-06-02 2018-06-28 ジェネンテック, インコーポレイテッド Compositions and methods for treating neurological disorders using anti-IL-34 antibodies
WO2016196975A1 (en) 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
US10711064B2 (en) 2015-06-04 2020-07-14 University Of Southern California Lym-1 and Lym-2 targeted CAR cell immunotherapy
AU2016270858B2 (en) 2015-06-05 2022-04-28 Ac Immune Sa Anti-Tau antibodies and methods of use
JP2018518483A (en) 2015-06-08 2018-07-12 ジェネンテック, インコーポレイテッド Methods of treating cancer using anti-OX40 antibodies and PD-1 axis binding antagonists
JP2018521019A (en) 2015-06-08 2018-08-02 ジェネンテック, インコーポレイテッド Method of treating cancer using anti-OX40 antibody
JP2018518491A (en) 2015-06-12 2018-07-12 アレクトル エルエルシー Anti-CD33 antibody and method of use thereof
CN116063499A (en) 2015-06-12 2023-05-05 艾利妥 anti-CD 33 antibodies and methods of use thereof
AR104987A1 (en) 2015-06-15 2017-08-30 Genentech Inc ANTIBODY-DRUG IMMUNOCUJADOS UNITED BY NON-PEPTIDIC LINKERS
WO2016205520A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Humanized and affinity matured antibodies to fcrh5 and methods of use
US10501545B2 (en) 2015-06-16 2019-12-10 Genentech, Inc. Anti-CLL-1 antibodies and methods of use
EP3310811B1 (en) 2015-06-16 2021-06-16 Genentech, Inc. Anti-cd3 antibodies and methods of use
CA2986263A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
AU2016280159A1 (en) 2015-06-17 2017-12-07 Genentech, Inc. Anti-HER2 antibodies and methods of use
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
US20180188257A1 (en) 2015-06-19 2018-07-05 University Of Rochester Septin proteins as novel biomarkers for detection and treatment of müllerian cancers
CA2990360C (en) 2015-06-24 2024-02-13 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
MX2017016645A (en) 2015-06-29 2018-11-09 Genentech Inc Type ii anti-cd20 antibody for use in organ transplantation.
HUE053619T2 (en) 2015-06-29 2021-07-28 Immunogen Inc Anti-cd123 antibodies and conjugates and derivatives thereof
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
WO2017015334A1 (en) 2015-07-21 2017-01-26 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
EP4218792A1 (en) 2015-08-04 2023-08-02 Acceleron Pharma Inc. Composition for treating myeloproliferative disorders
CN105384825B (en) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
CN114605548A (en) 2015-09-01 2022-06-10 艾吉纳斯公司 anti-PD-1 antibodies and methods of use thereof
EP3349796A4 (en) 2015-09-17 2019-05-29 ImmunoGen, Inc. Therapeutic combinations comprising anti-folr1 immunoconjugates
CN108271372B (en) 2015-09-18 2021-07-09 中外制药株式会社 IL-8-binding antibodies and uses thereof
BR112018005737A2 (en) 2015-09-23 2018-10-09 Genentech Inc antibodies, polynucleotide, vector, host cell, method for producing antibody, for reducing or inhibiting angiogenesis, for treating a disorder associated with angiogenesis, for inhibiting vascular permeability, composition, antibody conjugate, fusion protein, for identifying a change residues, antibody use, conjugate use and protein use
EP3569244A1 (en) 2015-09-23 2019-11-20 CytoImmune Therapeutics, LLC Flt3 directed car cells for immunotherapy
AU2016326609B2 (en) 2015-09-23 2023-03-09 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
EP3352791B1 (en) 2015-09-24 2019-10-30 AbVitro LLC Hiv antibody compositions and methods of use
CA3000386A1 (en) 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
JP6654694B2 (en) 2015-10-02 2020-02-26 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Anti-PD1 antibody and method of use
US11161912B2 (en) 2015-10-13 2021-11-02 Technion Research & Development Foundation Limited Heparanase-neutralizing monoclonal antibodies
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
CN108350505A (en) 2015-10-22 2018-07-31 震动疗法股份有限公司 Genetic marker for measuring ICOS expression
SG11201802895QA (en) 2015-10-23 2018-05-30 Eureka Therapeutics Inc Antibody/t-cell receptor chimeric constructs and uses thereof
SG11201802887PA (en) 2015-10-27 2018-05-30 Ucb Biopharma Sprl Methods of treatment using anti-il-17a/f antibodies
US20180348224A1 (en) 2015-10-28 2018-12-06 Friedrich Miescher Institute For Biomedical Resear Ch Tenascin-w and biliary tract cancers
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
AU2016344399B2 (en) 2015-10-30 2019-03-28 Genentech, Inc. Anti-HtrA1 antibodies and methods of use thereof
US11273151B2 (en) 2015-11-04 2022-03-15 Icahn School Of Medicine At Mount Sinai Methods of treating tumors and cancer, and identifying candidate subjects for such treatment
EP3371217A1 (en) 2015-11-08 2018-09-12 H. Hoffnabb-La Roche Ag Methods of screening for multispecific antibodies
EP3374398B1 (en) 2015-11-10 2020-03-18 MedImmune, LLC Binding molecules specific for asct2 and uses thereof
IL302822A (en) 2015-11-12 2023-07-01 Seagen Inc Glycan-interacting compounds and methods of use
US10550170B2 (en) 2015-11-23 2020-02-04 Acceleron Pharma Inc. Methods for treating vascular eye disorders with actrii antagonists
MX2018006613A (en) 2015-12-02 2019-01-30 Stcube & Co Inc Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof.
KR20180100122A (en) 2015-12-02 2018-09-07 주식회사 에스티사이언스 Antibodies specific for glycated BTLA (B- and T-lymphocyte weakening factor)
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
MX2018005229A (en) 2015-12-09 2019-04-29 F Hoffmann­La Roche Ag Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies.
WO2017097889A1 (en) 2015-12-10 2017-06-15 Katholieke Universiteit Leuven Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device
CN108401431B (en) 2015-12-18 2022-01-25 中外制药株式会社 anti-C5 antibodies and methods of use
EP3405478A4 (en) 2015-12-23 2019-10-30 Moonshot Pharma LLC Methods for inducing an immune response by inhibition of nonsense mediated decay
WO2017118307A1 (en) 2016-01-05 2017-07-13 江苏恒瑞医药股份有限公司 Pcsk9 antibody, antigen-binding fragment thereof, and medical uses thereof
SG11201805557SA (en) 2016-01-08 2018-07-30 Bioalliance Cv Tetravalent anti-psgl-1 antibodies and uses thereof
CN108368179B (en) 2016-01-08 2022-08-23 豪夫迈·罗氏有限公司 Methods of treating CEA positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD 3 bispecific antibodies
CA3011739A1 (en) 2016-01-20 2017-07-27 Genentech, Inc. High dose treatments for alzheimer's disease
SG11201805872SA (en) 2016-01-21 2018-08-30 Pfizer Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
DK3405490T3 (en) 2016-01-21 2022-01-10 Pfizer MONO- AND BISPECIFIC ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III AND CD3 AND USES THEREOF
GB201602413D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Method
TWI756204B (en) 2016-02-12 2022-03-01 比利時商楊森製藥公司 Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
CA3015528A1 (en) 2016-02-29 2017-09-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
JP6987072B2 (en) 2016-03-10 2021-12-22 アクセレロン ファーマ インコーポレーテッド Activin type 2 receptor binding protein and its use
BR112018067951A2 (en) 2016-03-10 2019-02-05 Viela Bio Inc ilt7-binding molecules and methods of using these
AU2017235097B2 (en) 2016-03-15 2023-08-31 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
CA3018081A1 (en) 2016-03-22 2017-09-28 Bionomics Limited Administration of an anti-lgr5 monoclonal antibody
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
CA3019164A1 (en) 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2017180864A1 (en) 2016-04-14 2017-10-19 Genentech, Inc. Anti-rspo3 antibodies and methods of use
PL3443350T3 (en) 2016-04-15 2021-05-31 F. Hoffmann-La Roche Ag Methods for monitoring and treating cancer
JP2019515670A (en) 2016-04-15 2019-06-13 ジェネンテック, インコーポレイテッド Methods for monitoring and treating cancer
EP3448881B1 (en) 2016-04-26 2023-06-07 Icahn School of Medicine at Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
PE20181890A1 (en) 2016-05-02 2018-12-11 Hoffmann La Roche CONTORSBODY - A MONOCATENARIO DIANA LEAGUE
WO2017194441A1 (en) 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Modified anti-tenascin antibodies and methods of use
JP7084878B2 (en) 2016-05-16 2022-06-15 武田薬品工業株式会社 Anti-factor IX Padua antibody
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
WO2017205465A2 (en) 2016-05-24 2017-11-30 Griswold Karl Edwin Antibodies and methods of making same
CN109313200B (en) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 Bioanalytical methods for characterizing site-specific antibody-drug conjugates
CA3024508A1 (en) 2016-05-27 2017-11-30 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
TW201902512A (en) 2016-06-02 2019-01-16 瑞士商赫孚孟拉羅股份公司 treatment method
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
MY194619A (en) 2016-06-02 2022-12-07 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
EP3464345A1 (en) 2016-06-06 2019-04-10 F. Hoffmann-La Roche AG Fusion proteins for ophthalmology with increased eye retention
CN116143918A (en) 2016-06-24 2023-05-23 豪夫迈·罗氏有限公司 Anti-polyubiquitin multispecific antibodies
JP6983824B2 (en) 2016-07-04 2021-12-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft New antibody format
EP3481835A4 (en) 2016-07-05 2020-02-26 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
CN109689685A (en) 2016-07-08 2019-04-26 斯塔滕生物技术有限公司 Anti- APOC3 antibody and its application method
AU2017296237A1 (en) 2016-07-15 2019-01-03 Poseida Therapeutics, Inc. Chimeric antigen receptors (CARS) specific for MUC1 and methods for their use
US10722558B2 (en) 2016-07-15 2020-07-28 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
AU2017296236A1 (en) 2016-07-15 2019-01-03 Poseida Therapeutics, Inc. Chimeric antigen receptors and methods for use
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
MA45811A (en) 2016-07-27 2019-06-05 Acceleron Pharma Inc METHODS AND COMPOSITIONS OF TREATMENT OF DISEASE.
KR102591955B1 (en) 2016-07-29 2023-10-19 추가이 세이야쿠 가부시키가이샤 Bispecific Antibody with Enhanced FVIII Carrier Function Replacement Activity
WO2018027204A1 (en) 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
CN109689090B (en) 2016-08-05 2023-12-26 免疫医疗有限责任公司 anti-O2 antibodies and uses thereof
US11053308B2 (en) 2016-08-05 2021-07-06 Chugai Seiyaku Kabushiki Kaisha Method for treating IL-8-related diseases
JP7250674B2 (en) 2016-08-08 2023-04-03 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト CANCER TREATMENT AND DIAGNOSTIC METHOD
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP6976315B2 (en) 2016-09-19 2021-12-08 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Affinity chromatography based on complement factors
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
AU2017331592A1 (en) 2016-09-23 2019-04-11 Teva Pharmaceuticals International Gmbh Treating cluster headache
PT3528838T (en) 2016-09-23 2023-09-04 Hoffmann La Roche Uses of il-13 antagonists for treating atopic dermatitis
AU2017336523B2 (en) 2016-09-28 2022-07-21 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
MX2019003703A (en) 2016-09-30 2020-08-13 Janssen Biotech Inc Safe and effective method of treating psoriasis with anti-il23 specific antibody.
CN110198743B (en) 2016-10-05 2023-07-18 艾科赛扬制药股份有限公司 Compositions and methods for treating kidney disease
EP3522933B1 (en) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Methods for preparing antibody drug conjugates
EP3523451A1 (en) 2016-10-06 2019-08-14 Genentech, Inc. Therapeutic and diagnostic methods for cancer
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
AU2017343621B2 (en) 2016-10-11 2021-12-02 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
WO2018075408A1 (en) 2016-10-17 2018-04-26 Alexion Pharmaceuticals, Inc. Methods of treating acute myeloid leukemia (aml) with combinations of anti-cd200 antibodies, cytarabine, and daunorubicin
JP7160484B2 (en) 2016-10-19 2022-10-25 メディミューン,エルエルシー ANTI-O1 ANTIBODY AND USES THEREOF
US11249082B2 (en) 2016-10-29 2022-02-15 University Of Miami Zika virus assay systems
CN110267678A (en) 2016-10-29 2019-09-20 霍夫曼-拉罗奇有限公司 Anti- MIC antibody and application method
SG11201903842YA (en) 2016-11-02 2019-05-30 Immunogen Inc Combination treatment with antibody-drug conjugates and parp inhibitors
RS62589B1 (en) 2016-11-02 2021-12-31 Jounce Therapeutics Inc Antibodies to pd-1 and uses thereof
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CA3042989A1 (en) 2016-11-07 2018-05-11 Junho Chung Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
AU2017362222A1 (en) 2016-11-16 2019-05-30 Janssen Biotech, Inc. Method of treating psoriasis with anti-IL-23 specific antibody
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
TW201829463A (en) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 Anti-hla-g antibodies and use thereof
JP7080234B2 (en) 2016-11-23 2022-06-03 トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー Benzamide and active compound compositions and methods of use
KR20190080949A (en) 2016-11-23 2019-07-08 바이오버라티브 테라퓨틱스 인크. A bispecific antibody that binds to coagulation factor IX and coagulation factor X
WO2018102594A1 (en) 2016-12-01 2018-06-07 Alexion Pharmaceuticals, Inc. Methods of treating solid tumors with anti-cd200 antibodies
SG10201911351SA (en) 2016-12-07 2020-02-27 Genentech Inc Anti-tau antibodies and methods of use
EP3551660B1 (en) 2016-12-07 2023-09-13 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
JP7106538B2 (en) 2016-12-07 2022-07-26 アジェナス インコーポレイテッド Antibodies and methods of their use
JP2020511937A (en) 2016-12-07 2020-04-23 ジェネンテック, インコーポレイテッド Anti-TAU antibody and method of use
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
AU2017381656B2 (en) 2016-12-21 2020-07-02 F. Hoffmann-La Roche Ag Re-use of enzymes in in vitro glycoengineering of antibodies
EP3559249A1 (en) 2016-12-21 2019-10-30 H. Hoffnabb-La Roche Ag Method for in vitro glycoengineering of antibodies
AU2017384276B9 (en) 2016-12-21 2020-11-26 F. Hoffmann-La Roche Ag In vitro glycoengineering of antibodies
US11274157B2 (en) 2017-01-12 2022-03-15 Eureka Therapeutics, Inc. Constructs targeting histone H3 peptide/MHC complexes and uses thereof
MA47362A (en) 2017-01-30 2019-12-04 Janssen Biotech Inc ANTI-TNF ANTIBODIES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACTIVE PSORIASIC RHEUMATISM
WO2018147915A1 (en) 2017-02-07 2018-08-16 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
AU2018219283B2 (en) 2017-02-08 2022-05-19 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
TWI778018B (en) 2017-02-10 2022-09-21 美商建南德克公司 Anti-tryptase antibodies, compositions thereof, and uses thereof
US11021535B2 (en) 2017-02-10 2021-06-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
WO2018157027A1 (en) 2017-02-27 2018-08-30 Regeneron Pharmaceuticals, Inc. Humanized model of kidney and liver disorders
MX2019010295A (en) 2017-03-01 2019-11-21 Genentech Inc Diagnostic and therapeutic methods for cancer.
US20190071490A1 (en) 2017-03-02 2019-03-07 Beth Israel Deaconess Medical Center, Inc. Preventing Post-Ictal Headaches
JP2020510671A (en) 2017-03-03 2020-04-09 シアトル ジェネティックス, インコーポレイテッド Glycan interacting compounds and methods of use
SG11201908418RA (en) 2017-03-13 2019-10-30 Poseida Therapeutics Inc Compositions and methods for selective elimination and replacement of hematopoietic stem cells
AU2018240375C1 (en) 2017-03-22 2024-02-01 Ascendis Pharma A/S Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
CR20190481A (en) 2017-03-22 2020-01-06 Genentech Inc Optimized antibody compositions for treatment of ocular disorders
AU2018241625A1 (en) 2017-03-27 2019-09-05 F. Hoffmann-La Roche Ag Improved antigen binding receptor formats
JP2020515256A (en) 2017-03-27 2020-05-28 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Improved antigen binding receptor
CN110494452B (en) 2017-04-03 2023-08-25 豪夫迈·罗氏有限公司 Antibodies that bind STEAP-1
WO2018184965A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
PE20191494A1 (en) 2017-04-03 2019-10-21 Hoffmann La Roche IMMUNOCONJUGATES OF AN ANTI-PD-1 ANTIBODY WITH A MUTANT IL-2 OR IL-15
EP3606955A1 (en) 2017-04-05 2020-02-12 H. Hoffnabb-La Roche Ag Bispecific antibodies specifically binding to pd1 and lag3
DK3606954T3 (en) 2017-04-05 2022-09-26 Hoffmann La Roche Anti-LAG3-antistoffer
AU2018253176B2 (en) 2017-04-13 2023-02-02 Agenus Inc. Anti-CD137 antibodies and methods of use thereof
WO2018189379A1 (en) 2017-04-14 2018-10-18 Gamamabs Pharma Amhrii-binding compounds for preventing or treating cancers
MX2019012136A (en) 2017-04-14 2020-07-20 Gamamabs Pharma Amhrii-binding compounds for preventing or treating lung cancers.
TW201841656A (en) 2017-04-21 2018-12-01 美商建南德克公司 Use of klk5 antagonists for treatment of a disease
JP2020517242A (en) 2017-04-21 2020-06-18 スターテン・バイオテクノロジー・ベー・フェー Anti-ApoC3 antibody and method of using the same
US11236151B2 (en) 2017-04-25 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
WO2018200586A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
WO2018200583A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
US20220135670A1 (en) 2017-04-27 2022-05-05 Tesaro, Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
HUE062927T2 (en) 2017-05-01 2023-12-28 Agenus Inc Anti-tigit antibodies and methods of use thereof
JOP20190256A1 (en) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
EP3625251A1 (en) 2017-05-15 2020-03-25 University Of Rochester Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
EP3630835A1 (en) 2017-05-31 2020-04-08 STCube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
KR20200024158A (en) 2017-05-31 2020-03-06 주식회사 에스티큐브앤컴퍼니 How to treat cancer using antibodies and molecules that immunospecifically bind to BTN1A1
RU2758513C2 (en) 2017-06-02 2021-10-29 Пфайзер Инк. Antibodies specific to flt3 and their applications
SG10202108528QA (en) 2017-06-02 2021-09-29 Pfizer Chimeric antigen receptors targeting flt3
KR20200026209A (en) 2017-06-06 2020-03-10 주식회사 에스티큐브앤컴퍼니 How to treat cancer using antibodies and molecules that bind BTN1A1 or BTN1A1-ligand
GB201709379D0 (en) 2017-06-13 2017-07-26 Univ Leuven Kath Humanised ADAMTS13 binding antibodies
WO2018236904A1 (en) 2017-06-19 2018-12-27 Surface Oncology, Inc. Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
US11654135B2 (en) 2017-06-22 2023-05-23 Moonshot Pharma Llc Methods for treating colon cancer with compositions comprising amlexanox and immune checkpoint inhibitors
MA49565A (en) 2017-07-11 2020-05-20 Compass Therapeutics Llc AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND THEIR USES
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
WO2019018647A1 (en) 2017-07-20 2019-01-24 Pfizer Inc. Anti-gd3 antibodies and antibody-drug conjugates
JP2020527351A (en) 2017-07-21 2020-09-10 ジェネンテック, インコーポレイテッド Cancer treatment and diagnosis
LT3661954T (en) 2017-08-03 2022-04-11 Amgen Inc. Interleukin-21 muteins and methods of treatment
MA47691A (en) 2017-08-03 2020-01-08 Alector Llc ANTI-CD33 ANTIBODIES AND PROCESSES FOR USE
EP3684811A2 (en) 2017-08-17 2020-07-29 Massachusetts Institute of Technology Multiple specificity binders of cxc chemokines and uses thereof
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
US20210130845A1 (en) 2017-09-08 2021-05-06 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression
EP3679040B1 (en) 2017-09-08 2022-08-03 Amgen Inc. Inhibitors of kras g12c and methods of using the same
TW201922780A (en) 2017-09-25 2019-06-16 美商健生生物科技公司 Safe and effective method of treating Lupus with anti-IL12/IL23 antibody
WO2019067499A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-cd200 therapy
SG10202007194PA (en) 2017-09-29 2020-08-28 Chugai Pharmaceutical Co Ltd Multispecific antigen-binding molecules having blood coagulation factor viii (fviii) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ing
WO2019073069A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh Human antibodies to thomsen-nouvelle (tn) antigen
TW201922294A (en) 2017-10-31 2019-06-16 美商伊繆諾金公司 Combination treatment with antibody-drug conjugates and cytarabine
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
US20190125799A1 (en) 2017-10-31 2019-05-02 Allogene Therapeutics, Inc. Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
AU2018361957B2 (en) 2017-10-31 2023-05-25 Staten Biotechnology B.V. Anti-ApoC3 antibodies and methods of use thereof
EP3704150A1 (en) 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG The compbody - a multivalent target binder
JP7092881B2 (en) 2017-11-01 2022-06-28 エフ.ホフマン-ラ ロシュ アーゲー TriFab Contour Body
MX2020004567A (en) 2017-11-06 2020-08-13 Genentech Inc Diagnostic and therapeutic methods for cancer.
WO2019094595A2 (en) 2017-11-09 2019-05-16 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
WO2019100052A2 (en) 2017-11-20 2019-05-23 Compass Therapeutics Llc Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
JP7165193B2 (en) 2017-11-27 2022-11-02 パーデュー、ファーマ、リミテッド、パートナーシップ Humanized antibody targeting human tissue factor
US20210087267A1 (en) 2017-12-20 2021-03-25 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
JP2021508246A (en) 2017-12-21 2021-03-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト CAR-T cell assay for specificity testing of novel antigen binding moiety
PE20201149A1 (en) 2017-12-21 2020-10-26 Hoffmann La Roche HLA-A2 / WT1 BINDING ANTIBODIES
CN111247429A (en) 2017-12-21 2020-06-05 豪夫迈·罗氏有限公司 Universal reporter cell assay for specific testing of novel antigen binding modules
EP3728321A1 (en) 2017-12-22 2020-10-28 F. Hoffmann-La Roche AG Use of pilra binding agents for treatment of a disease
SG11202004806SA (en) 2017-12-22 2020-06-29 Jounce Therapeutics Inc Antibodies to lilrb2
CN111542543B (en) 2017-12-28 2023-12-22 南京传奇生物科技有限公司 Antibodies to PD-L1 and variants thereof
JP7369127B2 (en) 2017-12-28 2023-10-25 ナンジン レジェンド バイオテック カンパニー,リミテッド Single domain antibodies against TIGIT and variants thereof
WO2019133512A1 (en) 2017-12-29 2019-07-04 Alector Llc Anti-tmem106b antibodies and methods of use thereof
KR20200110358A (en) 2018-01-12 2020-09-23 암젠 인크 Anti-PD-1 Antibodies and Methods of Treatment
CN111770936A (en) 2018-01-12 2020-10-13 百时美施贵宝公司 Combination therapy of anti-IL-8 and anti-PD-1 antibodies for the treatment of cancer
WO2019137541A1 (en) 2018-01-15 2019-07-18 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-1
US20200339686A1 (en) 2018-01-16 2020-10-29 Lakepharma, Inc. Bispecific antibody that binds cd3 and another target
WO2019152715A1 (en) 2018-01-31 2019-08-08 Alector Llc Anti-ms4a4a antibodies and methods of use thereof
US11396551B2 (en) 2018-02-01 2022-07-26 Pfizer Inc. Chimeric antigen receptors targeting CD70
EP3746482A1 (en) 2018-02-01 2020-12-09 Pfizer Inc Antibodies specific for cd70 and their uses
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
AU2019218786A1 (en) 2018-02-07 2020-07-30 Dana-Farber Cancer Institute, Inc. Cell-permeable stapled peptide modules for cellular delivery
MA51793A (en) 2018-02-08 2020-12-16 Hoffmann La Roche BISPECIFIC ANTIGEN BINDING MOLECULES AND METHODS OF USE
CR20200341A (en) 2018-02-09 2020-11-02 Hoffmann La Roche Antibodies binding to gprc5d
EP3749362A1 (en) 2018-02-09 2020-12-16 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
WO2019160976A1 (en) 2018-02-14 2019-08-22 Viela Bio, Inc. Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
TW202000702A (en) 2018-02-26 2020-01-01 美商建南德克公司 Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
CN111742219A (en) 2018-03-01 2020-10-02 豪夫迈·罗氏有限公司 Specific assays for novel target antigen binding modules
WO2019169212A1 (en) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
CA3092551A1 (en) 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
BR112020018480B1 (en) 2018-03-14 2022-09-27 Surface Oncology, Inc USES OF ANTIBODIES THAT BIND CD39 IN THE TREATMENT OF CANCER
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
US11891432B2 (en) 2018-03-15 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use
MA52094A (en) 2018-03-22 2021-01-27 Adimab Llc ANTI-IL-27 ANTIBODIES AND THEIR USES
WO2019190877A1 (en) 2018-03-26 2019-10-03 Alexion Pharmaceuticals, Inc. High throughput method for measuring the protease activity of complement c3 convertase
TWI790370B (en) 2018-04-02 2023-01-21 美商必治妥美雅史谷比公司 Anti-trem-1 antibodies and uses thereof
US11840568B2 (en) 2018-04-02 2023-12-12 Mab-Venture Biopharm Co., Ltd. Lymphocyte activation gene-3 (LAG-3) binding antibody and use thereof
TW202011029A (en) 2018-04-04 2020-03-16 美商建南德克公司 Methods for detecting and quantifying FGF21
CN112424601A (en) 2018-04-04 2021-02-26 豪夫迈·罗氏有限公司 Diagnostic assay for detecting tumor antigens in cancer patients
JP7394067B2 (en) 2018-04-04 2023-12-07 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Diagnostic assays for detecting tumor antigens in cancer patients
WO2019200357A1 (en) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarker for cd47 targeting therapeutics and uses therefor
AR115052A1 (en) 2018-04-18 2020-11-25 Hoffmann La Roche MULTI-SPECIFIC ANTIBODIES AND THE USE OF THEM
AR114789A1 (en) 2018-04-18 2020-10-14 Hoffmann La Roche ANTI-HLA-G ANTIBODIES AND THE USE OF THEM
EP3784274A1 (en) 2018-04-27 2021-03-03 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
WO2019213384A1 (en) 2018-05-03 2019-11-07 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof
MA52590A (en) 2018-05-11 2021-03-17 Janssen Biotech Inc METHODS OF TREATING DEPRESSION USING IL-23 ANTIBODIES
US20210171647A1 (en) 2018-05-11 2021-06-10 Wuxi Biologics (Shanghai) Co., Ltd. Fully human antibodies against ox40, method for preparing the same, and use thereof
WO2019222130A1 (en) 2018-05-15 2019-11-21 Immunogen, Inc. Combination treatment with antibody-drug conjugates and flt3 inhibitors
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
US20200109195A1 (en) 2018-05-21 2020-04-09 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
MX2020012607A (en) 2018-05-23 2021-01-29 Pfizer Antibodies specific for gucy2c and uses thereof.
US11434292B2 (en) 2018-05-23 2022-09-06 Pfizer Inc. Antibodies specific for CD3 and uses thereof
BR112020023844A2 (en) 2018-05-25 2021-04-13 Alector Llc ANTIBODIES, CANCER TREATMENT METHODS AND PRODUCTION OF AN ANTIBODY, NUCLEIC ACID, VECTOR, HOST CELLS AND PHARMACEUTICAL COMPOSITION
US11830582B2 (en) 2018-06-14 2023-11-28 University Of Miami Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents
MX2020013808A (en) 2018-06-18 2021-05-27 UCB Biopharma SRL Gremlin-1 antagonist for the prevention and treatment of cancer.
CN112533629A (en) 2018-06-19 2021-03-19 阿尔莫生物科技股份有限公司 Compositions and methods for combined use of IL-10 agents with chimeric antigen receptor cell therapy
TW202016144A (en) 2018-06-21 2020-05-01 日商第一三共股份有限公司 Compositions including cd3 antigen binding fragments and uses thereof
MX2020014091A (en) 2018-06-23 2021-05-27 Genentech Inc Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor.
WO2020006374A2 (en) 2018-06-29 2020-01-02 Alector Llc Anti-sirp-beta1 antibodies and methods of use thereof
PL3618928T3 (en) 2018-07-13 2023-05-02 Alector Llc Anti-sortilin antibodies and methods of use thereof
BR112021000673A2 (en) 2018-07-18 2021-04-20 Genentech, Inc. methods for treating an individual with lung cancer, kits, anti-pd-l1 antibody and compositions
EP3824295A4 (en) 2018-07-18 2022-04-27 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
JP2021531007A (en) 2018-07-20 2021-11-18 ピエール、ファーブル、メディカマン Receptor for VISTA
EP3833442A2 (en) 2018-08-09 2021-06-16 Compass Therapeutics LLC Antibodies that bind cd277 and uses thereof
EP3833443A1 (en) 2018-08-09 2021-06-16 Compass Therapeutics LLC Antigen binding agents that bind cd277 and uses thereof
WO2020033925A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
AR114550A1 (en) 2018-08-10 2020-09-16 Chugai Pharmaceutical Co Ltd ANTI-CD137 ANTIGEN BINDING MOLECULES AND THEIR USES
MX2021001672A (en) 2018-08-10 2021-07-15 Eutilex Co Ltd Chimeric antigen receptor binding to hla-dr, and car-t cell.
US11548938B2 (en) 2018-08-21 2023-01-10 Quidel Corporation DbpA antibodies and uses thereof
CN113801229A (en) 2018-08-31 2021-12-17 艾利妥 anti-CD 33 antibodies and methods of use thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
US10899826B1 (en) 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
WO2020061060A1 (en) 2018-09-19 2020-03-26 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
MX2021003213A (en) 2018-09-21 2021-05-12 Genentech Inc Diagnostic methods for triple-negative breast cancer.
KR20230148273A (en) 2018-09-24 2023-10-24 얀센 바이오테크 인코포레이티드 Safe and effective method of treating ulcerative colitis with anti-IL12/IL23 antibody
AU2019352017A1 (en) 2018-10-03 2021-05-06 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof
US20210395391A1 (en) 2018-10-11 2021-12-23 Pfizer Inc. Dosage Regimen for TFPI Antagonists
WO2020081767A1 (en) 2018-10-18 2020-04-23 Genentech, Inc. Diagnostic and therapeutic methods for sarcomatoid kidney cancer
GB201817309D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
GB201817311D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
EP3870235A1 (en) 2018-10-24 2021-09-01 F. Hoffmann-La Roche AG Conjugated chemical inducers of degradation and methods of use
SG11202104104VA (en) 2018-11-05 2021-05-28 Genentech Inc Methods of producing two chain proteins in prokaryotic host cells
SG11202105010UA (en) 2018-11-16 2021-06-29 Memorial Sloan Kettering Cancer Center Antibodies to mucin-16 and methods of use thereof
WO2020104943A2 (en) 2018-11-20 2020-05-28 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il-23 specific antibody
JP2022507836A (en) 2018-11-20 2022-01-18 タケダ ワクチン,インコーポレイテッド New anti-Zika virus antibody and its use
WO2020118011A1 (en) 2018-12-06 2020-06-11 Alexion Pharmaceuticals, Inc. Anti-alk2 antibodies and uses thereof
KR20210100668A (en) 2018-12-06 2021-08-17 제넨테크, 인크. Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugate, an alkylating agent and an anti-CD20 antibody
JP2022513198A (en) 2018-12-10 2022-02-07 ジェネンテック, インコーポレイテッド Photocrosslinkable peptide for site-specific conjugation to Fc-containing proteins
US20200197517A1 (en) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
US20220089694A1 (en) 2018-12-20 2022-03-24 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
KR20210105947A (en) 2018-12-20 2021-08-27 포세이다 테라퓨틱스, 인크. Nanotransposon compositions and methods of use
JP2022514290A (en) 2018-12-20 2022-02-10 ジェネンテック, インコーポレイテッド Modified antibody FC and usage
JP2022514082A (en) 2018-12-21 2022-02-09 ジェネンテック, インコーポレイテッド Methods of Producing Polypeptides Using Cell Lines Resistant to Apoptosis
PE20211294A1 (en) 2018-12-21 2021-07-20 Hoffmann La Roche ANTIBODY JOINING VEGF AND IL-1BETA AND METHODS OF USE
WO2020136060A1 (en) 2018-12-28 2020-07-02 F. Hoffmann-La Roche Ag A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
KR20210111792A (en) 2018-12-28 2021-09-13 스팍스 테라퓨틱스 인크. Binding molecules specific for claudin 18.2, compositions and methods thereof for treating cancer and other diseases
AU2020208828A1 (en) 2019-01-15 2021-08-05 Janssen Biotech, Inc. Anti-TNF antibody compositions and methods for the treatment of juvenile idiopathic arthritis
EP3911679A1 (en) 2019-01-16 2021-11-24 Compass Therapeutics LLC Formulations of antibodies that bind human cd137 and uses thereof
GB201900732D0 (en) 2019-01-18 2019-03-06 Ucb Biopharma Sprl Antibodies
EP3914618A1 (en) 2019-01-23 2021-12-01 Janssen Biotech, Inc. Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
WO2020154410A1 (en) 2019-01-23 2020-07-30 Genentech, Inc. Methods of producing multimeric proteins in eukaryotic host cells
WO2020153467A1 (en) 2019-01-24 2020-07-30 中外製薬株式会社 Novel cancer antigens and antibodies of said antigens
US20220073600A1 (en) 2019-01-28 2022-03-10 Maple Biotech Llc Methods for treating disease using psmp antagonists
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
MA55080A (en) 2019-02-26 2022-01-05 Inspirna Inc HIGH AFFINITY ANTI-MERTK ANTIBODIES AND ASSOCIATED USES
AU2020228383A1 (en) 2019-02-27 2021-09-23 Genentech, Inc. Dosing for treatment with anti-tigit and anti-CD20 or anti-CD38 antibodies
TW202101000A (en) 2019-03-08 2021-01-01 美商建南德克公司 Methods for detecting and quantifying membrane-associated proteins
US20220144934A1 (en) 2019-03-14 2022-05-12 Janssen Biotech, Inc. Methods for Producing Anti-TNF Antibody Compositions
EA202192508A1 (en) 2019-03-14 2022-03-29 Янссен Байотек, Инк. METHODS FOR OBTAINING COMPOSITIONS OF ANTIBODIES TO TNF
US20220153830A1 (en) 2019-03-14 2022-05-19 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-TNF Antibody Compositions
EP3938384A4 (en) 2019-03-14 2022-12-28 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
WO2020188466A1 (en) 2019-03-18 2020-09-24 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
US20220169706A1 (en) 2019-03-28 2022-06-02 Danisco Us Inc Engineered antibodies
SG11202109510YA (en) 2019-03-29 2021-10-28 Genentech Inc Modulators of cell surface protein interactions and methods and compositions related to same
CN114364703A (en) 2019-04-19 2022-04-15 豪夫迈·罗氏有限公司 Anti-merk antibodies and methods of use thereof
US20220227853A1 (en) 2019-05-03 2022-07-21 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
TW202108178A (en) 2019-05-14 2021-03-01 美商建南德克公司 METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES TO TREAT FOLLICULAR LYMPHOMA
US20230085439A1 (en) 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
CA3141531A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
CN113939531A (en) 2019-06-03 2022-01-14 詹森生物科技公司 anti-TNF antibody compositions and methods for treating psoriatic arthritis
CA3142580A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
US20200392229A1 (en) 2019-06-11 2020-12-17 Alector Llc Methods of use of anti-sortilin antibodies
CN114051500A (en) 2019-07-02 2022-02-15 豪夫迈·罗氏有限公司 Immunoconjugates comprising interleukin-2 mutants and anti-CD 8 antibodies
AR119393A1 (en) 2019-07-15 2021-12-15 Hoffmann La Roche ANTIBODIES THAT BIND NKG2D
CN114144436A (en) 2019-07-24 2022-03-04 H.隆德贝克有限公司 anti-mGluR 5 antibodies and uses thereof
CN114341181A (en) 2019-07-31 2022-04-12 艾莱克特有限责任公司 anti-MS 4A4A antibodies and methods of use thereof
JP2022543551A (en) 2019-07-31 2022-10-13 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Antibody that binds to GPRC5D
CR20220019A (en) 2019-07-31 2022-02-11 Hoffmann La Roche Antibodies binding to gprc5d
CN114641490B (en) 2019-08-06 2023-06-06 新旭生技股份有限公司 Antibodies that bind to pathological TAU species and uses thereof
TW202120551A (en) 2019-08-12 2021-06-01 美商普瑞諾生物科技公司 Methods and compositions for promoting and potentiating t‐cell mediated immune responses through adcc targeting of cd39 expressing cells
BR112022002761A2 (en) 2019-08-12 2022-08-09 Aptevo Res & Development Llc 4-1BB AND OX40 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS, 4-1BB ANTIBODIES, OX40 ANTIBODIES
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
JP2022545741A (en) 2019-08-30 2022-10-28 アジェナス インコーポレイテッド ANTI-CD96 ANTIBODY AND METHODS OF USE THEREOF
US20220306736A1 (en) 2019-09-04 2022-09-29 Y-Biologics Inc. Anti-vsig4 antibody or antigen binding fragment and uses thereof
WO2021046261A1 (en) 2019-09-05 2021-03-11 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
MX2022002963A (en) 2019-09-12 2022-04-06 Genentech Inc Compositions and methods of treating lupus nephritis.
BR112022002351A2 (en) 2019-09-16 2022-07-19 Surface Oncology Inc ANTI-CD39 ANTIBODY COMPOSITIONS AND METHODS
CA3150999A1 (en) 2019-09-18 2021-03-25 James Thomas Koerber Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
CR20220149A (en) 2019-09-20 2022-05-23 Genentech Inc Dosing for anti-tryptase antibodies
US20210115127A1 (en) 2019-09-25 2021-04-22 Surface Oncology, Inc. Anti-il-27 antibodies and uses thereof
US20220411511A1 (en) 2019-09-26 2022-12-29 Stcube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
CN114829401A (en) 2019-09-27 2022-07-29 南京金斯瑞生物科技有限公司 anti-VHH domain antibodies and uses thereof
US11760801B2 (en) 2019-09-27 2023-09-19 Janssen Biotech, Inc. Anti-CEACAM antibodies and uses thereof
CA3151406A1 (en) 2019-09-27 2021-04-01 Raymond D. Meng Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
US20220356248A1 (en) 2019-10-09 2022-11-10 Stcube & Co Antibodies specific to glycosylated lag3 and methods of use thereof
TW202122114A (en) 2019-10-18 2021-06-16 美商建南德克公司 Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
EP3812008A1 (en) 2019-10-23 2021-04-28 Gamamabs Pharma Amh-competitive antagonist antibody
US11459389B2 (en) 2019-10-24 2022-10-04 Massachusetts Institute Of Technology Monoclonal antibodies that bind human CD161
IL292458A (en) 2019-11-06 2022-06-01 Genentech Inc Diagnostic and therapeutic methods for treatment of hematologic cancers
GB201917480D0 (en) 2019-11-29 2020-01-15 Univ Oxford Innovation Ltd Antibodies
CR20230210A (en) 2019-12-13 2023-06-14 Genentech Inc Anti-ly6g6d antibodies and methods of use
BR112022011570A2 (en) 2019-12-13 2022-12-13 Alector Llc ANTI-MERTK ANTIBODIES AND METHODS OF THEIR USE
EP4076666A1 (en) 2019-12-18 2022-10-26 F. Hoffmann-La Roche AG Antibodies binding to hla-a2/mage-a4
CA3161024A1 (en) 2019-12-19 2021-06-24 Quidel Corporation Monoclonal antibody fusions
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
JP2023510121A (en) 2019-12-20 2023-03-13 ポセイダ セラピューティクス,インコーポレイティド Anti-Muc1 compositions and methods of use
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
MX2022007840A (en) 2019-12-27 2022-07-19 Chugai Pharmaceutical Co Ltd Anti-ctla-4 antibody and use thereof.
TW202138388A (en) 2019-12-30 2021-10-16 美商西根公司 Methods of treating cancer with nonfucosylated anti-cd70 antibodies
CN114929278A (en) 2020-01-06 2022-08-19 瓦西尼斯公司 anti-CCR 8 antibodies and uses thereof
CN110818795B (en) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 anti-TIGIT antibodies and methods of use
JP2023511274A (en) 2020-01-14 2023-03-17 シンセカイン インコーポレイテッド IL2 orthologs and usage
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
CN115427453A (en) 2020-02-10 2022-12-02 上海诗健生物科技有限公司 CLDN18.2 antibodies and uses thereof
AU2021218927A1 (en) 2020-02-10 2022-09-22 Shanghai Escugen Biotechnology Co., Ltd. Claudin 18.2 antibody and use thereof
TW202144395A (en) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 Anti-CD137 antigen-binding molecule for use in cancer treatment
US20230096030A1 (en) 2020-02-13 2023-03-30 UCB Biopharma SRL Bispecific antibodies against cd9 and cd7
EP4103612A1 (en) 2020-02-13 2022-12-21 UCB Biopharma SRL Bispecific antibodies against cd9
US20230192900A1 (en) 2020-02-13 2023-06-22 UCB Biopharma SRL Bispecific antibodies binding hvem and cd9
US20230151108A1 (en) 2020-02-13 2023-05-18 UCB Biopharma SRL Bispecific antibodies against cd9 and cd137
US20230125234A1 (en) 2020-02-13 2023-04-27 UCB Biopharma SRL Anti cd44-ctla4 bispecific antibodies
CA3169451A1 (en) 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
JP2023513834A (en) 2020-02-18 2023-04-03 アレクトル エルエルシー PILRA antibody and method of use thereof
KR20220145859A (en) 2020-02-28 2022-10-31 상하이 헨리우스 바이오테크, 인크. Anti-CD137 constructs, multispecific antibodies and uses thereof
AU2021225920A1 (en) 2020-02-28 2022-09-15 Shanghai Henlius Biotech, Inc. Anti-CD137 construct and use thereof
WO2021176424A1 (en) 2020-03-06 2021-09-10 Ona Therapeutics, S.L. Anti-cd36 antibodies and their use to treat cancer
US11896619B2 (en) 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
US20230121433A1 (en) 2020-03-11 2023-04-20 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
KR20220152262A (en) 2020-03-13 2022-11-15 제넨테크, 인크. Anti-interleukin-33 antibodies and uses thereof
CA3169626A1 (en) 2020-03-19 2021-09-23 Genentech, Inc. Isoform-selective anti-tgf-beta antibodies and methods of use
JP2023519213A (en) 2020-03-24 2023-05-10 ジェネンテック, インコーポレイテッド TIE2 binding agents and methods of use
WO2021202473A2 (en) 2020-03-30 2021-10-07 Danisco Us Inc Engineered antibodies
EP4126940A1 (en) 2020-03-30 2023-02-08 F. Hoffmann-La Roche AG Antibody that binds to vegf and pdgf-b and methods of use
CN116075525A (en) 2020-03-31 2023-05-05 艾莱克特有限责任公司 anti-MERTK antibodies and methods of use thereof
JP2023519930A (en) 2020-04-01 2023-05-15 ユニバーシティ オブ ロチェスター Monoclonal Antibodies Against Hemagglutinin (HA) and Neuraminidase (NA) of Influenza H3N2 Virus
WO2021202959A1 (en) 2020-04-03 2021-10-07 Genentech, Inc. Therapeutic and diagnostic methods for cancer
IL297025A (en) 2020-04-14 2022-12-01 Poseida Therapeutics Inc Compositions and methods for use in the treatment of cancer
BR112022020629A2 (en) 2020-04-15 2022-11-29 Hoffmann La Roche INTERLEUKIN-7 (IL-7) POLYPEPTIDE, IMMUNOCONJUGATE, ONE OR MORE POLYNUCLEOTIDES ISOLATED, HOST CELL, METHODS FOR PRODUCING AN IL-7 POLYPEPTIDE MUTANT OR AN IMMUNOCONJUGATE, FOR TREAT A DISEASE, AND FOR STIMULATING THE IMMUNE SYSTEM, IL-7 POLYPEPTIDE OR IMMUNOCONJUGATE 7 MUTANT, PHARMACEUTICAL COMPOSITION, USE OF THE IL-7 MUTANT POLYPEPTIDE AND INVENTION
TW202206111A (en) 2020-04-24 2022-02-16 美商建南德克公司 Methods of using anti-cd79b immunoconjugates
EP4143345A1 (en) 2020-04-28 2023-03-08 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
SG11202112792WA (en) 2020-04-28 2021-12-30 Univ Rockefeller Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
IL297830A (en) 2020-05-03 2023-01-01 Levena Suzhou Biopharma Co Ltd Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same
WO2021226290A1 (en) 2020-05-05 2021-11-11 10X Genomics, Inc. Methods for identification of antigen-binding molecules
CN115697491A (en) 2020-05-17 2023-02-03 阿斯利康(英国)有限公司 SARS-COV-2 antibodies and methods of selection and use thereof
US20230220057A1 (en) 2020-05-27 2023-07-13 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing nerve growth factor and uses thereof
WO2021247618A1 (en) 2020-06-02 2021-12-09 10X Genomics, Inc. Enrichment of nucleic acid sequences
CN116529260A (en) 2020-06-02 2023-08-01 当康生物技术有限责任公司 anti-CD 93 constructs and uses thereof
KR20230037532A (en) 2020-06-02 2023-03-16 다이내믹큐어 바이오테크놀로지 엘엘씨 Anti-CD93 constructs and uses thereof
CR20220659A (en) 2020-06-08 2023-08-21 Hoffmann La Roche Anti-hbv antibodies and methods of use
GB202008651D0 (en) 2020-06-09 2020-07-22 Univ Newcastle Method of identifying complement modulators
JP2023529206A (en) 2020-06-12 2023-07-07 ジェネンテック, インコーポレイテッド Methods and compositions for cancer immunotherapy
IL299039A (en) 2020-06-16 2023-02-01 Genentech Inc Methods and compositions for treating triple-negative breast cancer
CA3181672A1 (en) 2020-06-18 2021-12-23 Shi Li Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
AU2021308653A1 (en) 2020-07-17 2023-02-16 Genentech, Inc. Anti-Notch2 antibodies and methods of use
CN116323668A (en) 2020-07-17 2023-06-23 辉瑞公司 Therapeutic antibodies and uses thereof
EP4182343A2 (en) 2020-07-20 2023-05-24 AstraZeneca UK Limited Sars-cov-2 proteins, anti-sars-cov-2 antibodies, and methods of using the same
WO2022020456A2 (en) 2020-07-21 2022-01-27 Allogene Therapeutics, Inc. Chimeric antigen receptors with enhanced signaling and activities and uses thereof
TW202216215A (en) 2020-07-21 2022-05-01 美商建南德克公司 Antibody-conjugated chemical inducers of degradation of brm and methods thereof
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2022026763A1 (en) 2020-07-29 2022-02-03 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
US11725052B2 (en) 2020-08-18 2023-08-15 Cephalon Llc Anti-PAR-2 antibodies and methods of use thereof
KR20230084497A (en) 2020-09-11 2023-06-13 메디뮨 리미티드 Therapeutic B7-H4 binding molecules
JP2023542301A (en) 2020-09-12 2023-10-06 メディミューン リミテッド Scoring method for anti-B7H4 antibody drug conjugate therapy
EP3981789A1 (en) 2020-10-12 2022-04-13 Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives Anti-lilrb antibodies and uses thereof
EP4229081A1 (en) 2020-10-15 2023-08-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
AU2021359092A1 (en) 2020-10-15 2023-06-01 UCB Biopharma SRL Binding molecules that multimerise cd45
WO2022084210A1 (en) 2020-10-20 2022-04-28 F. Hoffmann-La Roche Ag Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
JP2023547447A (en) 2020-10-28 2023-11-10 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Improved antigen binding receptor
WO2022098638A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
AU2021374590A1 (en) 2020-11-04 2023-06-01 Genentech, Inc. Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
AU2021374594A1 (en) 2020-11-04 2023-06-01 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
US11919945B2 (en) 2020-11-04 2024-03-05 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies
JP2023551907A (en) 2020-12-01 2023-12-13 アプティーボ リサーチ アンド デベロップメント エルエルシー Tumor-associated antigens and CD3 binding proteins, related compositions, and methods
WO2022120352A1 (en) 2020-12-02 2022-06-09 Alector Llc Methods of use of anti-sortilin antibodies
WO2022118197A1 (en) 2020-12-02 2022-06-09 Pfizer Inc. Time to resolution of axitinib-related adverse events
AU2021395729A1 (en) 2020-12-07 2023-07-13 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
AU2021398385A1 (en) 2020-12-07 2023-07-13 UCB Biopharma SRL Antibodies against interleukin-22
WO2022132904A1 (en) 2020-12-17 2022-06-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies targeting sars-cov-2
CA3204702A1 (en) 2020-12-17 2022-06-23 F. Hoffmann-La Roche Ag Anti-hla-g antibodies and use thereof
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
CA3204731A1 (en) 2021-01-13 2022-07-21 John T. POIRIER Anti-dll3 antibody-drug conjugate
WO2022153194A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Antibody-pyrrolobenzodiazepine derivative conjugate
WO2022155324A1 (en) 2021-01-15 2022-07-21 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
WO2022173689A1 (en) 2021-02-09 2022-08-18 University Of Georgia Research Foundation, Inc. Human monoclonal antibodies against pneumococcal antigens
JP2024506315A (en) 2021-02-09 2024-02-13 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ Antibodies that target the coronavirus spike protein
JP2024509165A (en) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー Treating and/or reducing the occurrence of migraine
TW202302645A (en) 2021-03-03 2023-01-16 法商皮爾法伯製藥公司 Anti-vsig4 antibody or antigen binding fragment and uses thereof
CN117440832A (en) 2021-03-03 2024-01-23 索伦托药业有限公司 Antibody-drug conjugates comprising anti-BCMA antibodies
WO2022187863A1 (en) 2021-03-05 2022-09-09 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
KR20230156764A (en) 2021-03-12 2023-11-14 얀센 바이오테크 인코포레이티드 Method for treating psoriatic arthritis patients with inadequate response to TNF therapy by anti-IL23 specific antibody
AU2022233792A1 (en) 2021-03-12 2023-10-26 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
CN117062839A (en) 2021-03-12 2023-11-14 基因泰克公司 anti-KLK 7 antibodies, anti-KLK 5 antibodies, multispecific anti-KLK 5/KLK7 antibodies, and methods of use
AU2022238526A1 (en) 2021-03-15 2023-09-07 F. Hoffmann-La Roche Ag Compositions and methods of treating lupus nephritis
WO2022195028A2 (en) 2021-03-18 2022-09-22 Medimmune Limited Therapeutic binding molecules
CN116981696A (en) 2021-03-18 2023-10-31 艾莱克特有限责任公司 anti-TMEM 106B antibodies and methods of use thereof
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
EP4314063A1 (en) 2021-03-23 2024-02-07 Alector LLC Anti-tmem106b antibodies for treating and preventing coronavirus infections
CN117616041A (en) 2021-03-25 2024-02-27 当康生物技术有限责任公司 anti-IGFBP 7 constructs and uses thereof
EP4067381A1 (en) 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Novel tnfr2 binding molecules
AR125344A1 (en) 2021-04-15 2023-07-05 Chugai Pharmaceutical Co Ltd ANTI-C1S ANTIBODY
JP2024509664A (en) 2021-04-30 2024-03-05 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Medication for treatment with anti-CD20/anti-CD3 bispecific antibodies
CN117321078A (en) 2021-04-30 2023-12-29 豪夫迈·罗氏有限公司 Administration for combination therapy with anti-CD 20/anti-CD 3 bispecific antibody and anti-CD 79B antibody drug conjugates
EP4334355A1 (en) 2021-05-03 2024-03-13 UCB Biopharma SRL Antibodies
EP4334343A2 (en) 2021-05-06 2024-03-13 The Rockefeller University Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
KR20240005809A (en) 2021-05-07 2024-01-12 서피스 온콜로지, 엘엘씨 Anti-IL-27 antibodies and uses thereof
CA3218170A1 (en) 2021-05-12 2022-11-17 Jamie Harue HIRATA Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
CN113278071B (en) 2021-05-27 2021-12-21 江苏荃信生物医药股份有限公司 Anti-human interferon alpha receptor1 monoclonal antibody and application thereof
CA3220629A1 (en) 2021-05-28 2022-12-01 Tobin J. CAMMETT Methods for detecting cm-tma biomarkers
WO2022256313A1 (en) 2021-06-01 2022-12-08 10X Genomics, Inc. Validation of a unique molecular identifier associated with a nucleic acid sequence of interest
AR126054A1 (en) 2021-06-04 2023-09-06 Chugai Pharmaceutical Co Ltd ANTI-DDR2 ANTIBODIES AND USES OF THESE
BR112023025738A2 (en) 2021-06-09 2024-02-27 Hoffmann La Roche COMBINATION OF A BRAF INHIBITOR AND A PD-1 AXIS BINDING ANTAGONIST, USE OF A COMBINATION OF A BRAF INHIBITOR AND A PD-1 AXIS BINDING ANTAGONIST, METHOD FOR THE TREATMENT OR PROPHYLAXIS OF CANCER, PHARMACEUTICAL COMPOSITION AND INVENTION
WO2022263357A1 (en) 2021-06-14 2022-12-22 Argenx Iip Bv Anti-il-9 antibodies and methods of use thereof
WO2022266223A1 (en) 2021-06-16 2022-12-22 Alector Llc Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
WO2022266221A1 (en) 2021-06-16 2022-12-22 Alector Llc Monovalent anti-mertk antibodies and methods of use thereof
WO2022266660A1 (en) 2021-06-17 2022-12-22 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
IL309115A (en) 2021-06-25 2024-02-01 Chugai Pharmaceutical Co Ltd Anti–ctla-4 antibody
CN117545779A (en) 2021-06-25 2024-02-09 中外制药株式会社 Use of anti-CTLA-4 antibodies
TW202317190A (en) 2021-06-29 2023-05-01 美商思進公司 Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
WO2023283611A1 (en) 2021-07-08 2023-01-12 Staidson Biopharma Inc. Antibodies specifically recognizing tnfr2 and uses thereof
WO2023281466A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
AU2022308201A1 (en) 2021-07-09 2024-02-22 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
WO2023281462A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
WO2023285878A1 (en) 2021-07-13 2023-01-19 Aviation-Ophthalmology Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
CN115812082A (en) 2021-07-14 2023-03-17 舒泰神(北京)生物制药股份有限公司 Antibody specifically recognizing CD40 and application thereof
WO2023004386A1 (en) 2021-07-22 2023-01-26 Genentech, Inc. Brain targeting compositions and methods of use thereof
WO2023001884A1 (en) 2021-07-22 2023-01-26 F. Hoffmann-La Roche Ag Heterodimeric fc domain antibodies
WO2023007472A1 (en) 2021-07-30 2023-02-02 ONA Therapeutics S.L. Anti-cd36 antibodies and their use to treat cancer
WO2023012147A1 (en) 2021-08-03 2023-02-09 F. Hoffmann-La Roche Ag Bispecific antibodies and methods of use
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
CA3227511A1 (en) 2021-08-06 2023-02-09 Lætitia LINARES Methods for the treatment of cancer
WO2023019239A1 (en) 2021-08-13 2023-02-16 Genentech, Inc. Dosing for anti-tryptase antibodies
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
WO2023034750A1 (en) 2021-08-30 2023-03-09 Genentech, Inc. Anti-polyubiquitin multispecific antibodies
CA3230815A1 (en) 2021-09-03 2023-03-09 University Of Bern Compositions and methods for treating long ot syndrome
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
WO2023060088A1 (en) 2021-10-04 2023-04-13 Poseida Therapeutics, Inc. Transposon compositions and methods of use thereof
TW202327595A (en) 2021-10-05 2023-07-16 美商輝瑞大藥廠 Combinations of azalactam compounds for the treatment of cancer
WO2023062048A1 (en) 2021-10-14 2023-04-20 F. Hoffmann-La Roche Ag Alternative pd1-il7v immunoconjugates for the treatment of cancer
WO2023062050A1 (en) 2021-10-14 2023-04-20 F. Hoffmann-La Roche Ag New interleukin-7 immunoconjugates
WO2023069919A1 (en) 2021-10-19 2023-04-27 Alector Llc Anti-cd300lb antibodies and methods of use thereof
WO2023073615A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
EP4177266A1 (en) 2021-11-05 2023-05-10 Katholieke Universiteit Leuven Neutralizing anti-sars-cov-2 human antibodies
WO2023086807A1 (en) 2021-11-10 2023-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
WO2023086824A1 (en) 2021-11-10 2023-05-19 10X Genomics, Inc. Methods for identification of antigen-binding molecules
US20230151087A1 (en) 2021-11-15 2023-05-18 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
WO2023091887A1 (en) 2021-11-16 2023-05-25 Genentech, Inc. Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
US20230159633A1 (en) 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
TW202340251A (en) 2022-01-19 2023-10-16 美商建南德克公司 Anti-notch2 antibodies and conjugates and methods of use
WO2023141576A1 (en) 2022-01-21 2023-07-27 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
WO2023147399A1 (en) 2022-01-27 2023-08-03 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
WO2023154824A1 (en) 2022-02-10 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that broadly target coronaviruses
TW202348252A (en) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 Combination therapies for treatment of cancer with therapeutic binding molecules
WO2023169896A1 (en) 2022-03-09 2023-09-14 Astrazeneca Ab BINDING MOLECULES AGAINST FRα
WO2023170216A1 (en) 2022-03-11 2023-09-14 Astrazeneca Ab A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
WO2023175614A1 (en) 2022-03-15 2023-09-21 Yeda Research And Development Co. Ltd. Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof
TW202346365A (en) 2022-03-23 2023-12-01 瑞士商赫孚孟拉羅股份公司 Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
WO2023180511A1 (en) 2022-03-25 2023-09-28 F. Hoffmann-La Roche Ag Improved chimeric receptors
US20230312703A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of Treating Psoriasis with IL-23 Specific Antibody
WO2023192436A1 (en) 2022-03-31 2023-10-05 Alexion Pharmaceuticals, Inc. Singleplex or multiplexed assay for complement markers in fresh biological samples
WO2023192478A1 (en) 2022-04-01 2023-10-05 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
US20230416361A1 (en) 2022-04-06 2023-12-28 Mirobio Limited Engineered cd200r antibodies and uses thereof
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
WO2023198727A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
WO2023209177A1 (en) 2022-04-29 2023-11-02 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
WO2023215737A1 (en) 2022-05-03 2023-11-09 Genentech, Inc. Anti-ly6e antibodies, immunoconjugates, and uses thereof
US20230374122A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer
WO2023250402A2 (en) 2022-06-22 2023-12-28 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
WO2024020407A1 (en) 2022-07-19 2024-01-25 Staidson Biopharma Inc. Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
WO2024020564A1 (en) 2022-07-22 2024-01-25 Genentech, Inc. Anti-steap1 antigen-binding molecules and uses thereof
WO2024026472A2 (en) 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2024026447A1 (en) 2022-07-29 2024-02-01 Alector Llc Anti-gpnmb antibodies and methods of use thereof
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2024030829A1 (en) 2022-08-01 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024050354A1 (en) 2022-08-31 2024-03-07 Washington University Alphavirus antigen binding antibodies and uses thereof
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
WO2024049949A1 (en) 2022-09-01 2024-03-07 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
WO2024050526A1 (en) 2022-09-02 2024-03-07 Biomarin Pharmaceutical Inc. Compositions and methods for treating long qt syndrome

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002809A1 (en) * 1988-09-02 1990-03-22 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
WO1990004788A1 (en) * 1988-10-28 1990-05-03 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853832A (en) * 1971-04-27 1974-12-10 Harmone Res Foundation Synthetic human pituitary growth hormone and method of producing it
US3853833A (en) * 1971-04-27 1974-12-10 Hormone Res Foundation Synthetic human growth-promoting and lactogenic hormones and method of producing same
US4880910A (en) * 1981-09-18 1989-11-14 Genentech, Inc. Terminal methionyl bovine growth hormone and its use
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4446235A (en) * 1982-03-22 1984-05-01 Genentech, Inc. Method for cloning human growth hormone varient genes
US4670393A (en) * 1982-03-22 1987-06-02 Genentech, Inc. DNA vectors encoding a novel human growth hormone-variant protein
US4673641A (en) * 1982-12-16 1987-06-16 Molecular Genetics Research And Development Limited Partnership Co-aggregate purification of proteins
US4699897A (en) * 1983-06-04 1987-10-13 Amgen Biologically active peptides structurally related to regions within growth hormones
US4888286A (en) * 1984-02-06 1989-12-19 Creative Biomolecules, Inc. Production of gene and protein analogs through synthetic gene design using double stranded synthetic oligonucleotides
US4655160A (en) * 1985-09-10 1987-04-07 David R. Ligh Deck box
US5013653A (en) * 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
IT1223577B (en) * 1987-12-22 1990-09-19 Eniricerche Spa IMPROVED PROCEDURE FOR THE PREPARATION OF THE NATURAL HUMAN GROWTH HORMONE IN PURE FORM
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5688666A (en) * 1988-10-28 1997-11-18 Genentech, Inc. Growth hormone variants with altered binding properties
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770434A (en) * 1990-09-28 1998-06-23 Ixsys Incorporated Soluble peptides having constrained, secondary conformation in solution and method of making same
US5780279A (en) * 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
ATE164395T1 (en) * 1990-12-03 1998-04-15 Genentech Inc METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES
US5955341A (en) * 1991-04-10 1999-09-21 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
CA2108147C (en) * 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ES2168277T3 (en) * 1992-09-04 2002-06-16 Scripps Research Inst PHAGEMIDS THAT CO-EXPRESS A SURFACE RECEIVER AND A SURFACE HETEROLOGY PROTEIN.
CA2115811A1 (en) * 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
SE9304060D0 (en) * 1993-12-06 1993-12-06 Bioinvent Int Ab Methods to select specific bacteriophages
US5811093A (en) * 1994-04-05 1998-09-22 Exponential Biotherapies, Inc. Bacteriophage genotypically modified to delay inactivations by the host defense system
EP0760012A4 (en) * 1994-06-10 1997-07-02 Symbiotech Inc Method of detecting compounds utilizing genetically modified lambdoid bacteriophage
US5516637A (en) * 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5627024A (en) * 1994-08-05 1997-05-06 The Scripps Research Institute Lambdoid bacteriophage vectors for expression and display of foreign proteins
GB9500851D0 (en) * 1995-01-17 1995-03-08 Bionvent International Ab Method of selecting specific bacteriophages
US5702892A (en) * 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
EP0854933B1 (en) * 1995-09-07 2003-05-07 Novozymes A/S Phage display for detergent enzyme activity
US5622699A (en) * 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
EP0904541B1 (en) * 1996-03-20 2004-10-06 Dyax Corp. PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (tPA)
WO1997044491A1 (en) * 1996-05-22 1997-11-27 The Johns Hopkins University Methods of detection utilizing modified bacteriophage
AU734638B2 (en) * 1996-06-06 2001-06-21 Lajolla Pharmaceutical Company aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies
DE69731226T2 (en) * 1996-06-10 2006-03-09 The Scripps Research Institute, La Jolla USE OF SUBSTRATE SUBTRACTION LIBRARIES FOR THE DISTINCTION OF ENZYME SPECIFICATIONS
WO1998005344A1 (en) * 1996-08-05 1998-02-12 Brigham And Women's Hospital, Inc. Bacteriophage-mediated gene therapy
ATE230850T1 (en) * 1996-10-08 2003-01-15 Bisys B V U METHOD AND MEANS FOR SELECTING PEPTIDES AND PROTEINS WITH SPECIFIC AFFINITY FOR A TARGET MOLECULE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002809A1 (en) * 1988-09-02 1990-03-22 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
WO1990004788A1 (en) * 1988-10-28 1990-05-03 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Protein Engineering, editors D.L. Oxender et al.; Alan R. Liss Inc., 1987, (New York, US) W.J. Rutter et al.: "Redesigning proteins via genetic engineering", pages 257-267, see the whole article *
Science, volume 247, 23 March 1990; B.C. Cunningham et al.: "Engineering human prolactin to bind to the human growth hormone receptor", pages 1461-1465, see the whole article (cited in the application) *

Cited By (1264)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854026A (en) * 1988-10-28 1998-12-29 Genentech, Inc. Human growth hormone variant having enhanced affinity for human growth hormone receptor at site 1
US6022711A (en) * 1988-10-28 2000-02-08 Genentech, Inc. Human growth hormone variants having enhanced affinity for human growth hormone receptor at site 1
US6143523A (en) * 1988-10-28 2000-11-07 Genentech, Inc. Human growth hormone variants
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5688666A (en) * 1988-10-28 1997-11-18 Genentech, Inc. Growth hormone variants with altered binding properties
US5681809A (en) * 1989-10-12 1997-10-28 Ohio University Growth hormone antagonists
US7553617B1 (en) 1990-06-20 2009-06-30 Affymax, Inc. Peptide library and screening systems
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5432018A (en) * 1990-06-20 1995-07-11 Affymax Technologies N.V. Peptide library and screening systems
US7732377B2 (en) 1990-07-10 2010-06-08 Medical Research Council Methods for producing members of specific binding pairs
US6806079B1 (en) 1990-07-10 2004-10-19 Medical Research Council Methods for producing members of specific binding pairs
US7723270B1 (en) 1990-07-10 2010-05-25 Medical Research Council Methods for producing members of specific binding pairs
US7662557B2 (en) 1990-07-10 2010-02-16 Medical Research Council Methods for producing members of specific binding pairs
US7635666B1 (en) 1990-07-10 2009-12-22 Medical Research Council Methods for producing members of specific binding pairs
US5969108A (en) * 1990-07-10 1999-10-19 Medical Research Council Methods for producing members of specific binding pairs
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
US6936440B1 (en) 1991-05-10 2005-08-30 Genentech, Inc. Selecting ligand agonists and antagonists
US6800740B1 (en) 1991-05-10 2004-10-05 Genentech, Inc. Variants of native growth hormones having non naturally occurring amino acid sequences or covalent modifications
US5871907A (en) * 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US6291650B1 (en) 1991-05-15 2001-09-18 Cambridge Antibody Technology, Ltd. Methods for producing members of specific binding pairs
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US6730483B2 (en) 1991-07-08 2004-05-04 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Phagemid for antibody screening
US5985588A (en) * 1991-07-08 1999-11-16 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Phagemid for antibody screening
US6387627B1 (en) 1991-07-08 2002-05-14 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Phagemid for antibody screening
WO1993001288A1 (en) * 1991-07-08 1993-01-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Phagemide for screening antibodies
EP1065271A1 (en) * 1991-07-08 2001-01-03 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Phagemide for screening antibodies
US5849500A (en) * 1991-07-08 1998-12-15 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Phagemid for antibody screening
US6127132A (en) * 1991-07-08 2000-10-03 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Phagemid library for antibody screening
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5733731A (en) * 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US6156511A (en) * 1991-10-16 2000-12-05 Affymax Technologies N.V. Peptide library and screening method
US5498530A (en) * 1991-10-16 1996-03-12 Affymax Technologies, N.V. Peptide library and screening method
US6544731B1 (en) 1991-12-02 2003-04-08 Medical Research Council Production of anti-self antibodies from antibody segment repertories and displayed on phage
US7195866B2 (en) 1991-12-02 2007-03-27 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US6521404B1 (en) 1991-12-02 2003-02-18 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US6555313B1 (en) 1991-12-02 2003-04-29 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US6582915B1 (en) 1991-12-02 2003-06-24 Medical Research Council Production of anti-self bodies from antibody segment repertories and displayed on phage
US6593081B1 (en) 1991-12-02 2003-07-15 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5885793A (en) * 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US6140471A (en) * 1992-03-24 2000-10-31 Cambridge Antibody Technology, Ltd. Methods for producing members of specific binding pairs
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5962255A (en) * 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US5858657A (en) * 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US6136563A (en) * 1993-05-25 2000-10-24 Genentech, Inc. Human growth hormone variants comprising amino acid substitutions
US6004931A (en) * 1993-05-25 1999-12-21 Genentech, Inc. Method for inhibiting growth hormone action
US5763575A (en) * 1993-07-26 1998-06-09 Cor Therapeutics, Inc. Agonist and antagonist peptides of the C140 receptor
US7834143B2 (en) 1993-07-26 2010-11-16 Johan Sundelin Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor
US7351792B2 (en) 1993-07-26 2008-04-01 Millennium Pharmaceuticals, Inc. Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor
WO1995018856A1 (en) 1993-12-30 1995-07-13 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing hedgehog-like proteins
EP1958966A2 (en) 1994-07-01 2008-08-20 Dana-Farber Cancer Institute Methods for modulating T cell responses by manipulating a common cytokine receptor gamma chain
US6335319B1 (en) * 1994-11-15 2002-01-01 Metabolic Pharmaceuticals, Inc. Treatment of obesity
EP1568772A3 (en) * 1995-09-21 2006-05-17 Genentech, Inc. Human growth hormone variants
EP1568771A3 (en) * 1995-09-21 2006-05-17 Genentech, Inc. Human growth hormone variants
EP1568771A2 (en) * 1995-09-21 2005-08-31 Genentech, Inc. Human growth hormone variants
EP1568772A2 (en) * 1995-09-21 2005-08-31 Genentech, Inc. Human growth hormone variants
US6057292A (en) * 1995-09-21 2000-05-02 Genentech, Inc. Method for inhibiting growth hormone action
US5849535A (en) * 1995-09-21 1998-12-15 Genentech, Inc. Human growth hormone variants
AU718439B2 (en) * 1995-09-21 2000-04-13 Genentech Inc. Human growth hormone variants
WO1997011178A1 (en) * 1995-09-21 1997-03-27 Genentech, Inc. Human growth hormone variants
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
WO1997017613A1 (en) * 1995-11-10 1997-05-15 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
EP1281718A2 (en) * 1995-11-10 2003-02-05 ELAN CORPORATION, Plc Peptides which enhance transport across tissues
EP1281718A3 (en) * 1995-11-10 2005-01-19 ELAN CORPORATION, Plc Peptides which enhance transport across tissues
WO1997017614A1 (en) * 1995-11-10 1997-05-15 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
EP2305713A1 (en) 1996-02-09 2011-04-06 Abbott Biotechnology Ltd Human antibodies that bind human TNFalpha
EP2397494A1 (en) 1996-02-09 2011-12-21 Abbott Biotechnology Ltd Human antibodies that bind human TNFalpha
EP2305712A1 (en) 1996-02-09 2011-04-06 Abbott Biotechnology Ltd Human antibodies that bind human TNFalpha
EP2357200A1 (en) 1996-02-09 2011-08-17 Abbott Biotechnology Ltd Human antibodies that bind human TNFalpha
EP2930186A1 (en) 1996-02-09 2015-10-14 AbbVie Biotechnology Ltd Human antibodies that bind human tnfalpha
EP2930187A1 (en) 1996-02-09 2015-10-14 AbbVie Biotechnology Ltd Human antibodies that bind human tnfalpha
EP2930185A1 (en) 1996-02-09 2015-10-14 AbbVie Biotechnology Ltd Human antibodies that bind human tnfalpha
EP2933267A1 (en) 1996-02-09 2015-10-21 AbbVie Biotechnology Ltd Human antibodies that bind human tnfalpha
WO1997035194A3 (en) * 1996-03-21 1997-12-18 Enantiomeric screening process, and compositions therefor
WO1997035194A2 (en) * 1996-03-21 1997-09-25 President And Fellows Of Harvard College Enantiomeric screening process, and compositions therefor
US8362084B2 (en) 1996-03-26 2013-01-29 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US8426592B2 (en) 1996-03-26 2013-04-23 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US8399233B2 (en) 1996-03-26 2013-03-19 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US8329945B2 (en) 1996-03-26 2012-12-11 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US8329946B2 (en) 1996-03-26 2012-12-11 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US7566766B2 (en) 1996-11-08 2009-07-28 EUSA Pharma Ltd. Peptides which enhance transport across tissues and methods of identifying and using the same
US6361938B1 (en) 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
US6497874B1 (en) 1997-02-05 2002-12-24 Maardh Sven Recombinant phages
EP2298899A2 (en) 1997-04-16 2011-03-23 Millennium Pharmaceuticals, Inc. CRSP proteins (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor
US6770624B2 (en) 1997-06-04 2004-08-03 The Regents Of The University Of California Treatment of heart failure with growth hormone
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
US8563687B2 (en) 1997-07-21 2013-10-22 Ohio University Synthetic genes for plant gums and other hydroxyproline rich glycoproteins
US7378506B2 (en) 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US8871468B2 (en) 1997-07-21 2014-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6667150B1 (en) 1997-08-01 2003-12-23 Morphosys Ag Method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly) peptide complex
US7049135B2 (en) 1997-08-01 2006-05-23 Morphosys Ag Method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
GB2375765B (en) * 1997-11-14 2003-02-26 Kymed Gb Ltd Tagged growth hormone molecules
GB2375765A (en) * 1997-11-14 2002-11-27 Kymed Gb Ltd Tagged growth hormone molecules
US6680207B1 (en) 1997-11-14 2004-01-20 Generic Biologicals Limited Detection of molecules in samples
WO1999026069A1 (en) * 1997-11-14 1999-05-27 Generic Biologicals Limited Improvements in or relating to detection of molecules in samples
US7056517B2 (en) 1998-04-13 2006-06-06 The Forsyth Institute Glucosyltransferase immunogens
US7163682B2 (en) 1998-04-13 2007-01-16 The Forsyth Institute Glucan binding protein and glucosyltransferase immunogens
WO2000006717A3 (en) * 1998-07-27 2000-06-29 Genentech Inc Improved transformation efficiency in phage display through modification of a coat protein
WO2000006717A2 (en) * 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
US8685893B2 (en) 1998-07-27 2014-04-01 Genentech, Inc. Phage display
WO2000018933A1 (en) * 1998-09-30 2000-04-06 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
US6485972B1 (en) 1998-10-15 2002-11-26 President And Fellows Of Harvard College WNT signalling in reproductive organs
US6420110B1 (en) 1998-10-19 2002-07-16 Gpc Biotech, Inc. Methods and reagents for isolating biologically active peptides
EP2301947A2 (en) 1999-02-26 2011-03-30 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US6616926B1 (en) 1999-03-03 2003-09-09 Curis, Inc. Methods of modulating lipid metabolism and storage
EP2301970A1 (en) 1999-03-25 2011-03-30 Abbott GmbH & Co. KG Human antibodies that bind human IL-12 and methods for producing
EP2168984A1 (en) 1999-03-25 2010-03-31 Abbott GmbH & Co. KG Human antibodies that bind human IL-12 and methods for producing
US8865174B2 (en) 1999-03-25 2014-10-21 Abbvie Inc. Methods of treatment using human antibodies that bind IL-12
US7504485B2 (en) 1999-03-25 2009-03-17 Abbott Gmbh & Co., Kg Human antibodies that bind human IL-12
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US9035030B2 (en) 1999-03-25 2015-05-19 AbbVie Deutschland GmbH & Co. KG Human antibodies that bind the P40 subunit of human IL-12 and methods for using the same
EP2319870A2 (en) 1999-03-25 2011-05-11 Abbott GmbH & Co. KG Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US8765918B2 (en) 1999-03-25 2014-07-01 Abbott Gmbh & Co., Kg Human antibodies that bind human interleukin-12
US6777194B1 (en) 1999-04-01 2004-08-17 Dakocytomation Denmark A/S Monoclonal antibodies against human protein Mcm3, process for their production, and their use
US7151169B2 (en) 1999-04-30 2006-12-19 Cambridge Antibody Technology Limited Specific binding members for TGFβ1
US7396905B1 (en) 1999-05-21 2008-07-08 Mckeon Frank Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto
US8137923B2 (en) 1999-06-30 2012-03-20 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7597888B2 (en) 1999-06-30 2009-10-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
WO2001000810A1 (en) 1999-06-30 2001-01-04 Millennium Pharmaceuticals, Inc. Glycoprotein vi and uses thereof
US7101549B2 (en) 1999-06-30 2006-09-05 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
EP2322558A1 (en) 1999-06-30 2011-05-18 Millennium Pharmaceuticals, Inc. Antibodies directed against glycoprotein VI and uses thereof
EP2902414A1 (en) 1999-06-30 2015-08-05 Millennium Pharmaceuticals, Inc. Antibodies directed against glycoprotein VI and uses thereof
EP1990409A2 (en) 1999-07-20 2008-11-12 MorphoSys AG Bacteriophage
EP2360254A1 (en) 1999-08-23 2011-08-24 Dana-Farber Cancer Institute, Inc. Assays for screening anti-pd-1 antibodies and uses thereof
US8168178B2 (en) 1999-11-30 2012-05-01 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US6951839B1 (en) 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
EP1626056A2 (en) 1999-12-30 2006-02-15 President And Fellows of Harvard College Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or T cell subset activity by modulation of XBP-1 activity
US7767207B2 (en) 2000-02-10 2010-08-03 Abbott Laboratories Antibodies that bind IL-18 and methods of inhibiting IL-18 activity
EP2338515A2 (en) 2000-02-10 2011-06-29 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
EP2332579A2 (en) 2000-02-10 2011-06-15 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
EP2360184A2 (en) 2000-02-10 2011-08-24 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
WO2001058956A2 (en) 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US7094539B2 (en) 2000-03-02 2006-08-22 Promega Corporation Bacillus stearothermophilus reverse transcription compositions and kits
US6632645B1 (en) 2000-03-02 2003-10-14 Promega Corporation Thermophilic DNA polymerases from Thermoactinomyces vulgaris
US6436677B1 (en) 2000-03-02 2002-08-20 Promega Corporation Method of reverse transcription
US7504220B2 (en) 2000-03-02 2009-03-17 Promega Corporation Method of reverse transcription
WO2001064954A1 (en) 2000-03-02 2001-09-07 Promega Corporation Method of reverse transcription using bacillus steraothermophilus or thermoactinomyces vulgaris dna polymerase
US7214522B2 (en) 2000-03-02 2007-05-08 Promega Corporation Thermophilic DNA polymerases from Thermoactinomyces vulgaris
US8895284B2 (en) 2000-03-03 2014-11-25 President And Fellows Of Harvard College Class II human histone deacetylases, and uses related thereto
US8435780B2 (en) 2000-03-03 2013-05-07 President And Fellows Of Harvard College Class II human histone deacetylases, and uses related thereto
EP1714661A2 (en) 2000-05-19 2006-10-25 The Center for Blood Research, INC. Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
US6573370B1 (en) 2000-05-19 2003-06-03 Regents Of The University Of Michigan PON3 and uses thereof
US6916472B2 (en) 2000-05-19 2005-07-12 Regents Of The University Of Michigan PON3 and uses thereof
EP2251026A1 (en) 2000-06-08 2010-11-17 Immune Disease Institute, Inc. Methods and compositions for inhibiting immunoglobulin-mediated reperfusion injury
WO2002000730A2 (en) 2000-06-28 2002-01-03 Genetics Institute, Llc. Pd-l2 molecules: novel pd-1 ligands and uses therefor
US8475766B2 (en) 2000-06-29 2013-07-02 Abbvie Inc. Dual specificity antibodies and methods of making and using
EP2386575A2 (en) 2000-06-29 2011-11-16 Abbott Laboratories Dual specificity antibodies and methods of making and using
EP2042518A2 (en) 2000-06-29 2009-04-01 Abbott Laboratories Dual specificity antibodies and methods of making and using
US7491516B2 (en) 2000-06-29 2009-02-17 Abbott Laboratories Dual specificity antibodies and methods of making and using
EP2899210A2 (en) 2000-06-29 2015-07-29 Abbvie Inc. Dual specificity antibodies and methods of making and using
WO2002028893A2 (en) 2000-07-14 2002-04-11 Cropdesign N.V. Plant cyclin-dependent kinase inhibitors
US6878861B2 (en) 2000-07-21 2005-04-12 Washington State University Research Foundation Acyl coenzyme A thioesterases
US7405276B2 (en) 2000-11-01 2008-07-29 Elusys Therapeutics, Inc. Method of producing bispecific molecules by protein trans-splicing
EP2316976A1 (en) 2000-11-28 2011-05-04 Wyeth LLC Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
EP2295606A1 (en) 2000-11-28 2011-03-16 Wyeth LLC Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US7815907B2 (en) 2001-01-05 2010-10-19 Amgen Fremont Inc. Antibodies to insulin-like growth factor I receptor
EP2796468A2 (en) 2001-01-05 2014-10-29 Pfizer Inc Antibodies to insulin-like growth factor I receptor
US8642037B2 (en) 2001-01-05 2014-02-04 Amgen Fremont Inc. Antibodies to insulin-like growth factor I receptor
US7700742B2 (en) 2001-01-05 2010-04-20 Amgen Fremont Antibodies to insulin-like growth factor I receptor
US9234041B2 (en) 2001-01-05 2016-01-12 Pfizer Inc. Antibodies to insulin-like growth factor I receptor
EP2194067A2 (en) 2001-01-05 2010-06-09 Pfizer Inc. Antibodies to insulin-like growth factor I receptor (IGF-IR)
US7037498B2 (en) 2001-01-05 2006-05-02 Abgenix, Inc. Antibodies to insulin-like growth factor I receptor
US7982024B2 (en) 2001-01-05 2011-07-19 Amgen Fremont Inc. Antibodies to insulin-like growth factor I receptor
EP2292301A2 (en) 2001-02-22 2011-03-09 Genentech, Inc. Anti-interferon-alpha antibodies
EP2065467A2 (en) 2001-02-22 2009-06-03 Genentech, Inc. Anti-interferon-alpha antibodies
EP2077324A2 (en) 2001-02-23 2009-07-08 DSM IP Assets B.V. Genes encoding proteolytic enzymes from aspargilli
EP2123749A2 (en) 2001-02-23 2009-11-25 DSM IP Assets B.V. Novel genes encoding novel proteolytic enzymes
EP1975620A2 (en) 2001-03-02 2008-10-01 GPC Biotech AG Three hybrid assay system
EP2294917A1 (en) 2001-03-22 2011-03-16 Abbott GmbH & Co. KG Transgenic animals expressing antibodies specific for genes of interest and uses thereof
US7795494B2 (en) 2001-03-22 2010-09-14 Abbott Laboratories Transgenic mice expressing antibodies specific for genes of interest and uses thereof
EP2388590A1 (en) 2001-04-02 2011-11-23 Dana Farber Cancer Institute PD-1, a receptor for B7-4, and uses thereof
EP2278013A1 (en) 2001-04-16 2011-01-26 Wyeth Holdings Corporation Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
EP2258718A1 (en) 2001-04-16 2010-12-08 Wyeth Holdings Corporation Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
EP2258842A1 (en) 2001-04-16 2010-12-08 Wyeth Holdings Corporation Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
EP2261241A1 (en) 2001-04-16 2010-12-15 Wyeth Holdings Corporation Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
EP2277897A1 (en) 2001-04-16 2011-01-26 Wyeth Holdings Corporation Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
US8178579B2 (en) 2001-05-09 2012-05-15 President And Fellows Of Harvard College Dioxanes and uses thereof
EP2940044A1 (en) 2001-06-08 2015-11-04 AbbVie Biotechnology Ltd Methods of administering anti-tnfalpha antibodies
EP2364731A2 (en) 2001-06-08 2011-09-14 Abbott Biotechnology Ltd Methods of administering anti-TNFalpha antibodies
EP3190124A1 (en) 2001-06-08 2017-07-12 AbbVie Biotechnology Ltd Adalimumab for use in therapy of rheumatoid arthritis
WO2002100330A2 (en) 2001-06-08 2002-12-19 Abbott Biotechnology Ltd METHODS OF ADMINISTERING ANTI-TNFα ANTIBODIES
EP2324851A1 (en) 2001-06-08 2011-05-25 Abbott Biotechnology Ltd Methods of administering anti-TNFalpha antibodies
EP2359855A2 (en) 2001-06-08 2011-08-24 Abbott Biotechnology Ltd Methods of administering anti-TNFalpha antibodies
EP2270187A2 (en) 2001-06-22 2011-01-05 Pioneer Hi-Bred International, Inc. Defensin polynucleotides and methods of use
EP2270186A2 (en) 2001-06-22 2011-01-05 Pioneer Hi-Bred International, Inc. Defensin polynucleotides and methods of use
EP2270185A2 (en) 2001-06-22 2011-01-05 Pioneer Hi-Bred International, Inc. Defensin polynucleotides and methods of use
EP2270165A2 (en) 2001-06-22 2011-01-05 Pioneer Hi-Bred International, Inc. Defensin polynucleotides and methods of use
EP2270188A2 (en) 2001-06-22 2011-01-05 Pioneer Hi-Bred International, Inc. Defensin polynucleotides and methods of use
EP2270184A2 (en) 2001-06-22 2011-01-05 Pioneer Hi-Bred International, Inc. Defensin polynucleotides and methods of use
EP2333070A2 (en) 2001-06-22 2011-06-15 Pioneer Hi-Bred International, Inc. Defensin polynucleotides and methods of use
US7745391B2 (en) 2001-09-14 2010-06-29 Compugen Ltd. Human thrombospondin polypeptide
US7288251B2 (en) 2001-11-09 2007-10-30 Abgenix, Inc. Antibodies to CD40
US7626012B2 (en) 2001-11-09 2009-12-01 Amgen Fremont Inc. Nucleic acid molecules which encode antibodies that bind CD40
EP2343086A2 (en) 2001-11-09 2011-07-13 Pfizer Products Inc. Antibodies to CD40
US7618633B2 (en) 2001-11-09 2009-11-17 Amgen Fremont Inc. Antibodies that bind CD40 and methods of treating cancer and enhancing immune responses
WO2003040170A2 (en) 2001-11-09 2003-05-15 Pfizer Products Inc. Antibodies to cd40
US7338660B2 (en) 2001-11-09 2008-03-04 Abgenix, Inc. Methods of treating cancer and enhancing immune responses with antibodies that bind CD40
US8388971B2 (en) 2001-11-09 2013-03-05 Amgen Fremont Inc. Antibodies that bind CD40 and methods of treating cancer and enhancing immune responses
US7563442B2 (en) 2001-11-09 2009-07-21 Abgenix, Inc. Antibodies to CD40 and methods of treating cancer and enhancing immune responses
US7572886B2 (en) 2001-12-18 2009-08-11 Centre National De La Recherche Scientifique Death associated proteins, and THAP1 and PAR4 pathways in apoptosis control
US7892727B2 (en) 2001-12-18 2011-02-22 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
US7087418B2 (en) 2001-12-19 2006-08-08 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
EP2060628A1 (en) 2002-02-13 2009-05-20 XOMA Technology Ltd. Eukaryotic signal sequences for polypeptide expression and polypeptide display libraries
US7323175B2 (en) 2002-03-07 2008-01-29 The Forsyth Institute Immunogenicity of glucan binding protein
WO2003082914A1 (en) 2002-04-03 2003-10-09 The University Of Queensland Prothrombin activating protein
EP2347766A1 (en) 2002-04-26 2011-07-27 Abbott Biotechnology Ltd Use of TNFalpha antibodies and another drug
EP2196218A2 (en) 2002-04-26 2010-06-16 Abbott Biotechnology Ltd Use of anti-TNFalpha antibodies and another drug
US7588925B2 (en) 2002-05-21 2009-09-15 Dsm Ip Assets B.V. Phospholipases and uses thereof
US7838274B2 (en) 2002-05-21 2010-11-23 Dsm Ip Assets B.V. Phospholipases and uses thereof
US7667099B2 (en) 2002-06-20 2010-02-23 Board Of Trustees Of Michigan State University Plastid division and related genes and proteins, and methods of use
US9303081B2 (en) 2002-07-18 2016-04-05 Merus B.V. Recombinant production of mixtures of antibodies
US7932360B2 (en) 2002-07-18 2011-04-26 Merus B.V. Recombinant production of mixtures of antibodies
US10934571B2 (en) 2002-07-18 2021-03-02 Merus N.V. Recombinant production of mixtures of antibodies
US7927834B2 (en) 2002-07-18 2011-04-19 Merus B.V. Recombinant production of mixtures of antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
EP2371859A2 (en) 2002-07-19 2011-10-05 Abbott Biotechnology Ltd Treatment of TNF alpha related disorders
EP2336182A1 (en) 2002-07-19 2011-06-22 Abbott Biotechnology Ltd Treatment of TNF alpha related disorders
EP1944322A2 (en) 2002-07-19 2008-07-16 Abbott Biotechnology Ltd. Treatment of TNF alpha related disorders
EP2298810A2 (en) 2002-07-19 2011-03-23 Abbott Biotechnology Ltd Treatment of TNF alpha related disorders
EP2942359A1 (en) 2002-07-19 2015-11-11 AbbVie Biotechnology Ltd Treatment of TNF alpha related disorders
US7250551B2 (en) 2002-07-24 2007-07-31 President And Fellows Of Harvard College Transgenic mice expressing inducible human p25
US8030456B2 (en) 2002-08-10 2011-10-04 Yale University Nogo receptor antagonists
US7465705B2 (en) 2002-08-10 2008-12-16 Yale University Nogo receptor antagonists
US8216586B2 (en) 2002-08-19 2012-07-10 Dsm Ip Assets B.V. Lipases and uses thereof
EP2338986A1 (en) 2002-08-19 2011-06-29 DSM IP Assets B.V. Novel lipases and uses thereof
US7550280B2 (en) 2002-08-19 2009-06-23 Dsm Ip Assets B.V. Lipases and uses thereof
EP2311979A1 (en) 2002-08-20 2011-04-20 Millennium Pharmaceuticals, Inc. Compositions, kits and methods for identification, assessment, prevention and therapy of cervical cancer
EP2311978A1 (en) 2002-08-20 2011-04-20 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
EP2314716A1 (en) 2002-08-20 2011-04-27 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
EP2305836A1 (en) 2002-08-20 2011-04-06 Millennium Pharmaceuticals, Inc. Compositions, kits and methods for identification, assessment, prevention and therapy of cervical cancer
US7455989B2 (en) 2002-08-20 2008-11-25 Yeda Research And Development Co. Ltd. AKAP84 and its use for visualization of biological structures
EP2311980A1 (en) 2002-08-20 2011-04-20 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
EP2181711A1 (en) 2002-09-04 2010-05-05 Biopolymer Engineering, Inc. Cancer therapy using whole glucan particles and antibodies
EP2290107A1 (en) 2003-01-07 2011-03-02 Dyax Corporation Kunitz domain library
EP2336160A2 (en) 2003-01-31 2011-06-22 Abbott GmbH & Co. KG Amyloid-beta(1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use thereof.
EP2336159A2 (en) 2003-01-31 2011-06-22 Abbott GmbH & Co. KG Amyloid-beta(1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use thereof.
EP2336161A2 (en) 2003-01-31 2011-06-22 Abbott GmbH & Co. KG Amyloid-beta(1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use thereof.
US10464976B2 (en) 2003-01-31 2019-11-05 AbbVie Deutschland GmbH & Co. KG Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
EP1592777A2 (en) * 2003-02-01 2005-11-09 Tanox, Inc. A method for generating high affinity antibodies
EP1592777A4 (en) * 2003-02-01 2008-06-04 Tanox Inc A method for generating high affinity antibodies
EP2316969A1 (en) 2003-03-13 2011-05-04 Fujirebio America, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
AU2004232962B2 (en) * 2003-04-16 2012-02-02 Genentech, Inc. Compositions and methods relating to STOP-1
US7799899B2 (en) 2003-04-16 2010-09-21 Genentech, Inc. Compositions and methods relating to STOP-1
WO2004094476A3 (en) * 2003-04-16 2005-06-16 Genentech Inc Compositions and methods relating to stop-1
EP2386318A1 (en) 2003-05-15 2011-11-16 Iogenetics, Inc. Targeted biocides
US9738701B2 (en) 2003-05-30 2017-08-22 Merus N.V. Method for selecting a single cell expressing a heterogeneous combination of antibodies
US10605808B2 (en) 2003-05-30 2020-03-31 Merus N.V. Antibody producing non-human animals
US7919257B2 (en) 2003-05-30 2011-04-05 Merus Biopharmaceuticals, B.V.I.O. Method for selecting a single cell expressing a heterogeneous combination of antibodies
US10670599B2 (en) 2003-05-30 2020-06-02 Merus N.V. Method for selecting a single cell expressing a heterogeneous combination of antibodies
EP2508608A1 (en) 2003-06-09 2012-10-10 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
US8562985B2 (en) 2003-08-04 2013-10-22 Amgen Fremont Inc. Antibodies to c-Met
US7498420B2 (en) 2003-08-04 2009-03-03 Amgen Fremont Inc. Antibodies to c-Met
US8163280B2 (en) 2003-08-04 2012-04-24 Amgen Fremont Inc. Antibodies to c-Met
US8821869B2 (en) 2003-08-04 2014-09-02 Amgen Fremont Inc. Treatment methods using c-Met antibodies
US7326414B2 (en) 2003-09-10 2008-02-05 Warner-Lambert Company Llc Antibodies to M-CSF
US10280219B2 (en) 2003-09-10 2019-05-07 Amgen Fremont Inc. Antibodies to M-CSF
US9718883B2 (en) 2003-09-10 2017-08-01 Amgen Fremont Inc. Antibodies to M-CSF
EP3170840A1 (en) 2003-09-10 2017-05-24 Warner-Lambert Company LLC Antibodies to m-csf
EP2051077A2 (en) 2003-10-07 2009-04-22 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
EP2261667A2 (en) 2003-10-07 2010-12-15 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and their therapy of ovarian cancer
EP2441474A1 (en) 2003-10-17 2012-04-18 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
EP2460830A2 (en) 2003-11-12 2012-06-06 Abbott Laboratories IL-18 binding proteins
EP2385070A1 (en) 2003-11-12 2011-11-09 Abbott Laboratories Il-18 binding proteins
EP2395020A2 (en) 2003-11-12 2011-12-14 Abbott Laboratories IL-18 binding proteins
EP2460829A2 (en) 2003-11-12 2012-06-06 Abbott Laboratories IL-18 binding proteins
US10259872B2 (en) 2004-01-09 2019-04-16 Pfizer, Inc. Antibodies to MAdCAM
USRE45847E1 (en) 2004-01-09 2016-01-19 Pfizer Inc. Antibodies to MAdCAM
US7932372B2 (en) 2004-01-09 2011-04-26 Amgen Fremont Inc. Antibodies to MAdCAM
EP2177537A2 (en) 2004-01-09 2010-04-21 Pfizer Inc. Antibodies to MAdCAM
US9328169B2 (en) 2004-01-09 2016-05-03 Pfizer Inc. Human antibodies that bind human MAdCAM
EP2133427A1 (en) 2004-01-14 2009-12-16 Ohio University Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
US9006410B2 (en) 2004-01-14 2015-04-14 Ohio University Nucleic acid for plant expression of a fusion protein comprising hydroxyproline O-glycosylation glycomodule
US9012371B2 (en) 2004-01-20 2015-04-21 Merus B.V. Mixtures of binding proteins
US8268756B2 (en) 2004-01-20 2012-09-18 Merus B.V. Mixture of binding proteins
EP2444805A2 (en) 2004-01-21 2012-04-25 Fujirebio America, Inc. Detection of mesothelin-/megakaryocyte potentiating factor-related peptides in peritoneal fluid for assessment of the peritoneum and the peritoneal cavity
EP2368579A1 (en) 2004-01-21 2011-09-28 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
EP2033662A1 (en) 2004-01-21 2009-03-11 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
EP2290077A2 (en) 2004-03-01 2011-03-02 Immune Disease Institute, Inc. Natural IGM antibodies and inhibitors thereof
EP2293069A2 (en) 2004-03-24 2011-03-09 Tripath Imaging, Inc. Methods and compositions for the detection of cervical disease
EP2335732A2 (en) 2004-04-09 2011-06-22 Abbott Biotechnology Ltd Multiple-variable dose regimen for treating TNF-alpha-related disorders
EP2338516A2 (en) 2004-04-09 2011-06-29 Abbott Biotechnology Ltd Multiple-variable dose regimen for treating TNF-alpha-related disorders
EP2335731A2 (en) 2004-04-09 2011-06-22 Abbott Biotechnology Ltd Multiple-variable dose regimen for treating TNF-alpha-related disorders
US8623812B2 (en) 2004-04-19 2014-01-07 Ohio University Cross-linkable glycoproteins and methods of making the same
EP2270034A2 (en) 2004-06-03 2011-01-05 Athlomics Pty Ltd Agents and methods for diagnosing stress
EP2527447A1 (en) 2004-06-03 2012-11-28 Athlomics Pty Ltd Agents and methods for diagnosing stress
EP2527446A1 (en) 2004-06-03 2012-11-28 Athlomics Pty Ltd Agents and methods for diagnosing stress
US9017287B2 (en) 2004-06-23 2015-04-28 Abbvie Biotechnology Ltd Automatic injection devices
US7618626B2 (en) 2004-07-16 2009-11-17 Pfizer Inc Combination treatment for non-hematologic malignancies
WO2006014744A2 (en) 2004-07-23 2006-02-09 University Of Massachusetts Compounds that inhibit hsp90 protein-protein interactions with iap proteins
EP2290086A2 (en) 2004-12-22 2011-03-02 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
EP2290088A1 (en) 2004-12-22 2011-03-02 Genentech, Inc. Methods for producing soluble multi-menbrane-spanning proteins
EP2290087A2 (en) 2004-12-22 2011-03-02 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
US9856311B2 (en) 2005-01-05 2018-01-02 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
US10385118B2 (en) 2005-01-05 2019-08-20 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
EP2392353A1 (en) 2005-01-28 2011-12-07 Janssen Alzheimer Immunotherapy Anti A beta antibody formulation
US9572854B2 (en) 2005-03-22 2017-02-21 President And Fellows Of Harvard College Treatment of protein degradation disorders
US10172905B1 (en) 2005-03-22 2019-01-08 President And Fellows Of Harvard College Treatment of protein degradation disorders
US8999289B2 (en) 2005-03-22 2015-04-07 President And Fellows Of Harvard College Treatment of protein degradation disorders
EP3312196A1 (en) 2005-03-23 2018-04-25 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
EP2551282A2 (en) 2005-03-23 2013-01-30 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
EP3153525A1 (en) 2005-03-23 2017-04-12 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
EP2567976A2 (en) 2005-03-23 2013-03-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
EP2535355A2 (en) 2005-03-23 2012-12-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
EP2295466A2 (en) 2005-04-25 2011-03-16 Pfizer Inc. Antibodies to myostatin
EP2444419A1 (en) 2005-04-26 2012-04-25 Pfizer Inc. P-Cadherin antibodies
EP2444420A1 (en) 2005-04-26 2012-04-25 Pfizer Inc. P-Cadherin antibodies
EP2444421A1 (en) 2005-04-26 2012-04-25 Pfizer Inc. P-Cadherin antibodies
WO2006116442A2 (en) 2005-04-27 2006-11-02 Tripath Imaging, Inc. Monoclonal antibodies and methods for their use in the detection of cervical disease
EP2332988A2 (en) 2005-04-27 2011-06-15 Tripath Imaging, Inc. Monoclonal antibodies and methods for their use in the detection of cervical disease
EP2500037A2 (en) 2005-05-16 2012-09-19 Abbott Biotechnology Ltd Use of TNF alpha inhibitor for treatment of erosive polyarthritis
EP3263581A1 (en) 2005-05-17 2018-01-03 University of Connecticut Compositions and methods for immunomodulation in an organism
EP2460831A2 (en) 2005-05-27 2012-06-06 Biogen Idec MA Inc. Tweak binding antibodies
EP2460832A2 (en) 2005-05-27 2012-06-06 Biogen Idec MA Inc. TWEAK binding antibodies
EP2388274A1 (en) 2005-06-17 2011-11-23 Janssen Alzheimer Immunotherapy Methods of purifying anti A Beta antibodies
US7700739B2 (en) 2005-06-30 2010-04-20 Abbott Laboratories IL-12/p40 binding proteins
US8629257B2 (en) 2005-06-30 2014-01-14 Abbvie Inc. IL-12/p40 binding proteins
EP2476761A2 (en) 2005-07-07 2012-07-18 Athlomics Pty Ltd Polynucleotide marker genes and their expression, for diagnosis of endotoxemia
EP2216653A1 (en) 2005-08-02 2010-08-11 XBiotech, Inc Diagnosis, treatment and prevention of vascular disorders using il-1alpha autoantibodies
WO2007024715A2 (en) 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
EP2500358A2 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500356A2 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500353A2 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500354A2 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500355A2 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500359A2 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2520588A1 (en) 2005-08-19 2012-11-07 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500352A1 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500357A2 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007024705A2 (en) 2005-08-19 2007-03-01 Abbott Biotechnology Ltd. Method of treating depression using a tnf-alpha antibody
EP2495257A2 (en) 2005-08-19 2012-09-05 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8080646B2 (en) 2005-09-07 2011-12-20 Amgen Fremont, Inc. Human monoclonal antibodies to activin receptor-like kinase-1
EP2447283A2 (en) 2005-09-07 2012-05-02 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1 (ALK-1)
US9221915B2 (en) 2005-09-07 2015-12-29 Pfizer Inc. Human monoclonal antibodies to activin receptor-like kinase-1
US7537762B2 (en) 2005-09-07 2009-05-26 Amgen Fremont, Inc. Human monoclonal antibodies to activin receptor-like kinase-1
EP2960253A1 (en) 2005-09-07 2015-12-30 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
EP3381945A1 (en) 2005-09-07 2018-10-03 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
EP2862867A2 (en) 2005-10-25 2015-04-22 The Johns Hopkins University Methods and compositions for the treatment of Marfan syndrome and associated disorders
EP2357479A1 (en) 2005-11-01 2011-08-17 Abbott Biotechnology Ltd Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
WO2007089303A2 (en) 2005-11-01 2007-08-09 Abbott Biotechnology Ltd. Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
EP2365334A1 (en) 2005-11-14 2011-09-14 MetaMol Theranostics, LLC Peptide sequence that promotes tumor invasion
US7807790B2 (en) 2005-11-14 2010-10-05 Metamol Theranostics, Llc Peptide sequence that promotes tumor invasion
US8969020B2 (en) 2005-11-14 2015-03-03 Metamol Theranostics Llc Peptide sequence that promotes tumor invasion
EP2410335A1 (en) 2005-11-30 2012-01-25 Massachusetts Institute of Technology (MIT) Pathogen detection biosensor
US10208109B2 (en) 2005-11-30 2019-02-19 Abbvie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
EP2289909A1 (en) 2005-11-30 2011-03-02 Abbott Laboratories Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
US10323084B2 (en) 2005-11-30 2019-06-18 Abbvie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
US10538581B2 (en) 2005-11-30 2020-01-21 Abbvie Inc. Anti-Aβ globulomer 4D10 antibodies
US8957187B2 (en) 2005-12-02 2015-02-17 Genentech, Inc. Binding polypeptides and uses thereof
EP2336170A2 (en) 2005-12-15 2011-06-22 Industrial Technology Research Institute Recombinant triplex scaffold-based polypeptides
EP2325208A1 (en) 2005-12-15 2011-05-25 Genentech, Inc. Polyubiquitin antibodies
EP3309170A1 (en) 2005-12-15 2018-04-18 Genentech, Inc. Polyubiquitin antibodies
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
EP2338912A2 (en) 2005-12-15 2011-06-29 Industrial Technology Research Institute Recombinant triplex scaffold-base polypeptides
EP2455395A1 (en) 2005-12-19 2012-05-23 Tripath Imaging, Inc. MCM6 monoclonal antibodies and methods for their use in the detection of cervical disease
EP3156418A1 (en) 2006-01-05 2017-04-19 Genentech, Inc. Anti-ephb4 antibodies and methods using same
EP2402373A2 (en) 2006-01-05 2012-01-04 Genentech, Inc. Anti-EphB4 Antibodies and Methods Using Same
EP2363711A1 (en) 2006-01-27 2011-09-07 Tripath Imaging, Inc. Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
US9228015B2 (en) 2006-01-27 2016-01-05 Biogen Idec Ma Inc. Nogo receptor antagonists and methods of increasing neurite outgrowth
US8669345B2 (en) 2006-01-27 2014-03-11 Biogen Idec Ma Inc. Nogo receptor antagonists
EP2526968A2 (en) 2006-01-27 2012-11-28 Biogen Idec MA Inc. Nogo receptor antagonists
US7846439B2 (en) 2006-02-01 2010-12-07 Cephalon Australia Pty Ltd Domain antibody construct
US8754237B2 (en) 2006-02-14 2014-06-17 President And Fellows Of Harvard College Bifunctional histone deacetylase inhibitors
US8222423B2 (en) 2006-02-14 2012-07-17 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
EP2327423A2 (en) 2006-02-21 2011-06-01 Wyeth LLC Human antibodies against human interleukin-22 (IL-22)
EP3020729A1 (en) 2006-02-21 2016-05-18 Wyeth LLC Antibodies against human il-22 and uses therefor
EP2431392A1 (en) 2006-02-21 2012-03-21 Wyeth LLC Antibodies against human IL-22 and uses therefor
EP2468772A2 (en) 2006-03-16 2012-06-27 Genentech, Inc. Antibodies to EGFL7 and methods for their use
US8278421B2 (en) 2006-03-20 2012-10-02 Xoma Techolology Ltd. Human antibodies specific for gastrin materials and methods
EP3088410A2 (en) 2006-04-05 2016-11-02 AbbVie Biotechnology Ltd Antibody purification
EP2738179A1 (en) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
EP2738178A1 (en) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
EP2708242A2 (en) 2006-04-10 2014-03-19 Abbott Biotechnology Ltd Uses and compositions for treatment of ankylosing spondylitis
EP2666478A2 (en) 2006-04-10 2013-11-27 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriasis
EP2666480A2 (en) 2006-04-10 2013-11-27 Abbott Biotechnology Ltd Uses and compositions for treatment of Crohn's desease
EP2703010A2 (en) 2006-04-10 2014-03-05 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
EP2666479A2 (en) 2006-04-10 2013-11-27 Abbott Biotechnology Ltd Uses and compositions for treatment of juvenile rheumatoid arthritis
EP2666472A2 (en) 2006-04-10 2013-11-27 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
US10529441B2 (en) 2006-05-03 2020-01-07 Population Bio, Inc. Evaluating genetic disorders
US10210306B2 (en) 2006-05-03 2019-02-19 Population Bio, Inc. Evaluating genetic disorders
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
US8304451B2 (en) 2006-05-03 2012-11-06 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
EP2447282A2 (en) 2006-05-30 2012-05-02 Genentech, Inc. Anti-CD22 Antibodies, their Immunoconjugates and uses thereof
EP2446904A2 (en) 2006-05-30 2012-05-02 Genentech, Inc. Anti-CD22 antibodies, their immunoconjugates and uses thereof
US7803377B2 (en) 2006-06-06 2010-09-28 Genentech, Inc. Anti-DLL4 antibodies and methods using same
US9486584B2 (en) 2006-06-30 2016-11-08 Abbvie Biotechnology Ltd. Automatic injection device
EP3034607A1 (en) 2006-07-05 2016-06-22 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
EP2402438A2 (en) 2006-07-05 2012-01-04 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
EP2402437A2 (en) 2006-07-05 2012-01-04 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
US11827720B2 (en) 2006-07-05 2023-11-28 F-Star Therapeutics Limited Multivalent immunoglobulins
EP2511301A2 (en) 2006-08-04 2012-10-17 Medimmune Limited Human antibodies to ERBB2
EP3339445A1 (en) 2006-09-08 2018-06-27 AbbVie Bahamas Ltd. Interleukin -13 binding proteins
US10086076B2 (en) 2006-09-08 2018-10-02 Abbvie Inc. Interleukin-13 binding proteins
EP3524685A1 (en) 2006-09-08 2019-08-14 AbbVie Bahamas Ltd. Interleukin -13 binding proteins
EP3910065A1 (en) 2006-09-08 2021-11-17 AbbVie Bahamas Ltd. Interleukin -13 binding proteins
US11344621B2 (en) 2006-09-08 2022-05-31 Abbvie, Inc. Interleukin-13 binding proteins
EP3569245A1 (en) 2006-09-26 2019-11-20 Genmab A/S Combination treatment of cd38-expressing tumors
EP3753576A1 (en) 2006-09-26 2020-12-23 Genmab A/S Combination treatment of cd38-expressing tumors
US7744890B2 (en) 2006-10-12 2010-06-29 Wyeth Llc Methods and compositions with reduced opalescence
EP2845866A1 (en) 2006-10-27 2015-03-11 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
WO2008052187A2 (en) 2006-10-27 2008-05-02 Genentech. Inc. Antibodies and immunoconjugates and uses therefor
EP2395077A1 (en) 2006-11-03 2011-12-14 Wyeth LLC Glycolysis-inhibiting substances in cell culture
US8192951B2 (en) 2006-11-03 2012-06-05 Wyeth Llc Glycolysis-inhibiting substances in cell culture
EP2514439A1 (en) 2006-11-15 2012-10-24 Functional Genetics, Inc. Anti-TSG101antibodies and their uses for treatment of viral infections
US7964708B2 (en) 2006-11-15 2011-06-21 Limin Li Anti-TSG101 antibodies and their uses for treatment of viral infections
US8796423B2 (en) 2006-11-15 2014-08-05 Eli Lilly And Company Anti-TSG101 antibodies and their uses for treatment of viral infections
US7488807B2 (en) 2006-11-22 2009-02-10 3M Innovative Properties Company Antibody with protein A selectivity
US9951125B2 (en) 2006-11-30 2018-04-24 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8637244B2 (en) 2006-12-05 2014-01-28 Decode Genetics Ehf. Genetic markers for risk management of atrial fibrillation, atrial flutter, and stroke
EP3124045A2 (en) 2006-12-20 2017-02-01 Xoma (Us) Llc Treatment of il-1 beta related diseases
WO2008083174A2 (en) 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
EP3064220A2 (en) 2006-12-27 2016-09-07 Emory University Compositions and methods for the treatment of infections and tumors
EP2133365A2 (en) 2006-12-27 2009-12-16 Emory University Compositions and methods for the treatment of infections and tumors
EP3721903A1 (en) 2006-12-27 2020-10-14 Emory University Compositions and methods for the treatment of infections and tumors
US8324350B2 (en) 2006-12-29 2012-12-04 Abbott Laboratories Dual-specific IL-1α/IL-1β antibodies
EP2839743A1 (en) 2007-01-16 2015-02-25 Abbvie Inc. Methods for treating psoriasis
US7776331B1 (en) 2007-01-16 2010-08-17 Abbott Laboratories Methods of treating plaque psoriasis
US9051368B2 (en) 2007-01-16 2015-06-09 Abbvie, Inc. Methods for treating psoriasis by administering an antibody which binds an epitope of the p40 subunit of IL-12 and/or IL-23
US8865400B2 (en) 2007-02-07 2014-10-21 Decode Genetics Ehf. Genetic variants contributing to risk of prostate cancer
US9617597B2 (en) 2007-02-21 2017-04-11 Decode Genetics Ehf Genetic susceptibility variants associated with cardiovascular disease
US11673938B2 (en) 2007-03-22 2023-06-13 Heptares Therapeutics Limited Mutant G-protein coupled receptors and methods for selecting them
US8785135B2 (en) 2007-03-22 2014-07-22 Heptares Therapeutics Limited Mutant G-protein coupled receptors and methods for selecting them
US10317393B2 (en) 2007-03-23 2019-06-11 Academia Sinica Alkynyl sugar analogs for labeling and visualization of glycoconjugates in cells
US8940873B2 (en) 2007-03-29 2015-01-27 Abbvie Inc. Crystalline anti-human IL-12 antibodies
US8168760B2 (en) 2007-03-29 2012-05-01 Abbott Laboratories Crystalline anti-human IL-12 antibodies
US8404819B2 (en) 2007-03-29 2013-03-26 Abbvie Inc. Crystalline anti-human IL-12 antibodies
US7867494B2 (en) 2007-04-02 2011-01-11 Amgen Fremont Inc. Anti-IgE antibodies
EP2481797A1 (en) 2007-04-13 2012-08-01 Catalyst Biosciences, Inc. Modified factor VII polypeptides and uses thereof
EP2535425A1 (en) 2007-05-25 2012-12-19 Decode Genetics EHF. Variantes génétiques sur les chr 10q26 utilisées comme marqueurs dans l'évaluation, le diagnostic, le pronostic et le traitement d'un risque de cancer du sein
US8580501B2 (en) 2007-05-25 2013-11-12 Decode Genetics Ehf. Genetic variants on chr 5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
US8138313B2 (en) 2007-06-15 2012-03-20 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Treatment of tumors using specific anti-L1 antibody
US9260521B2 (en) 2007-06-15 2016-02-16 Medigene Ag Treatment of tumors using specific anti-L1 antibody
WO2008151819A2 (en) 2007-06-15 2008-12-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Treatment of tumors using specific anti-l1 antibody
EP3241842A1 (en) 2007-06-26 2017-11-08 F-Star Biotechnologische Forschungs- und Entwicklungsges.m.b.H Display of binding agents
US8921279B2 (en) 2007-06-26 2014-12-30 F-Star Biotechnologische Forschungs—und Entwicklungsges. m.b.H Display of binding agents
US9651559B2 (en) 2007-06-26 2017-05-16 F-star Biotechnologische Forschungs— und Entwicklungsges.m.b.H Display of binding agents
EP2474557A2 (en) 2007-07-16 2012-07-11 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
EP2502937A2 (en) 2007-07-16 2012-09-26 Genentech, Inc. Anti-CD 79b Antibodies And Immunoconjugates And Methods Of Use
EP2641618A2 (en) 2007-07-16 2013-09-25 Genentech, Inc. Humanized anti-CD79B antibodies and immunoconjugates and methods of use
US9062097B2 (en) 2007-08-21 2015-06-23 Morpho Sys AG Methods for the formation of disulphide bonds
WO2009024593A1 (en) 2007-08-21 2009-02-26 Morphosys Ag Improved methods for the formation of disulphide bonds
EP3173425A1 (en) 2007-11-30 2017-05-31 Genentech, Inc. Anti-vegf antibodies
US8697360B2 (en) 2007-11-30 2014-04-15 Decode Genetics Ehf. Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition
EP2851372A1 (en) 2007-11-30 2015-03-25 Genentech, Inc. Anti-VEGF antibodies
EP2065402A1 (en) 2007-11-30 2009-06-03 Industrial Technology Research Institut Trimeric collagen scaffold antibodies
US8748182B2 (en) 2007-12-08 2014-06-10 Heptares Therapeutics Limited Mutant proteins and methods for producing them
US10126313B2 (en) 2007-12-20 2018-11-13 Heptares Therapeutics Limited Methods for screening for binding partners of G-protein coupled receptors
EP2851373A1 (en) 2007-12-20 2015-03-25 Xoma (Us) Llc Methods for the treatment of gout
EP2573563A1 (en) 2007-12-20 2013-03-27 Heptares Therapeutics Limited Screening
US8790933B2 (en) 2007-12-20 2014-07-29 Heptares Therapeutics Limited Screening
WO2009086003A1 (en) 2007-12-20 2009-07-09 Xoma Technology Ltd. Methods for the treatment of gout
US9260505B2 (en) 2007-12-20 2016-02-16 Heptares Therapeutics Limited Methods for screening for binding partners of G-protein coupled receptors
WO2009086539A2 (en) 2007-12-28 2009-07-09 Elan Pharmaceuticals, Inc. Treatment and prophylaxis of amyloidosis
EP3693470A1 (en) 2007-12-28 2020-08-12 Prothena Therapeutics Limited Treatment and prophylaxis of amyloidosis
EP2730659A2 (en) 2007-12-28 2014-05-14 Elan Pharmaceuticals Inc. Treatment and Prophylaxis of Amyloidosis
EP2657253A2 (en) 2008-01-31 2013-10-30 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
US9081020B2 (en) 2008-02-11 2015-07-14 Heptares Therapeutics Limited Mutant proteins and methods for selecting them
US8828657B2 (en) 2008-02-14 2014-09-09 Decode Genetics Ehf. Susceptibility variants for lung cancer
US8697374B2 (en) 2008-02-28 2014-04-15 3M Innovative Properties Company Antibodies to Clostridium difficile spores and uses thereof
US9605069B2 (en) 2008-02-29 2017-03-28 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM a protein and uses thereof
EP3309173A1 (en) 2008-02-29 2018-04-18 AbbVie Deutschland GmbH & Co KG Monoclonal antibodies against the rgm a protein and uses thereof
WO2009109572A3 (en) * 2008-03-03 2009-11-12 Ablynx Nv Monovalent phage display of single variable domains
WO2009109572A2 (en) * 2008-03-03 2009-09-11 Ablynx Nv Monovalent phage display of single variable domains
EP2810954A2 (en) 2008-03-18 2014-12-10 Abbvie Inc. Methods for treating psoriasis
US8178092B2 (en) 2008-03-18 2012-05-15 Abbott Laboratories Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23
US8945545B2 (en) 2008-03-18 2015-02-03 Abbvie Inc. Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23
US8808985B2 (en) 2008-04-01 2014-08-19 Decode Genetics Ehf. Susceptibility variants for peripheral arterial disease and abdominal aortic aneurysm
EP3670538A1 (en) 2008-04-25 2020-06-24 Dyax Corp. Antibodies against fcrn and use thereof
EP3348573A1 (en) 2008-04-25 2018-07-18 Dyax Corp. Method of producing antibodies against fcrn and use thereof
US9260520B2 (en) 2008-04-25 2016-02-16 Dyax Corp. Antibodies to FeRn and uses thereof
EP2899209A1 (en) 2008-04-29 2015-07-29 Abbvie Inc. Dual Variable Domain Immunoglobulins and uses thereof
US9029508B2 (en) 2008-04-29 2015-05-12 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US10125197B2 (en) 2008-05-02 2018-11-13 F-Star Biotechnologische Forschungs-Und Entwicklungsges.M.B.H Cytotoxic immunoglobulin
US9255149B2 (en) 2008-05-02 2016-02-09 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Cytotoxic immunoglobulin
EP2698165A1 (en) 2008-05-02 2014-02-19 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Cytotoxic immunoglobulin
EP2630970A1 (en) 2008-05-02 2013-08-28 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
US8859738B2 (en) 2008-05-02 2014-10-14 F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H Cytotoxic immunoglobulin
US9394363B2 (en) 2008-05-09 2016-07-19 AbbVie Deutschland GmbH & Co. KG Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
US8323651B2 (en) 2008-05-09 2012-12-04 Abbott Laboratories Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
EP3059248A1 (en) 2008-05-09 2016-08-24 Abbvie Deutschland GmbH & Co. KG Antibodies to receptor of advanced glycation end products (rage) and uses thereof
EP2116556A1 (en) 2008-05-09 2009-11-11 Abbott GmbH & Co. KG Antibodies to receptor of advanced glycation end products (rage) and uses thereof
EP2500361A1 (en) 2008-05-09 2012-09-19 Abbott GmbH & Co. KG Antibodies to receptor of advanced glycation end products (rage) and uses thereof
WO2009149185A2 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
US9109026B2 (en) 2008-06-03 2015-08-18 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
US9035027B2 (en) 2008-06-03 2015-05-19 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US11237165B2 (en) 2008-06-27 2022-02-01 Merus N.V. Antibody producing non-human animals
US8951735B2 (en) 2008-07-07 2015-02-10 Decode Genetics Ehf. Genetic variants for breast cancer risk assessment
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
EP2810654A1 (en) 2008-07-08 2014-12-10 AbbVie Inc. Prostaglandin E2 binding proteins and uses thereof
US9745375B2 (en) 2008-07-09 2017-08-29 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
US10274488B2 (en) 2008-07-15 2019-04-30 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
US8440716B2 (en) 2008-07-23 2013-05-14 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
US9434686B2 (en) 2008-07-23 2016-09-06 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
US8865868B2 (en) 2008-08-06 2014-10-21 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy
US9771574B2 (en) 2008-09-05 2017-09-26 President And Fellows Of Harvard College Apparatus for continuous directed evolution of proteins and nucleic acids
EP3199630A1 (en) 2008-09-05 2017-08-02 President and Fellows of Harvard College Continuous directed evolution of proteins and nucleic acids
US9023594B2 (en) 2008-09-05 2015-05-05 President And Fellows Of Harvard College Continuous directed evolution of proteins and nucleic acids
WO2010039536A2 (en) 2008-09-23 2010-04-08 President And Fellows Of Harvard College Sirt4 and uses thereof
WO2010039533A2 (en) 2008-09-23 2010-04-08 Wyeth Methods for predicting production of activating signals by cross-linked binding proteins
US10370448B2 (en) 2008-09-26 2019-08-06 Emory University Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
EP3530672A1 (en) 2008-09-26 2019-08-28 Dana Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
US10011656B2 (en) 2008-09-26 2018-07-03 Emory University Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
US8313942B2 (en) 2008-09-26 2012-11-20 Wyeth Llc Compatible display vector systems
US9102727B2 (en) 2008-09-26 2015-08-11 Emory University Human anti-PD-1 antibodies and uses therefor
US9523092B2 (en) 2008-09-26 2016-12-20 Wyeth Llc Compatible display vector systems
US11261251B2 (en) 2008-09-26 2022-03-01 Dana-Farber Cancer Institute, Inc. Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
EP3335728A1 (en) 2008-10-10 2018-06-20 Children's Medical Center Corporation Biochemically stabilized hiv-1 env trimer vaccine
WO2010045315A1 (en) 2008-10-14 2010-04-22 Dyax Corp. Use of igf-ii/igf-iie binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis
EP2921501A1 (en) 2008-10-20 2015-09-23 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
EP3011953A1 (en) 2008-10-29 2016-04-27 Ablynx N.V. Stabilised formulations of single domain antigen binding molecules
US9393304B2 (en) 2008-10-29 2016-07-19 Ablynx N.V. Formulations of single domain antigen binding molecules
EP4104821A1 (en) 2008-10-29 2022-12-21 Ablynx N.V. Formulations of single domain antigen binding molecules
EP3199553A1 (en) 2008-10-29 2017-08-02 China Synthetic Rubber Corporation Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
US11370835B2 (en) 2008-10-29 2022-06-28 Ablynx N.V. Methods for purification of single domain antigen binding molecules
US9993552B2 (en) 2008-10-29 2018-06-12 Ablynx N.V. Formulations of single domain antigen binding molecules
US10118962B2 (en) 2008-10-29 2018-11-06 Ablynx N.V. Methods for purification of single domain antigen binding molecules
WO2010062995A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2
WO2010063011A2 (en) 2008-11-28 2010-06-03 Emory University Methods for the treatment of infections and tumors
WO2010080985A1 (en) 2009-01-08 2010-07-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
US8513192B2 (en) 2009-01-22 2013-08-20 Novo Nordisk A/S Stable growth hormone compounds resistant to proteolytic degradation
WO2010084173A1 (en) 2009-01-22 2010-07-29 Novo Nordisk Health Care Ag Stable growth hormone compounds
US8383778B2 (en) 2009-01-29 2013-02-26 Abbvie Inc. IL-1 binding proteins
USRE45763E1 (en) 2009-02-24 2015-10-20 Abbott Laboratories Antibodies to troponin I and methods of use thereof
WO2010099079A1 (en) 2009-02-24 2010-09-02 Abbott Laboratories Antibodies to troponin i and methods of use thereof
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
EP2853540A1 (en) 2009-02-24 2015-04-01 Abbott Laboratories Antibodies to troponin I and methods of use therof
WO2010102167A1 (en) 2009-03-05 2010-09-10 Becton, Dickinson And Company Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer
EP2810652A2 (en) 2009-03-05 2014-12-10 AbbVie Inc. IL-17 binding proteins
EP2772269A2 (en) 2009-03-05 2014-09-03 Abbvie Inc. IL-17 binding proteins
US9663587B2 (en) 2009-03-05 2017-05-30 Abbvie Inc. IL-17 binding proteins
WO2010102177A1 (en) 2009-03-06 2010-09-10 Becton, Dickinson And Company Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer
US9161977B2 (en) 2009-03-25 2015-10-20 F. Hoffmann-La Roche Ag Anti-FGFR3 antibodies and methods using same
US8710189B2 (en) 2009-03-25 2014-04-29 Genentech, Inc. Anti-FGFR3 antibodies and methods using same
US10287356B2 (en) 2009-03-25 2019-05-14 Genentech, Inc. Anti-FGFR3 antibodies and methods using same
US9499623B2 (en) 2009-03-25 2016-11-22 Genentech, Inc. Anti-FGFR3 antibodies and methods using same
WO2010111367A1 (en) 2009-03-25 2010-09-30 Genentech, Inc. Anti-fgfr3 antibodies and methods using same
EP2679600A1 (en) 2009-03-25 2014-01-01 Genentech, Inc. Anti-FGFR3 antibodies and methods using same
US11401333B2 (en) 2009-03-25 2022-08-02 Genentech, Inc. Anti-FGFR3 antibodies and methods using same
US8410250B2 (en) 2009-03-25 2013-04-02 Genentech, Inc. Anti-FGFR3 antibodies and methods using same
US10000571B2 (en) 2009-03-25 2018-06-19 Genentech, Inc. Anti-FGFR3 antibodies and methods using same
WO2010120561A1 (en) 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
US8795963B2 (en) 2009-04-03 2014-08-05 Decode Genetics Ehf. Genetic markers for risk management of atrial fibrillation and stroke
EP2799453A1 (en) 2009-04-29 2014-11-05 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. ERG monoclonal antibodies
US9561328B2 (en) 2009-04-29 2017-02-07 Abbvie Biotechnology Ltd Automatic injection device
EP2261242A1 (en) 2009-06-10 2010-12-15 Universite Catholique De Louvain Aspartate-N-acetyltransferase enzyme, diagnostic method and therapeutic method
US8703915B2 (en) 2009-06-22 2014-04-22 Heptares Therapeutics Limited Mutant proteins and methods for producing them
EP2272979A1 (en) 2009-06-30 2011-01-12 Centre National de la Recherche Scientifique (CNRS) Method for testing a subject thought to be predisposed to having cancer
WO2011003996A1 (en) 2009-07-09 2011-01-13 F. Hoffmann-La Roche Ag In vivo tumor vasculature imaging
US8796182B2 (en) 2009-07-10 2014-08-05 Decode Genetics Ehf. Genetic markers associated with risk of diabetes mellitus
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
US9259476B2 (en) 2009-07-31 2016-02-16 Wayne State University Monophosphorylated lipid A derivatives
US8809285B2 (en) 2009-07-31 2014-08-19 Wayne State University Monophosphorylated lipid A derivatives
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
US10059657B2 (en) 2009-08-11 2018-08-28 President And Fellows Of Harvard College Class-and isoform-specific HDAC inhibitors and uses thereof
US9540317B2 (en) 2009-08-11 2017-01-10 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
EP3029070A1 (en) 2009-08-29 2016-06-08 AbbVie Inc. Therapeutic dll4 binding proteins
US9469688B2 (en) 2009-08-29 2016-10-18 Abbvie Inc. Therapeutic DLL4 binding proteins
WO2011025964A2 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
US8623358B2 (en) 2009-08-29 2014-01-07 Abbvie Inc. Therapeutic DLL4 binding proteins
US9132190B2 (en) 2009-08-29 2015-09-15 Abbvie Inc. Therapeutic DLL4 binding proteins
US8586714B2 (en) 2009-09-01 2013-11-19 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
WO2011028950A1 (en) 2009-09-02 2011-03-10 Genentech, Inc. Mutant smoothened and methods of using the same
US8557239B2 (en) 2009-09-14 2013-10-15 Abbvie Inc. Methods for treating psoriasis using antibodies that bind to the P40 subunit of IL-12 and/or IL-23
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
EP2957296A1 (en) 2009-09-25 2015-12-23 Xoma (Us) Llc Insulin receptor binding antibodies
EP3187877A1 (en) 2009-09-25 2017-07-05 XOMA Technology Ltd. Screening methods
WO2011038290A2 (en) 2009-09-25 2011-03-31 The U. S. A., As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
WO2011038302A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Novel modulators
WO2011036555A1 (en) 2009-09-25 2011-03-31 University Of Oslo Multivalent phage display systems and methods
US9885711B2 (en) 2009-09-25 2018-02-06 Xoma Technology Ltd. Screening methods
WO2011038301A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
WO2011041584A2 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
WO2011041582A2 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
US8716450B2 (en) 2009-10-15 2014-05-06 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9975948B2 (en) 2009-10-20 2018-05-22 Abbvie, Inc. Isolation and purification of anti-IL-13 antibodies using protein A affinity chromatography
US9266950B2 (en) 2009-10-20 2016-02-23 Abbvie Inc. Isolation and purification of anti-IL-13 antibodies using protein a affinity chromatography
US11390668B2 (en) 2009-10-20 2022-07-19 Abbvie Inc. Isolation and purification of anti-IL-13 antibodies using protein a affinity chromatography
EP3037104A1 (en) 2009-10-20 2016-06-29 AbbVie Inc. Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
WO2011050188A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Anti-hepsin antibodies and methods using same
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011053538A1 (en) 2009-10-27 2011-05-05 Exxonmobil Research And Engineering Company Multi-stage processes and control thereof
US8722855B2 (en) 2009-10-28 2014-05-13 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9067996B2 (en) 2009-10-31 2015-06-30 Abbvie Inc. Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
US8420083B2 (en) 2009-10-31 2013-04-16 Abbvie Inc. Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
WO2011057120A1 (en) 2009-11-05 2011-05-12 Genentech, Inc. Methods and composition for secretion of heterologous polypeptides
WO2011058087A1 (en) 2009-11-11 2011-05-19 Gentian As Immunoassay for assessing related analytes of different origin
EP3168232A1 (en) 2009-11-13 2017-05-17 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11267870B2 (en) 2009-12-02 2022-03-08 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US9175075B2 (en) 2009-12-08 2015-11-03 AbbVie Deutschland GmbH & Co. KG Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
WO2011070045A1 (en) 2009-12-08 2011-06-16 Abbott Gmbh & Co. Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
WO2011071577A1 (en) 2009-12-11 2011-06-16 Genentech, Inc. Anti-vegf-c antibodies and methods using same
WO2011084750A1 (en) 2009-12-21 2011-07-14 Genentech, Inc. Antibody formulation
EP3616719A1 (en) 2009-12-21 2020-03-04 F. Hoffmann-La Roche AG Antibody formulation
WO2011079185A1 (en) 2009-12-23 2011-06-30 Genentech, Inc. Anti-bv8 antibodies and uses thereof
EP4011917A1 (en) 2010-01-06 2022-06-15 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
WO2011085103A2 (en) 2010-01-06 2011-07-14 Dyax Corp. Plasma kallikrein binding proteins
EP3459564A1 (en) 2010-01-06 2019-03-27 Dyax Corp. Plasma kallikrein binding proteins
WO2011088163A1 (en) 2010-01-14 2011-07-21 President And Fellows Of Harvard College Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
WO2011089250A3 (en) * 2010-01-22 2011-10-13 Novo Nordisk Health Care Ag Stable growth hormone compounds
WO2011089250A2 (en) 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Stable growth hormone compounds
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
WO2011091134A2 (en) 2010-01-22 2011-07-28 Dana-Farber Cancer Institute, Inc. Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
US9695226B2 (en) 2010-01-22 2017-07-04 Novo Nordisk Healthcare Ag Growth hormones with prolonged in-vivo efficacy
US8779109B2 (en) 2010-01-22 2014-07-15 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
WO2011097301A2 (en) 2010-02-02 2011-08-11 Abbott Biotechnology Ltd. METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR
WO2011095894A2 (en) 2010-02-04 2011-08-11 Jichi Medical University Identification, assessment, and therapy of cancers with innate or acquired resistance to alk inhibitors
EP3680253A2 (en) 2010-03-02 2020-07-15 AbbVie Inc. Therapeutic dll4 binding proteins
US9115195B2 (en) 2010-03-02 2015-08-25 Abbvie Inc. Therapeutic DLL4 binding proteins
US9469689B2 (en) 2010-03-02 2016-10-18 Abbvie Inc. Therapeutic DLL4 binding proteins
EP3072904A1 (en) 2010-03-02 2016-09-28 Abbvie Inc. Therapeutic dll4 binding proteins
EP4012714A1 (en) 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
US9822171B2 (en) 2010-04-15 2017-11-21 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US9447184B2 (en) 2010-05-14 2016-09-20 Abbvie Inc. IL-1 binding proteins
WO2011143562A2 (en) 2010-05-14 2011-11-17 Abbott Laboratories Il-1 binding proteins
US8771966B2 (en) 2010-06-03 2014-07-08 Genentech, Inc. Immuno-PET imaging of antibodies and immunoconjugates and uses therefor
WO2011153346A1 (en) 2010-06-03 2011-12-08 Genentech, Inc. Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
WO2011153477A2 (en) 2010-06-03 2011-12-08 Abbott Biotechnology Ltd. Uses and compositions for treatment of hidradenitis suppurativa (hs)
WO2012047324A2 (en) 2010-06-10 2012-04-12 President And Fellows Of Harvard College Systems and methods for amplification and phage display
US9405884B2 (en) 2010-06-16 2016-08-02 Abbvie Inc. Methods and systems for the analysis of protein samples
US9170262B2 (en) 2010-06-16 2015-10-27 Abbvie, Inc. Comparison of protein samples
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
EP2921177A2 (en) 2010-07-09 2015-09-23 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012007880A2 (en) 2010-07-16 2012-01-19 Ablynx Nv Modified single domain antigen binding molecules and uses thereof
WO2012010516A1 (en) 2010-07-22 2012-01-26 Novo Nordisk Health Care Ag Growth hormone conjugates
US11788142B2 (en) 2010-08-02 2023-10-17 Population Bio, Inc. Compositions and methods for discovery of causative mutations in genetic disorders
US10059997B2 (en) 2010-08-02 2018-08-28 Population Bio, Inc. Compositions and methods for discovery of causative mutations in genetic disorders
EP3252072A2 (en) 2010-08-03 2017-12-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
US9493560B2 (en) 2010-08-03 2016-11-15 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
WO2012020072A1 (en) 2010-08-12 2012-02-16 Westfälische Wilhelms-Universität Muenster Anti-syndecan-4 antibodies
EP2420250A1 (en) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4 antibodies
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US10047121B2 (en) 2010-08-14 2018-08-14 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9505829B2 (en) 2010-08-19 2016-11-29 Zoetis Belgium S.A. Anti-NGF antibodies and their use
US10093725B2 (en) 2010-08-19 2018-10-09 Zoetis Belgium S.A. Anti-NGF antibodies and their use
EP3333188A1 (en) 2010-08-19 2018-06-13 Zoetis Belgium S.A. Anti-ngf antibodies and their use
WO2012024650A2 (en) 2010-08-19 2012-02-23 Abbott Laboratories Anti-ngf antibodies and their use
US10125192B2 (en) 2010-08-19 2018-11-13 Zoetis Belgium S.A. Caninized anti-NGF antibodies and their use
EP4056589A1 (en) 2010-08-19 2022-09-14 Zoetis Belgium S.A. Anti-ngf antibodies and their use
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012027723A1 (en) 2010-08-27 2012-03-01 Stem Centrx, Inc Notum protein modulators and methods of use
WO2012031273A2 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
WO2012040041A1 (en) 2010-09-20 2012-03-29 Abbott Laboratories Purification of antibodies using simulated moving bed chromatography
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
WO2012041981A2 (en) 2010-09-30 2012-04-05 Laboratorios Del Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
WO2012044921A1 (en) 2010-10-01 2012-04-05 St. Jude Children's Research Hospital Methods and compositions for typing molecular subgroups of medulloblastoma
WO2012047968A2 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
WO2012052391A1 (en) 2010-10-19 2012-04-26 Glaxo Group Limited Polypeptide with jmjd3 catalytic activity
WO2012068463A2 (en) 2010-11-18 2012-05-24 Beth Israel Deaconess Medicall Center, Inc. Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
WO2012078813A2 (en) 2010-12-08 2012-06-14 Stem Centrx, Inc. Novel modulators and methods of use
WO2012118547A1 (en) 2010-12-08 2012-09-07 Stem Centrx, Inc. Novel modulators and methods of use
WO2012088094A2 (en) 2010-12-21 2012-06-28 Abbott Laboratories Il-1 binding proteins
WO2012121775A2 (en) 2010-12-21 2012-09-13 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
US11214792B2 (en) 2010-12-22 2022-01-04 President And Fellows Of Harvard College Continuous directed evolution
US9394537B2 (en) 2010-12-22 2016-07-19 President And Fellows Of Harvard College Continuous directed evolution
US10336997B2 (en) 2010-12-22 2019-07-02 President And Fellows Of Harvard College Continuous directed evolution
WO2012092323A1 (en) 2010-12-28 2012-07-05 Xoma Technology Ltd. Cell surface display using pdz domains
WO2012089814A1 (en) 2010-12-30 2012-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigen binding formats for use in therapeutic treatments or diagnostic assays
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US11565048B2 (en) 2011-01-24 2023-01-31 Abbvie Biotechnology Ltd. Automatic injection devices having overmolded gripping surfaces
US9878102B2 (en) 2011-01-24 2018-01-30 Abbvie Biotechnology Ltd. Automatic injection devices having overmolded gripping surfaces
US9956236B2 (en) 2011-02-07 2018-05-01 Cornell University Methods for increasing immune responses using agents that directly bind to and activate IRE-1
EP3763388A1 (en) 2011-02-18 2021-01-13 AbbVie Stemcentrx LLC Novel modulators and methods of use
WO2012112943A1 (en) 2011-02-18 2012-08-23 Stem Centrx, Inc. Novel modulators and methods of use
WO2012119129A1 (en) 2011-03-02 2012-09-07 Berg Biosystems, Llc Interrogatory cell-based assays and uses thereof
US9383364B2 (en) 2011-03-07 2016-07-05 University Of Louisville Research Foundation, Inc. Predictive marker of DNMT1 inhibitor therapeutic efficacy and methods of using the marker
WO2012125735A1 (en) 2011-03-15 2012-09-20 Abott Laboratories An integrated approach to the isolation and purification of antibodies
WO2012128810A1 (en) 2011-03-23 2012-09-27 Abbott Laboratories Methods and systems for the analysis of protein samples
WO2012131053A1 (en) 2011-03-30 2012-10-04 Ablynx Nv Methods of treating immune disorders with single domain antibodies against tnf-alpha
WO2012134813A1 (en) 2011-03-31 2012-10-04 St. Jude Children's Research Hospital Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
WO2012139058A1 (en) 2011-04-08 2012-10-11 Biogen Idec Ma Inc. BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO IFNβ AND USES THEREOF
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
US11739152B2 (en) 2011-06-02 2023-08-29 Takeda Pharmaceutical Company Limited Antibodies which bind Fc receptors (FcRn)
US11014988B2 (en) 2011-06-02 2021-05-25 Dyax Corp. Nucleic acids encoding anti-neonatal Fc receptor (FcRn) antibodies
EP2966089A1 (en) 2011-06-02 2016-01-13 Dyax Corp. Fc receptor binding proteins
US10479834B2 (en) 2011-06-02 2019-11-19 Dyax Corp. Fc receptor antibodies and methods of use thereof
US9862768B2 (en) 2011-06-02 2018-01-09 Dyax Corp. Methods of producing antibodies to neonatal Fc receptor (FcRn)
US9359438B2 (en) 2011-06-02 2016-06-07 Dyax Corporation Human neonatal Fc receptor antibodies and methods of use thereof
EP3954704A1 (en) 2011-06-03 2022-02-16 XOMA Technology Ltd. Antibodies specific for tgf-beta
WO2012167143A1 (en) 2011-06-03 2012-12-06 Xoma Technology Ltd. Antibodies specific for tgf-beta
EP3574919A1 (en) 2011-07-13 2019-12-04 AbbVie Inc. Methods and compositions for treating asthma using anti-il-13 antibodies
EP3564261A1 (en) 2011-08-23 2019-11-06 Foundation Medicine, Inc. Kif5b-ret fusion molecules and uses thereof
WO2013028817A1 (en) 2011-08-23 2013-02-28 Foundation Medicine , Inc. Novel kif5b-ret fusion molecules and uses thereof
WO2013039996A1 (en) 2011-09-13 2013-03-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using fndc5
WO2013040142A2 (en) 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2013054200A2 (en) 2011-10-10 2013-04-18 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
US11339439B2 (en) 2011-10-10 2022-05-24 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
WO2013063114A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against tnf
WO2013063095A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against sclerostin
WO2013067268A1 (en) 2011-11-03 2013-05-10 Tripath Imaging, Inc. Methods and compositions for preparing samples for immunostaining
WO2013067451A2 (en) 2011-11-04 2013-05-10 Population Diagnostics Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
US11180807B2 (en) 2011-11-04 2021-11-23 Population Bio, Inc. Methods for detecting a genetic variation in attractin-like 1 (ATRNL1) gene in subject with Parkinson's disease
WO2013068902A1 (en) 2011-11-08 2013-05-16 Pfizer Inc. Methods of treating inflammatory disorders using anti-m-csf antibodies
WO2013078377A1 (en) 2011-11-23 2013-05-30 Igenica, Inc. Anti-cd98 antibodies and methods of use thereof
WO2013080050A2 (en) 2011-11-30 2013-06-06 Universitaetsklinikum Erlangen Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
US10118958B2 (en) 2011-12-14 2018-11-06 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
WO2013090633A2 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
WO2013090635A2 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
EP3800200A1 (en) 2011-12-14 2021-04-07 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
US10822403B2 (en) 2011-12-14 2020-11-03 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
US9636398B2 (en) 2011-12-14 2017-05-02 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
EP3050900A1 (en) 2011-12-19 2016-08-03 Xoma (Us) Llc Methods for treating acne
WO2013096516A1 (en) 2011-12-19 2013-06-27 Xoma Technology Ltd. Methods for treating acne
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
EP3663314A1 (en) 2012-01-09 2020-06-10 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
WO2013106485A2 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
WO2013106489A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
WO2013112922A1 (en) 2012-01-27 2013-08-01 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
US9102722B2 (en) 2012-01-27 2015-08-11 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
US9365643B2 (en) 2012-01-27 2016-06-14 AbbVie Deutschland GmbH & Co. KG Antibodies that bind to repulsive guidance molecule A (RGMA)
US10106602B2 (en) 2012-01-27 2018-10-23 AbbVie Deutschland GmbH & Co. KG Isolated monoclonal anti-repulsive guidance molecule A antibodies and uses thereof
EP3653647A1 (en) 2012-01-27 2020-05-20 AbbVie Deutschland GmbH & Co KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
EP3369746A1 (en) 2012-01-27 2018-09-05 AbbVie Deutschland GmbH & Co KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
WO2013119960A2 (en) 2012-02-08 2013-08-15 Stem Centrx, Inc. Novel modulators and methods of use
US10407724B2 (en) 2012-02-09 2019-09-10 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
US11174516B2 (en) 2012-02-09 2021-11-16 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
US9155803B1 (en) 2012-02-24 2015-10-13 Stemcentrx, Inc. Anti-DLL3 antibody drug conjugates and methods of use
US9931421B2 (en) 2012-02-24 2018-04-03 Abbvie Stemcentrx Llc Methods of delivering DLL3 antibody drug conjugates
US9878053B2 (en) 2012-02-24 2018-01-30 Abbvie Stemcentrx Llc Methods of delivering DLL3 antibody drug conjugates
US9345784B1 (en) 2012-02-24 2016-05-24 Stemcentrx, Inc. Methods of delivering DLL3 antibody drug conjugates
EP3095797A1 (en) 2012-02-24 2016-11-23 Stemcentrx, Inc. Anti dll3 antibodies and methods of use thereof
US8986972B2 (en) 2012-02-24 2015-03-24 Stem Centrx, Inc. Nucleic acid encoding DLL3 antibodies
US9107961B2 (en) 2012-02-24 2015-08-18 Stemcentrx, Inc. Anti-DLL3 antibody drug conjugates for treating cancer
US9334318B1 (en) 2012-02-24 2016-05-10 Stemcentrx, Inc. Multivalent DLL3 antibodies
US9480757B2 (en) 2012-02-24 2016-11-01 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates
US9867887B1 (en) 2012-02-24 2018-01-16 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates
US9173959B1 (en) 2012-02-24 2015-11-03 Stemcentrx, Inc. Anti-DLL3 antibody drug conjugates
US9486537B2 (en) 2012-02-24 2016-11-08 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates
US9090683B2 (en) 2012-02-24 2015-07-28 Stemcentrx, Inc. Methods of detection, diagnosis, and monitoring using anti-DLL3 antibodies
US11033634B2 (en) 2012-02-24 2021-06-15 Abbvie Stemcentrx Llc Light chain variable regions
US9133271B1 (en) 2012-02-24 2015-09-15 Stemcentrx, Inc. Anti-DLL3 antibody drug conjugates and methods of use
US9089615B2 (en) 2012-02-24 2015-07-28 Stemcentrx, Inc. Anti-DLL3 antibodies
US9861708B2 (en) 2012-02-24 2018-01-09 Abbvie Stemcentrx Llc Kits containing DLL3 antibody drug conjugates
US9089617B2 (en) 2012-02-24 2015-07-28 Stemcentrx, Inc. Anti-DLL3 antibody drug conjugates
US9481727B2 (en) 2012-02-24 2016-11-01 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates
US9353182B2 (en) 2012-02-24 2016-05-31 Stemcentrx, Inc. Anti-DLL3 antibodies
US9855343B2 (en) 2012-02-24 2018-01-02 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates
US9764042B1 (en) 2012-02-24 2017-09-19 Abbvie Stemcentrx Llc Methods of making DLL3 antibody drug conjugates
US9937268B2 (en) 2012-02-24 2018-04-10 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates and methods of use
US9089616B2 (en) 2012-02-24 2015-07-28 Stemcentrx, Inc. Anti-DLL3 antibody drug conjugates and methods of use
US9770518B1 (en) 2012-02-24 2017-09-26 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates
US9931420B2 (en) 2012-02-24 2018-04-03 Abbvie Stemcentrx Llc Methods of making DLL3 antibody drug conjugates
US10137204B2 (en) 2012-02-24 2018-11-27 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates for treating cancer
US9352051B1 (en) 2012-02-24 2016-05-31 Stemcentrx, Inc. Kits containing DLL3 antibody drug conjugates
US9775916B1 (en) 2012-02-24 2017-10-03 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates for treating cancer
US9358304B1 (en) 2012-02-24 2016-06-07 Stemcentrx, Inc. Methods of making DLL3 antibody drug conjugates
US9139659B2 (en) * 2012-03-28 2015-09-22 Genentech, Inc. Idiotypic antibodies and uses thereof
WO2013148373A1 (en) 2012-03-28 2013-10-03 Genentech, Inc. Anti-hcmv idiotypic antibodies and uses thereof
US20130266973A1 (en) * 2012-03-28 2013-10-10 Genentech, Inc. Idiotypic antibodies and uses thereof
WO2013151577A1 (en) 2012-04-02 2013-10-10 Berg Pharma Llc Interrogatory cell-based assays and uses thereof
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2014143184A1 (en) 2012-04-20 2014-09-18 Abbvie Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2013158275A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
US9758805B2 (en) 2012-04-20 2017-09-12 Merus N.V. Methods and means for the production of Ig-like molecules
US10752929B2 (en) 2012-04-20 2020-08-25 Merus N.V. Methods and means for the production of ig-like molecules
US11926859B2 (en) 2012-04-20 2024-03-12 Merus N.V. Methods and means for the production of Ig-like molecules
US10337045B2 (en) 2012-04-20 2019-07-02 Merus N.V. Methods and means for the production of Ig-like molecules
US10329596B2 (en) 2012-04-20 2019-06-25 Merus N.V. Methods and means for the production of Ig-like molecules
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
WO2013177115A2 (en) 2012-05-21 2013-11-28 Abbvie Inc. Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
WO2014143185A1 (en) 2012-05-24 2014-09-18 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
US9951128B2 (en) 2012-06-06 2018-04-24 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
US9670276B2 (en) 2012-07-12 2017-06-06 Abbvie Inc. IL-1 binding proteins
EP3613765A1 (en) 2012-08-03 2020-02-26 Dana-Farber Cancer Institute, Inc. Antibody against repulsive guidance molecule b (rgmb)
US10214765B2 (en) 2012-08-18 2019-02-26 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US9737493B2 (en) 2012-09-07 2017-08-22 University Of Louisville Research Foundation, Inc. Compositions and methods for modulating DNMT1 inhibitor activity
US11008614B2 (en) 2012-09-14 2021-05-18 Population Bio, Inc. Methods for diagnosing, prognosing, and treating parkinsonism
WO2014043519A1 (en) 2012-09-14 2014-03-20 Population Diagnostics Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
US9976180B2 (en) 2012-09-14 2018-05-22 Population Bio, Inc. Methods for detecting a genetic variation in subjects with parkinsonism
US11618925B2 (en) 2012-09-27 2023-04-04 Population Bio, Inc. Methods and compositions for screening and treating developmental disorders
US10597721B2 (en) 2012-09-27 2020-03-24 Population Bio, Inc. Methods and compositions for screening and treating developmental disorders
US10233495B2 (en) 2012-09-27 2019-03-19 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
EP3750560A2 (en) 2012-10-09 2020-12-16 Biogen MA Inc. Combination therapies and uses for treatment of demyelinating disorders
WO2014058875A2 (en) 2012-10-09 2014-04-17 Biogen Idec Ma Inc. Combination therapies and uses for treatment of demyelinating disorders
WO2014059028A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
US9163093B2 (en) 2012-11-01 2015-10-20 Abbvie Inc. Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
US9045551B2 (en) 2012-11-01 2015-06-02 Abbvie Inc. Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
US9944720B2 (en) 2012-11-01 2018-04-17 Abbvie Inc. Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
US11578372B2 (en) 2012-11-05 2023-02-14 Foundation Medicine, Inc. NTRK1 fusion molecules and uses thereof
WO2014071358A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
WO2014074942A1 (en) 2012-11-08 2014-05-15 Illumina, Inc. Risk variants of alzheimer's disease
US9951130B2 (en) 2012-11-08 2018-04-24 Eleven Biotherapeutics, Inc. IL-6 antagonists and uses thereof
US11459386B2 (en) 2012-11-08 2022-10-04 Sesen Bio, Inc. IL-6 antagonists and uses thereof
WO2014074905A1 (en) 2012-11-08 2014-05-15 Eleven Biotherapeutics, Inc. Il-6 antagonists and uses thereof
WO2014093396A1 (en) 2012-12-10 2014-06-19 Biogen Idec Ma Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof
EP3686218A1 (en) 2012-12-10 2020-07-29 Biogen MA Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof
US9550986B2 (en) 2012-12-21 2017-01-24 Abbvie Inc. High-throughput antibody humanization
WO2014100542A1 (en) 2012-12-21 2014-06-26 Abbvie, Inc. High-throughput antibody humanization
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
US11771698B2 (en) 2013-01-18 2023-10-03 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
EP3939614A1 (en) 2013-01-18 2022-01-19 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
WO2014113729A2 (en) 2013-01-18 2014-07-24 Foundation Mecicine, Inc. Methods of treating cholangiocarcinoma
WO2014123696A1 (en) 2013-01-25 2014-08-14 Thymon, Llc Compositions for selective reduction of circulating bioactive soluble tnf and methods for treating tnf-mediated disease
US9968687B2 (en) 2013-02-22 2018-05-15 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates
WO2014130879A2 (en) 2013-02-22 2014-08-28 Stem Centrx, Inc. Novel antibody conjugates and uses thereof
US10478509B2 (en) 2013-02-22 2019-11-19 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates for treating cancer
EP3556400A1 (en) 2013-02-22 2019-10-23 AbbVie Stemcentrx LLC Method of making antidll3-antibody pbd conjugates
CN105229035A (en) * 2013-03-11 2016-01-06 诺和诺德保健股份有限公司 Growth hormone compound
WO2014139994A1 (en) * 2013-03-11 2014-09-18 Novo Nordisk Health Care Ag Growth hormone compounds
WO2014160495A1 (en) 2013-03-13 2014-10-02 Genentech, Inc. Formulations with reduced oxidation
US11596620B2 (en) 2013-03-13 2023-03-07 F. Hoffmann-La Roche Ag Formulations with reduced oxidation
US10010611B2 (en) 2013-03-13 2018-07-03 Genentech, Inc. Antibody formulations
EP3744345A1 (en) 2013-03-13 2020-12-02 F. Hoffmann-La Roche AG Antibody formulations
WO2014160497A1 (en) 2013-03-13 2014-10-02 Genentech, Inc. Formulations with reduced oxidation
WO2014160490A1 (en) 2013-03-13 2014-10-02 Genetech, Inc. Antibody formulations
US10925966B2 (en) 2013-03-13 2021-02-23 Genentech, Inc. Antibody formulations
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
EP3564384A1 (en) 2013-03-14 2019-11-06 Abbott Laboratories Hcv core lipid binding domain monoclonal antibodies
US10345311B2 (en) 2013-03-14 2019-07-09 Abbott Laboratories Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies
WO2014142882A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
US9841427B2 (en) 2013-03-14 2017-12-12 Abbott Laboratories HCV antigen-antibody combination assay and methods and compositions for use therein
US10197573B2 (en) 2013-03-14 2019-02-05 Abbott Laboratories HCV core lipid binding domain monoclonal antibodies
WO2014159554A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
WO2014158231A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
US10444242B2 (en) 2013-03-14 2019-10-15 Abbott Laboratories Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies
WO2014153056A2 (en) 2013-03-14 2014-09-25 Parkash Gill Cancer treatment using antibodies that bing cell surface grp78
US9790478B2 (en) 2013-03-14 2017-10-17 Abbott Laboratories HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
US11428694B2 (en) 2013-03-14 2022-08-30 Abbott Laboratories Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies
EP3916103A1 (en) 2013-03-14 2021-12-01 Abbott Laboratories Hcv core lipid binding domain monoclonal antibodies
WO2014144355A2 (en) 2013-03-15 2014-09-18 Abbott Laboratories Anti-gp73 monoclonal antibodies and methods of obtaining the same
EP3527586A1 (en) 2013-03-15 2019-08-21 Abbott Laboratories Anti-gp73 monoclonal antibodies and methods of obtaining the same
US10829732B2 (en) 2013-03-15 2020-11-10 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
US10017732B2 (en) 2013-03-15 2018-07-10 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
EP4079760A2 (en) 2013-03-15 2022-10-26 Sanofi Pasteur Inc. Antibodies against clostridium difficile toxins and methods of using the same
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
EP3124499A1 (en) 2013-03-15 2017-02-01 Abbott Laboratories Anti-gp73 monoclonal antibodies and methods of obtaining the same
US10676710B2 (en) 2013-03-15 2020-06-09 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
US10308709B2 (en) 2013-03-15 2019-06-04 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
US8987418B2 (en) 2013-03-15 2015-03-24 Abbvie Inc. Dual specific binding proteins directed against IL-1β and/or IL-17
EP3712252A1 (en) 2013-03-15 2020-09-23 F. Hoffmann-La Roche AG Cell culture compositions with antioxidants and methods for polypeptide production
US9062108B2 (en) 2013-03-15 2015-06-23 Abbvie Inc. Dual specific binding proteins directed against IL-1 and/or IL-17
WO2014151680A1 (en) 2013-03-15 2014-09-25 Biogen Idec Ma Inc. Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
WO2014144292A2 (en) 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
WO2014145098A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
US11421023B2 (en) 2013-03-15 2022-08-23 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
US9441035B2 (en) 2013-03-15 2016-09-13 Genentech, Inc. Cell culture media and methods of antibody production
US10131873B2 (en) 2013-03-15 2018-11-20 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
US9499621B2 (en) 2013-04-08 2016-11-22 Cytodyn, Inc. Felinized antibodies and methods of treating retroviral infections in felines
EP3293275A1 (en) 2013-06-06 2018-03-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
US11897946B2 (en) 2013-06-07 2024-02-13 Duke University Methods of inhibiting complement factor H (CFH) comprising administering an antibody that binds CFH
US10183988B2 (en) 2013-06-07 2019-01-22 Duke University Anti-Complement factor H antibodies
US11136380B2 (en) 2013-06-07 2021-10-05 Duke University Anti-complement factor H antibodies
EP3632467A1 (en) 2013-06-07 2020-04-08 Duke University Inhibitors of complement factor h
WO2014197885A2 (en) 2013-06-07 2014-12-11 Duke University Inhibitors of complement factor h
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
WO2015010100A2 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
WO2015017529A2 (en) 2013-07-31 2015-02-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
EP3916081A2 (en) 2013-08-19 2021-12-01 Biogen MA Inc. Control of protein glycosylation by culture medium supplementation and cell culture process parameters
WO2015026846A1 (en) 2013-08-19 2015-02-26 Biogen Idec Ma Inc. Control of protein glycosylation by culture medium supplementation and cell culture process parameters
EP3338793A1 (en) 2013-08-28 2018-06-27 AbbVie Stemcentrx LLC Novel sez6 modulators and methods of use
US10035853B2 (en) 2013-08-28 2018-07-31 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
EP3892294A1 (en) 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Site-specific antibody conjugation methods and compositions
US10918714B2 (en) 2013-09-06 2021-02-16 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
US10111951B2 (en) 2013-09-06 2018-10-30 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
EP3903599A1 (en) 2013-09-25 2021-11-03 Bioverativ Therapeutics Inc. On-column viral inactivation methods
US10450566B2 (en) 2013-09-25 2019-10-22 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
US11578098B2 (en) 2013-09-25 2023-02-14 Bioverativ Therapeutics Inc. On-column viral inactivation methods
US10421965B2 (en) 2013-09-25 2019-09-24 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
US9957506B2 (en) 2013-09-25 2018-05-01 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015048520A1 (en) 2013-09-27 2015-04-02 Genentech, Inc. Anti-pdl1 antibody formulations
EP3626742A1 (en) 2013-09-27 2020-03-25 F. Hoffmann-La Roche AG Anti-pdl1 antibody formulations
US10875922B2 (en) 2013-09-27 2020-12-29 Genentech, Inc. Anti-PDL1 antibody formulations
WO2015057939A1 (en) 2013-10-18 2015-04-23 Biogen Idec Ma Inc. Anti-s1p4 antibodies and uses thereof
EP4331590A2 (en) 2013-10-29 2024-03-06 President and Fellows of Harvard College Nuclear factor erythroid 2-like 2 (nrf2) for use in treatment of age-related macular degeneration
EP3777980A1 (en) 2013-10-29 2021-02-17 President and Fellows of Harvard College Methods and compositions for inhibiting oxidative stress
WO2015066190A1 (en) 2013-10-29 2015-05-07 President And Fellows Of Harvard College Methods and compositions for inhibting oxidative stress
WO2015070068A1 (en) 2013-11-07 2015-05-14 Abbvie Inc. Isolation and purification of antibodies
US11384397B2 (en) 2013-11-12 2022-07-12 Population Bio, Inc. Methods and compositions for diagnosing, prognosing, and treating endometriosis
EP2891722A1 (en) 2013-11-12 2015-07-08 Population Diagnostics, Inc. Methods and compositions for diagnosing, prognosing, and treating endometriosis
US10174376B2 (en) 2013-11-12 2019-01-08 Population Bio, Inc. Methods and compositions for diagnosing, prognosing, and treating endometriosis
EP3511422A2 (en) 2013-11-12 2019-07-17 Population Bio, Inc. Methods and compositions for diagnosing, prognosing, and treating endometriosis
WO2015071759A1 (en) 2013-11-15 2015-05-21 Institut Pasteur A molecular marker of plasmodium falciparum artemisinin resistance
EP4026909A1 (en) 2013-12-19 2022-07-13 Novartis AG Human mesothelin chimeric antigen receptors and uses thereof
WO2015090230A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
WO2015095809A1 (en) 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
EP3722321A1 (en) 2013-12-23 2020-10-14 Institut Pasteur Phospholipase for treatment of immunosuppression
WO2015109180A2 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
US9982041B2 (en) 2014-01-16 2018-05-29 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
US10179911B2 (en) 2014-01-20 2019-01-15 President And Fellows Of Harvard College Negative selection and stringency modulation in continuous evolution systems
EP3738981A1 (en) 2014-01-24 2020-11-18 NGM Biopharmaceuticals, Inc. Antibodies binding beta klotho domain 2 and methods of use thereof
EP3514179A1 (en) 2014-01-24 2019-07-24 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
EP4324518A2 (en) 2014-01-31 2024-02-21 Novartis AG Antibody molecules to tim-3 and uses thereof
WO2015120075A2 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
EP4047015A1 (en) 2014-02-11 2022-08-24 Visterra, Inc. Antibody molecules to dengue virus and uses thereof
WO2015122995A1 (en) 2014-02-11 2015-08-20 Visterra, Inc. Antibody moleules to dengue virus and uses thereof
US10308721B2 (en) 2014-02-21 2019-06-04 Abbvie Stemcentrx Llc Anti-DLL3 antibodies and drug conjugates for use in melanoma
EP3660050A1 (en) 2014-03-14 2020-06-03 Novartis AG Antibody molecules to lag-3 and uses thereof
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
US11124760B2 (en) 2014-03-24 2021-09-21 Biogen Ma Inc. Methods for overcoming glutamine deprivation during mammalian cell culture
US10119972B2 (en) 2014-03-27 2018-11-06 Academia Sinica Reactive labelling compounds and uses thereof
WO2015175340A1 (en) 2014-05-13 2015-11-19 Bavarian Nordic, Inc. Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3
US10023892B2 (en) 2014-05-27 2018-07-17 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US11319567B2 (en) 2014-05-27 2022-05-03 Academia Sinica Fucosidase from bacteroides and methods using the same
US10618973B2 (en) 2014-05-27 2020-04-14 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
US10005847B2 (en) 2014-05-27 2018-06-26 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
US11884739B2 (en) 2014-05-27 2024-01-30 Academia Sinica Anti-CD20 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US11332523B2 (en) 2014-05-28 2022-05-17 Academia Sinica Anti-TNF-alpha glycoantibodies and uses thereof
WO2015187779A1 (en) 2014-06-03 2015-12-10 Xbiotech, Inc. Compositions and methods for treating and preventing staphylococcus aureus infections
EP3970747A2 (en) 2014-06-03 2022-03-23 XBiotech Inc. Compositions and methods for treating and preventing staphylococcus aureus infections
EP2960252A1 (en) 2014-06-26 2015-12-30 Institut Pasteur Phospholipase for treatment of immunosuppression
EP3722316A1 (en) 2014-07-21 2020-10-14 Novartis AG Treatment of cancer using a cd33 chimeric antigen receptor
EP3511413A1 (en) 2014-07-25 2019-07-17 Theravectys Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
EP3712171A1 (en) 2014-08-19 2020-09-23 Novartis AG Treatment of cancer using a cd123 chimeric antigen receptor
US11549145B2 (en) 2014-09-05 2023-01-10 Population Bio, Inc. Methods and compositions for inhibiting and treating neurological conditions
US10724096B2 (en) 2014-09-05 2020-07-28 Population Bio, Inc. Methods and compositions for inhibiting and treating neurological conditions
US10533034B2 (en) 2014-09-08 2020-01-14 Academia Sinica Human iNKT cell activation using glycolipids
US9879042B2 (en) 2014-09-08 2018-01-30 Academia Sinica Human iNKT cell activation using glycolipids
EP3925622A1 (en) 2014-09-13 2021-12-22 Novartis AG Combination therapies
WO2016040892A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies
WO2016040880A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
EP3659621A1 (en) 2014-09-13 2020-06-03 Novartis AG Combination therapies for cancer
US11370833B2 (en) 2014-09-15 2022-06-28 Genentech, Inc. Antibody formulations
WO2016042412A1 (en) 2014-09-16 2016-03-24 Symphogen A/S Anti-met antibodies and compositions
US10400037B2 (en) 2014-09-30 2019-09-03 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Binding molecules, especially antibodies, binding to L1CAM (CD171)
EP3662903A2 (en) 2014-10-03 2020-06-10 Novartis AG Combination therapies
WO2016054555A2 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
EP4245376A2 (en) 2014-10-14 2023-09-20 Novartis AG Antibody molecules to pd-l1 and uses thereof
WO2016061424A1 (en) 2014-10-17 2016-04-21 Biogen Ma Inc. Copper supplementation for control of glycosylation in mammalian cell culture process
US10920208B2 (en) 2014-10-22 2021-02-16 President And Fellows Of Harvard College Evolution of proteases
US11760986B2 (en) 2014-10-22 2023-09-19 President And Fellows Of Harvard College Evolution of proteases
WO2016070152A1 (en) 2014-10-31 2016-05-06 Biogen Ma Inc. Hypotaurine, gaba, beta-alanine, and choline for control of waste byproduct accumulation in mammalian cell culture process
US10208120B2 (en) 2014-11-05 2019-02-19 Genentech, Inc. Anti-FGFR2/3 antibodies and methods using same
WO2016073685A1 (en) 2014-11-05 2016-05-12 Annexon, Inc. Humanized anti-complement factor c1q antibodies and uses thereof
EP4295911A2 (en) 2014-11-05 2023-12-27 Annexon, Inc. Humanized anti-complement factor c1q antibodies and uses thereof
EP3632931A1 (en) 2014-11-07 2020-04-08 Sesen Bio, Inc. Improved il-6 antibodies
US11142571B2 (en) 2014-11-07 2021-10-12 Sesen Bio, Inc. IL-6 antibodies
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
EP4268843A2 (en) 2014-11-07 2023-11-01 F. Hoffmann-La Roche Ltd Improved il-6 antibodies
WO2016081835A2 (en) 2014-11-21 2016-05-26 University Of Maryland, Baltimore Targeted structure-specific particulate delivery systems
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2016118961A1 (en) 2015-01-24 2016-07-28 Academia Sinica Cancer markers and methods of use thereof
US10342858B2 (en) 2015-01-24 2019-07-09 Academia Sinica Glycan conjugates and methods of use thereof
WO2016123593A1 (en) 2015-01-30 2016-08-04 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
WO2016126972A1 (en) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened and methods of using the same
WO2016141111A1 (en) 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
US10711067B2 (en) 2015-03-03 2020-07-14 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
EP3735982A1 (en) 2015-03-10 2020-11-11 The University of Massachusetts Targeting gdf6 and bmp signaling for anti-melanoma therapy
WO2016144917A1 (en) 2015-03-10 2016-09-15 University Of Massachusetts Targeting gdf6 and bmp signaling for anti-melanoma therapy
WO2016161410A2 (en) 2015-04-03 2016-10-06 Xoma Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
EP3770171A1 (en) 2015-04-03 2021-01-27 XOMA Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
US11685775B2 (en) 2015-04-03 2023-06-27 Xoma Technology Ltd. Method of increasing the ratio of effector T cells to regulatory T cells in a tumor by administering to a subject a TGF-beta inhibitor and a PD-1 antibody
US10167334B2 (en) 2015-04-03 2019-01-01 Xoma Technology Ltd. Treatment of cancer using anti-TGF-BETA and PD-1 antibodies
US10683347B2 (en) 2015-04-03 2020-06-16 Xoma Technology Ltd. Treatment of cancer using anti-TGF-β and anti-PD-1 antibodies
US11299729B2 (en) 2015-04-17 2022-04-12 President And Fellows Of Harvard College Vector-based mutagenesis system
WO2016170022A1 (en) 2015-04-21 2016-10-27 Institut Gustave Roussy Therapeutic methods, products and compositions inhibiting znf555
EP3626744A1 (en) 2015-05-29 2020-03-25 AbbVie Inc. Anti-cd40 antibodies and uses thereof
EP4047022A1 (en) 2015-05-29 2022-08-24 AbbVie Inc. Anti-cd40 antibodies and uses thereof
US11208452B2 (en) 2015-06-02 2021-12-28 Novo Nordisk A/S Insulins with polar recombinant extensions
US9840554B2 (en) 2015-06-15 2017-12-12 Abbvie Inc. Antibodies against platelet-derived growth factor (PDGF)
US11905623B2 (en) 2015-07-22 2024-02-20 President And Fellows Of Harvard College Evolution of site-specific recombinases
US10392674B2 (en) 2015-07-22 2019-08-27 President And Fellows Of Harvard College Evolution of site-specific recombinases
US11104967B2 (en) 2015-07-22 2021-08-31 President And Fellows Of Harvard College Evolution of site-specific recombinases
US11524983B2 (en) 2015-07-23 2022-12-13 President And Fellows Of Harvard College Evolution of Bt toxins
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3964528A1 (en) 2015-07-29 2022-03-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
US10612011B2 (en) 2015-07-30 2020-04-07 President And Fellows Of Harvard College Evolution of TALENs
US11078469B2 (en) 2015-07-30 2021-08-03 President And Fellows Of Harvard College Evolution of TALENs
US11913040B2 (en) 2015-07-30 2024-02-27 President And Fellows Of Harvard College Evolution of TALENs
US11312936B2 (en) 2015-08-04 2022-04-26 Regeneron Pharmaceuticals, Inc. Taurine supplemented cell culture medium and methods of use
US10927342B2 (en) 2015-08-04 2021-02-23 Regeneran Pharmaceuticals, Inc. Taurine supplemented cell culture medium and methods of use
US10253101B2 (en) 2015-08-06 2019-04-09 Xoma (Us) Llc Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
WO2017040342A1 (en) 2015-08-28 2017-03-09 Genentech, Inc. Anti-hypusine antibodies and uses thereof
EP3932953A1 (en) 2015-08-28 2022-01-05 F. Hoffmann-La Roche AG Anti-hypusine antibodies and uses thereof
US10935544B2 (en) 2015-09-04 2021-03-02 Obi Pharma, Inc. Glycan arrays and method of use
WO2017049011A1 (en) 2015-09-15 2017-03-23 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
EP3922645A1 (en) 2015-09-15 2021-12-15 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
US10428145B2 (en) 2015-09-29 2019-10-01 Celgene Corporation PD-1 binding proteins and methods of use thereof
US11292825B2 (en) 2015-10-01 2022-04-05 Novo Nordisk A/S Protein conjugates
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
WO2017075329A2 (en) 2015-10-29 2017-05-04 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
WO2017077275A1 (en) * 2015-11-02 2017-05-11 Imperial Innovations Limited Phagemid vector
US11603540B2 (en) 2015-11-02 2023-03-14 Imperial College Innovations Limited Phagemid vector
WO2017083515A2 (en) 2015-11-10 2017-05-18 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
EP4285923A2 (en) 2015-11-25 2023-12-06 Visterra, Inc. Antibody molecules to april and uses thereof
WO2017091683A1 (en) 2015-11-25 2017-06-01 Visterra, Inc. Antibody molecules to april and uses thereof
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2017106810A2 (en) 2015-12-17 2017-06-22 Novartis Ag Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
US10525137B2 (en) 2015-12-30 2020-01-07 Genentech, Inc. Formulations with reduced degradation of polysorbate
WO2017117304A1 (en) 2015-12-30 2017-07-06 Genentech, Inc. Use of tryptophan derivatives for protein formulations
WO2017117311A1 (en) 2015-12-30 2017-07-06 Genentech, Inc. Formulations with reduced degradation of polysorbate
US10933141B2 (en) 2015-12-30 2021-03-02 Genentech, Inc. Formulations with reduced degradation of polysorbate
WO2017120523A2 (en) 2016-01-08 2017-07-13 Scholar Rock, Inc. Anti-pro/latent myostatin antibodies and methods of use thereof
WO2017136558A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same
US11725247B2 (en) 2016-02-29 2023-08-15 Foundation Medicine, Inc. Methods of treating cancer
US10336784B2 (en) 2016-03-08 2019-07-02 Academia Sinica Methods for modular synthesis of N-glycans and arrays thereof
EP4169942A1 (en) 2016-03-11 2023-04-26 Scholar Rock, Inc. Tgfbeta1-binding immunoglobulins and use thereof
WO2017156500A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgfb1-binding immunoglobulins and use thereof
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
WO2017158436A1 (en) 2016-03-17 2017-09-21 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2017165736A1 (en) 2016-03-25 2017-09-28 Visterra, Inc. Formulation of antibody molecules to dengue virus
US11833223B2 (en) 2016-03-29 2023-12-05 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US11041017B2 (en) 2016-03-29 2021-06-22 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
WO2017177199A2 (en) 2016-04-08 2017-10-12 Iti Health, Inc. Plectin-1 binding antibodies and uses thereof
WO2017181098A2 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
US11583577B2 (en) 2016-04-22 2023-02-21 Obi Pharma, Inc. Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
EP3992632A1 (en) 2016-06-27 2022-05-04 Juno Therapeutics, Inc. Mhc-e restricted epitopes, binding molecules and related methods and uses
WO2018005556A1 (en) 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Mhc-e restricted epitopes, binding molecules and related methods and uses
WO2018005559A1 (en) 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
WO2018013714A1 (en) 2016-07-13 2018-01-18 Biogen Ma Inc. Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
WO2018013918A2 (en) 2016-07-15 2018-01-18 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
WO2018022479A1 (en) 2016-07-25 2018-02-01 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
US11642400B2 (en) 2016-07-27 2023-05-09 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
US11643456B2 (en) 2016-07-29 2023-05-09 Obi Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
WO2018026748A1 (en) 2016-08-01 2018-02-08 Xoma (Us) Llc Parathyroid hormone receptor 1 (pth1r) antibodies and uses thereof
US10519250B2 (en) 2016-08-01 2019-12-31 Xoma (Us) Llc Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof
US11787876B2 (en) 2016-08-01 2023-10-17 Xoma (Us) Llc Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof
WO2018052556A1 (en) 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof
US11649285B2 (en) 2016-08-03 2023-05-16 Bio-Techne Corporation Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
US10538592B2 (en) 2016-08-22 2020-01-21 Cho Pharma, Inc. Antibodies, binding fragments, and methods of use
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
US10751414B2 (en) 2016-09-19 2020-08-25 Celgene Corporation Methods of treating psoriasis using PD-1 binding antibodies
US11673971B2 (en) 2016-09-23 2023-06-13 Marengo Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
WO2018057955A1 (en) 2016-09-23 2018-03-29 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
US10858428B2 (en) 2016-09-28 2020-12-08 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
WO2018064255A2 (en) 2016-09-28 2018-04-05 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
WO2018067468A1 (en) 2016-10-03 2018-04-12 Abbott Laboratories Improved methods of assessing uch-l1 status in patient samples
WO2018067474A1 (en) 2016-10-03 2018-04-12 Abbott Laboratories Improved methods of assessing gfap status in patient samples
WO2018067992A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
WO2018071576A1 (en) 2016-10-14 2018-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of tumors by inhibition of cd300f
US11000601B2 (en) 2016-11-21 2021-05-11 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
WO2018119402A1 (en) 2016-12-23 2018-06-28 Visterra, Inc. Binding polypeptides and methods of making the same
WO2018129395A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
WO2018129329A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF
EP4218817A2 (en) 2017-01-06 2023-08-02 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
WO2018130661A1 (en) 2017-01-13 2018-07-19 Academia Sinica Reloadable hydrogel system for treating brain conditions
WO2018130660A1 (en) 2017-01-13 2018-07-19 Academia Sinica Reloadable hydrogel system for treating myocardial infarction
WO2018136626A1 (en) 2017-01-18 2018-07-26 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
WO2018136553A1 (en) 2017-01-18 2018-07-26 Genentech, Inc. Idiotypic antibodies against anti-pd-l1 antibodies and uses thereof
US11279762B2 (en) 2017-01-18 2022-03-22 Genentech, Inc. Idiotypic antibodies against anti-PD-L1 antibodies and uses thereof
US10941448B1 (en) 2017-02-03 2021-03-09 The Universite Paris-Saclay Methods for assessing risk of developing a viral disease using a genetic test
US10544463B2 (en) 2017-02-03 2020-01-28 Pml Screening, Llc Methods for assessing risk of developing a viral disease using a genetic test
US10563264B2 (en) 2017-02-03 2020-02-18 Pml Screening, Llc Methods for assessing risk of developing a viral disease using a genetic test
US11913073B2 (en) 2017-02-03 2024-02-27 Pml Screening, Llc Methods for assessing risk of developing a viral disease using a genetic test
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
US11623945B2 (en) 2017-02-06 2023-04-11 The United States Of America, As Represented By The Secretary Of Agriculture Immunostimulating compositions and uses therefore
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
WO2018158719A1 (en) 2017-03-02 2018-09-07 Novartis Ag Engineered heterodimeric proteins
WO2018175942A1 (en) 2017-03-23 2018-09-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
WO2018176019A1 (en) 2017-03-24 2018-09-27 The Regents Of The University Of California Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom
WO2018187227A1 (en) 2017-04-03 2018-10-11 Concologie, Inc. Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
US11471537B2 (en) 2017-04-05 2022-10-18 Novo Nordisk A/S Oligomer extended insulin-Fc conjugates
WO2018189611A1 (en) 2017-04-12 2018-10-18 Pfizer Inc. Antibodies having conditional affinity and methods of use thereof
WO2018191531A1 (en) 2017-04-15 2018-10-18 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
WO2018195283A1 (en) 2017-04-19 2018-10-25 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
US11820792B2 (en) 2017-04-24 2023-11-21 Imperial College Innovations Limited Cancer treatment
WO2018197859A1 (en) * 2017-04-24 2018-11-01 Imperial Innovations Limited Cancer treatment
CN110546253A (en) * 2017-04-24 2019-12-06 帝国创新有限公司 cancer treatment
WO2018201047A1 (en) 2017-04-28 2018-11-01 Elstar Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
WO2018200823A1 (en) 2017-04-28 2018-11-01 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
EP4328241A2 (en) 2017-04-28 2024-02-28 Marengo Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
WO2018215535A1 (en) 2017-05-23 2018-11-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
WO2018218169A1 (en) 2017-05-25 2018-11-29 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
WO2018222783A1 (en) 2017-05-30 2018-12-06 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i and early biomarkers
WO2018222784A1 (en) 2017-05-30 2018-12-06 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i
WO2018222901A1 (en) 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
WO2018226336A1 (en) 2017-06-09 2018-12-13 Providence Health & Services - Oregon Utilization of cd39 and cd103 for identification of human tumor reactive cells for treatment of cancer
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
US11897958B2 (en) 2017-06-26 2024-02-13 Bio-Techne Corporation Hybridoma clones, monoclonal antibodies to VSIG-4, and methods of making and using
US10752689B2 (en) 2017-06-26 2020-08-25 Bio-Techne Corporation Hybridoma clones, monoclonal antibodies to VSIG-4, and methods of making and using
WO2019006007A1 (en) 2017-06-27 2019-01-03 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
WO2019010131A1 (en) 2017-07-03 2019-01-10 Abbott Laboratories Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
US11447809B2 (en) 2017-07-06 2022-09-20 President And Fellows Of Harvard College Evolution of tRNA synthetases
US11802156B2 (en) 2017-07-14 2023-10-31 Pfizer Inc. Antibodies to MAdCAM
WO2019014572A1 (en) 2017-07-14 2019-01-17 Pfizer, Inc. Antibodies to madcam
WO2019016213A1 (en) 2017-07-19 2019-01-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. ANTI- ISOASP7 AMYLOID β (Aβ) ANTIBODIES AND USES THEREOF
US11703511B2 (en) 2017-07-19 2023-07-18 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-isoAsp7 amyloid β (Aβ) antibodies and uses thereof
EP3431496A1 (en) 2017-07-19 2019-01-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti- isoasp7 amyloid beta antibodies and uses thereof
WO2019018730A1 (en) 2017-07-20 2019-01-24 Novartis Ag Dosage regimens of anti-lag-3 antibodies and uses thereof
WO2019023661A1 (en) 2017-07-28 2019-01-31 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Multispecific molecules that bind to bcma and uses thereof
US11624130B2 (en) 2017-09-18 2023-04-11 President And Fellows Of Harvard College Continuous evolution for stabilized proteins
WO2019068733A1 (en) 2017-10-02 2019-04-11 Certest Biotec, S.L. Antibodies and test devices for the detection of bacteria of the genus campylobacter
WO2019070726A1 (en) 2017-10-02 2019-04-11 Visterra, Inc. Antibody molecules to cd138 and uses thereof
EP3461841A1 (en) 2017-10-02 2019-04-03 Certest Biotec, S.L. Antibodies and test devices for the detection of bacteria of the genus campylobacter
US11215618B2 (en) 2017-10-04 2022-01-04 Hesperix SA Articles and methods directed to personalized therapy of cancer
WO2019070161A2 (en) 2017-10-04 2019-04-11 Opko Pharmaceuticals, Llc Articles and methods directed to personalized therapy of cancer
WO2019077132A1 (en) 2017-10-19 2019-04-25 Debiopharm International S.A. Combination product for the treatment of cancer
WO2019077165A1 (en) 2017-10-20 2019-04-25 Institut Curie Dap10/12 based cars adapted for rush
WO2019099838A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
WO2019108755A1 (en) 2017-11-30 2019-06-06 Genentech, Inc. Anti-pd-l1 antibodies and methods of using the same for detection of pd-l1
US11292843B2 (en) 2017-11-30 2022-04-05 Genentech, Inc. Anti-PD-L1 antibodies and methods of using the same for detection of PD-L1
WO2019113464A1 (en) 2017-12-08 2019-06-13 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
WO2019112860A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
WO2019113525A2 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
WO2019152810A1 (en) 2018-02-02 2019-08-08 Bio-Techne Corporation Compounds that modulate the interaction of vista and vsig3 and methods of making and using
US11787857B2 (en) 2018-02-02 2023-10-17 Bio-Techne Corporation Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using
US10982002B2 (en) 2018-03-12 2021-04-20 Zoetis Services Llc Anti-NGF antibodies and methods thereof
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019178364A2 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
WO2019180272A1 (en) 2018-03-23 2019-09-26 Fundación Instituto De Investigación Sanitaria De Santiago De Compostela Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases
EP4253958A2 (en) 2018-03-26 2023-10-04 Glycanostics s.r.o. Means and methods for glycoprofiling of a protein
WO2019185515A1 (en) 2018-03-26 2019-10-03 Glycanostics S.R.O. Means and methods for glycoprofiling of a protein
WO2019200229A1 (en) 2018-04-13 2019-10-17 Novartis Ag Dosage regimens for anti-pd-l1 antibodies and uses thereof
WO2019229658A1 (en) 2018-05-30 2019-12-05 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
US11913044B2 (en) 2018-06-14 2024-02-27 President And Fellows Of Harvard College Evolution of cytidine deaminases
WO2019246293A2 (en) 2018-06-19 2019-12-26 Atarga, Llc Antibody molecules to complement component 5 and uses thereof
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
DE202019005887U1 (en) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
US11845797B2 (en) 2018-07-03 2023-12-19 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
WO2020008083A1 (en) 2018-07-05 2020-01-09 Consejo Superior De Investigaciones Científicas Therapeutic target in chemokine receptors for the screening of compounds useful for the treatment of pathological processes involving chemokine signaling
EP3677278A1 (en) 2018-07-11 2020-07-08 Scholar Rock, Inc. Isoform selective tgfbeta1 inhibitors and use thereof
WO2020014473A1 (en) 2018-07-11 2020-01-16 Scholar Rock, Inc. TGFβ1 INHIBITORS AND USE THEREOF
WO2020014460A1 (en) 2018-07-11 2020-01-16 Scholar Rock, Inc. HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF
EP4019046A1 (en) 2018-07-11 2022-06-29 Scholar Rock, Inc. Isoform selective tgfbeta1 inhibitors and use thereof
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
WO2020033485A1 (en) 2018-08-08 2020-02-13 Genentech, Inc. Use of tryptophan derivatives and l-methionine for protein formulation
US11913074B2 (en) 2018-08-08 2024-02-27 Pml Screening, Llc Methods for assessing risk of developing a viral disease using a genetic test
US10961585B2 (en) 2018-08-08 2021-03-30 Pml Screening, Llc Methods for assessing risk of developing a viral of disease using a genetic test
WO2020069372A1 (en) 2018-09-27 2020-04-02 Elstar Therapeutics, Inc. Csf1r/ccr2 multispecific antibodies
WO2020065594A1 (en) 2018-09-28 2020-04-02 Kyowa Kirin Co., Ltd. Il-36 antibodies and uses thereof
WO2020070303A1 (en) 2018-10-05 2020-04-09 Bavarian Nordic A/S Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
WO2020079580A1 (en) 2018-10-15 2020-04-23 Novartis Ag Trem2 stabilizing antibodies
WO2020086736A1 (en) 2018-10-23 2020-04-30 Scholar Rock, Inc. Rgmc-selective inhibitors and use thereof
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
WO2020104531A1 (en) 2018-11-20 2020-05-28 Bavarian Nordic A/S Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l
WO2020128898A1 (en) 2018-12-20 2020-06-25 Novartis Ag Pharmaceutical combinations
WO2020128927A1 (en) 2018-12-20 2020-06-25 Kyowa Kirin Co., Ltd. Fn14 antibodies and uses thereof
EP3689905A2 (en) 2019-01-30 2020-08-05 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf-beta and uses thereof
WO2020160291A2 (en) 2019-01-30 2020-08-06 Scholar Rock, Inc. LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF
US11738050B2 (en) 2019-02-01 2023-08-29 Regents Of The University Of Minnesota Compounds binding to fibroblast activation protein alpha
EP3693063A1 (en) 2019-02-06 2020-08-12 Diaccurate Methods and compositions for treating cancer
WO2020161165A1 (en) 2019-02-06 2020-08-13 Diaccurate Methods and compositions for treating cancer
EP3696191A1 (en) 2019-02-14 2020-08-19 Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) Car t-cells for the treatment of cd1a-positive cancer
WO2020165350A1 (en) 2019-02-14 2020-08-20 Fundación Instituo De Investigación Contra La Leucemia Josep Carreras (Ijc) Car t-cells for the treatment of cd1a-positive cancer
WO2020165868A1 (en) 2019-02-15 2020-08-20 Perkinelmer Cellular Technologies Germany Gmbh Low-power microscope-objective pre-scan and high-power microscope-objective scan in x,y and z-direction for imaging objects such as cells using a microscope
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
WO2020172598A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
WO2020172601A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020172596A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and thereof
WO2020172571A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
WO2020205523A1 (en) 2019-03-29 2020-10-08 Atarga, Llc Anti fgf23 antibody
WO2020213724A1 (en) 2019-04-19 2020-10-22 中外製薬株式会社 Chimeric receptor recognizing modification site of antibody
WO2020257289A2 (en) 2019-06-17 2020-12-24 Visterra, Inc. Humanized antibody molecules to cd138 and uses thereof
WO2021010326A1 (en) 2019-07-12 2021-01-21 中外製薬株式会社 Anti-mutation type fgfr3 antibody and use therefor
WO2021021606A1 (en) 2019-07-26 2021-02-04 Visterra, Inc. Interleukin-2 agents and uses thereof
WO2021023721A1 (en) 2019-08-02 2021-02-11 Fundacio Clinic Per A La Recerca Biomedica Car t-cells against bcma for the treatment of multiple myeloma
EP4272837A2 (en) 2019-08-02 2023-11-08 Fundacio de Recerca Clinic Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer Car t-cells against bcma for the treatment of multiple myeloma
WO2021023860A1 (en) 2019-08-07 2021-02-11 Db Biotech, As Improved horseradish peroxidase polypeptides
WO2021044009A1 (en) 2019-09-04 2021-03-11 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Herv inhibitors for use in treating tauopathies
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
WO2021053560A1 (en) 2019-09-18 2021-03-25 Novartis Ag Combination therapy with entpd2 and cd73 antibodies
WO2021079195A1 (en) 2019-10-21 2021-04-29 Novartis Ag Tim-3 inhibitors and uses thereof
WO2021079188A1 (en) 2019-10-21 2021-04-29 Novartis Ag Combination therapies with venetoclax and tim-3 inhibitors
WO2021099586A1 (en) 2019-11-20 2021-05-27 Bavarian Nordic A/S Recombinant mva viruses for intratumoral and/or intravenous administration for treating cancer
WO2021123902A1 (en) 2019-12-20 2021-06-24 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
WO2021123996A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
WO2021142427A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. TGFβ INHIBITORS AND USE THEREOF
WO2021142448A2 (en) 2020-01-11 2021-07-15 Scholar Rock,Inc. Tgf-beta inhibitors and use thereof
WO2021146320A1 (en) 2020-01-13 2021-07-22 Visterra, Inc. Antibody molecules to c5ar1 and uses thereof
WO2021144657A1 (en) 2020-01-17 2021-07-22 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
WO2021159024A1 (en) 2020-02-05 2021-08-12 Larimar Therapeutics, Inc. Tat peptide binding proteins and uses thereof
WO2021180890A1 (en) 2020-03-11 2021-09-16 Fundació Institut De Recerca Contra La Leucèmia Josep Carreras Cd22 targeting-moiety for the treatment of b-cell acute lymphoblastic leukemia (b-all)
WO2021203024A1 (en) 2020-04-03 2021-10-07 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
WO2021211331A1 (en) 2020-04-13 2021-10-21 Abbott Point Of Care Inc. METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE
WO2021217085A1 (en) 2020-04-24 2021-10-28 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
WO2021222333A1 (en) 2020-04-30 2021-11-04 Genentech, Inc. Kras specific antibodies and uses thereof
WO2021220215A1 (en) 2020-05-01 2021-11-04 Novartis Ag Engineered immunoglobulins
WO2021220218A1 (en) 2020-05-01 2021-11-04 Novartis Ag Immunoglobulin variants
WO2021239666A1 (en) 2020-05-26 2021-12-02 Diaccurate Therapeutic methods
WO2021247908A1 (en) 2020-06-03 2021-12-09 Bionecure Therapeutics, Inc. Trophoblast cell-surface antigen-2 (trop-2) antibodies
WO2021262999A1 (en) 2020-06-24 2021-12-30 Visterra, Inc. Antibody molecules to april and uses thereof
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
WO2022031804A1 (en) 2020-08-04 2022-02-10 Abbott Laboratories Improved methods and kits for detecting sars-cov-2 protein in a sample
WO2022046920A2 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2022046922A2 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
WO2022047046A1 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Methods of detecting trbc1 or trbc2
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022081718A1 (en) 2020-10-14 2022-04-21 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
WO2022115538A1 (en) 2020-11-24 2022-06-02 Bio-Techne Corporation Anti-severe acute respiratory syndrome coronavirus antibodies
WO2022119841A1 (en) 2020-12-01 2022-06-09 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2022120224A1 (en) 2020-12-04 2022-06-09 Visterra, Inc. Methods of using interleukin-2 agents
WO2022133191A2 (en) 2020-12-18 2022-06-23 Kiniksa Pharmaceuticals, Ltd. Protein compositions and methods for producing and using the same
WO2022147147A1 (en) 2020-12-30 2022-07-07 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
WO2022147463A2 (en) 2020-12-31 2022-07-07 Alamar Biosciences, Inc. Binder molecules with high affinity and/ or specificity and methods of making and use thereof
WO2022159590A1 (en) 2021-01-20 2022-07-28 Visterra, Inc. Interleukin-2 mutants and uses thereof
WO2022162569A1 (en) 2021-01-29 2022-08-04 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
WO2022182872A2 (en) 2021-02-24 2022-09-01 Alladapt Immunotherapeutics, Inc. Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
WO2022187440A1 (en) 2021-03-03 2022-09-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services La protien as a novel regulator of osteoclastogenesis
WO2022195551A1 (en) 2021-03-18 2022-09-22 Novartis Ag Biomarkers for cancer and methods of use thereof
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022215011A1 (en) 2021-04-07 2022-10-13 Novartis Ag USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof
WO2022245920A1 (en) 2021-05-18 2022-11-24 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
WO2022261018A1 (en) 2021-06-07 2022-12-15 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
WO2022266034A1 (en) 2021-06-14 2022-12-22 Abbott Laboratories Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
WO2022271867A1 (en) 2021-06-23 2022-12-29 Scholar Rock, Inc. A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
WO2023288267A1 (en) 2021-07-14 2023-01-19 2Seventy Bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
WO2023018803A1 (en) 2021-08-10 2023-02-16 Byomass Inc. Anti-gdf15 antibodies, compositions and uses thereof
WO2023025927A1 (en) 2021-08-26 2023-03-02 Glycanostics S.R.O Glycoprotein biomarkers for diagnosing cancer
WO2023034777A1 (en) 2021-08-31 2023-03-09 Abbott Laboratories Methods and systems of diagnosing brain injury
WO2023041565A1 (en) 2021-09-14 2023-03-23 Glycanostics S.R.O Use of lectins to determine mammaglobin-a glycoforms in breast cancer
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023044094A1 (en) 2021-09-20 2023-03-23 Alnylam Pharmaceuticals, Inc. Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
WO2023056268A1 (en) 2021-09-30 2023-04-06 Abbott Laboratories Methods and systems of diagnosing brain injury
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2023069421A1 (en) 2021-10-18 2023-04-27 Byomass Inc. Anti-activin a antibodies, compositions and uses thereof
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023097254A1 (en) 2021-11-24 2023-06-01 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2023102463A1 (en) 2021-12-01 2023-06-08 Visterra, Inc. Methods of using interleukin-2 agents
WO2023114978A1 (en) 2021-12-17 2023-06-22 Abbott Laboratories Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
WO2023129942A1 (en) 2021-12-28 2023-07-06 Abbott Laboratories Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
WO2023147107A1 (en) 2022-01-31 2023-08-03 Byomass Inc. Myeloproliferative conditions
WO2023150652A1 (en) 2022-02-04 2023-08-10 Abbott Laboratories Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
WO2023150778A1 (en) 2022-02-07 2023-08-10 Visterra, Inc. Anti-idiotype antibody molecules and uses thereof
WO2023212518A1 (en) 2022-04-25 2023-11-02 Visterra, Inc. Antibody molecules to april and uses thereof
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023239803A1 (en) 2022-06-08 2023-12-14 Angiex, Inc. Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
EP4296279A1 (en) 2022-06-23 2023-12-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-transthyretin (ttr) binding proteins and uses thereof
WO2023247312A1 (en) 2022-06-23 2023-12-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-transthyretin (ttr) binding proteins and uses thereof
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
WO2024030976A2 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier

Also Published As

Publication number Publication date
US20080038717A1 (en) 2008-02-14
EP0564531A1 (en) 1993-10-13
CA2405246A1 (en) 1992-06-11
US20060115874A1 (en) 2006-06-01
US5834598A (en) 1998-11-10
DE69129154T2 (en) 1998-08-20
US5821047A (en) 1998-10-13
US5750373A (en) 1998-05-12
DK0564531T3 (en) 1998-09-28
ATE164395T1 (en) 1998-04-15
US6040136A (en) 2000-03-21
CA2095633A1 (en) 1992-06-04
EP0564531B1 (en) 1998-03-25
CA2095633C (en) 2003-02-04
WO1992009690A3 (en) 1992-12-10
DE69129154D1 (en) 1998-04-30
ES2113940T3 (en) 1998-05-16
US20100035236A1 (en) 2010-02-11
GR3026468T3 (en) 1998-06-30

Similar Documents

Publication Publication Date Title
EP0564531B1 (en) Enrichment method for variant proteins with altered binding properties
US5688666A (en) Growth hormone variants with altered binding properties
US5780279A (en) Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
EP1127142B1 (en) Modulation of polypeptide display on modified filamentous phage
CA2001774C (en) Method for identifying active domains and amino acid residues in polypeptides and hormone variants
AU696293B2 (en) Process for generating specific antibodies
CA2286397C (en) Humanized antibodies and methods for forming humanized antibodies
US5854026A (en) Human growth hormone variant having enhanced affinity for human growth hormone receptor at site 1
US6057098A (en) Polyvalent display libraries
Gram et al. Phage display as a rapid gene expression system: production of bioactive cytokine-phage and generation of neutralizing monoclonal antibodies
WO1995011922A1 (en) In vitro peptide and antibody display libraries
WO1998047343A9 (en) Antibodies or binding protein libraries displayed on phage, cells, or other replicatable genetic packages
JP2006104205A (en) Human growth hormone variant
WO1995034683A1 (en) Method of detecting compounds utilizing genetically modified lambdoid bacteriophage
US6555310B1 (en) Polyclonal libraries
JPH08505524A (en) Soluble peptide having a secondary conformation constrained in solution, and process for producing the same
WO2001057065A2 (en) Combinatorial protein domains
JP3765959B2 (en) Hormone variant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

WWE Wipo information: entry into national phase

Ref document number: 08050058

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2095633

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1992902109

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992902109

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1992902109

Country of ref document: EP